data_2dh7_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2dh7 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 61.1 m170 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.822 0.344 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -107.86 121.53 44.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -84.09 123.97 30.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.0 t -112.3 122.86 67.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.105 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.433 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 2.1 t80 -83.02 141.21 32.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.854 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.457 HG11 ' CD2' ' A' ' 104' ' ' LEU . 96.1 t -135.55 110.67 11.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.155 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.12 -174.25 30.26 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 45.73 52.6 9.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.457 ' CD2' HG11 ' A' ' 101' ' ' VAL . 21.3 mt -91.41 100.28 13.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -36.19 153.56 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.692 0.758 . . . . 0.0 110.869 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -27.23 26.67 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.726 2.284 . . . . 0.0 112.317 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -75.97 -12.41 60.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.446 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 24.1 mm -63.45 157.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.157 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.438 ' N ' HG23 ' A' ' 108' ' ' ILE . 77.7 p -145.66 144.04 30.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.168 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 76.5 m -44.64 -38.08 4.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -70.89 -35.96 72.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 116' ' ' ALA . 27.1 m-20 -63.58 -52.14 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.489 HG23 ' CD1' ' A' ' 117' ' ' PHE . 51.9 mt -56.67 -46.04 82.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.459 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 68.0 mttt -56.7 -33.87 66.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.963 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -94.01 -18.44 21.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.432 ' CB ' HD13 ' A' ' 163' ' ' LEU . . . -85.3 -13.05 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.12 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.489 ' CD1' HG23 ' A' ' 113' ' ' ILE . 14.7 m-85 -115.87 -6.55 12.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.852 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.575 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.68 -46.11 99.78 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.571 0.7 . . . . 0.0 111.118 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.575 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.93 -17.19 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.562 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 48.0 m-85 -90.47 -48.18 7.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -176.45 175.56 47.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.467 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.8 tptp -62.86 134.83 56.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.771 0.32 . . . . 0.0 110.882 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.459 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 77.3 mt -101.31 133.04 45.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 39.8 t -106.76 -40.43 5.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -143.48 122.52 12.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -149.94 133.15 16.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 22.2 ptt180 -155.41 153.15 29.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.49 100.0 9.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 78.8 t -49.85 114.3 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.133 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.467 ' HG2' ' N ' ' A' ' 137' ' ' SER . 41.7 mttt -118.07 155.67 29.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.21 149.58 49.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 mmt -91.92 -8.73 45.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.71 -58.52 2.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.092 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 11.8 p -87.69 -38.54 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.11 34.38 14.9 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -118.3 138.96 52.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.77 0.319 . . . . 0.0 110.905 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.467 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 21.4 t -40.9 104.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.89 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 21.3 mttp -45.25 -36.76 4.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.926 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.31 23.37 2.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.501 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -165.52 143.06 5.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.929 0.395 . . . . 0.0 110.914 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.15 -173.37 19.73 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.442 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -133.24 141.16 47.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.907 0.384 . . . . 0.0 110.906 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.19 106.34 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 50.9 m -86.36 154.29 21.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -130.89 147.22 52.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -60.96 -40.72 94.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.94 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -122.76 176.23 6.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -83.54 -55.68 4.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 19.1 tp -42.75 -53.97 4.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -51.6 -45.78 63.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -61.0 -51.54 68.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -50.02 -42.62 49.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.891 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -52.2 -48.98 64.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.535 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -68.0 -52.34 36.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.09 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.561 HD13 ' CZ2' ' A' ' 172' ' ' TRP . 88.5 mt -44.03 -38.78 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.146 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.92 -54.53 8.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.114 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -58.84 -64.16 1.04 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.562 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 89.5 mmm -57.54 -39.72 77.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.69 93.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 94.31 -29.5 8.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.499 ' N ' ' O ' ' A' ' 158' ' ' MET . 71.8 tp60 -38.86 148.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.361 . . . . 0.0 110.917 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 91.1 m95 -90.7 92.54 8.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.432 HD13 ' CB ' ' A' ' 116' ' ' ALA . 3.4 tt -88.7 -69.81 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.934 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.14 117.03 3.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.445 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.57 -91.3 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.494 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.3 mpt_? -83.14 175.73 9.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.859 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 51.0 mt-30 -77.08 177.43 7.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.442 HD12 ' CE ' ' A' ' 158' ' ' MET . 19.8 pt -137.35 162.69 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.07 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.3 mmt180 -118.98 165.07 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' THR . . . . . 0.451 ' O ' ' ND2' ' A' ' 171' ' ' ASN . 3.8 p -149.81 141.4 23.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.108 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . 0.451 ' ND2' ' O ' ' A' ' 170' ' ' THR . 35.0 m120 -159.88 165.17 32.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.561 ' CZ2' HD13 ' A' ' 155' ' ' ILE . 91.9 m95 -83.95 84.17 7.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 179.893 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . 0.419 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 44.5 m170 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.828 0.346 . . . . 0.0 110.888 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -103.03 128.14 50.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 29.6 m-70 -83.4 131.85 35.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.831 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 58.6 t -118.51 124.37 73.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.099 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 140' ' ' TYR . 10.4 t80 -86.41 138.85 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 92.7 t -132.34 111.8 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.097 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.31 -175.32 26.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 49.35 41.66 20.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.431 ' O ' ' C ' ' A' ' 105' ' ' SER . 67.9 mt -85.78 108.02 17.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.8 t -35.94 152.16 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.658 0.742 . . . . 0.0 110.855 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -19.43 35.88 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.684 2.256 . . . . 0.0 112.316 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -87.81 1.4 54.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 15.8 mm -75.38 146.34 9.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.123 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.6 p -139.59 145.79 39.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.175 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 88.6 m -39.01 -35.97 0.25 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.192 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -67.34 -48.89 66.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 116' ' ' ALA . 8.8 t0 -54.39 -52.72 60.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.511 HG21 ' CD1' ' A' ' 117' ' ' PHE . 64.6 mt -56.69 -42.68 77.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.159 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.428 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 36.0 mttt -63.51 -37.56 87.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.932 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -92.55 -8.93 42.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.841 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -97.4 -23.59 16.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.061 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.565 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 22.7 m-85 -105.29 -11.59 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.583 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -52.51 -45.9 95.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.603 0.716 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.3 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 0.0 112.336 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.561 ' CE1' ' HA ' ' A' ' 154' ' ' ALA . 58.7 m-85 -90.31 -51.19 5.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -178.46 158.64 23.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.498 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.4 tptt -48.64 128.7 15.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.712 0.291 . . . . 0.0 110.856 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.428 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 60.0 mt -96.39 137.76 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 10.6 t -112.88 -39.52 4.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.865 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -134.92 103.0 5.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -136.18 131.5 34.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 22.5 ptt180 -155.55 156.38 35.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.62 100.44 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.107 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.474 HG12 ' CG ' ' A' ' 138' ' ' LYS . 75.8 t -52.34 122.81 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.104 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -119.03 155.53 31.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.883 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.95 148.66 51.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 35.1 mtm -95.46 -9.41 32.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -91.13 -52.5 4.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.086 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.7 p -100.89 -40.38 7.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.152 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.59 26.25 8.21 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.48 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -109.3 149.27 29.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.915 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 11.9 m -43.09 114.65 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.824 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.474 ' CG ' HG12 ' A' ' 129' ' ' VAL . 13.2 mtpt -53.6 -39.82 65.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.927 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.77 19.34 1.83 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 100' ' ' PHE . 44.2 p90 -167.53 150.28 6.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.899 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.65 -171.5 16.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.453 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -136.48 136.91 39.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.907 0.384 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.451 HG13 ' CE2' ' A' ' 145' ' ' PHE . 70.2 t -140.53 108.31 2.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.182 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.3 t -93.52 141.82 28.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.451 ' CE2' HG13 ' A' ' 143' ' ' VAL . 44.8 m-85 -117.27 147.21 42.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.419 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 10.1 m-85 -57.79 -38.22 75.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -124.95 155.64 39.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.87 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -61.43 -60.55 3.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 21.1 tp -40.01 -49.95 2.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -49.49 -40.68 38.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.845 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -69.3 -48.87 60.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.07 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -52.57 -38.89 60.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.924 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -56.53 -54.5 45.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.561 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -61.31 -61.62 2.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.559 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 68.3 mt -38.64 -39.73 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.159 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 20.3 t -70.55 -64.37 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.132 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 77.6 m-70 -63.63 -61.17 2.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.565 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 29.0 mmt -43.9 -48.44 8.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.44 92.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 97.68 -30.1 9.88 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.525 ' CD ' ' N ' ' A' ' 162' ' ' TRP . 1.0 OUTLIER -36.74 154.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.811 0.338 . . . . 0.0 110.863 -179.851 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.572 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 77.1 m95 -101.43 91.24 4.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.978 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.456 HD12 ' CB ' ' A' ' 116' ' ' ALA . 4.2 tt -84.29 -70.89 0.54 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.921 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -125.58 120.33 3.82 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.458 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 57.37 -95.3 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -81.15 179.26 7.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.744 0.306 . . . . 0.0 110.921 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.572 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 53.9 mt-30 -79.57 -178.43 6.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.434 ' O ' ' N ' ' A' ' 160' ' ' GLY . 20.8 pt -136.66 162.19 35.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.7 ttm180 -126.4 144.07 50.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' THR . . . . . 0.416 ' O ' ' CG ' ' A' ' 171' ' ' ASN . 1.3 p -121.6 153.18 38.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . 0.416 ' CG ' ' O ' ' A' ' 170' ' ' THR . 12.0 m120 -169.15 159.97 9.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.559 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 94.9 m95 -89.41 129.42 35.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.07 179.881 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . 0.434 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 38.1 m170 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.798 0.332 . . . . 0.0 110.885 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -104.72 121.4 43.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 5.2 m-70 -89.3 134.42 34.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.21 122.1 68.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 45.4 t80 -84.91 141.43 30.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.6 t -125.73 143.05 40.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.44 159.22 23.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.459 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 t0 68.06 33.77 4.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.88 0.372 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.433 ' O ' ' C ' ' A' ' 105' ' ' SER . 31.3 mt -70.91 99.06 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.4 t -35.85 153.22 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.739 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -18.93 36.6 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.335 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.452 ' CG ' ' O ' ' A' ' 107' ' ' GLU . 9.6 tt0 -87.71 -3.43 58.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.415 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 18.1 mm -69.36 144.59 13.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.6 p -134.49 148.8 50.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.118 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 88.4 m -50.87 -30.71 15.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.183 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -78.23 -23.16 47.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -78.91 -48.92 13.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.42 HG21 ' CE1' ' A' ' 117' ' ' PHE . 17.5 mt -57.85 -42.42 82.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.144 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.3 mttt -58.45 -43.98 89.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.7 t -81.94 -16.87 49.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -89.5 -20.11 24.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.566 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.3 m-85 -108.63 -10.59 15.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.855 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.585 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.12 -45.43 99.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.57 0.7 . . . . 0.0 111.042 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -47.98 -17.03 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.706 2.27 . . . . 0.0 112.33 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.551 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 34.6 m-85 -93.58 -32.13 14.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.16 178.79 36.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.555 ' HG3' ' CE1' ' A' ' 146' ' ' TYR . 32.0 tptt -62.82 143.68 57.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.802 0.334 . . . . 0.0 110.877 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 62.6 mt -113.57 126.24 70.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 1.7 t -93.77 -37.44 11.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -145.89 117.43 8.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -146.43 119.2 8.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -148.45 163.27 37.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.9 p -115.76 104.26 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.128 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.0 t -57.49 124.65 11.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -122.36 157.98 30.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.912 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -64.83 158.23 25.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.932 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 42.7 mmm -101.92 -13.13 17.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.883 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.36 -47.69 7.59 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.119 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.8 p -102.55 -38.86 7.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.104 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.28 32.79 9.25 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.9 mttt -111.84 155.5 23.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.741 0.305 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.1 t -55.23 102.61 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 65.0 mttt -45.03 -39.0 5.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.892 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.92 16.96 2.87 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.455 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.422 ' C ' HD13 ' A' ' 104' ' ' LEU . 32.8 p90 -160.5 145.81 14.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.976 0.417 . . . . 0.0 110.927 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -141.55 -176.17 15.64 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -129.82 142.15 50.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.869 0.366 . . . . 0.0 110.924 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 19.8 t -149.35 106.03 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.155 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 48.9 m -92.0 142.1 27.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 23.7 m-85 -112.42 144.67 41.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.913 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.555 ' CE1' ' HG3' ' A' ' 122' ' ' LYS . 8.5 m-85 -56.98 -35.75 69.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.557 ' ND2' ' N ' ' A' ' 147' ' ' ASN . 0.0 OUTLIER -127.15 179.7 5.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.901 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -86.98 -40.96 14.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 55.9 tp -52.44 -65.07 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.456 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 14.6 p-10 -43.8 -53.63 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.844 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -55.0 -57.16 12.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.066 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -46.38 -47.21 18.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.888 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 64.6 m-20 -49.8 -55.09 15.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.546 ' HB1' ' CD2' ' A' ' 120' ' ' PHE . . . -57.05 -60.73 3.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.081 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.561 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 83.3 mt -39.31 -37.72 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.152 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.4 t -77.76 -48.6 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.139 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -75.56 -62.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.566 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 23.2 mmt -45.31 -47.27 13.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.45 94.96 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.446 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 96.59 -30.69 8.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.486 ' N ' ' O ' ' A' ' 158' ' ' MET . 6.2 tm0? -38.25 157.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 110.923 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 87.1 m95 -102.56 95.0 5.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.958 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.405 ' C ' ' CD2' ' A' ' 163' ' ' LEU . 4.3 tt -90.88 -70.5 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.415 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.09 116.77 3.53 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.505 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.42 -91.53 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -82.07 178.81 8.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.839 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 43.9 mt-30 -80.63 177.83 8.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 7.7 pt -137.3 170.19 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.111 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.4 ttm-85 -131.29 149.57 52.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.9 p -126.67 150.85 48.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -168.77 154.56 6.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.561 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.2 m95 -81.05 113.24 19.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.111 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.6 m170 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.862 0.363 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -94.12 130.24 40.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . 0.44 ' CB ' ' HB1' ' A' ' 173' ' ' ALA . 54.6 m-70 -88.28 128.12 35.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 95.6 t -116.44 124.65 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -89.57 141.86 28.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.2 t -131.59 134.89 60.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.46 17.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.479 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.96 36.09 23.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.879 0.371 . . . . 0.0 110.836 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 31.2 mt -81.1 110.03 16.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.929 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -41.61 153.31 0.27 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -23.64 30.52 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.336 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -75.84 -18.53 59.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.449 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 20.2 mm -66.33 133.09 31.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 60.8 p -121.21 151.42 39.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 52.9 m -43.98 -34.54 1.74 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.136 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -70.93 -43.81 67.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.4 m-20 -58.76 -53.83 53.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 43.3 mt -56.34 -38.68 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -63.58 -39.13 93.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.3 t -93.3 -11.92 31.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.836 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -90.72 -20.94 21.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.09 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.569 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 19.6 m-85 -107.4 -8.65 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.73 -45.66 99.8 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.589 0.709 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -48.0 -17.07 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.283 . . . . 0.0 112.361 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.7 m-85 -90.73 -38.84 12.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.896 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.97 167.29 31.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -54.54 126.63 24.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 85.7 mt -95.76 132.85 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.147 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 92.1 p -99.99 -44.92 5.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.1 120.65 13.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -143.21 128.32 18.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.099 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 -156.44 151.75 26.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.59 100.08 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.148 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 68.7 t -49.49 130.37 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.077 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.405 ' HG2' ' C ' ' A' ' 136' ' ' LYS . 29.9 mtmt -125.55 167.75 14.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 30.3 t0 -68.53 157.33 36.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -94.57 -12.53 27.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.58 -62.55 1.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.6 p -81.08 -28.38 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.131 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.26 33.45 53.71 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.405 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 7.1 mmpt? -106.03 158.33 16.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.307 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.5 m -65.47 100.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 37.4 mttt -44.21 -36.77 2.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 121.17 18.58 3.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.485 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -156.71 142.45 17.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.908 0.385 . . . . 0.0 110.952 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.1 -169.76 12.26 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -134.23 142.38 47.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 73.1 t -144.83 110.55 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.136 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 15.8 m -89.67 145.01 25.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -121.88 149.18 43.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -58.63 -46.64 86.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -128.66 165.23 21.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' A' ' 151' ' ' ALA . 14.3 ttmt -62.13 -62.22 1.92 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 65.0 tp -38.19 -50.88 1.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -55.68 -39.62 71.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.907 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.521 ' HB3' ' CH2' ' A' ' 172' ' ' TRP . . . -67.02 -51.19 57.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.149 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -50.14 -48.04 53.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -42.03 -36.59 1.16 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.559 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -86.0 -54.53 4.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.095 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.567 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 76.1 mt -47.67 -34.31 3.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.16 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 46.7 t -81.37 -46.33 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.129 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -74.92 -65.26 0.89 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.892 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.569 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 8.1 mmt -42.33 -48.66 5.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -35.51 103.04 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.467 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 82.08 -32.53 2.74 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.3 tp-100 -34.32 149.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.756 0.312 . . . . 0.0 110.966 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.548 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 90.8 m95 -99.89 92.51 5.32 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.926 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.414 HD22 ' C ' ' A' ' 163' ' ' LEU . 7.0 tt -87.24 -71.04 0.58 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.449 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.63 117.67 3.59 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.483 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.94 -92.78 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.504 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.735 0.302 . . . . 0.0 110.864 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.548 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 71.5 mt-30 -77.15 -178.96 5.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 25.0 pt -137.96 163.68 29.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . 0.466 ' HD3' ' N ' ' A' ' 170' ' ' THR . 0.1 OUTLIER -126.45 152.14 46.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.944 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' THR . . . . . 0.466 ' N ' ' HD3' ' A' ' 169' ' ' ARG . 16.4 p -134.16 158.46 43.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.156 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . 0.419 ' HB2' ' NH1' ' A' ' 169' ' ' ARG . 24.4 t-20 -172.07 173.18 4.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.843 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.567 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 83.8 m95 -95.04 106.97 19.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . 0.44 ' HB1' ' CB ' ' A' ' 98' ' ' HIS . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 19.4 m170 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.828 0.347 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.523 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 58.2 m-85 -113.48 134.24 54.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -91.29 128.35 37.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 151' ' ' ALA . 98.3 t -111.59 135.48 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.508 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 2.7 t80 -100.24 139.38 36.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 54.7 t -131.39 114.78 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.42 172.83 19.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 139' ' ' GLY . 1.6 m-20 58.71 37.73 25.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.359 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.464 HD13 ' N ' ' A' ' 141' ' ' GLY . 31.7 mt -71.88 101.08 2.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 104' ' ' LEU . 0.7 OUTLIER -36.64 155.23 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.663 0.744 . . . . 0.0 110.88 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -13.11 34.14 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -89.9 -16.72 29.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.894 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 10.7 mm -66.93 144.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 80.4 p -142.55 145.93 34.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.183 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 49.2 m -39.75 -37.49 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.101 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -68.27 -45.35 73.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.492 ' O ' ' N ' ' A' ' 116' ' ' ALA . 75.4 m-20 -64.32 -50.72 66.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.519 HG22 ' CD1' ' A' ' 117' ' ' PHE . 13.1 mt -53.52 -45.4 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.463 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 13.3 mtpt -61.35 -35.64 77.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.2 t -91.54 -13.59 31.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.492 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -95.71 -17.59 21.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.058 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.578 ' CE1' ' SD ' ' A' ' 158' ' ' MET . 25.5 m-85 -108.34 -11.03 15.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.845 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.591 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.16 -44.79 99.06 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 0.0 111.106 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -48.06 -16.75 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.261 . . . . 0.0 112.341 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 42.1 m-85 -94.31 -41.47 9.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 174.5 147.94 6.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -43.89 126.89 5.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.463 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 62.5 mt -91.63 134.33 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.9 p -100.29 -42.92 6.46 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -145.39 107.31 4.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.858 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -137.34 135.46 37.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.077 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -157.6 165.99 34.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.8 p -123.07 100.04 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.142 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 41.9 t -53.4 128.04 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.4 ' HG2' ' C ' ' A' ' 136' ' ' LYS . 49.6 mttt -121.26 171.31 8.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.82 159.29 31.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.85 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' MET . . . . . 0.424 ' N ' ' SD ' ' A' ' 132' ' ' MET . 0.3 OUTLIER -101.95 9.55 40.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.994 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -122.72 -44.01 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.5 p -98.92 -31.23 11.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.98 30.09 56.2 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.4 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 51.5 mmtt -114.06 155.14 26.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.1 t -50.67 110.9 0.46 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.852 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -53.32 -34.74 58.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.935 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 123.99 11.17 4.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -154.97 159.24 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.892 0.377 . . . . 0.0 110.966 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.464 ' N ' HD13 ' A' ' 104' ' ' LEU . . . -160.06 -167.95 21.35 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.476 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -141.37 152.39 44.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.38 . . . . 0.0 110.902 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.543 HG13 ' CE2' ' A' ' 145' ' ' PHE . 43.0 t -153.91 109.52 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.182 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 70.8 m -85.07 150.89 24.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.543 ' CE2' HG13 ' A' ' 143' ' ' VAL . 26.8 m-85 -129.89 149.15 51.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.859 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -63.3 -43.55 97.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.927 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -120.06 157.96 27.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.523 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 57.3 tttt -65.51 -49.99 66.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.5 tp -47.65 -56.08 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -45.83 -39.46 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.416 ' HB2' ' CG2' ' A' ' 99' ' ' VAL . . . -67.8 -49.58 61.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.125 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -51.47 -46.31 63.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.918 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -52.68 -47.9 66.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.875 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.556 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -64.27 -55.93 18.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.515 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 96.4 mt -50.0 -35.01 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 74.3 t -78.98 -49.33 20.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.135 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.7 m-70 -72.67 -67.07 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.578 ' SD ' ' CE1' ' A' ' 117' ' ' PHE . 14.9 mmt -44.86 -47.28 11.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.53 101.22 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 84.5 -31.57 3.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.527 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.9 tp-100 -34.78 151.51 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.819 0.342 . . . . 0.0 110.91 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.576 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 92.9 m95 -97.02 90.63 5.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.92 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.426 HD12 ' CB ' ' A' ' 116' ' ' ALA . 5.5 tt -85.31 -70.08 0.61 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.1 117.94 3.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.506 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.78 -93.68 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 27.7 mtt85 -80.47 -179.73 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.733 0.302 . . . . 0.0 110.897 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.576 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 40.1 mt-30 -83.77 176.16 9.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.935 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.424 ' O ' ' N ' ' A' ' 160' ' ' GLY . 18.9 pt -131.81 167.79 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -130.91 149.23 52.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 20.1 p -126.54 162.09 26.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -173.0 156.9 3.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.913 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.515 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 98.0 m95 -87.07 119.19 27.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.139 179.884 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.0 m170 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.881 0.372 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.527 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 88.7 m-85 -89.43 154.35 20.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -111.77 135.77 51.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 60.7 t -126.65 121.07 57.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.156 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 87.6 t80 -86.14 139.34 31.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.0 t -130.11 120.17 48.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.178 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -111.43 -175.36 20.09 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 46.34 43.64 11.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.871 0.367 . . . . 0.0 110.838 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.43 HD13 ' N ' ' A' ' 141' ' ' GLY . 39.5 mt -85.0 110.1 18.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -39.67 153.44 0.19 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.686 0.755 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -20.01 35.44 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 0.0 112.345 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -82.98 -20.62 34.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.876 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 46.8 mm -50.0 151.02 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.127 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 37.3 p -139.14 148.29 43.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.157 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 27.7 m -48.91 -38.11 21.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.153 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -71.89 -32.7 67.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.496 ' O ' ' N ' ' A' ' 116' ' ' ALA . 10.9 m-20 -65.21 -53.59 42.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 31.6 mt -56.25 -48.01 80.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.091 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.41 ' NZ ' HG21 ' A' ' 123' ' ' ILE . 32.9 mttm -56.41 -39.32 72.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.913 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.4 t -92.37 -8.98 43.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.496 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -94.21 -13.9 26.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.121 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.568 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.6 m-85 -115.49 -11.6 11.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.568 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -49.82 -46.63 80.63 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.603 0.716 . . . . 0.0 111.157 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.568 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 63.8 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.695 2.263 . . . . 0.0 112.31 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.569 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 50.0 m-85 -92.42 -33.05 14.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.921 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.06 157.84 9.18 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.527 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.425 ' NZ ' ' O ' ' A' ' 123' ' ' ILE . 18.5 tptp -49.09 145.29 4.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.425 ' O ' ' NZ ' ' A' ' 122' ' ' LYS . 53.6 mt -115.21 143.42 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.191 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 51.4 p -108.26 -33.98 6.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.76 136.35 22.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -164.68 129.12 2.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 9.0 ptp85 -150.42 154.23 37.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.12 100.08 9.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.1 t -51.74 114.26 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.455 ' HG2' ' N ' ' A' ' 137' ' ' SER . 32.3 mtmt -109.09 163.14 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 158.3 7.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.865 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 ttt -98.93 -8.52 25.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -108.06 -48.79 3.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.11 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.9 p -96.96 -24.45 15.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.089 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.92 19.97 78.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.468 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -95.99 143.29 27.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.455 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 37.3 m -47.61 106.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -50.15 -45.1 52.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 133.26 29.99 0.48 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.414 ' C ' HD13 ' A' ' 104' ' ' LEU . 41.3 p90 -171.98 144.68 1.74 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.956 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.43 ' N ' HD13 ' A' ' 104' ' ' LEU . . . -145.96 -172.01 15.95 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.498 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -131.57 140.78 49.54 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.897 0.38 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.8 t -140.78 122.15 14.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.089 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 63.6 p -101.68 147.67 26.17 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.873 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -125.36 148.68 48.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.833 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -64.5 -35.99 82.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.934 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -130.62 154.39 47.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.916 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.527 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 11.3 ttmt -60.1 -66.74 0.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.906 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 148' ' ' LYS . 14.9 tp -35.3 -59.49 0.52 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -47.47 -41.86 21.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -71.52 -54.07 11.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -47.82 -39.39 18.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.911 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -52.3 -46.39 65.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.558 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -65.64 -53.21 44.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 81.9 mt -41.01 -35.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.4 t -89.23 -53.74 8.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -59.27 -62.45 1.88 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.838 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.569 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 83.7 mmm -64.04 -36.36 83.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.37 92.03 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.91 -28.58 12.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.7 tp-100 -38.61 155.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.882 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.1 m95 -95.64 90.91 5.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.959 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.9 tt -87.09 -69.83 0.66 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.888 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.72 116.97 3.44 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.94 -91.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.8 mtt180 -82.63 178.14 8.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.838 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 34.0 mt-30 -78.14 175.47 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.929 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.45 HD11 ' CE ' ' A' ' 158' ' ' MET . 32.9 pt -132.64 168.64 23.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.127 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 65.2 ttt180 -126.39 160.87 29.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 31.7 p -146.8 147.58 31.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.134 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -160.77 164.05 31.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 11.7 m95 -79.14 83.37 5.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.951 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.123 179.872 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.1 m170 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.791 0.329 . . . . 0.0 110.846 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -96.96 128.97 44.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -87.71 119.6 28.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 65.6 t -109.79 119.75 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.13 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.425 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 3.2 t80 -84.14 145.4 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.458 HG11 ' N ' ' A' ' 102' ' ' GLY . 61.9 t -132.76 140.79 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.458 ' N ' HG11 ' A' ' 101' ' ' VAL . . . -130.23 -169.37 12.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.501 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 44.9 36.71 2.0 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.831 0.348 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 40.9 mt -78.74 106.15 10.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.961 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -40.44 153.6 0.21 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.685 0.755 . . . . 0.0 110.844 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -28.31 25.51 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.733 2.289 . . . . 0.0 112.325 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -77.41 -7.4 56.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.862 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.444 ' CG2' ' N ' ' A' ' 109' ' ' THR . 9.5 mm -68.56 161.96 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.444 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 56.4 p -142.96 172.1 13.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.5 m -69.0 -39.15 79.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -74.0 -17.95 60.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.93 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 17.9 m-20 -75.32 -54.54 6.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.5 mt -53.62 -48.18 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.8 mtpp -54.57 -41.78 70.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -87.32 -15.88 36.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.881 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.453 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -90.28 -14.8 32.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.067 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.598 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 16.4 m-85 -114.65 -8.82 12.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.576 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.0 -46.28 98.69 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.594 0.712 . . . . 0.0 111.105 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.4 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.658 2.238 . . . . 0.0 112.388 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.518 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 56.6 m-85 -89.98 -32.87 16.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.81 171.14 26.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.492 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.551 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 0.0 OUTLIER -55.86 132.62 50.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.762 0.315 . . . . 0.0 110.872 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 96.5 mt -102.52 123.84 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.14 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 83.9 p -86.02 -49.69 7.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.841 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -143.84 117.6 9.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.852 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -141.75 134.31 28.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.461 ' CZ ' ' HB3' ' A' ' 127' ' ' ARG . 1.7 ptp180 -158.81 164.93 35.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.3 p -112.94 100.06 9.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.093 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -49.68 126.5 4.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.192 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -121.46 171.99 8.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -76.76 156.96 31.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.89 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 17.2 ttp -94.89 -11.79 28.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.92 -62.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 71.1 p -82.9 -30.69 28.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.98 28.45 60.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.5 mmtp -106.32 152.3 23.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.829 0.347 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 50.6 p -45.99 109.59 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.846 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -53.95 -36.3 62.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.97 12.81 4.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.503 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 30.8 p90 -162.64 146.73 11.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.907 0.384 . . . . 0.0 110.922 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -133.97 -169.59 12.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.479 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -136.99 141.87 42.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.526 HG11 ' CE2' ' A' ' 145' ' ' PHE . 41.4 t -145.04 108.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 13.3 t -88.48 150.98 22.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.526 ' CE2' HG11 ' A' ' 143' ' ' VAL . 57.6 m-85 -127.54 151.62 48.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.551 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 14.3 m-85 -69.38 -42.42 75.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -115.23 178.96 4.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.908 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.8 tttm -87.15 -41.59 13.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 14.4 tp -53.49 -65.06 0.63 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.459 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 12.4 p-10 -41.81 -53.97 3.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.456 ' HB3' ' CD2' ' A' ' 145' ' ' PHE . . . -53.95 -51.11 64.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.123 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -53.39 -44.81 68.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -50.25 -48.58 54.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.857 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.418 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -67.07 -60.56 2.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.101 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.57 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 97.4 mt -38.32 -41.26 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.3 t -79.66 -58.48 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 30.2 m-70 -57.81 -65.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.897 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.598 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 15.8 mmt -46.59 -45.84 19.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -40.16 91.77 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 99.77 -32.08 7.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.506 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 162' ' ' TRP . 3.2 tp-100 -39.06 149.02 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.835 0.35 . . . . 0.0 110.92 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.546 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 78.9 m95 -95.31 91.65 6.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.472 ' CD2' ' C ' ' A' ' 163' ' ' LEU . 4.1 tt -87.34 -71.71 0.55 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.474 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.89 119.26 4.18 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.476 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.39 -92.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.497 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -85.42 169.3 13.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.756 0.312 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.546 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 85.7 mt-30 -68.65 177.18 2.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 29.1 pt -135.8 169.87 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -137.23 163.43 30.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.832 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 42.8 p -140.18 163.51 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -162.86 157.77 21.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.57 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 82.6 m95 -88.69 96.96 10.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.925 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.847 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . 0.503 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 48.6 m170 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.55 ' CE1' ' HE3' ' A' ' 148' ' ' LYS . 85.2 m-85 -89.6 131.86 35.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -93.25 124.82 37.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.819 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 65.5 t -111.26 130.96 63.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.491 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 1.9 t80 -98.9 140.74 32.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.55 134.99 61.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.114 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.75 172.79 16.45 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.534 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.0 t0 58.63 40.3 23.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 110.877 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' A' ' 105' ' ' SER . 35.6 mt -77.28 97.58 4.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.912 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.6 t -35.0 152.45 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.655 0.74 . . . . 0.0 110.882 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 -14.13 35.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.728 2.286 . . . . 0.0 112.37 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -93.42 1.68 56.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.419 HG23 ' N ' ' A' ' 109' ' ' THR . 9.4 mm -76.77 146.82 8.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.109 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.419 ' N ' HG23 ' A' ' 108' ' ' ILE . 57.6 p -134.43 158.99 42.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 90.0 m -57.22 -33.69 67.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.142 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -75.93 -17.67 59.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' CB ' ' A' ' 116' ' ' ALA . 11.9 m-20 -81.78 -48.08 12.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 30.9 mt -64.39 -39.58 86.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.142 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 57.8 mttt -63.83 -42.83 97.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 1.3 t -86.08 -16.47 37.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 112' ' ' ASP . . . -85.51 -29.63 24.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.497 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 9.0 m-85 -100.39 -8.3 23.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.71 -46.45 99.36 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.569 0.7 . . . . 0.0 111.108 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.2 Cg_exo -47.98 -17.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.642 2.228 . . . . 0.0 112.358 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.504 ' CD2' ' HB3' ' A' ' 154' ' ' ALA . 46.4 m-85 -91.56 -36.4 13.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.09 176.9 40.02 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.3 tttt -68.5 121.2 15.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.758 0.313 . . . . 0.0 110.92 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 56.8 mt -91.89 127.77 43.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.128 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.6 t -92.45 -42.34 9.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.882 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -142.66 124.56 15.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.892 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -154.73 126.81 7.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.7 ptm180 -150.55 156.32 41.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -108.59 99.95 9.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.115 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.6 t -51.84 122.55 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.445 ' HG2' ' N ' ' A' ' 137' ' ' SER . 69.4 mttt -115.92 172.45 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.901 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -75.25 143.51 43.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.893 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 25.3 tpp -89.28 3.41 52.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -106.64 -62.94 1.33 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.119 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.7 p -91.94 -27.53 17.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.144 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.38 30.34 22.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 137' ' ' SER . 49.1 mtmt -112.03 135.71 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.76 0.314 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.445 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 67.4 m -37.24 119.31 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.803 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -60.75 -42.35 97.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.46 26.91 0.64 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.42 ' C ' HD13 ' A' ' 104' ' ' LEU . 16.4 p90 -169.82 144.77 2.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.944 0.402 . . . . 0.0 110.904 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -138.4 -177.99 15.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.486 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -134.2 139.7 45.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 53.5 t -141.85 127.9 18.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.5 m -104.92 144.45 31.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -124.1 145.1 49.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.855 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.503 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.7 m-85 -62.0 -46.95 86.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.966 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -118.45 165.8 13.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.55 ' HE3' ' CE1' ' A' ' 97' ' ' PHE . 10.9 ttmt -67.52 -56.19 10.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.945 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.7 tp -39.26 -53.9 1.87 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -51.28 -39.44 56.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -70.24 -58.03 4.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -46.88 -47.48 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 28.1 m-20 -51.01 -47.38 61.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.504 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -69.08 -49.71 54.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.61 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 91.8 mt -48.54 -34.53 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.136 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 88.1 t -89.41 -55.8 5.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -57.01 -63.01 1.35 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.503 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 92.0 mmm -57.53 -40.03 77.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 92.25 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.529 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.48 -29.35 9.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.498 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.2 tp-100 -37.3 153.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.796 0.332 . . . . 0.0 110.888 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.554 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 90.7 m95 -96.82 91.02 5.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.965 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.411 ' C ' HD21 ' A' ' 163' ' ' LEU . 4.8 tt -85.47 -70.22 0.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.11 118.02 3.43 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.04 -93.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.52 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -82.25 174.31 11.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.842 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.554 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 84.5 mt-30 -76.16 178.23 6.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.44 HD12 ' CE ' ' A' ' 158' ' ' MET . 9.2 pt -139.91 166.99 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 51.8 mtt180 -126.71 167.74 15.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 4.2 p -147.76 143.76 27.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.165 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -153.67 166.95 31.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.61 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 97.0 m95 -88.11 109.87 20.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.12 179.869 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.7 m170 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.838 0.351 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.56 ' CE1' ' HD3' ' A' ' 148' ' ' LYS . 90.5 m-85 -93.45 157.64 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.904 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -112.66 129.12 56.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 49.5 t -119.88 117.63 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.46 132.52 34.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 91.1 t -124.11 120.49 59.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -110.46 177.78 19.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 53.83 46.35 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 110.913 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 28.1 mt -90.85 113.81 26.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -45.53 152.73 0.65 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.715 0.769 . . . . 0.0 110.847 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -33.96 15.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.658 2.239 . . . . 0.0 112.317 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -66.41 -22.95 66.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.902 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.404 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 22.6 mm -55.41 150.31 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.157 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 44.3 p -130.74 164.01 26.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.185 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 90.6 m -64.63 -32.64 74.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.11 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -79.95 -11.84 59.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -83.53 -50.53 8.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.881 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.453 HG23 ' CD1' ' A' ' 117' ' ' PHE . 5.6 mt -57.84 -39.57 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.157 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 58.7 mttt -60.43 -35.77 76.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.4 t -92.48 -16.18 26.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.845 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.467 ' CB ' ' CD1' ' A' ' 163' ' ' LEU . . . -89.34 -16.27 31.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.085 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.1 m-85 -112.19 -9.5 13.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.64 -46.09 99.38 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.548 0.689 . . . . 0.0 111.102 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.1 Cg_exo -48.01 -17.08 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.71 2.273 . . . . 0.0 112.335 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.567 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 49.3 m-85 -91.27 -31.95 15.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 159.67 172.49 26.92 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.9 tttt -58.37 140.07 54.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 110.912 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 89.6 mt -109.92 131.02 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 79.3 p -96.57 -26.0 15.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -159.81 125.04 4.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -150.16 124.4 9.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.459 ' HD3' ' N ' ' A' ' 128' ' ' VAL . 0.0 OUTLIER -151.32 155.56 38.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.459 ' N ' ' HD3' ' A' ' 127' ' ' ARG . 7.0 p -108.22 100.06 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.123 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.4 t -49.03 122.67 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.168 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 38.4 mttt -119.1 168.9 10.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -73.34 145.69 45.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 tpt -87.41 15.72 6.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -130.19 -55.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.134 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 7.5 p -85.93 -28.47 24.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.122 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.03 22.69 70.81 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.3 mmpt? -106.59 150.11 26.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 44.6 m -54.2 109.27 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.865 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -49.35 -35.29 18.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.45 15.25 2.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -160.91 144.34 13.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.934 0.397 . . . . 0.0 110.92 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -136.13 -176.0 14.12 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -129.29 136.44 50.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.16 119.07 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.133 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 11.4 m -99.18 145.3 27.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -124.51 148.99 47.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -65.1 -46.33 81.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -119.77 150.56 40.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.56 ' HD3' ' CE1' ' A' ' 97' ' ' PHE . 20.8 tptt -55.88 -56.66 17.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' LYS . 28.8 tp -37.36 -49.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.944 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 1.0 OUTLIER -57.26 -42.09 80.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.809 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.458 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -64.85 -47.02 79.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -58.15 -46.43 85.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -48.78 -46.85 42.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.916 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.53 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -70.72 -60.44 2.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.512 HD13 ' CE2' ' A' ' 172' ' ' TRP . 66.6 mt -39.03 -36.78 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.116 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 69.2 t -78.7 -60.76 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -62.88 -66.13 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.851 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.567 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 29.4 mmt -37.8 -50.63 1.25 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.926 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.14 102.43 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.525 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 88.58 -30.66 5.21 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.496 ' N ' ' O ' ' A' ' 158' ' ' MET . 51.0 tp60 -35.27 152.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.759 0.314 . . . . 0.0 110.923 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.56 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 84.8 m95 -100.76 91.42 4.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.937 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.467 ' CD1' ' CB ' ' A' ' 116' ' ' ALA . 5.4 tt -87.42 -70.36 0.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.406 ' N ' HD23 ' A' ' 163' ' ' LEU . . . -120.22 118.72 3.97 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.532 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.29 -92.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.442 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.6 mtt180 -80.4 178.07 8.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.56 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 22.4 mt-30 -79.24 -178.79 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 23.2 pt -138.33 171.17 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -136.45 141.95 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 24.0 p -127.11 148.69 50.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.129 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -159.94 166.41 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.512 ' CE2' HD13 ' A' ' 155' ' ' ILE . 85.8 m95 -82.7 107.01 15.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 179.87 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . 0.496 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 60.0 m170 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.846 0.355 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.524 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 25.4 m-85 -107.19 133.33 51.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -87.88 129.02 35.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.877 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.0 t -120.39 122.83 69.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.551 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 0.6 OUTLIER -86.46 145.47 26.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 98.7 t -137.53 110.74 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -102.05 -172.77 27.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.503 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 45.78 46.34 11.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 65.7 mt -87.69 109.49 19.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.4 t -43.12 153.23 0.35 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.627 0.727 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -18.23 36.92 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.662 2.241 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -87.4 -4.41 59.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.435 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 24.5 mm -69.19 147.82 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 70.3 p -136.49 144.6 44.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.157 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 89.6 m -46.77 -35.71 6.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -72.29 -31.57 65.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -69.49 -49.18 57.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 17.6 mt -58.44 -47.25 88.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.134 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.471 ' CG ' ' HB1' ' A' ' 126' ' ' ALA . 27.8 mtpt -60.09 -35.2 74.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.942 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 30.0 t -90.74 -8.67 49.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.64 -24.91 14.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.068 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.9 m-85 -100.59 -8.68 22.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.577 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.07 -46.19 98.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.729 . . . . 0.0 111.107 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.577 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -48.0 -17.16 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.564 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 52.2 m-85 -90.99 -38.31 12.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.39 179.28 41.74 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.455 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.446 ' HG2' ' CZ ' ' A' ' 146' ' ' TYR . 20.9 tptt -66.1 133.26 50.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.727 0.299 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 67.9 mt -106.4 128.42 60.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.6 t -100.57 -27.82 13.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -148.43 138.76 22.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.824 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.471 ' HB1' ' CG ' ' A' ' 114' ' ' LYS . . . -168.08 123.4 0.99 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 14.6 ptp180 -148.07 156.6 42.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.873 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.39 100.61 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.101 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 23.0 t -53.25 119.44 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.069 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.456 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.6 mttm -119.62 157.8 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -64.07 153.95 35.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.884 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 48.2 tpp -95.52 -13.32 24.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.85 -56.39 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -87.83 -34.91 18.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.165 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.56 29.98 31.22 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 14.5 mmtp -112.18 147.68 35.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.882 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.456 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 39.1 t -49.09 104.8 0.07 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 58.0 mttt -44.75 -36.13 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.904 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.21 27.67 1.32 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -167.37 151.64 6.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.935 0.398 . . . . 0.0 110.904 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -150.13 -177.81 24.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -133.9 141.22 47.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.882 0.372 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 90.4 t -143.64 116.57 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 67.6 m -94.04 139.11 31.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -117.65 138.44 51.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.496 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 6.5 m-85 -51.79 -45.52 63.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.7 168.9 11.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.91 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.524 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 53.0 tttt -74.58 -59.26 2.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.1 tp -39.69 -49.02 2.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -58.97 -40.24 84.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.406 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -67.99 -43.93 77.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -56.66 -44.73 81.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -52.26 -46.47 65.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.52 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.97 -51.89 34.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.674 ' CD1' ' CZ2' ' A' ' 172' ' ' TRP . 96.9 mt -46.0 -37.27 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.4 t -86.58 -54.94 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -57.31 -60.74 3.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.564 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 94.2 mmm -60.5 -38.93 85.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.13 94.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.0 -31.59 5.86 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.518 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.4 tp-100 -35.21 152.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.807 0.337 . . . . 0.0 110.888 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.557 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -93.99 91.01 6.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.9 tt -87.57 -70.26 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -118.5 116.62 3.45 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.55 -91.11 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -83.84 174.19 10.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.793 0.33 . . . . 0.0 110.819 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.557 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 58.9 mt-30 -75.51 170.69 15.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.963 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.436 HD13 ' CE ' ' A' ' 158' ' ' MET . 15.7 pt -129.03 167.27 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.118 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 8.6 mmt85 -121.59 165.4 15.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.868 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 2.6 p -149.77 128.28 12.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.166 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -144.47 157.78 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.674 ' CZ2' ' CD1' ' A' ' 155' ' ' ILE . 79.0 m95 -81.01 107.24 13.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.914 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.114 179.866 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 21.9 m170 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 94.8 m-85 -103.34 136.88 42.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 60.0 m-70 -96.07 127.0 41.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.41 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 25.2 t -117.19 131.95 68.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' OD1' ' A' ' 171' ' ' ASN . 2.2 t80 -97.64 138.78 34.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.44 ' CG1' HD23 ' A' ' 104' ' ' LEU . 88.4 t -125.05 115.42 44.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.152 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.03 -178.72 30.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 45.78 47.02 12.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.831 0.348 . . . . 0.0 110.903 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.44 HD23 ' CG1' ' A' ' 101' ' ' VAL . 32.7 mt -78.88 100.49 7.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -40.81 155.2 0.2 Allowed Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.634 0.73 . . . . 0.0 110.882 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -19.01 36.51 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.698 2.265 . . . . 0.0 112.292 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -82.02 -22.44 36.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.848 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 6.8 mm -60.91 137.97 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.111 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.437 ' O ' ' N ' ' A' ' 111' ' ' GLU . 52.8 p -133.0 140.5 47.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 109' ' ' THR . 91.2 m -36.74 -32.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.159 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 109' ' ' THR . 15.0 tt0 -73.74 -48.96 27.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.466 ' O ' ' N ' ' A' ' 116' ' ' ALA . 77.1 m-20 -58.6 -51.33 70.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.2 mt -50.76 -38.8 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.112 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.455 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 22.3 mttp -67.18 -35.34 79.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 22.9 t -92.95 -11.1 34.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.835 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.549 ' CB ' ' CD1' ' A' ' 163' ' ' LEU . . . -90.85 -32.89 15.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.083 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.7 m-85 -95.85 -5.02 42.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.567 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.67 -46.64 99.74 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.603 0.715 . . . . 0.0 111.087 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.696 2.264 . . . . 0.0 112.32 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.566 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 36.0 m-85 -93.2 -30.67 15.09 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.848 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.18 179.93 36.23 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.515 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.523 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 41.1 tptt -63.82 140.24 58.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.761 0.315 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.455 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 97.7 mt -108.34 130.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.9 p -98.31 -50.76 4.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.863 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -136.44 118.83 15.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -142.11 124.82 15.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.091 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -148.09 156.15 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -113.13 100.11 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.126 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.481 ' CG1' ' CE1' ' A' ' 140' ' ' TYR . 46.1 t -49.12 127.52 4.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -130.53 151.87 50.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.82 155.88 5.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 5.2 ptp -97.62 -17.79 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.857 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.75 -57.54 2.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.147 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.7 p -81.51 -32.78 32.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.123 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.43 28.38 61.77 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.474 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -101.88 162.62 12.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.804 0.335 . . . . 0.0 110.877 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 77.7 p -58.86 98.45 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.849 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.502 ' HB3' ' CE2' ' A' ' 140' ' ' TYR . 20.5 mmtt -42.95 -42.98 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.87 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.41 19.18 4.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.502 ' CE2' ' HB3' ' A' ' 138' ' ' LYS . 47.7 p90 -163.37 153.45 15.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.892 0.377 . . . . 0.0 110.951 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -151.22 -172.01 19.78 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -135.54 140.16 44.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.875 0.369 . . . . 0.0 110.875 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 28.6 t -145.52 107.64 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 3.5 t -89.19 154.06 20.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -129.46 150.34 50.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.865 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.523 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 16.0 m-85 -66.37 -33.52 75.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.895 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -129.52 165.44 21.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.441 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . 22.9 tttm -69.35 -61.97 1.57 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.7 tp -39.4 -63.19 0.58 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -40.77 -45.31 2.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.41 ' HB1' ' CG2' ' A' ' 99' ' ' VAL . . . -69.76 -60.75 2.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -40.41 -47.06 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 17.7 m-80 -47.66 -56.97 6.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.524 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -56.72 -53.72 54.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.435 HD12 ' CE2' ' A' ' 172' ' ' TRP . 47.7 mt -41.86 -35.39 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.8 t -84.5 -56.64 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 66.3 m-70 -62.09 -64.67 0.86 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.567 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 11.9 mmt -44.86 -47.01 11.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.56 102.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.74 -28.67 3.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.497 ' N ' ' O ' ' A' ' 158' ' ' MET . 62.7 tp60 -35.8 152.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.79 0.328 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.578 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 85.2 m95 -99.16 91.02 4.79 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.549 ' CD1' ' CB ' ' A' ' 116' ' ' ALA . 6.6 tt -86.77 -70.45 0.61 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.902 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.18 118.43 3.78 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.461 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.65 -92.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.488 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 14.7 mtt-85 -79.41 -178.38 6.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.759 0.314 . . . . 0.0 110.87 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.578 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 30.1 mt-30 -84.14 179.82 7.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.419 ' O ' ' N ' ' A' ' 160' ' ' GLY . 19.7 pt -136.87 171.95 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 41.3 ttt180 -134.64 160.5 37.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.858 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 17.1 p -145.12 152.54 40.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . 0.576 ' OD1' ' CD1' ' A' ' 100' ' ' PHE . 3.0 p30 -172.96 149.9 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.435 ' CE2' HD12 ' A' ' 155' ' ' ILE . 99.2 m95 -68.98 133.14 47.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.089 179.871 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 56.7 m170 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.856 0.36 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.416 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 66.9 m-85 -96.68 140.95 30.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.888 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -100.57 131.89 46.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 58.5 t -122.27 124.48 71.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -91.2 140.02 30.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 77.7 t -127.6 126.78 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -121.93 -178.45 15.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.475 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 50.87 39.63 22.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.83 0.348 . . . . 0.0 110.852 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.0 mt -84.21 126.03 32.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 t -50.51 152.15 3.48 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.678 0.751 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 -14.18 35.83 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -91.8 -6.73 51.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.29 153.1 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 40.5 p -139.09 -179.96 6.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.8 m -69.92 -40.42 75.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.094 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -70.65 -36.74 73.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 116' ' ' ALA . 5.0 m-20 -58.09 -52.31 66.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.443 HG22 ' CG2' ' A' ' 143' ' ' VAL . 5.5 mt -60.69 -42.41 91.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 14.2 mtpt -59.69 -36.6 76.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.883 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.5 t -94.03 -17.4 22.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.456 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -84.62 -18.31 35.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.3 m-85 -111.63 -5.49 14.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.569 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.1 -46.2 99.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.559 0.695 . . . . 0.0 111.09 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.569 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.02 -19.57 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.563 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 45.0 m-85 -87.96 -36.93 16.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.96 -161.95 34.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.496 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.9 tmtt? -87.17 124.64 33.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.883 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 46.6 mt -96.54 134.28 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.107 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.6 p -100.13 -45.88 5.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -134.41 122.02 21.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.837 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -151.16 122.61 7.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.41 ' NE ' ' HB2' ' A' ' 142' ' ' PHE . 0.0 OUTLIER -146.62 159.49 43.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -114.15 99.95 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.143 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 23.5 t -51.73 134.14 13.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.11 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.443 ' HG2' ' N ' ' A' ' 137' ' ' SER . 35.5 mttt -124.98 168.15 13.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -75.73 152.11 37.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 mpp? -97.49 16.71 19.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -123.67 -38.26 2.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 13.7 p -111.25 -24.15 10.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 78.33 20.61 71.84 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 20.0 mmtp -106.63 154.19 21.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.761 0.315 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.443 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 28.3 m -51.18 120.11 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.852 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -60.18 -36.77 78.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.52 13.9 2.47 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.497 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -158.74 145.59 17.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 0.0 110.905 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -137.7 -175.85 14.11 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 0.41 ' HB2' ' NE ' ' A' ' 127' ' ' ARG . 41.6 m-85 -133.4 143.24 48.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.949 0.404 . . . . 0.0 110.888 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.443 ' CG2' HG22 ' A' ' 113' ' ' ILE . 45.0 t -145.51 127.38 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 32.2 t -105.13 151.15 24.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.457 ' CD2' ' HA ' ' A' ' 151' ' ' ALA . 73.6 m-85 -129.32 138.99 51.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -50.43 -42.47 53.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.941 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -127.27 164.55 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.914 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.475 ' O ' ' N ' ' A' ' 151' ' ' ALA . 13.7 ttmt -62.41 -62.37 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 148' ' ' LYS . 58.5 tp -34.58 -58.29 0.5 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.963 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -48.5 -42.47 33.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.475 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -70.69 -50.44 36.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.088 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -53.75 -46.12 70.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -45.99 -47.84 16.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.537 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -66.08 -63.18 1.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 154' ' ' ALA . 45.6 mt -34.76 -46.53 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.77 -61.19 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.164 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -65.8 -64.66 0.81 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.835 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.567 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 18.5 mmt -42.11 -48.6 4.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.41 100.71 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.508 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.21 -28.12 5.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.486 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.0 tp-100 -37.14 154.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.758 0.313 . . . . 0.0 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.4 m95 -98.7 90.99 4.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.508 ' CD2' ' C ' ' A' ' 163' ' ' LEU . 2.6 tt -85.06 -71.32 0.53 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.464 ' N ' HD21 ' A' ' 163' ' ' LEU . . . -122.24 118.25 3.6 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.456 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.93 -93.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.503 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.2 mtt85 -79.5 178.45 8.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.745 0.307 . . . . 0.0 110.862 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 86.2 mt-30 -79.96 178.85 7.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.417 ' O ' ' N ' ' A' ' 160' ' ' GLY . 32.1 pt -137.64 170.33 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.143 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 27.6 ttm-85 -133.68 154.98 50.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 5.7 p -138.87 147.27 42.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -157.63 151.86 24.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 76.9 m95 -72.44 130.1 39.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.077 179.904 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . 0.443 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 27.3 m170 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.836 0.351 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.522 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 5.3 m-85 -99.81 133.91 43.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.846 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -95.35 135.67 36.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 78.8 t -121.43 121.22 64.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -85.02 145.9 27.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.7 t -135.45 128.1 47.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.15 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -118.08 -179.05 17.25 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.512 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 48.38 46.86 20.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.878 0.37 . . . . 0.0 110.845 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.431 ' O ' ' C ' ' A' ' 105' ' ' SER . 34.0 mt -88.13 105.35 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.936 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -36.09 153.39 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.654 0.74 . . . . 0.0 110.893 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -23.66 30.73 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.737 2.291 . . . . 0.0 112.327 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -79.3 -10.96 59.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.439 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 17.3 mm -65.69 143.8 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 65.2 p -126.14 164.32 21.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 66.8 m -63.72 -29.69 70.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.097 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -79.97 -34.2 38.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.429 ' O ' ' N ' ' A' ' 116' ' ' ALA . 98.1 m-20 -60.34 -55.53 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 mt -52.69 -40.12 33.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.462 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 62.7 mttt -64.34 -35.18 80.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.5 t -94.07 -9.71 35.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.429 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -95.14 -23.06 17.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.595 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 28.6 m-85 -105.92 -6.8 18.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.574 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.26 -45.98 99.68 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.559 0.695 . . . . 0.0 111.133 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.96 -17.1 0.7 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.653 2.235 . . . . 0.0 112.352 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.567 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 46.2 m-85 -90.66 -41.44 11.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.87 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 175.68 -174.16 46.69 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.7 tptm -71.46 138.43 49.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.751 0.31 . . . . 0.0 110.923 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.462 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 97.1 mt -104.01 139.34 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 5.8 t -116.49 -37.64 3.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -142.57 105.4 4.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -138.75 121.56 16.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.47 ' CZ ' ' HB3' ' A' ' 127' ' ' ARG . 2.4 ptp180 -153.11 154.71 35.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.88 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.4 p -107.72 100.05 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.148 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -50.04 133.87 9.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.436 ' HG2' ' N ' ' A' ' 137' ' ' SER . 20.5 mtmt -129.52 162.53 27.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.924 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -64.4 159.45 21.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 9.7 ttp -107.55 3.48 24.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -103.74 -45.67 4.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.121 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.3 p -110.52 -38.8 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.156 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 94.8 40.9 4.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.3 mttm -116.11 143.67 45.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.436 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 17.1 p -45.92 109.25 0.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 59.7 mttt -54.41 -35.67 63.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.99 19.35 4.02 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -161.2 146.69 14.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.909 0.385 . . . . 0.0 110.929 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.97 177.83 21.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -123.85 140.12 53.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.428 HG12 ' CE2' ' A' ' 145' ' ' PHE . 40.9 t -139.31 117.03 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 49.8 m -102.15 147.6 26.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.428 ' CE2' HG12 ' A' ' 143' ' ' VAL . 43.7 m-85 -123.49 145.13 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.884 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.443 ' HA ' ' CE1' ' A' ' 96' ' ' HIS . 19.2 m-85 -58.24 -36.65 73.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.952 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -121.34 174.26 6.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.869 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.522 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 44.6 tttt -85.01 -52.35 6.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.859 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.7 tp -47.68 -53.6 14.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.955 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -49.19 -44.36 43.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -62.53 -52.3 64.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -49.49 -43.11 45.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.903 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -48.24 -51.79 24.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.559 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.49 -65.89 0.62 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.057 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.441 ' C ' ' O ' ' A' ' 154' ' ' ALA . 80.9 mt -34.59 -34.79 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.124 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 154' ' ' ALA . 20.1 t -74.02 -63.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.163 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -69.44 -59.2 3.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.595 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 20.1 mmt -40.39 -51.11 2.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.15 102.33 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.491 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 87.94 -31.3 4.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.465 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.483 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.9 tp60 -34.27 150.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.561 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.3 m95 -96.96 91.03 5.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.937 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.418 ' CD1' ' CB ' ' A' ' 116' ' ' ALA . 5.9 tt -87.47 -70.56 0.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.907 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.439 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.52 117.35 3.67 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.475 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -91.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.457 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 15.0 mtp180 -79.55 -174.81 4.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.766 0.317 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.561 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 63.9 mt-30 -86.09 179.43 6.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.418 ' O ' ' N ' ' A' ' 160' ' ' GLY . 9.3 pt -136.84 169.31 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 30.2 ttp180 -129.25 162.87 26.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 32.6 p -141.38 150.5 42.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.091 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -163.02 164.32 25.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.437 ' CE2' HD11 ' A' ' 155' ' ' ILE . 94.2 m95 -93.65 107.95 19.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.064 179.889 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 36.1 m170 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.817 0.342 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.532 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 74.5 m-85 -100.0 161.38 13.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.6 m-70 -114.22 134.35 54.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.427 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 97.9 t -124.58 118.25 52.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.137 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 16.5 t80 -88.47 129.73 35.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.18 111.99 36.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.113 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.83 -179.09 29.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 48.0 54.84 9.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.438 ' O ' ' C ' ' A' ' 105' ' ' SER . 33.8 mt -92.31 106.58 18.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.5 t -35.51 152.33 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.707 0.765 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -18.77 36.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.5 ' CG ' ' O ' ' A' ' 107' ' ' GLU . 9.3 tt0 -90.08 1.13 56.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.938 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 17.4 mm -74.72 147.38 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.128 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 51.3 p -132.04 163.58 28.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.086 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 25.5 m -58.71 -41.06 85.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.414 ' HG3' ' N ' ' A' ' 112' ' ' ASP . 0.3 OUTLIER -68.91 -35.4 76.8 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 179.978 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 116' ' ' ALA . 64.0 m-20 -60.17 -54.59 44.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.851 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.496 HG23 ' CD1' ' A' ' 117' ' ' PHE . 4.9 mt -57.99 -45.82 87.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.118 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.2 mtpp -57.44 -39.01 75.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.865 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 32.7 t -92.35 -9.15 42.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.839 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -95.64 -9.6 31.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.104 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.546 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.0 m-85 -120.26 -8.75 9.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.915 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.582 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.1 -45.97 98.9 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.639 0.733 . . . . 0.0 111.093 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.8 Cg_exo -47.98 -22.76 3.71 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.708 2.272 . . . . 0.0 112.321 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.498 ' CD2' ' HA ' ' A' ' 117' ' ' PHE . 39.7 m-85 -85.66 -35.62 20.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.863 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.59 174.7 34.63 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.453 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.646 ' CG ' ' CE1' ' A' ' 146' ' ' TYR . 0.8 OUTLIER -59.46 140.36 56.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.768 0.318 . . . . 0.0 110.877 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.445 ' CG2' ' HB1' ' A' ' 126' ' ' ALA . 82.7 mt -111.91 105.37 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 52.2 p -67.69 -32.15 72.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -159.67 123.93 3.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.445 ' HB1' ' CG2' ' A' ' 123' ' ' ILE . . . -146.51 125.45 12.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.097 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.2 ptm180 -149.12 166.76 27.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.3 p -120.36 99.85 8.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.173 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.46 HG12 ' CD ' ' A' ' 138' ' ' LYS . 43.3 t -51.18 119.77 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.412 ' CA ' ' HG3' ' A' ' 138' ' ' LYS . 29.0 mtmt -114.81 152.38 32.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -56.72 155.45 7.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.07 -6.79 31.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -102.82 -61.64 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.14 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.9 p -81.67 -34.57 30.65 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.12 33.46 26.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -117.68 152.12 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.8 m -43.34 108.95 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.46 ' CD ' HG12 ' A' ' 129' ' ' VAL . 6.4 mtpm? -51.41 -38.19 52.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 125.35 12.94 3.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.462 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 32.5 p90 -161.8 154.18 19.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.921 0.391 . . . . 0.0 110.919 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.06 -175.42 19.95 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.492 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -131.27 140.28 49.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.891 0.377 . . . . 0.0 110.858 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.8 t -144.86 109.58 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.12 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 73.7 m -86.71 141.92 28.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -120.61 140.43 51.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.646 ' CE1' ' CG ' ' A' ' 122' ' ' LYS . 4.4 m-85 -54.48 -50.38 67.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.933 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -115.59 171.02 8.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.532 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 59.0 tttt -80.28 -38.44 30.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.893 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.6 tp -57.35 -51.93 67.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.94 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -56.78 -41.47 77.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.896 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.427 ' HB1' ' CG2' ' A' ' 99' ' ' VAL . . . -66.3 -49.11 68.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.092 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -51.0 -43.91 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 62.9 m-20 -49.56 -48.93 48.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.483 ' HB1' ' CD2' ' A' ' 120' ' ' PHE . . . -66.09 -54.88 20.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.518 HD13 ' CZ2' ' A' ' 172' ' ' TRP . 97.5 mt -47.55 -35.29 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 77.5 t -82.24 -49.03 17.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.0 m-70 -71.51 -65.46 0.75 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.546 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 8.2 mmt -45.21 -46.52 12.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.48 103.6 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.458 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.41 -29.61 3.94 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.491 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.9 tp60 -40.98 149.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.926 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.438 ' N ' ' HG3' ' A' ' 161' ' ' GLN . 84.0 m95 -93.87 92.33 7.36 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.428 ' CD2' ' C ' ' A' ' 163' ' ' LEU . 5.5 tt -87.03 -72.34 0.52 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.487 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -120.33 117.11 3.43 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 56.09 -93.05 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.5 mpt_? -83.52 175.99 9.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.749 0.309 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.421 ' HG2' ' CE2' ' A' ' 162' ' ' TRP . 32.7 mt-30 -74.61 177.33 6.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.917 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 22.0 pt -136.23 165.09 30.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -129.56 152.33 49.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 29.8 p -130.07 160.46 33.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.166 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -169.81 163.35 9.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.518 ' CZ2' HD13 ' A' ' 155' ' ' ILE . 85.5 m95 -90.87 100.23 13.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.084 179.944 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 28.1 m170 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.847 0.356 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.518 ' CD1' ' HD3' ' A' ' 148' ' ' LYS . 90.6 m-85 -102.44 145.09 30.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -100.27 138.68 37.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.846 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 25.2 t -124.23 130.23 73.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.184 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -91.77 138.09 31.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.7 118.31 46.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.62 172.05 17.95 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.513 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 54.53 53.37 10.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.407 ' O ' ' C ' ' A' ' 105' ' ' SER . 26.1 mt -87.93 104.48 16.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -38.03 153.57 0.13 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.702 0.763 . . . . 0.0 110.877 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -20.48 34.86 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.736 2.29 . . . . 0.0 112.31 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -83.21 -17.9 41.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 37.1 mm -57.61 156.95 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.123 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 40.5 p -143.87 170.61 15.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 56.9 m -66.13 -33.87 76.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -78.24 -35.21 48.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 67.1 m-20 -59.1 -55.89 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.841 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.422 HG22 ' CG2' ' A' ' 143' ' ' VAL . 7.8 mt -55.6 -42.68 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.11 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 17.7 mttp -61.64 -36.34 80.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.922 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.1 t -93.4 -10.41 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.848 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.47 ' CB ' HD12 ' A' ' 163' ' ' LEU . . . -94.02 -18.77 21.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 7.1 m-85 -111.57 -5.78 14.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.586 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.41 -45.71 99.89 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.593 0.711 . . . . 0.0 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.7 Cg_exo -48.04 -25.23 6.24 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.659 2.239 . . . . 0.0 112.382 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.554 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 54.0 m-85 -78.83 -38.84 37.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 168.02 179.13 40.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 35.2 tptt -59.41 142.21 52.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.77 0.319 . . . . 0.0 110.942 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.429 HG23 ' N ' ' A' ' 124' ' ' SER . 76.7 mt -114.33 137.1 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' SER . . . . . 0.429 ' N ' HG23 ' A' ' 123' ' ' ILE . 6.3 p -112.35 -23.6 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -154.02 143.31 21.41 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -174.77 123.62 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.06 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -148.2 159.35 44.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.6 p -112.55 99.9 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.165 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 80.5 t -51.32 126.59 6.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.152 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.467 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.2 mttm -125.84 159.94 31.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -62.52 159.51 15.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.873 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 ptp -102.38 -14.78 16.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.39 -38.02 8.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.076 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.6 p -105.78 -29.42 10.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.05 36.85 45.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.478 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mmtm -119.86 151.3 39.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.816 0.341 . . . . 0.0 110.893 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.467 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 56.2 p -45.97 113.26 0.59 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.873 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -59.57 -36.73 76.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.37 14.25 2.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.43 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 34.1 p90 -160.83 149.89 16.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.867 0.365 . . . . 0.0 110.937 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.28 -177.54 18.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -127.33 140.72 52.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.422 ' CG2' HG22 ' A' ' 113' ' ' ILE . 25.3 t -140.7 118.94 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.4 p -98.58 149.76 22.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -129.0 150.66 50.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -65.59 -40.73 93.03 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.88 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -125.24 162.81 23.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.526 ' HE3' ' CZ3' ' A' ' 172' ' ' TRP . 15.0 tptm -67.42 -58.5 4.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.9 tp -39.11 -51.03 1.9 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.924 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -51.92 -41.92 62.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -65.18 -53.31 46.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.062 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -49.46 -41.09 39.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -57.3 -52.68 64.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.471 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -61.76 -51.11 69.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.629 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 95.0 mt -43.96 -51.69 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 63.9 t -72.62 -59.76 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -50.92 -64.7 0.73 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 92.7 mmm -57.77 -39.24 77.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.97 94.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.46 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 91.87 -29.46 7.42 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.504 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.1 tp60 -36.3 152.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.761 0.315 . . . . 0.0 110.952 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.566 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.0 m95 -96.71 91.68 5.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.937 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.47 HD12 ' CB ' ' A' ' 116' ' ' ALA . 2.0 tt -88.64 -69.84 0.68 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.936 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -117.68 116.98 3.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 50.95 -90.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 164' ' ' GLY . 40.9 mtt180 -80.3 179.98 7.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.827 0.346 . . . . 0.0 110.836 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.566 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 45.7 mt-30 -81.77 179.84 7.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.466 ' CD1' ' HE3' ' A' ' 158' ' ' MET . 15.3 pt -139.14 163.52 26.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.117 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 46.9 ttt-85 -129.71 156.53 44.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.6 p -129.83 162.46 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -168.55 163.69 12.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.864 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.629 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 97.5 m95 -94.16 114.25 26.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.109 179.898 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 48.3 m170 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.858 0.361 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.44 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 93.8 m-85 -90.65 135.37 33.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 82.4 m-70 -94.13 124.37 38.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 63.7 t -112.67 116.17 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.127 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.54 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 1.4 t80 -84.28 136.74 33.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.9 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.418 HG11 ' CD2' ' A' ' 104' ' ' LEU . 38.6 t -127.16 115.54 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.113 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.73 -174.48 25.8 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 46.29 50.74 11.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.903 0.382 . . . . 0.0 110.912 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.418 ' CD2' HG11 ' A' ' 101' ' ' VAL . 67.5 mt -91.28 110.61 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -42.41 153.68 0.3 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.696 0.76 . . . . 0.0 110.863 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -20.0 35.4 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.719 2.279 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -84.08 -14.02 51.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 20.4 mm -60.58 150.36 6.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.147 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.6 p -142.91 154.86 44.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.16 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 18.2 m -48.05 -42.18 27.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -65.47 -43.18 91.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.49 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.9 m-20 -59.22 -52.96 63.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.486 HG21 ' CE1' ' A' ' 117' ' ' PHE . 30.6 mt -60.96 -43.0 95.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 30.0 mttm -62.35 -36.17 81.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 38.6 t -94.01 -13.27 27.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.49 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -91.93 -13.21 31.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.507 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.1 m-85 -113.0 -9.8 13.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.03 -45.5 99.53 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.586 0.707 . . . . 0.0 111.06 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.97 -17.08 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.656 2.237 . . . . 0.0 112.341 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.555 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 38.9 m-85 -91.9 -40.36 11.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.14 174.56 44.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -67.54 120.9 14.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.812 0.339 . . . . 0.0 110.883 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 93.3 mt -85.77 140.08 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.118 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.5 p -110.58 -30.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -156.31 123.93 5.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -150.07 132.38 15.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.105 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 19.9 ptt180 -152.06 147.43 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -108.46 99.94 9.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.473 HG11 ' CG ' ' A' ' 138' ' ' LYS . 73.0 t -52.43 114.67 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 43.8 mttm -113.08 160.98 17.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -68.59 157.86 35.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.845 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 tpt -94.35 -27.86 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.65 -55.71 3.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 65.3 p -80.73 -38.78 28.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.136 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.43 18.62 61.91 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.479 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -105.75 146.9 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 110.906 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.1 t -39.03 114.26 0.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.473 ' CG ' HG11 ' A' ' 129' ' ' VAL . 12.3 mtpt -52.94 -38.79 62.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.97 20.65 1.44 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.525 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -171.39 154.04 3.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.96 0.41 . . . . 0.0 110.9 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.99 16.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.78 142.48 38.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.902 0.382 . . . . 0.0 110.831 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.48 HG12 ' CE2' ' A' ' 145' ' ' PHE . 43.3 t -147.3 108.97 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 44.3 m -92.25 149.27 21.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.48 ' CE2' HG12 ' A' ' 143' ' ' VAL . 36.6 m-85 -126.46 152.89 45.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -60.66 -45.66 93.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.908 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -127.72 160.14 32.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.896 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 151' ' ' ALA . 12.2 tptm -58.66 -60.3 4.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 49.0 tp -38.47 -47.4 1.27 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -57.94 -38.89 76.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.479 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -68.92 -57.07 6.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -43.32 -46.64 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -40.09 -47.48 2.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.555 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -76.93 -55.99 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.577 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 87.8 mt -42.93 -38.58 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 42.2 t -81.33 -48.7 18.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.118 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 -75.3 -67.11 0.69 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.507 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 23.2 mmt -42.17 -47.97 4.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.42 102.18 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.467 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.92 -34.51 3.55 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.479 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.445 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.4 tp60 -35.14 151.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.798 0.333 . . . . 0.0 110.927 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.556 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 86.1 m95 -98.15 91.36 5.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.418 ' CD2' ' C ' ' A' ' 163' ' ' LEU . 4.9 tt -85.41 -71.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.925 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.88 118.05 3.58 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.4 -93.05 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.514 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -82.13 170.35 15.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.759 0.314 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.556 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 80.8 mt-30 -71.3 -179.4 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 15.5 pt -136.98 168.77 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.5 ttp180 -131.88 158.71 40.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' THR . . . . . 0.424 ' CB ' ' HA ' ' A' ' 155' ' ' ILE . 0.9 OUTLIER -139.64 150.9 45.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.148 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 22.1 m-20 -166.96 158.46 12.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.577 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 98.0 m95 -85.48 100.54 11.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.919 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.9 m170 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.851 0.357 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -91.03 133.0 35.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.928 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -96.58 122.3 39.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.861 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.5 t -109.81 126.04 66.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.2 t80 -90.48 138.49 31.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.461 HG12 ' CD2' ' A' ' 104' ' ' LEU . 92.7 t -128.7 124.55 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -115.65 -179.25 18.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 54.23 34.15 19.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.893 0.378 . . . . 0.0 110.917 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.461 ' CD2' HG12 ' A' ' 101' ' ' VAL . 40.5 mt -80.12 113.4 18.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -45.3 153.54 0.55 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.665 0.745 . . . . 0.0 110.832 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -25.88 28.44 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.671 2.248 . . . . 0.0 112.396 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -77.89 -7.72 57.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 6.4 mm -72.81 148.09 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.13 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.2 p -134.93 159.97 39.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.099 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 36.3 m -54.66 -44.65 73.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -63.05 -31.14 72.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.431 ' O ' ' N ' ' A' ' 116' ' ' ALA . 92.9 m-20 -69.7 -51.37 35.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.843 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 17.0 mt -58.49 -43.93 87.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.07 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 58.3 mttt -60.62 -34.9 74.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 28.1 t -93.96 -11.99 29.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.431 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -95.84 -13.72 23.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.088 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.494 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 13.3 m-85 -116.11 -11.56 11.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.588 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.5 -45.14 99.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.065 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -47.96 -17.14 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.313 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.568 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 59.5 m-85 -88.69 -41.34 12.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.855 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 173.59 148.98 6.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -40.96 128.92 2.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.0 110.866 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 58.4 mt -101.22 147.6 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 4.4 p -115.2 -36.59 4.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -140.92 133.81 29.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -164.2 128.76 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.088 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.422 ' HB2' ' NH1' ' A' ' 127' ' ' ARG . 0.3 OUTLIER -151.92 161.64 42.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.847 -179.926 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -118.48 99.85 8.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.144 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.408 HG12 ' NZ ' ' A' ' 138' ' ' LYS . 51.5 t -51.24 117.06 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.456 ' HG2' ' N ' ' A' ' 137' ' ' SER . 12.7 mttp -110.03 160.34 16.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.915 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -66.6 156.34 35.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.903 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 8.5 tpt -96.56 -10.41 27.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.66 -50.72 3.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.3 p -94.05 -29.26 15.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.65 17.89 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.438 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.1 mtpp -101.19 145.73 28.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.879 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.456 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 68.3 m -47.07 105.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.408 ' NZ ' HG12 ' A' ' 129' ' ' VAL . 12.6 mttp -44.03 -36.3 2.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 126.94 14.19 2.82 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.535 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -155.7 152.81 29.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.945 0.403 . . . . 0.0 110.901 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.459 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -148.43 -171.19 17.05 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -134.68 137.6 43.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.874 0.369 . . . . 0.0 110.868 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 92.5 t -137.47 118.05 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.134 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 88.8 p -98.08 152.85 18.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.41 ' CD2' ' HA ' ' A' ' 151' ' ' ALA . 26.7 m-85 -129.53 141.44 50.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.897 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -57.59 -40.86 79.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.862 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -117.7 178.81 4.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 45.7 tttt -87.18 -48.38 8.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 18.3 tp -48.02 -65.1 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -41.98 -51.32 4.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.41 ' HA ' ' CD2' ' A' ' 145' ' ' PHE . . . -55.52 -47.15 76.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -57.81 -42.1 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.914 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -51.3 -47.69 62.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.561 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -68.43 -53.97 20.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.062 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.429 ' CD1' ' CZ2' ' A' ' 172' ' ' TRP . 96.6 mt -41.37 -35.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 95.4 t -91.4 -47.43 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.148 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -63.82 -63.77 1.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 93.0 mmm -60.52 -37.99 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.929 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 94.06 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.58 -28.31 9.36 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.508 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . 73.3 tp60 -37.69 156.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.778 0.323 . . . . 0.0 110.92 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.556 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.6 m95 -98.95 90.99 4.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.403 ' C ' HD23 ' A' ' 163' ' ' LEU . 5.1 tt -86.15 -70.14 0.62 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.881 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.33 117.74 3.54 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.92 -92.7 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.3 mtt85 -80.89 179.66 7.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.314 . . . . 0.0 110.865 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.556 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 80.9 mt-30 -80.9 178.01 8.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.424 HD13 ' CE ' ' A' ' 158' ' ' MET . 29.4 pt -133.52 168.63 23.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 55.9 ttt180 -129.54 154.23 47.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.885 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 44.5 p -141.95 148.22 38.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.083 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -174.24 147.07 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.429 ' CZ2' ' CD1' ' A' ' 155' ' ' ILE . 96.5 m95 -61.7 122.72 16.02 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.959 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.931 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . 0.507 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 7.1 m170 . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.843 0.354 . . . . 0.0 110.838 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.555 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 3.9 m-85 -91.14 139.61 30.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -93.16 131.86 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.926 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 48.2 t -124.05 129.34 74.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' ND2' ' A' ' 171' ' ' ASN . 1.8 t80 -99.42 149.86 22.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.5 t -137.41 130.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.25 173.29 16.27 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 139' ' ' GLY . 5.4 m-20 61.74 36.38 16.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.819 0.342 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 39.1 mt -80.18 110.87 16.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -38.66 153.06 0.16 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 121.634 0.731 . . . . 0.0 110.874 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -15.21 36.79 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.678 2.252 . . . . 0.0 112.307 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.416 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 7.6 tt0 -90.63 -6.19 54.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.909 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 25.5 mm -67.48 156.06 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 76.1 p -145.72 157.29 43.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 32.4 m -55.03 -39.06 68.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.074 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -71.58 -17.0 62.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -84.49 -46.32 11.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.7 mt -63.23 -38.76 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.4 mtpt -60.09 -36.12 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -92.84 -20.01 21.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.444 ' CB ' HD12 ' A' ' 163' ' ' LEU . . . -83.88 -16.92 42.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.8 m-85 -115.24 -7.55 12.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.581 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.72 -45.72 99.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.612 0.72 . . . . 0.0 111.114 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.0 Cg_exo -47.99 -18.1 1.04 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.654 2.236 . . . . 0.0 112.353 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.558 ' CD2' ' HB1' ' A' ' 154' ' ' ALA . 44.0 m-85 -89.77 -37.11 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . 0.422 ' HA3' ' CG ' ' A' ' 150' ' ' ASP . . . 172.97 -171.24 44.3 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.467 ' HD2' ' N ' ' A' ' 123' ' ' ILE . 0.0 OUTLIER -77.77 120.05 22.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.781 0.324 . . . . 0.0 110.929 179.97 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.467 ' N ' ' HD2' ' A' ' 122' ' ' LYS . 95.8 mt -91.91 101.12 12.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 93.1 p -67.84 -27.42 66.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.819 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -156.23 140.0 16.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -163.29 126.71 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.098 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -143.69 162.78 35.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.854 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.5 p -121.15 100.19 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.094 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.0 t -53.73 120.38 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.463 ' HG2' ' N ' ' A' ' 137' ' ' SER . 32.1 mttm -115.29 164.88 13.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -65.44 148.61 51.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -90.91 -3.44 57.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.856 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -111.5 -54.91 2.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.11 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 24.5 p -89.76 -27.19 20.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.59 28.13 59.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 pttt -108.58 138.83 44.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.78 0.324 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.463 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 14.6 t -41.85 109.17 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -51.19 -33.77 28.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.5 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 121.38 20.44 3.27 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.429 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -161.05 140.96 10.84 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.957 0.408 . . . . 0.0 110.924 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -136.61 -168.74 11.52 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -138.54 143.87 39.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.4 t -144.02 124.73 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.17 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.2 m -100.82 141.13 34.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.839 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -125.01 133.92 52.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.879 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.507 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.1 m-85 -53.35 -48.92 68.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -113.31 167.24 10.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.555 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 30.4 tttp -74.68 -42.29 58.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -46.86 -52.09 15.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.422 ' CG ' ' HA3' ' A' ' 121' ' ' GLY . 88.9 m-20 -54.42 -43.79 71.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -66.54 -61.12 2.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.072 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -41.16 -44.31 2.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 -55.29 -59.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.558 ' HB1' ' CD2' ' A' ' 120' ' ' PHE . . . -58.09 -54.25 49.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.508 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 85.4 mt -44.42 -35.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.75 -60.98 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.118 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.7 m-70 -56.68 -66.96 0.35 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.811 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.567 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 24.3 mmt -43.51 -47.12 7.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.93 95.22 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.458 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.77 -30.72 6.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.491 ' N ' ' O ' ' A' ' 158' ' ' MET . 7.5 tp60 -37.5 155.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.905 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.529 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 89.2 m95 -101.15 91.7 4.65 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.92 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.444 HD12 ' CB ' ' A' ' 116' ' ' ALA . 4.0 tt -86.18 -70.7 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.73 118.1 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.492 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -92.14 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.503 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -80.25 175.12 10.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.758 0.313 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.529 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 38.8 mt-30 -74.01 177.43 5.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 20.0 pt -135.31 164.62 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.134 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 29.7 ttp180 -128.01 154.13 45.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 22.4 p -142.68 154.05 43.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . 0.534 ' ND2' ' CD1' ' A' ' 100' ' ' PHE . 4.6 p30 -173.44 163.33 4.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.508 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 88.4 m95 -80.73 123.44 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.922 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.085 179.886 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . 0.491 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 28.2 m170 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.838 0.352 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 26.9 m-85 -102.2 129.67 48.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -96.34 133.39 40.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 62.3 t -114.01 127.19 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -87.63 136.4 32.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.8 t -125.72 135.74 62.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.105 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.67 178.05 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 55.34 32.25 18.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 33.1 mt -78.85 118.84 21.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.6 t -50.36 152.47 3.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.82 23.45 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.678 2.252 . . . . 0.0 112.327 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -69.32 -13.2 62.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.466 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 14.6 mm -66.1 159.1 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.16 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 68.9 p -134.9 -175.82 4.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.178 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 97.3 m -78.97 -36.98 40.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.126 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -78.95 -16.35 57.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -72.29 -48.42 42.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.408 HG21 ' CG2' ' A' ' 143' ' ' VAL . 5.0 mt -62.25 -42.48 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.13 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 65.2 mttt -57.28 -35.26 69.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 6.9 t -93.83 -19.33 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.486 ' CB ' ' CD1' ' A' ' 163' ' ' LEU . . . -83.62 -20.09 34.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.089 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.559 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 12.9 m-85 -110.96 -7.16 14.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.53 -45.98 99.82 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.535 0.683 . . . . 0.0 111.076 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.01 -17.09 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.136 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.435 ' CD2' ' HA ' ' A' ' 117' ' ' PHE . 47.9 m-85 -90.69 -32.85 16.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.874 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.85 -165.6 37.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.512 ' HG2' ' CE1' ' A' ' 146' ' ' TYR . 72.4 tttt -78.84 131.71 36.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -104.44 113.64 41.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.105 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 3.2 t -79.46 -32.39 42.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -152.5 143.5 23.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -173.25 132.36 0.49 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.155 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -152.06 164.65 36.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -114.58 100.7 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -52.88 122.76 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.449 ' HG2' ' N ' ' A' ' 137' ' ' SER . 78.0 mttt -120.92 161.26 21.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -71.38 158.51 36.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.838 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -95.85 -15.83 22.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -94.63 -60.44 1.71 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 15.3 p -83.42 -31.19 26.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.16 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.2 25.6 63.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.3 mmtm -108.24 144.63 35.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.842 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.449 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 11.2 t -46.76 105.89 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -44.14 -37.82 3.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.22 10.08 3.52 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.8 p90 -153.56 153.13 31.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.946 0.403 . . . . 0.0 110.907 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -148.18 -171.73 17.42 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -130.97 142.12 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.897 0.38 . . . . 0.0 110.874 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.408 ' CG2' HG21 ' A' ' 113' ' ' ILE . 25.3 t -140.9 105.61 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.158 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 17.8 m -85.77 147.91 26.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.872 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.518 ' CD2' ' HA ' ' A' ' 151' ' ' ALA . 11.1 m-85 -129.23 129.21 44.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.512 ' CE1' ' HG2' ' A' ' 122' ' ' LYS . 21.1 m-85 -43.8 -46.96 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.95 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 23.7 m-20 -114.32 -178.87 3.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.853 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.545 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 25.9 tttm -87.1 -48.74 7.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.901 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.1 tp -50.11 -64.97 0.65 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 20.2 p-10 -39.73 -51.88 2.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.518 ' HA ' ' CD2' ' A' ' 145' ' ' PHE . . . -60.41 -58.37 8.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.082 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -43.58 -47.39 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -45.36 -50.64 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.461 ' O ' ' N ' ' A' ' 158' ' ' MET . . . -61.67 -52.34 64.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.098 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 92.1 mt -44.15 -39.54 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.8 t -77.29 -48.48 24.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 64.8 m-70 -72.05 -65.56 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.559 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.3 mmt -43.3 -49.61 6.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.2 96.6 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.455 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.59 -30.29 7.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.482 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.473 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.8 tp60 -40.16 154.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.915 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.56 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -98.92 91.17 4.92 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.486 ' CD1' ' CB ' ' A' ' 116' ' ' ALA . 5.6 tt -85.54 -73.14 0.46 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.466 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.94 117.17 3.57 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.477 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.69 -92.7 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.458 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -80.95 -177.29 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.861 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.56 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 33.3 mt-30 -82.5 177.15 8.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.492 ' CD1' ' SD ' ' A' ' 158' ' ' MET . 41.9 pt -134.4 173.95 13.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.138 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -136.76 158.46 44.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.04 156.1 47.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -163.88 168.25 19.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.879 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -94.83 105.68 17.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.951 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.887 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 38.5 m170 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.803 0.335 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.527 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 85.3 m-85 -86.89 124.92 33.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -93.02 134.82 34.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 28.9 t -115.82 128.47 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.17 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -89.82 131.08 35.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.46 HG12 ' CD2' ' A' ' 104' ' ' LEU . 82.2 t -119.99 133.38 66.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.133 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -125.35 -178.43 15.31 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.526 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 47.4 43.58 15.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.883 0.373 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.46 ' CD2' HG12 ' A' ' 101' ' ' VAL . 45.1 mt -79.57 97.02 6.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -35.74 153.64 0.07 OUTLIER Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.684 0.754 . . . . 0.0 110.839 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.83 -14.6 36.09 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.622 2.215 . . . . 0.0 112.341 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -89.82 -3.62 58.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 15.1 mm -76.79 156.86 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.079 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 26.7 p -142.19 160.93 39.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.184 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 21.0 m -56.14 -33.43 65.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.173 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -74.6 -39.08 62.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.5 ' O ' ' N ' ' A' ' 116' ' ' ALA . 19.2 m-20 -55.06 -57.44 11.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.462 HG22 ' CG2' ' A' ' 143' ' ' VAL . 28.1 mt -52.77 -39.79 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.128 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.428 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 6.9 mtpm? -62.89 -41.86 99.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.6 t -90.53 -10.17 44.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.877 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.5 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -93.27 -23.44 18.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.128 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' PHE . . . . . 0.566 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.7 m-85 -105.05 -6.98 19.5 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . 0.572 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -55.15 -46.43 99.68 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.553 0.692 . . . . 0.0 111.083 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.572 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.4 Cg_exo -47.96 -19.0 1.32 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.354 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.479 ' CE1' ' HA ' ' A' ' 154' ' ' ALA . 44.2 m-85 -89.41 -50.24 6.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.81 165.7 33.69 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.455 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -50.83 131.54 26.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.428 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 57.3 mt -99.44 117.48 44.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 57.8 p -86.93 -31.21 20.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -152.1 122.87 7.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.839 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -149.13 114.21 5.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.129 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.1 155.15 47.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.905 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 5.0 p -112.51 99.94 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.178 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 25.9 t -52.65 122.81 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.106 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.417 ' C ' ' HG3' ' A' ' 138' ' ' LYS . 4.3 mtmp? -117.16 156.76 27.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.886 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -58.16 151.36 19.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.894 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' MET . . . . . 0.403 ' O ' ' SD ' ' A' ' 132' ' ' MET . 0.0 OUTLIER -96.47 16.34 18.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -131.14 -56.38 1.03 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.1 p -84.53 -28.46 26.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.12 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.77 23.17 62.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.494 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.404 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 13.8 mmtp -108.48 167.35 10.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.777 0.322 . . . . 0.0 110.911 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 80.1 p -57.07 117.65 4.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.867 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.417 ' HG3' ' C ' ' A' ' 130' ' ' LYS . 41.5 mttt -60.54 -39.53 88.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.62 16.72 2.22 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.511 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -166.08 151.42 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.902 0.382 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.56 -171.9 14.09 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -138.69 139.33 38.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.462 ' CG2' HG22 ' A' ' 113' ' ' ILE . 54.4 t -145.09 108.22 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 6.0 m -86.05 154.75 21.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -130.7 141.46 50.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.874 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -60.42 -32.86 71.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -125.54 162.35 25.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.934 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.527 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 70.8 tttt -73.94 -47.87 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -52.04 -43.05 63.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -60.29 -34.26 73.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.836 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -74.51 -45.22 47.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.117 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 17.0 mt-10 -58.22 -42.14 85.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -53.14 -54.87 29.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . 0.479 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -62.42 -55.88 23.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.431 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 79.2 mt -42.0 -37.78 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 82.5 t -80.15 -58.84 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.173 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -59.64 -65.42 0.68 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' MET . . . . . 0.566 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.7 mmt -42.54 -48.12 5.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.54 104.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.484 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.81 -31.46 3.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.496 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' GLN . . . . . 0.499 ' N ' ' O ' ' A' ' 158' ' ' MET . 34.1 tp60 -37.28 149.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' TRP . . . . . 0.57 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 81.5 m95 -96.24 93.55 6.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.455 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.5 tt -86.36 -70.43 0.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.97 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -125.6 118.81 3.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 58.4 -95.28 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -84.86 170.26 13.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.57 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 39.0 mt-30 -68.7 172.28 6.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 14.9 pt -129.59 164.7 31.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.159 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . 0.437 ' HG3' ' N ' ' A' ' 170' ' ' THR . 21.0 tpp180 -125.05 156.44 38.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.922 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' THR . . . . . 0.437 ' N ' ' HG3' ' A' ' 169' ' ' ARG . 72.2 p -144.52 156.87 44.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -174.37 173.58 2.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' TRP . . . . . 0.431 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 98.2 m95 -90.91 108.55 19.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.042 179.9 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.5 t -79.28 153.4 29.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.922 0.391 . . . . 0.0 110.809 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.1 m -98.4 173.67 6.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.9 -161.27 10.3 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.1 m -81.9 151.94 27.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.876 0.369 . . . . 0.0 110.845 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 45.9 t -68.8 96.99 0.78 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.841 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -103.81 44.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -70.03 169.23 13.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 110.876 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 15.2 tptm -92.79 -55.1 3.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -128.3 133.47 48.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -61.13 108.87 0.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 37.4 p -56.58 131.14 47.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -82.61 72.91 9.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.882 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 58.93 42.79 18.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 61.1 m170 -82.84 170.47 14.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.858 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -107.86 121.53 44.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -84.09 123.97 30.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.0 t -112.3 122.86 67.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.105 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.433 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 2.1 t80 -83.02 141.21 32.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.854 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.457 HG11 ' CD2' ' A' ' 104' ' ' LEU . 96.1 t -135.55 110.67 11.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.155 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.12 -174.25 30.26 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 45.73 52.6 9.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.457 ' CD2' HG11 ' A' ' 101' ' ' VAL . 21.3 mt -91.41 100.28 13.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -36.19 153.56 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.692 0.758 . . . . 0.0 110.869 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -27.23 26.67 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.726 2.284 . . . . 0.0 112.317 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -75.97 -12.41 60.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.446 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 24.1 mm -63.45 157.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.157 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.438 ' N ' HG23 ' A' ' 108' ' ' ILE . 77.7 p -145.66 144.04 30.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.168 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 76.5 m -44.64 -38.08 4.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -70.89 -35.96 72.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 116' ' ' ALA . 27.1 m-20 -63.58 -52.14 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.489 HG23 ' CD1' ' A' ' 117' ' ' PHE . 51.9 mt -56.67 -46.04 82.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.459 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 68.0 mttt -56.7 -33.87 66.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.963 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -94.01 -18.44 21.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.432 ' CB ' HD13 ' A' ' 163' ' ' LEU . . . -85.3 -13.05 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.12 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.489 ' CD1' HG23 ' A' ' 113' ' ' ILE . 14.7 m-85 -115.87 -6.55 12.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.852 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.575 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.68 -46.11 99.78 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.571 0.7 . . . . 0.0 111.118 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.575 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.93 -17.19 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.562 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 48.0 m-85 -90.47 -48.18 7.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -176.45 175.56 47.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.467 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.8 tptp -62.86 134.83 56.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.771 0.32 . . . . 0.0 110.882 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.459 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 77.3 mt -101.31 133.04 45.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 39.8 t -106.76 -40.43 5.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -143.48 122.52 12.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -149.94 133.15 16.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 22.2 ptt180 -155.41 153.15 29.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.49 100.0 9.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 78.8 t -49.85 114.3 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.133 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.467 ' HG2' ' N ' ' A' ' 137' ' ' SER . 41.7 mttt -118.07 155.67 29.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.21 149.58 49.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 mmt -91.92 -8.73 45.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.71 -58.52 2.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.092 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 11.8 p -87.69 -38.54 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.11 34.38 14.9 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -118.3 138.96 52.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.77 0.319 . . . . 0.0 110.905 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.467 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 21.4 t -40.9 104.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.89 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 21.3 mttp -45.25 -36.76 4.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.926 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.31 23.37 2.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.501 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 52.4 p90 -165.52 143.06 5.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.929 0.395 . . . . 0.0 110.914 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.15 -173.37 19.73 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.442 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -133.24 141.16 47.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.907 0.384 . . . . 0.0 110.906 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.19 106.34 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 50.9 m -86.36 154.29 21.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -130.89 147.22 52.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -60.96 -40.72 94.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.94 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -122.76 176.23 6.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -83.54 -55.68 4.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 19.1 tp -42.75 -53.97 4.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -51.6 -45.78 63.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -61.0 -51.54 68.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -50.02 -42.62 49.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.891 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -52.2 -48.98 64.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.535 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -68.0 -52.34 36.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.09 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.561 HD13 ' CZ2' ' A' ' 172' ' ' TRP . 88.5 mt -44.03 -38.78 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.146 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.92 -54.53 8.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.114 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -58.84 -64.16 1.04 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.562 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 89.5 mmm -57.54 -39.72 77.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.69 93.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 94.31 -29.5 8.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.499 ' N ' ' O ' ' A' ' 158' ' ' MET . 71.8 tp60 -38.86 148.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.361 . . . . 0.0 110.917 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 91.1 m95 -90.7 92.54 8.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.432 HD13 ' CB ' ' A' ' 116' ' ' ALA . 3.4 tt -88.7 -69.81 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.934 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.14 117.03 3.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.445 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.57 -91.3 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.494 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.3 mpt_? -83.14 175.73 9.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.859 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 51.0 mt-30 -77.08 177.43 7.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.442 HD12 ' CE ' ' A' ' 158' ' ' MET . 19.8 pt -137.35 162.69 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.07 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.3 mmt180 -118.98 165.07 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' THR . . . . . 0.451 ' O ' ' ND2' ' A' ' 171' ' ' ASN . 3.8 p -149.81 141.4 23.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.108 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . 0.451 ' ND2' ' O ' ' A' ' 170' ' ' THR . 35.0 m120 -159.88 165.17 32.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.561 ' CZ2' HD13 ' A' ' 155' ' ' ILE . 91.9 m95 -83.95 84.17 7.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -41.06 -38.79 1.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 26.4 m -63.87 137.31 57.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.157 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 16.4 ttt85 -121.74 135.67 54.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 67.9 mttt -118.09 141.68 29.77 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.531 0.681 . . . . 0.0 110.927 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 143.11 50.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.687 2.258 . . . . 0.0 112.366 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 141.94 46.59 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.711 2.274 . . . . 0.0 112.352 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -74.61 144.07 79.94 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.576 0.703 . . . . 0.0 111.108 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 179.47 3.68 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 25.0 p -129.01 175.78 8.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -139.44 71.42 0.44 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 173.4 11.01 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.674 2.249 . . . . 0.0 112.361 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 78.3 p -170.78 130.4 0.82 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 86.1 p -155.01 169.88 23.06 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.86 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.487 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 68.9 m -125.62 177.41 6.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.955 0.407 . . . . 0.0 110.834 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 26.1 m -114.97 177.38 4.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.846 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 85.99 72.18 1.29 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 78.0 p -113.41 129.99 56.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.7 t -72.37 -60.37 2.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -104.66 158.77 16.25 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.526 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -92.04 158.5 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.884 0.373 . . . . 0.0 110.903 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -110.76 167.0 10.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.882 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.2 mtmm -94.28 40.61 1.09 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.918 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -165.18 141.39 5.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.936 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 41.8 p -60.18 124.07 19.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.149 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 40.7 t -117.52 -60.78 1.78 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.841 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -110.85 41.97 1.7 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.93 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . 0.419 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 44.5 m170 -110.76 155.93 21.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -103.03 128.14 50.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 29.6 m-70 -83.4 131.85 35.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.831 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 58.6 t -118.51 124.37 73.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.099 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 140' ' ' TYR . 10.4 t80 -86.41 138.85 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 92.7 t -132.34 111.8 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.097 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.31 -175.32 26.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 49.35 41.66 20.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.431 ' O ' ' C ' ' A' ' 105' ' ' SER . 67.9 mt -85.78 108.02 17.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.8 t -35.94 152.16 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.658 0.742 . . . . 0.0 110.855 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -19.43 35.88 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.684 2.256 . . . . 0.0 112.316 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -87.81 1.4 54.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 15.8 mm -75.38 146.34 9.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.123 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.6 p -139.59 145.79 39.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.175 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 88.6 m -39.01 -35.97 0.25 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.192 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -67.34 -48.89 66.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 116' ' ' ALA . 8.8 t0 -54.39 -52.72 60.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.511 HG21 ' CD1' ' A' ' 117' ' ' PHE . 64.6 mt -56.69 -42.68 77.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.159 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.428 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 36.0 mttt -63.51 -37.56 87.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.932 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -92.55 -8.93 42.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.841 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -97.4 -23.59 16.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.061 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.565 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 22.7 m-85 -105.29 -11.59 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.583 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -52.51 -45.9 95.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.603 0.716 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.3 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 0.0 112.336 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.561 ' CE1' ' HA ' ' A' ' 154' ' ' ALA . 58.7 m-85 -90.31 -51.19 5.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -178.46 158.64 23.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.498 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.4 tptt -48.64 128.7 15.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.712 0.291 . . . . 0.0 110.856 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.428 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 60.0 mt -96.39 137.76 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 10.6 t -112.88 -39.52 4.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.865 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -134.92 103.0 5.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -136.18 131.5 34.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 22.5 ptt180 -155.55 156.38 35.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.62 100.44 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.107 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.474 HG12 ' CG ' ' A' ' 138' ' ' LYS . 75.8 t -52.34 122.81 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.104 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -119.03 155.53 31.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.883 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.95 148.66 51.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 35.1 mtm -95.46 -9.41 32.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -91.13 -52.5 4.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.086 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.7 p -100.89 -40.38 7.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.152 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.59 26.25 8.21 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.48 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -109.3 149.27 29.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.915 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 11.9 m -43.09 114.65 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.824 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.474 ' CG ' HG12 ' A' ' 129' ' ' VAL . 13.2 mtpt -53.6 -39.82 65.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.927 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.77 19.34 1.83 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 100' ' ' PHE . 44.2 p90 -167.53 150.28 6.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.899 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.65 -171.5 16.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.453 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -136.48 136.91 39.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.907 0.384 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.451 HG13 ' CE2' ' A' ' 145' ' ' PHE . 70.2 t -140.53 108.31 2.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.182 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.3 t -93.52 141.82 28.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.451 ' CE2' HG13 ' A' ' 143' ' ' VAL . 44.8 m-85 -117.27 147.21 42.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.419 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 10.1 m-85 -57.79 -38.22 75.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -124.95 155.64 39.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.87 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -61.43 -60.55 3.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 21.1 tp -40.01 -49.95 2.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -49.49 -40.68 38.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.845 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -69.3 -48.87 60.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.07 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -52.57 -38.89 60.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.924 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -56.53 -54.5 45.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.561 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -61.31 -61.62 2.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.559 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 68.3 mt -38.64 -39.73 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.159 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 20.3 t -70.55 -64.37 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.132 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 77.6 m-70 -63.63 -61.17 2.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.565 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 29.0 mmt -43.9 -48.44 8.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.44 92.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 97.68 -30.1 9.88 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.525 ' CD ' ' N ' ' A' ' 162' ' ' TRP . 1.0 OUTLIER -36.74 154.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.811 0.338 . . . . 0.0 110.863 -179.851 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.572 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 77.1 m95 -101.43 91.24 4.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.978 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.456 HD12 ' CB ' ' A' ' 116' ' ' ALA . 4.2 tt -84.29 -70.89 0.54 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.921 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -125.58 120.33 3.82 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.458 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 57.37 -95.3 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -81.15 179.26 7.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.744 0.306 . . . . 0.0 110.921 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.572 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 53.9 mt-30 -79.57 -178.43 6.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.434 ' O ' ' N ' ' A' ' 160' ' ' GLY . 20.8 pt -136.66 162.19 35.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.7 ttm180 -126.4 144.07 50.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' THR . . . . . 0.416 ' O ' ' CG ' ' A' ' 171' ' ' ASN . 1.3 p -121.6 153.18 38.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . 0.416 ' CG ' ' O ' ' A' ' 170' ' ' THR . 12.0 m120 -169.15 159.97 9.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.559 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 94.9 m95 -89.41 129.42 35.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -94.21 -44.19 8.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.07 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 39.8 m -52.89 103.58 0.07 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.094 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 34.0 mtt-85 -134.94 147.07 49.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 17.4 ttmt 65.55 52.4 0.93 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.522 0.677 . . . . 0.0 110.925 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.7 Cg_endo -69.72 149.23 66.87 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.362 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 130.71 19.79 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.655 2.237 . . . . 0.0 112.33 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -169.11 145.13 2.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.594 0.711 . . . . 0.0 111.079 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 139.17 39.33 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.696 2.264 . . . . 0.0 112.323 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 55.7 m -85.36 90.61 7.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 67.92 81.38 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 136.63 33.46 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.712 2.275 . . . . 0.0 112.34 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 17.9 t -105.9 99.08 8.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.842 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 54.5 p -58.98 141.69 53.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.864 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.498 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 32.0 m -122.37 -53.46 1.91 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.894 0.378 . . . . 0.0 110.9 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 13.8 t -63.71 169.3 4.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.836 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.24 110.12 3.45 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 15.4 m -122.02 123.89 42.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 0.0 110.844 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 47.5 t -68.9 117.66 10.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 61.95 101.62 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 54.1 mt-30 -81.6 102.55 10.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.857 0.36 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 16.3 ttmt -110.49 125.19 53.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.915 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -94.14 28.61 2.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.914 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.436 ' O ' ' C ' ' A' ' 93' ' ' THR . 1.1 m-20 53.0 50.75 17.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.453 ' O ' ' N ' ' A' ' 95' ' ' ASN . 41.1 p 34.17 53.03 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.154 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 95' ' ' ASN . 1.3 t -44.96 92.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.843 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.453 ' N ' ' O ' ' A' ' 93' ' ' THR . 24.5 p30 34.43 36.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . 0.436 ' N ' ' O ' ' A' ' 94' ' ' SER . 38.1 m170 -50.66 174.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -104.72 121.4 43.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 5.2 m-70 -89.3 134.42 34.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.21 122.1 68.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 45.4 t80 -84.91 141.43 30.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.6 t -125.73 143.05 40.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.44 159.22 23.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.459 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 t0 68.06 33.77 4.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.88 0.372 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.433 ' O ' ' C ' ' A' ' 105' ' ' SER . 31.3 mt -70.91 99.06 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.4 t -35.85 153.22 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.739 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -18.93 36.6 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.335 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.452 ' CG ' ' O ' ' A' ' 107' ' ' GLU . 9.6 tt0 -87.71 -3.43 58.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.415 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 18.1 mm -69.36 144.59 13.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.6 p -134.49 148.8 50.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.118 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 88.4 m -50.87 -30.71 15.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.183 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -78.23 -23.16 47.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -78.91 -48.92 13.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.42 HG21 ' CE1' ' A' ' 117' ' ' PHE . 17.5 mt -57.85 -42.42 82.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.144 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.3 mttt -58.45 -43.98 89.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.7 t -81.94 -16.87 49.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -89.5 -20.11 24.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.566 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.3 m-85 -108.63 -10.59 15.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.855 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.585 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.12 -45.43 99.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.57 0.7 . . . . 0.0 111.042 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -47.98 -17.03 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.706 2.27 . . . . 0.0 112.33 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.551 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 34.6 m-85 -93.58 -32.13 14.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.16 178.79 36.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.555 ' HG3' ' CE1' ' A' ' 146' ' ' TYR . 32.0 tptt -62.82 143.68 57.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.802 0.334 . . . . 0.0 110.877 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 62.6 mt -113.57 126.24 70.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 1.7 t -93.77 -37.44 11.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -145.89 117.43 8.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -146.43 119.2 8.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -148.45 163.27 37.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.9 p -115.76 104.26 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.128 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.0 t -57.49 124.65 11.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -122.36 157.98 30.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.912 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -64.83 158.23 25.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.932 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 42.7 mmm -101.92 -13.13 17.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.883 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.36 -47.69 7.59 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.119 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.8 p -102.55 -38.86 7.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.104 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.28 32.79 9.25 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.9 mttt -111.84 155.5 23.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.741 0.305 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.1 t -55.23 102.61 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 65.0 mttt -45.03 -39.0 5.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.892 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.92 16.96 2.87 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.455 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.422 ' C ' HD13 ' A' ' 104' ' ' LEU . 32.8 p90 -160.5 145.81 14.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.976 0.417 . . . . 0.0 110.927 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -141.55 -176.17 15.64 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -129.82 142.15 50.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.869 0.366 . . . . 0.0 110.924 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 19.8 t -149.35 106.03 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.155 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 48.9 m -92.0 142.1 27.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 23.7 m-85 -112.42 144.67 41.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.913 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.555 ' CE1' ' HG3' ' A' ' 122' ' ' LYS . 8.5 m-85 -56.98 -35.75 69.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.557 ' ND2' ' N ' ' A' ' 147' ' ' ASN . 0.0 OUTLIER -127.15 179.7 5.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.901 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -86.98 -40.96 14.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 55.9 tp -52.44 -65.07 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.456 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 14.6 p-10 -43.8 -53.63 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.844 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -55.0 -57.16 12.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.066 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -46.38 -47.21 18.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.888 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 64.6 m-20 -49.8 -55.09 15.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.546 ' HB1' ' CD2' ' A' ' 120' ' ' PHE . . . -57.05 -60.73 3.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.081 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.561 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 83.3 mt -39.31 -37.72 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.152 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.4 t -77.76 -48.6 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.139 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -75.56 -62.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.566 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 23.2 mmt -45.31 -47.27 13.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.45 94.96 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.446 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 96.59 -30.69 8.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.486 ' N ' ' O ' ' A' ' 158' ' ' MET . 6.2 tm0? -38.25 157.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 110.923 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 87.1 m95 -102.56 95.0 5.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.958 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.405 ' C ' ' CD2' ' A' ' 163' ' ' LEU . 4.3 tt -90.88 -70.5 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.415 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.09 116.77 3.53 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.505 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.42 -91.53 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -82.07 178.81 8.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.839 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 43.9 mt-30 -80.63 177.83 8.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 7.7 pt -137.3 170.19 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.111 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.4 ttm-85 -131.29 149.57 52.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.9 p -126.67 150.85 48.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -168.77 154.56 6.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.561 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.2 m95 -81.05 113.24 19.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -52.45 -52.24 55.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.111 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 13.1 t -100.59 152.76 20.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.101 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.414 ' HB2' ' NH1' ' A' ' 175' ' ' ARG . 22.4 mtm105 -117.01 146.14 43.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.407 ' HD3' ' C ' ' A' ' 176' ' ' LYS . 0.0 OUTLIER -107.62 146.59 33.67 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.567 0.699 . . . . 0.0 110.92 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 158.89 55.41 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.712 2.275 . . . . 0.0 112.314 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 100.76 0.85 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.688 2.259 . . . . 0.0 112.35 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -53.82 151.71 11.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.555 0.693 . . . . 0.0 111.144 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -44.53 2.05 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.701 2.267 . . . . 0.0 112.349 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 84.4 p -59.3 175.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.825 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 155.86 76.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.48 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 148.53 65.5 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.726 2.284 . . . . 0.0 112.364 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 t -146.67 120.21 9.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 10.7 t -168.04 152.77 6.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.836 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.453 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.3 m -154.67 158.28 39.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.869 0.366 . . . . 0.0 110.897 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.6 m -119.58 128.67 54.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 70.0 173.03 10.98 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.502 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -108.31 -57.32 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.891 0.377 . . . . 0.0 110.859 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 29.0 m -55.93 -49.62 72.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 115.9 159.4 11.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.515 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -99.16 -55.74 2.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -95.29 46.78 1.12 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -53.23 106.3 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 93' ' ' THR . 0.4 OUTLIER -67.85 119.04 11.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.852 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 92' ' ' ASP . 22.5 p -35.29 125.79 0.61 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.1 t -128.33 -50.35 1.29 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -117.27 43.15 2.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.899 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -122.88 153.03 40.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.817 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -94.12 130.24 40.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . 0.44 ' CB ' ' HB1' ' A' ' 173' ' ' ALA . 54.6 m-70 -88.28 128.12 35.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 95.6 t -116.44 124.65 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -89.57 141.86 28.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.2 t -131.59 134.89 60.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.46 17.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.479 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.96 36.09 23.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.879 0.371 . . . . 0.0 110.836 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 31.2 mt -81.1 110.03 16.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.929 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -41.61 153.31 0.27 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -23.64 30.52 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.336 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -75.84 -18.53 59.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.449 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 20.2 mm -66.33 133.09 31.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 60.8 p -121.21 151.42 39.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 52.9 m -43.98 -34.54 1.74 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.136 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -70.93 -43.81 67.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.4 m-20 -58.76 -53.83 53.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 43.3 mt -56.34 -38.68 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -63.58 -39.13 93.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.3 t -93.3 -11.92 31.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.836 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -90.72 -20.94 21.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.09 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.569 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 19.6 m-85 -107.4 -8.65 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.73 -45.66 99.8 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.589 0.709 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -48.0 -17.07 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.283 . . . . 0.0 112.361 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.7 m-85 -90.73 -38.84 12.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.896 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.97 167.29 31.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -54.54 126.63 24.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 85.7 mt -95.76 132.85 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.147 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 92.1 p -99.99 -44.92 5.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.1 120.65 13.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -143.21 128.32 18.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.099 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 -156.44 151.75 26.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.59 100.08 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.148 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 68.7 t -49.49 130.37 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.077 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.405 ' HG2' ' C ' ' A' ' 136' ' ' LYS . 29.9 mtmt -125.55 167.75 14.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 30.3 t0 -68.53 157.33 36.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -94.57 -12.53 27.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.58 -62.55 1.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.6 p -81.08 -28.38 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.131 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.26 33.45 53.71 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.405 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 7.1 mmpt? -106.03 158.33 16.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.307 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.5 m -65.47 100.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 37.4 mttt -44.21 -36.77 2.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 121.17 18.58 3.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.485 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -156.71 142.45 17.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.908 0.385 . . . . 0.0 110.952 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.1 -169.76 12.26 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -134.23 142.38 47.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 73.1 t -144.83 110.55 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.136 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 15.8 m -89.67 145.01 25.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -121.88 149.18 43.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -58.63 -46.64 86.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -128.66 165.23 21.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' A' ' 151' ' ' ALA . 14.3 ttmt -62.13 -62.22 1.92 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 65.0 tp -38.19 -50.88 1.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -55.68 -39.62 71.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.907 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.521 ' HB3' ' CH2' ' A' ' 172' ' ' TRP . . . -67.02 -51.19 57.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.149 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -50.14 -48.04 53.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -42.03 -36.59 1.16 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.559 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -86.0 -54.53 4.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.095 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.567 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 76.1 mt -47.67 -34.31 3.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.16 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 46.7 t -81.37 -46.33 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.129 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -74.92 -65.26 0.89 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.892 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.569 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 8.1 mmt -42.33 -48.66 5.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -35.51 103.04 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.467 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 82.08 -32.53 2.74 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.3 tp-100 -34.32 149.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.756 0.312 . . . . 0.0 110.966 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.548 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 90.8 m95 -99.89 92.51 5.32 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.926 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.414 HD22 ' C ' ' A' ' 163' ' ' LEU . 7.0 tt -87.24 -71.04 0.58 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.449 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.63 117.67 3.59 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.483 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.94 -92.78 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.504 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.735 0.302 . . . . 0.0 110.864 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.548 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 71.5 mt-30 -77.15 -178.96 5.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 25.0 pt -137.96 163.68 29.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . 0.466 ' HD3' ' N ' ' A' ' 170' ' ' THR . 0.1 OUTLIER -126.45 152.14 46.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.944 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' THR . . . . . 0.466 ' N ' ' HD3' ' A' ' 169' ' ' ARG . 16.4 p -134.16 158.46 43.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.156 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . 0.419 ' HB2' ' NH1' ' A' ' 169' ' ' ARG . 24.4 t-20 -172.07 173.18 4.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.843 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.567 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 83.8 m95 -95.04 106.97 19.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . 0.44 ' HB1' ' CB ' ' A' ' 98' ' ' HIS . . . -53.84 -57.43 10.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 10.0 t -85.19 143.97 28.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.099 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.406 ' HD3' ' C ' ' A' ' 175' ' ' ARG . 0.0 OUTLIER -137.68 117.22 12.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 32.1 mttp -86.74 144.36 37.07 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.559 0.695 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 147.07 62.34 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.721 2.281 . . . . 0.0 112.346 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 151.03 68.9 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -134.22 142.6 43.7 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.577 0.704 . . . . 0.0 111.068 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 143.92 52.43 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.662 2.242 . . . . 0.0 112.373 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 8.4 t -79.19 172.9 13.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.826 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -132.85 152.88 20.45 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.484 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 163.59 37.72 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.715 2.277 . . . . 0.0 112.379 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 19.6 m -72.31 -56.26 5.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 46.8 p -89.65 134.74 34.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.966 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 20.2 m -143.44 144.54 32.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.9 0.381 . . . . 0.0 110.858 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 20.2 t -154.66 139.32 17.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.838 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 79.15 50.55 5.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.9 m -91.88 132.53 36.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.838 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 85.4 p -161.35 129.72 4.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.815 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -92.92 -114.17 2.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.419 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -105.45 91.12 3.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.882 0.373 . . . . 0.0 110.912 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -129.95 100.5 5.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.2 44.77 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.945 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -105.46 106.71 17.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.824 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.414 ' CG2' ' HB2' ' A' ' 124' ' ' SER . 69.1 p -96.49 105.9 18.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.5 m -124.32 -59.13 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -98.94 43.4 1.06 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -106.12 164.02 12.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.866 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.523 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 58.2 m-85 -113.48 134.24 54.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -91.29 128.35 37.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 151' ' ' ALA . 98.3 t -111.59 135.48 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.508 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 2.7 t80 -100.24 139.38 36.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 54.7 t -131.39 114.78 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.42 172.83 19.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 139' ' ' GLY . 1.6 m-20 58.71 37.73 25.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.359 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.464 HD13 ' N ' ' A' ' 141' ' ' GLY . 31.7 mt -71.88 101.08 2.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 104' ' ' LEU . 0.7 OUTLIER -36.64 155.23 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.663 0.744 . . . . 0.0 110.88 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -13.11 34.14 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -89.9 -16.72 29.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.894 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 10.7 mm -66.93 144.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 80.4 p -142.55 145.93 34.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.183 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 49.2 m -39.75 -37.49 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.101 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -68.27 -45.35 73.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.492 ' O ' ' N ' ' A' ' 116' ' ' ALA . 75.4 m-20 -64.32 -50.72 66.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.519 HG22 ' CD1' ' A' ' 117' ' ' PHE . 13.1 mt -53.52 -45.4 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.463 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 13.3 mtpt -61.35 -35.64 77.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.2 t -91.54 -13.59 31.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.492 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -95.71 -17.59 21.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.058 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.578 ' CE1' ' SD ' ' A' ' 158' ' ' MET . 25.5 m-85 -108.34 -11.03 15.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.845 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.591 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.16 -44.79 99.06 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 0.0 111.106 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -48.06 -16.75 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.261 . . . . 0.0 112.341 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 42.1 m-85 -94.31 -41.47 9.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 174.5 147.94 6.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -43.89 126.89 5.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.463 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 62.5 mt -91.63 134.33 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' SER . . . . . 0.414 ' HB2' ' CG2' ' A' ' 93' ' ' THR . 87.9 p -100.29 -42.92 6.46 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.859 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -145.39 107.31 4.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.858 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -137.34 135.46 37.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.077 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -157.6 165.99 34.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.8 p -123.07 100.04 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.142 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 41.9 t -53.4 128.04 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.4 ' HG2' ' C ' ' A' ' 136' ' ' LYS . 49.6 mttt -121.26 171.31 8.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.82 159.29 31.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.85 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' MET . . . . . 0.424 ' N ' ' SD ' ' A' ' 132' ' ' MET . 0.3 OUTLIER -101.95 9.55 40.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.994 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -122.72 -44.01 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.5 p -98.92 -31.23 11.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.98 30.09 56.2 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.4 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 51.5 mmtt -114.06 155.14 26.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.1 t -50.67 110.9 0.46 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.852 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -53.32 -34.74 58.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.935 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 123.99 11.17 4.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -154.97 159.24 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.892 0.377 . . . . 0.0 110.966 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.464 ' N ' HD13 ' A' ' 104' ' ' LEU . . . -160.06 -167.95 21.35 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.476 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -141.37 152.39 44.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.38 . . . . 0.0 110.902 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.543 HG13 ' CE2' ' A' ' 145' ' ' PHE . 43.0 t -153.91 109.52 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.182 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 70.8 m -85.07 150.89 24.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.543 ' CE2' HG13 ' A' ' 143' ' ' VAL . 26.8 m-85 -129.89 149.15 51.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.859 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -63.3 -43.55 97.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.927 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -120.06 157.96 27.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.523 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 57.3 tttt -65.51 -49.99 66.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.5 tp -47.65 -56.08 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -45.83 -39.46 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.416 ' HB2' ' CG2' ' A' ' 99' ' ' VAL . . . -67.8 -49.58 61.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.125 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -51.47 -46.31 63.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.918 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -52.68 -47.9 66.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.875 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.556 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -64.27 -55.93 18.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.515 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 96.4 mt -50.0 -35.01 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 74.3 t -78.98 -49.33 20.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.135 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.7 m-70 -72.67 -67.07 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.578 ' SD ' ' CE1' ' A' ' 117' ' ' PHE . 14.9 mmt -44.86 -47.28 11.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.53 101.22 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 84.5 -31.57 3.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.527 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.9 tp-100 -34.78 151.51 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.819 0.342 . . . . 0.0 110.91 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.576 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 92.9 m95 -97.02 90.63 5.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.92 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.426 HD12 ' CB ' ' A' ' 116' ' ' ALA . 5.5 tt -85.31 -70.08 0.61 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.1 117.94 3.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.506 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.78 -93.68 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 27.7 mtt85 -80.47 -179.73 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.733 0.302 . . . . 0.0 110.897 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.576 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 40.1 mt-30 -83.77 176.16 9.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.935 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.424 ' O ' ' N ' ' A' ' 160' ' ' GLY . 18.9 pt -131.81 167.79 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -130.91 149.23 52.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 20.1 p -126.54 162.09 26.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -173.0 156.9 3.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.913 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.515 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 98.0 m95 -87.07 119.19 27.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -87.53 42.97 1.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.139 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -115.47 142.45 46.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 50.3 mtt-85 -124.84 144.03 50.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.858 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.439 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 0.8 OUTLIER 43.97 54.74 11.89 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.585 0.707 . . . . 0.0 110.89 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.5 Cg_endo -69.76 159.74 52.28 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 157.58 59.94 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 0.0 112.354 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -158.38 152.53 20.02 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.732 . . . . 0.0 111.095 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 170.99 15.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.728 2.285 . . . . 0.0 112.308 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 5.6 t -117.73 105.39 11.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.877 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 86.85 178.71 49.09 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.474 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 128.43 16.03 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.707 2.271 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 1.8 m -132.05 121.87 24.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.852 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 24.8 t -140.25 131.0 25.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.833 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.383 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.9 t -71.24 135.32 47.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.881 0.372 . . . . 0.0 110.889 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 73.4 p -137.72 148.49 45.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.845 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 137.22 -142.58 13.63 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.522 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 t -133.49 146.3 50.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 110.904 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 22.0 m -76.84 97.97 4.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 50.82 93.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.502 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -79.31 115.83 19.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.901 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.8 pttt -98.26 -39.46 8.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -47.55 111.07 0.37 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -53.3 -60.68 2.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 37.3 p -46.96 132.39 11.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.133 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.1 t -129.93 -56.1 1.12 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 -61.21 -60.03 4.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.0 m170 -42.28 152.92 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.527 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 88.7 m-85 -89.43 154.35 20.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -111.77 135.77 51.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 60.7 t -126.65 121.07 57.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.156 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 87.6 t80 -86.14 139.34 31.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.0 t -130.11 120.17 48.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.178 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -111.43 -175.36 20.09 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 46.34 43.64 11.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.871 0.367 . . . . 0.0 110.838 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.43 HD13 ' N ' ' A' ' 141' ' ' GLY . 39.5 mt -85.0 110.1 18.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -39.67 153.44 0.19 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.686 0.755 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -20.01 35.44 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 0.0 112.345 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -82.98 -20.62 34.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.876 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 46.8 mm -50.0 151.02 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.127 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 37.3 p -139.14 148.29 43.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.157 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 27.7 m -48.91 -38.11 21.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.153 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -71.89 -32.7 67.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.496 ' O ' ' N ' ' A' ' 116' ' ' ALA . 10.9 m-20 -65.21 -53.59 42.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 31.6 mt -56.25 -48.01 80.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.091 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.41 ' NZ ' HG21 ' A' ' 123' ' ' ILE . 32.9 mttm -56.41 -39.32 72.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.913 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.4 t -92.37 -8.98 43.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.496 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -94.21 -13.9 26.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.121 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.568 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.6 m-85 -115.49 -11.6 11.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.568 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -49.82 -46.63 80.63 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.603 0.716 . . . . 0.0 111.157 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.568 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 63.8 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.695 2.263 . . . . 0.0 112.31 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.569 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 50.0 m-85 -92.42 -33.05 14.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.921 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.06 157.84 9.18 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.527 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.425 ' NZ ' ' O ' ' A' ' 123' ' ' ILE . 18.5 tptp -49.09 145.29 4.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.425 ' O ' ' NZ ' ' A' ' 122' ' ' LYS . 53.6 mt -115.21 143.42 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.191 179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 51.4 p -108.26 -33.98 6.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.76 136.35 22.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -164.68 129.12 2.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 9.0 ptp85 -150.42 154.23 37.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.12 100.08 9.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.1 t -51.74 114.26 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.455 ' HG2' ' N ' ' A' ' 137' ' ' SER . 32.3 mtmt -109.09 163.14 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 158.3 7.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.865 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 ttt -98.93 -8.52 25.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -108.06 -48.79 3.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.11 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.9 p -96.96 -24.45 15.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.089 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.92 19.97 78.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.468 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -95.99 143.29 27.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.455 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 37.3 m -47.61 106.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -50.15 -45.1 52.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 133.26 29.99 0.48 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.414 ' C ' HD13 ' A' ' 104' ' ' LEU . 41.3 p90 -171.98 144.68 1.74 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.956 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.43 ' N ' HD13 ' A' ' 104' ' ' LEU . . . -145.96 -172.01 15.95 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.498 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -131.57 140.78 49.54 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.897 0.38 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.8 t -140.78 122.15 14.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.089 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 63.6 p -101.68 147.67 26.17 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.873 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -125.36 148.68 48.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.833 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -64.5 -35.99 82.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.934 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -130.62 154.39 47.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.916 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.527 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 11.3 ttmt -60.1 -66.74 0.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.906 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 148' ' ' LYS . 14.9 tp -35.3 -59.49 0.52 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -47.47 -41.86 21.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -71.52 -54.07 11.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -47.82 -39.39 18.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.911 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -52.3 -46.39 65.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.558 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -65.64 -53.21 44.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 81.9 mt -41.01 -35.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.4 t -89.23 -53.74 8.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -59.27 -62.45 1.88 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.838 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.569 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 83.7 mmm -64.04 -36.36 83.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.37 92.03 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.91 -28.58 12.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.7 tp-100 -38.61 155.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.882 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.1 m95 -95.64 90.91 5.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.959 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.9 tt -87.09 -69.83 0.66 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.888 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.72 116.97 3.44 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.94 -91.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.8 mtt180 -82.63 178.14 8.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.838 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 34.0 mt-30 -78.14 175.47 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.929 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.45 HD11 ' CE ' ' A' ' 158' ' ' MET . 32.9 pt -132.64 168.64 23.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.127 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 65.2 ttt180 -126.39 160.87 29.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 31.7 p -146.8 147.58 31.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.134 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -160.77 164.05 31.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 11.7 m95 -79.14 83.37 5.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.951 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -39.52 -37.83 0.52 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.123 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 m -127.38 108.75 11.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.142 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 -82.03 -43.01 18.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.448 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 24.9 ttmt 40.94 53.64 6.65 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.534 0.683 . . . . 0.0 110.939 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.9 Cg_endo -69.75 164.04 36.0 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.688 2.259 . . . . 0.0 112.352 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 144.12 53.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.32 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -121.58 145.21 42.28 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.553 0.692 . . . . 0.0 111.081 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 181' ' ' SER . 53.5 Cg_endo -69.77 -14.2 35.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.677 2.252 . . . . 0.0 112.37 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 180' ' ' PRO . 7.7 t -36.42 120.6 0.68 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 93.33 73.31 1.22 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.43 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -19.03 36.58 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.694 2.262 . . . . 0.0 112.311 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 34.8 m -69.94 138.48 52.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.6 m -72.86 -45.23 59.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.855 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.483 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.9 p -116.21 161.84 18.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.885 0.374 . . . . 0.0 110.833 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 97.6 p -87.39 12.36 12.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.855 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -176.42 -84.19 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.492 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 63.5 p -156.56 157.9 36.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.89 0.376 . . . . 0.0 110.853 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 32.8 t -94.87 119.9 34.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.878 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -150.23 116.84 0.8 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.476 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -105.85 79.11 1.39 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 0.0 110.896 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 20.7 pttt -169.0 145.47 3.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.3 mttt -153.86 110.49 3.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -57.15 -69.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 60.6 p -69.44 112.16 5.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.137 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.5 m -111.76 -65.98 1.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -50.67 -41.81 56.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.1 m170 -57.48 151.76 16.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -96.96 128.97 44.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -87.71 119.6 28.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 65.6 t -109.79 119.75 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.13 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.425 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 3.2 t80 -84.14 145.4 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.458 HG11 ' N ' ' A' ' 102' ' ' GLY . 61.9 t -132.76 140.79 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.458 ' N ' HG11 ' A' ' 101' ' ' VAL . . . -130.23 -169.37 12.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.501 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 44.9 36.71 2.0 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.831 0.348 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 40.9 mt -78.74 106.15 10.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.961 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -40.44 153.6 0.21 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.685 0.755 . . . . 0.0 110.844 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -28.31 25.51 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.733 2.289 . . . . 0.0 112.325 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -77.41 -7.4 56.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.862 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.444 ' CG2' ' N ' ' A' ' 109' ' ' THR . 9.5 mm -68.56 161.96 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.444 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 56.4 p -142.96 172.1 13.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.5 m -69.0 -39.15 79.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -74.0 -17.95 60.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.93 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 17.9 m-20 -75.32 -54.54 6.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 14.5 mt -53.62 -48.18 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.8 mtpp -54.57 -41.78 70.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -87.32 -15.88 36.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.881 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.453 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -90.28 -14.8 32.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.067 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.598 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 16.4 m-85 -114.65 -8.82 12.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.576 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.0 -46.28 98.69 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.594 0.712 . . . . 0.0 111.105 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.4 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.658 2.238 . . . . 0.0 112.388 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.518 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 56.6 m-85 -89.98 -32.87 16.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.81 171.14 26.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.492 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.551 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 0.0 OUTLIER -55.86 132.62 50.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.762 0.315 . . . . 0.0 110.872 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 96.5 mt -102.52 123.84 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.14 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 83.9 p -86.02 -49.69 7.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.841 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -143.84 117.6 9.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.852 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -141.75 134.31 28.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.461 ' CZ ' ' HB3' ' A' ' 127' ' ' ARG . 1.7 ptp180 -158.81 164.93 35.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.3 p -112.94 100.06 9.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.093 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -49.68 126.5 4.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.192 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -121.46 171.99 8.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -76.76 156.96 31.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.89 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 17.2 ttp -94.89 -11.79 28.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.92 -62.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 71.1 p -82.9 -30.69 28.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.98 28.45 60.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.5 mmtp -106.32 152.3 23.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.829 0.347 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 50.6 p -45.99 109.59 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.846 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -53.95 -36.3 62.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.97 12.81 4.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.503 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 30.8 p90 -162.64 146.73 11.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.907 0.384 . . . . 0.0 110.922 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -133.97 -169.59 12.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.479 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -136.99 141.87 42.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.526 HG11 ' CE2' ' A' ' 145' ' ' PHE . 41.4 t -145.04 108.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 13.3 t -88.48 150.98 22.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.526 ' CE2' HG11 ' A' ' 143' ' ' VAL . 57.6 m-85 -127.54 151.62 48.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.551 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 14.3 m-85 -69.38 -42.42 75.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -115.23 178.96 4.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.908 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.8 tttm -87.15 -41.59 13.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 14.4 tp -53.49 -65.06 0.63 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.459 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 12.4 p-10 -41.81 -53.97 3.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.456 ' HB3' ' CD2' ' A' ' 145' ' ' PHE . . . -53.95 -51.11 64.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.123 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -53.39 -44.81 68.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -50.25 -48.58 54.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.857 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.418 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -67.07 -60.56 2.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.101 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.57 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 97.4 mt -38.32 -41.26 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.3 t -79.66 -58.48 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 30.2 m-70 -57.81 -65.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.897 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.598 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 15.8 mmt -46.59 -45.84 19.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -40.16 91.77 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 99.77 -32.08 7.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.506 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.446 ' HG3' ' N ' ' A' ' 162' ' ' TRP . 3.2 tp-100 -39.06 149.02 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.835 0.35 . . . . 0.0 110.92 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.546 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 78.9 m95 -95.31 91.65 6.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.472 ' CD2' ' C ' ' A' ' 163' ' ' LEU . 4.1 tt -87.34 -71.71 0.55 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.474 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.89 119.26 4.18 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.476 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.39 -92.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.497 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -85.42 169.3 13.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.756 0.312 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.546 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 85.7 mt-30 -68.65 177.18 2.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 29.1 pt -135.8 169.87 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -137.23 163.43 30.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.832 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 42.8 p -140.18 163.51 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -162.86 157.77 21.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.57 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 82.6 m95 -88.69 96.96 10.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.925 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.88 37.81 0.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.7 t -128.56 142.74 50.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.17 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -117.4 126.9 53.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.53 144.34 45.89 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 110.879 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 147.42 62.67 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.673 2.248 . . . . 0.0 112.299 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 145.95 58.49 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.641 2.227 . . . . 0.0 112.343 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -139.27 144.67 41.32 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.619 0.723 . . . . 0.0 111.109 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 176.98 6.08 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.719 2.279 . . . . 0.0 112.365 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 22.8 m -94.94 -45.27 7.34 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 116.72 166.39 14.28 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 166.31 27.98 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.712 2.275 . . . . 0.0 112.357 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.3 m -130.86 95.33 3.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 6.2 t -66.53 148.32 52.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.824 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.986 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 54.5 p -62.35 155.21 25.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.861 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 -44.09 2.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 66.43 0.74 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.515 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.2 t -97.77 148.49 23.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.86 0.362 . . . . 0.0 110.851 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 23.4 m -156.0 155.35 32.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.87 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.17 43.04 2.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.477 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -126.38 152.72 45.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.872 0.368 . . . . 0.0 110.923 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 33.8 mmtm -106.43 143.2 34.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.9 mmtp -150.82 143.47 24.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.85 174.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 70.6 p -82.73 125.56 31.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.159 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 23.6 t -102.53 87.43 3.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.858 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 46.46 43.52 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . 0.503 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 48.6 m170 -77.39 162.11 27.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.855 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.55 ' CE1' ' HE3' ' A' ' 148' ' ' LYS . 85.2 m-85 -89.6 131.86 35.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -93.25 124.82 37.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.819 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 65.5 t -111.26 130.96 63.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.491 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 1.9 t80 -98.9 140.74 32.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.55 134.99 61.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.114 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.75 172.79 16.45 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.534 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.0 t0 58.63 40.3 23.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 110.877 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' A' ' 105' ' ' SER . 35.6 mt -77.28 97.58 4.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.912 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.6 t -35.0 152.45 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.655 0.74 . . . . 0.0 110.882 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 -14.13 35.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.728 2.286 . . . . 0.0 112.37 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -93.42 1.68 56.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.419 HG23 ' N ' ' A' ' 109' ' ' THR . 9.4 mm -76.77 146.82 8.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.109 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.419 ' N ' HG23 ' A' ' 108' ' ' ILE . 57.6 p -134.43 158.99 42.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 90.0 m -57.22 -33.69 67.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.142 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -75.93 -17.67 59.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' CB ' ' A' ' 116' ' ' ALA . 11.9 m-20 -81.78 -48.08 12.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 30.9 mt -64.39 -39.58 86.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.142 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 57.8 mttt -63.83 -42.83 97.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 1.3 t -86.08 -16.47 37.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 112' ' ' ASP . . . -85.51 -29.63 24.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.497 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 9.0 m-85 -100.39 -8.3 23.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.71 -46.45 99.36 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.569 0.7 . . . . 0.0 111.108 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.2 Cg_exo -47.98 -17.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.642 2.228 . . . . 0.0 112.358 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.504 ' CD2' ' HB3' ' A' ' 154' ' ' ALA . 46.4 m-85 -91.56 -36.4 13.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.09 176.9 40.02 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.3 tttt -68.5 121.2 15.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.758 0.313 . . . . 0.0 110.92 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 56.8 mt -91.89 127.77 43.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.128 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.6 t -92.45 -42.34 9.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.882 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -142.66 124.56 15.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.892 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -154.73 126.81 7.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.7 ptm180 -150.55 156.32 41.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -108.59 99.95 9.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.115 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.6 t -51.84 122.55 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.445 ' HG2' ' N ' ' A' ' 137' ' ' SER . 69.4 mttt -115.92 172.45 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.901 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -75.25 143.51 43.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.893 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 25.3 tpp -89.28 3.41 52.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -106.64 -62.94 1.33 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.119 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.7 p -91.94 -27.53 17.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.144 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.38 30.34 22.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 137' ' ' SER . 49.1 mtmt -112.03 135.71 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.76 0.314 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.445 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 67.4 m -37.24 119.31 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.803 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -60.75 -42.35 97.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.46 26.91 0.64 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.42 ' C ' HD13 ' A' ' 104' ' ' LEU . 16.4 p90 -169.82 144.77 2.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.944 0.402 . . . . 0.0 110.904 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -138.4 -177.99 15.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.486 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -134.2 139.7 45.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 53.5 t -141.85 127.9 18.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.5 m -104.92 144.45 31.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -124.1 145.1 49.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.855 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.503 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.7 m-85 -62.0 -46.95 86.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.966 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -118.45 165.8 13.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.55 ' HE3' ' CE1' ' A' ' 97' ' ' PHE . 10.9 ttmt -67.52 -56.19 10.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.945 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.7 tp -39.26 -53.9 1.87 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -51.28 -39.44 56.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -70.24 -58.03 4.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -46.88 -47.48 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 28.1 m-20 -51.01 -47.38 61.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.504 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -69.08 -49.71 54.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.61 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 91.8 mt -48.54 -34.53 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.136 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 88.1 t -89.41 -55.8 5.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -57.01 -63.01 1.35 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.503 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 92.0 mmm -57.53 -40.03 77.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 92.25 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.529 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.48 -29.35 9.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.498 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.2 tp-100 -37.3 153.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.796 0.332 . . . . 0.0 110.888 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.554 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 90.7 m95 -96.82 91.02 5.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.965 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.411 ' C ' HD21 ' A' ' 163' ' ' LEU . 4.8 tt -85.47 -70.22 0.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.11 118.02 3.43 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.04 -93.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.52 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -82.25 174.31 11.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.842 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.554 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 84.5 mt-30 -76.16 178.23 6.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.44 HD12 ' CE ' ' A' ' 158' ' ' MET . 9.2 pt -139.91 166.99 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 51.8 mtt180 -126.71 167.74 15.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 4.2 p -147.76 143.76 27.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.165 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -153.67 166.95 31.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.61 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 97.0 m95 -88.11 109.87 20.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -81.55 62.71 5.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.12 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 79.4 m -132.98 122.6 24.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.152 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -100.71 85.72 2.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.2 ttpm? -167.32 137.49 2.36 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.581 0.705 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 151.92 68.8 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.707 2.271 . . . . 0.0 112.298 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 107.06 1.77 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.694 2.263 . . . . 0.0 112.349 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -61.86 144.86 93.16 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.63 0.729 . . . . 0.0 111.083 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 139.4 40.1 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.339 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 94.8 p -116.92 173.68 6.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -121.22 169.69 14.45 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 113.86 3.51 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.666 2.244 . . . . 0.0 112.381 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 50.8 m -91.37 166.4 12.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 15.7 m -115.22 167.93 10.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.484 179.997 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 88.8 p -166.31 124.65 1.47 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.359 . . . . 0.0 110.861 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 85.9 p -115.44 155.75 26.88 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.74 -79.05 0.63 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.49 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 9.8 t -71.02 144.99 50.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.83 0.348 . . . . 0.0 110.89 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -172.99 168.84 4.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.809 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -126.05 70.13 0.49 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.457 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -58.24 -35.78 72.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.811 0.339 . . . . 0.0 110.854 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -81.26 -32.42 33.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.92 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.3 tmtm? -163.5 108.72 1.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -79.38 146.85 32.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 41.4 p -108.27 123.1 48.27 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.117 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.5 p -130.04 -36.78 1.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.837 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -111.42 27.1 9.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.7 m170 -119.91 155.9 31.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.906 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.56 ' CE1' ' HD3' ' A' ' 148' ' ' LYS . 90.5 m-85 -93.45 157.64 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.904 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -112.66 129.12 56.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 49.5 t -119.88 117.63 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.46 132.52 34.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 91.1 t -124.11 120.49 59.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -110.46 177.78 19.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 53.83 46.35 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 110.913 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 28.1 mt -90.85 113.81 26.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -45.53 152.73 0.65 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.715 0.769 . . . . 0.0 110.847 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -33.96 15.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.658 2.239 . . . . 0.0 112.317 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -66.41 -22.95 66.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.902 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.404 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 22.6 mm -55.41 150.31 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.157 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 44.3 p -130.74 164.01 26.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.185 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 90.6 m -64.63 -32.64 74.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.11 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -79.95 -11.84 59.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -83.53 -50.53 8.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.881 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.453 HG23 ' CD1' ' A' ' 117' ' ' PHE . 5.6 mt -57.84 -39.57 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.157 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 58.7 mttt -60.43 -35.77 76.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.4 t -92.48 -16.18 26.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.845 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.467 ' CB ' ' CD1' ' A' ' 163' ' ' LEU . . . -89.34 -16.27 31.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.085 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.1 m-85 -112.19 -9.5 13.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.64 -46.09 99.38 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.548 0.689 . . . . 0.0 111.102 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.1 Cg_exo -48.01 -17.08 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.71 2.273 . . . . 0.0 112.335 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.567 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 49.3 m-85 -91.27 -31.95 15.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 159.67 172.49 26.92 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.9 tttt -58.37 140.07 54.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 110.912 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 89.6 mt -109.92 131.02 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 79.3 p -96.57 -26.0 15.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -159.81 125.04 4.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -150.16 124.4 9.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.459 ' HD3' ' N ' ' A' ' 128' ' ' VAL . 0.0 OUTLIER -151.32 155.56 38.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.459 ' N ' ' HD3' ' A' ' 127' ' ' ARG . 7.0 p -108.22 100.06 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.123 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.4 t -49.03 122.67 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.168 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 38.4 mttt -119.1 168.9 10.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -73.34 145.69 45.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 tpt -87.41 15.72 6.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -130.19 -55.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.134 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 7.5 p -85.93 -28.47 24.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.122 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.03 22.69 70.81 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.3 mmpt? -106.59 150.11 26.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 44.6 m -54.2 109.27 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.865 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -49.35 -35.29 18.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.45 15.25 2.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -160.91 144.34 13.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.934 0.397 . . . . 0.0 110.92 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -136.13 -176.0 14.12 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -129.29 136.44 50.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.16 119.07 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.133 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 11.4 m -99.18 145.3 27.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -124.51 148.99 47.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -65.1 -46.33 81.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -119.77 150.56 40.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.56 ' HD3' ' CE1' ' A' ' 97' ' ' PHE . 20.8 tptt -55.88 -56.66 17.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' LYS . 28.8 tp -37.36 -49.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.944 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 1.0 OUTLIER -57.26 -42.09 80.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.809 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.458 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -64.85 -47.02 79.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -58.15 -46.43 85.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -48.78 -46.85 42.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.916 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.53 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -70.72 -60.44 2.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.512 HD13 ' CE2' ' A' ' 172' ' ' TRP . 66.6 mt -39.03 -36.78 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.116 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 69.2 t -78.7 -60.76 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -62.88 -66.13 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.851 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.567 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 29.4 mmt -37.8 -50.63 1.25 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.926 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.14 102.43 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.525 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 88.58 -30.66 5.21 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.496 ' N ' ' O ' ' A' ' 158' ' ' MET . 51.0 tp60 -35.27 152.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.759 0.314 . . . . 0.0 110.923 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.56 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 84.8 m95 -100.76 91.42 4.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.937 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.467 ' CD1' ' CB ' ' A' ' 116' ' ' ALA . 5.4 tt -87.42 -70.36 0.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.406 ' N ' HD23 ' A' ' 163' ' ' LEU . . . -120.22 118.72 3.97 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.532 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.29 -92.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.442 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.6 mtt180 -80.4 178.07 8.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.56 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 22.4 mt-30 -79.24 -178.79 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 23.2 pt -138.33 171.17 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -136.45 141.95 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 24.0 p -127.11 148.69 50.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.129 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -159.94 166.41 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.512 ' CE2' HD13 ' A' ' 155' ' ' ILE . 85.8 m95 -82.7 107.01 15.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -53.86 89.98 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' THR . . . . . 0.4 ' N ' ' O ' ' A' ' 172' ' ' TRP . 39.2 m -124.19 140.56 52.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.124 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -122.65 142.42 50.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -134.09 136.4 26.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.522 0.677 . . . . 0.0 110.913 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 157.89 58.88 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.688 2.258 . . . . 0.0 112.352 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 81.45 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.7 2.267 . . . . 0.0 112.345 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -141.73 144.16 31.88 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.578 0.704 . . . . 0.0 111.077 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 131.13 20.61 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.711 2.274 . . . . 0.0 112.373 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 73.9 m -103.87 -46.32 4.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.802 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 139.92 173.92 13.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.514 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 -46.52 1.19 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.372 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 t -75.36 162.23 28.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.831 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 8.4 t -64.7 -48.95 72.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.831 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.471 -179.994 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 23.4 m -57.68 132.76 54.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.857 0.36 . . . . 0.0 110.872 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.0 p -153.13 156.37 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.842 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.38 130.99 1.18 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.515 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.5 m -149.73 174.36 12.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.879 0.371 . . . . 0.0 110.826 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 9.4 t -114.89 123.41 49.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.834 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 90' ' ' LYS . . . 167.51 114.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.506 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -48.02 93.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.842 0.353 . . . . 0.0 110.901 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' GLY . 35.8 mmtm -141.91 135.19 29.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.9 mtmt 43.61 26.57 0.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.918 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -106.03 108.33 19.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 5.0 p -91.99 140.58 29.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -130.77 -47.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.873 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -74.15 -28.41 61.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . 0.496 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 60.0 m170 -65.52 172.92 2.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.524 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 25.4 m-85 -107.19 133.33 51.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -87.88 129.02 35.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.877 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.0 t -120.39 122.83 69.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.551 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 0.6 OUTLIER -86.46 145.47 26.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 98.7 t -137.53 110.74 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -102.05 -172.77 27.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.503 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 45.78 46.34 11.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 65.7 mt -87.69 109.49 19.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.4 t -43.12 153.23 0.35 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.627 0.727 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -18.23 36.92 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.662 2.241 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -87.4 -4.41 59.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.435 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 24.5 mm -69.19 147.82 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 70.3 p -136.49 144.6 44.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.157 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 89.6 m -46.77 -35.71 6.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -72.29 -31.57 65.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -69.49 -49.18 57.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 17.6 mt -58.44 -47.25 88.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.134 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.471 ' CG ' ' HB1' ' A' ' 126' ' ' ALA . 27.8 mtpt -60.09 -35.2 74.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.942 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 30.0 t -90.74 -8.67 49.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.64 -24.91 14.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.068 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.9 m-85 -100.59 -8.68 22.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.577 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.07 -46.19 98.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.729 . . . . 0.0 111.107 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.577 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -48.0 -17.16 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.564 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 52.2 m-85 -90.99 -38.31 12.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.39 179.28 41.74 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.455 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.446 ' HG2' ' CZ ' ' A' ' 146' ' ' TYR . 20.9 tptt -66.1 133.26 50.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.727 0.299 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 67.9 mt -106.4 128.42 60.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.6 t -100.57 -27.82 13.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -148.43 138.76 22.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.824 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.471 ' HB1' ' CG ' ' A' ' 114' ' ' LYS . . . -168.08 123.4 0.99 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 14.6 ptp180 -148.07 156.6 42.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.873 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.39 100.61 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.101 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 23.0 t -53.25 119.44 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.069 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.456 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.6 mttm -119.62 157.8 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -64.07 153.95 35.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.884 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 48.2 tpp -95.52 -13.32 24.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.85 -56.39 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -87.83 -34.91 18.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.165 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.56 29.98 31.22 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 14.5 mmtp -112.18 147.68 35.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.882 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.456 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 39.1 t -49.09 104.8 0.07 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 58.0 mttt -44.75 -36.13 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.904 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.21 27.67 1.32 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -167.37 151.64 6.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.935 0.398 . . . . 0.0 110.904 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -150.13 -177.81 24.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -133.9 141.22 47.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.882 0.372 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 90.4 t -143.64 116.57 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 67.6 m -94.04 139.11 31.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -117.65 138.44 51.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.496 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 6.5 m-85 -51.79 -45.52 63.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.7 168.9 11.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.91 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.524 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 53.0 tttt -74.58 -59.26 2.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.1 tp -39.69 -49.02 2.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -58.97 -40.24 84.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.406 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -67.99 -43.93 77.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -56.66 -44.73 81.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -52.26 -46.47 65.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.52 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.97 -51.89 34.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.674 ' CD1' ' CZ2' ' A' ' 172' ' ' TRP . 96.9 mt -46.0 -37.27 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.4 t -86.58 -54.94 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -57.31 -60.74 3.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.564 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 94.2 mmm -60.5 -38.93 85.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.13 94.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.0 -31.59 5.86 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.518 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.4 tp-100 -35.21 152.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.807 0.337 . . . . 0.0 110.888 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.557 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -93.99 91.01 6.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.9 tt -87.57 -70.26 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -118.5 116.62 3.45 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.55 -91.11 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -83.84 174.19 10.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.793 0.33 . . . . 0.0 110.819 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.557 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 58.9 mt-30 -75.51 170.69 15.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.963 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.436 HD13 ' CE ' ' A' ' 158' ' ' MET . 15.7 pt -129.03 167.27 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.118 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 8.6 mmt85 -121.59 165.4 15.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.868 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 2.6 p -149.77 128.28 12.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.166 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -144.47 157.78 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.674 ' CZ2' ' CD1' ' A' ' 155' ' ' ILE . 79.0 m95 -81.01 107.24 13.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.914 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -89.12 80.12 7.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.114 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.4 t -159.3 144.03 15.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.173 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 1.3 tpm_? -86.11 148.97 25.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -93.71 129.73 37.28 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.556 0.693 . . . . 0.0 110.893 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 148.86 65.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.662 2.241 . . . . 0.0 112.328 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 163.98 36.23 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.64 2.226 . . . . 0.0 112.349 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -157.91 144.18 12.81 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.613 0.721 . . . . 0.0 111.064 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 108.01 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.645 2.23 . . . . 0.0 112.352 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 83.7 p -110.79 102.66 11.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -170.95 70.31 0.12 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 159.6 52.83 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.392 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 1.4 t -71.24 124.54 24.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.838 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 26.4 m 49.08 41.83 20.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.818 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.502 179.976 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.2 t -125.89 -51.43 1.57 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.831 0.348 . . . . 0.0 110.832 -179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 78.0 p -93.42 147.67 22.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.915 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -135.14 -72.87 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.501 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.7 m -148.56 114.0 5.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.918 0.389 . . . . 0.0 110.871 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 29.4 t -41.75 156.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.856 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.12 -75.75 0.12 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.47 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -126.8 37.91 4.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.892 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -99.03 163.94 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -140.04 157.59 45.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.88 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.429 ' O ' ' CE1' ' A' ' 96' ' ' HIS . 25.6 t70 -89.09 108.14 19.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 26.8 p -121.13 72.67 0.99 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.9 m -95.34 -38.24 10.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.819 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -116.58 19.73 14.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.86 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . 0.429 ' CE1' ' O ' ' A' ' 92' ' ' ASP . 21.9 m170 -99.35 157.46 16.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.886 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 94.8 m-85 -103.34 136.88 42.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 60.0 m-70 -96.07 127.0 41.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.41 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 25.2 t -117.19 131.95 68.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' OD1' ' A' ' 171' ' ' ASN . 2.2 t80 -97.64 138.78 34.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.44 ' CG1' HD23 ' A' ' 104' ' ' LEU . 88.4 t -125.05 115.42 44.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.152 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.03 -178.72 30.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 45.78 47.02 12.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.831 0.348 . . . . 0.0 110.903 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.44 HD23 ' CG1' ' A' ' 101' ' ' VAL . 32.7 mt -78.88 100.49 7.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -40.81 155.2 0.2 Allowed Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.634 0.73 . . . . 0.0 110.882 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -19.01 36.51 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.698 2.265 . . . . 0.0 112.292 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -82.02 -22.44 36.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.848 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 6.8 mm -60.91 137.97 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.111 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.437 ' O ' ' N ' ' A' ' 111' ' ' GLU . 52.8 p -133.0 140.5 47.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 109' ' ' THR . 91.2 m -36.74 -32.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.159 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 109' ' ' THR . 15.0 tt0 -73.74 -48.96 27.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.466 ' O ' ' N ' ' A' ' 116' ' ' ALA . 77.1 m-20 -58.6 -51.33 70.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.2 mt -50.76 -38.8 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.112 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.455 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 22.3 mttp -67.18 -35.34 79.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 22.9 t -92.95 -11.1 34.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.835 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.549 ' CB ' ' CD1' ' A' ' 163' ' ' LEU . . . -90.85 -32.89 15.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.083 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.7 m-85 -95.85 -5.02 42.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.567 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.67 -46.64 99.74 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.603 0.715 . . . . 0.0 111.087 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.696 2.264 . . . . 0.0 112.32 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.566 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 36.0 m-85 -93.2 -30.67 15.09 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.848 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.18 179.93 36.23 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.515 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.523 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 41.1 tptt -63.82 140.24 58.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.761 0.315 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.455 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 97.7 mt -108.34 130.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.9 p -98.31 -50.76 4.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.863 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -136.44 118.83 15.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -142.11 124.82 15.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.091 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -148.09 156.15 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -113.13 100.11 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.126 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.481 ' CG1' ' CE1' ' A' ' 140' ' ' TYR . 46.1 t -49.12 127.52 4.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -130.53 151.87 50.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.82 155.88 5.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 5.2 ptp -97.62 -17.79 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.857 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.75 -57.54 2.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.147 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.7 p -81.51 -32.78 32.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.123 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.43 28.38 61.77 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.474 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -101.88 162.62 12.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.804 0.335 . . . . 0.0 110.877 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 77.7 p -58.86 98.45 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.849 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.502 ' HB3' ' CE2' ' A' ' 140' ' ' TYR . 20.5 mmtt -42.95 -42.98 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.87 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.41 19.18 4.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.502 ' CE2' ' HB3' ' A' ' 138' ' ' LYS . 47.7 p90 -163.37 153.45 15.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.892 0.377 . . . . 0.0 110.951 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -151.22 -172.01 19.78 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -135.54 140.16 44.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.875 0.369 . . . . 0.0 110.875 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 28.6 t -145.52 107.64 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 3.5 t -89.19 154.06 20.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -129.46 150.34 50.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.865 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.523 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 16.0 m-85 -66.37 -33.52 75.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.895 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -129.52 165.44 21.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.441 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . 22.9 tttm -69.35 -61.97 1.57 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.7 tp -39.4 -63.19 0.58 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -40.77 -45.31 2.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.41 ' HB1' ' CG2' ' A' ' 99' ' ' VAL . . . -69.76 -60.75 2.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -40.41 -47.06 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 17.7 m-80 -47.66 -56.97 6.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.524 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -56.72 -53.72 54.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.435 HD12 ' CE2' ' A' ' 172' ' ' TRP . 47.7 mt -41.86 -35.39 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.8 t -84.5 -56.64 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 66.3 m-70 -62.09 -64.67 0.86 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.567 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 11.9 mmt -44.86 -47.01 11.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.56 102.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.74 -28.67 3.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.497 ' N ' ' O ' ' A' ' 158' ' ' MET . 62.7 tp60 -35.8 152.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.79 0.328 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.578 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 85.2 m95 -99.16 91.02 4.79 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.549 ' CD1' ' CB ' ' A' ' 116' ' ' ALA . 6.6 tt -86.77 -70.45 0.61 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.902 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.18 118.43 3.78 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.461 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.65 -92.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.488 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 14.7 mtt-85 -79.41 -178.38 6.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.759 0.314 . . . . 0.0 110.87 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.578 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 30.1 mt-30 -84.14 179.82 7.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.419 ' O ' ' N ' ' A' ' 160' ' ' GLY . 19.7 pt -136.87 171.95 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 41.3 ttt180 -134.64 160.5 37.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.858 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 17.1 p -145.12 152.54 40.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . 0.576 ' OD1' ' CD1' ' A' ' 100' ' ' PHE . 3.0 p30 -172.96 149.9 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.435 ' CE2' HD12 ' A' ' 155' ' ' ILE . 99.2 m95 -68.98 133.14 47.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.89 61.13 6.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.089 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 2.2 m -149.46 151.47 34.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.163 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.1 56.23 1.34 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -165.15 136.09 3.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.589 0.709 . . . . 0.0 110.944 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 140.37 42.42 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.648 2.232 . . . . 0.0 112.329 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 145.32 56.77 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.741 2.294 . . . . 0.0 112.342 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -65.58 144.04 98.8 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 0.0 111.097 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 119.38 6.34 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.73 2.287 . . . . 0.0 112.359 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 3.7 m -44.38 168.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.85 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -156.19 83.22 0.15 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.441 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 150.7 68.32 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.346 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 29.2 t -118.64 128.03 54.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 16.1 t -139.69 168.45 19.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.845 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.482 179.975 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.5 t -48.88 -46.39 42.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.844 0.354 . . . . 0.0 110.845 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -49.72 -47.31 50.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.838 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.29 145.04 44.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 3.1 t -88.38 153.41 21.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.849 0.357 . . . . 0.0 110.857 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 16.2 m -83.8 128.13 34.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.68 120.24 0.89 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 29.4 mt-30 -111.32 148.87 32.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.85 0.357 . . . . 0.0 110.926 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -113.3 41.65 2.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt 45.5 39.63 4.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.883 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -148.99 125.28 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 34.6 p -84.51 96.97 9.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 27.8 t -117.21 -49.25 2.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 t30 -64.22 -50.8 66.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -44.47 165.56 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.835 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.416 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 66.9 m-85 -96.68 140.95 30.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.888 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -100.57 131.89 46.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 58.5 t -122.27 124.48 71.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -91.2 140.02 30.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 77.7 t -127.6 126.78 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -121.93 -178.45 15.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.475 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 50.87 39.63 22.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.83 0.348 . . . . 0.0 110.852 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.0 mt -84.21 126.03 32.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 t -50.51 152.15 3.48 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.678 0.751 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 -14.18 35.83 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -91.8 -6.73 51.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.29 153.1 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 40.5 p -139.09 -179.96 6.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.8 m -69.92 -40.42 75.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.094 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -70.65 -36.74 73.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 116' ' ' ALA . 5.0 m-20 -58.09 -52.31 66.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.443 HG22 ' CG2' ' A' ' 143' ' ' VAL . 5.5 mt -60.69 -42.41 91.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 14.2 mtpt -59.69 -36.6 76.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.883 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.5 t -94.03 -17.4 22.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.456 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -84.62 -18.31 35.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.3 m-85 -111.63 -5.49 14.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.569 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.1 -46.2 99.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.559 0.695 . . . . 0.0 111.09 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.569 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.02 -19.57 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.563 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 45.0 m-85 -87.96 -36.93 16.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.96 -161.95 34.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.496 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.9 tmtt? -87.17 124.64 33.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.883 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 46.6 mt -96.54 134.28 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.107 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.6 p -100.13 -45.88 5.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -134.41 122.02 21.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.837 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -151.16 122.61 7.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.41 ' NE ' ' HB2' ' A' ' 142' ' ' PHE . 0.0 OUTLIER -146.62 159.49 43.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -114.15 99.95 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.143 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 23.5 t -51.73 134.14 13.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.11 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.443 ' HG2' ' N ' ' A' ' 137' ' ' SER . 35.5 mttt -124.98 168.15 13.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -75.73 152.11 37.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 mpp? -97.49 16.71 19.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -123.67 -38.26 2.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 13.7 p -111.25 -24.15 10.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 78.33 20.61 71.84 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 20.0 mmtp -106.63 154.19 21.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.761 0.315 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.443 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 28.3 m -51.18 120.11 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.852 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -60.18 -36.77 78.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.52 13.9 2.47 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.497 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -158.74 145.59 17.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 0.0 110.905 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -137.7 -175.85 14.11 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 0.41 ' HB2' ' NE ' ' A' ' 127' ' ' ARG . 41.6 m-85 -133.4 143.24 48.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.949 0.404 . . . . 0.0 110.888 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.443 ' CG2' HG22 ' A' ' 113' ' ' ILE . 45.0 t -145.51 127.38 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 32.2 t -105.13 151.15 24.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.457 ' CD2' ' HA ' ' A' ' 151' ' ' ALA . 73.6 m-85 -129.32 138.99 51.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -50.43 -42.47 53.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.941 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -127.27 164.55 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.914 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.475 ' O ' ' N ' ' A' ' 151' ' ' ALA . 13.7 ttmt -62.41 -62.37 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 148' ' ' LYS . 58.5 tp -34.58 -58.29 0.5 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.963 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -48.5 -42.47 33.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.475 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -70.69 -50.44 36.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.088 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -53.75 -46.12 70.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -45.99 -47.84 16.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.537 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -66.08 -63.18 1.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 154' ' ' ALA . 45.6 mt -34.76 -46.53 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.77 -61.19 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.164 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -65.8 -64.66 0.81 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.835 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.567 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 18.5 mmt -42.11 -48.6 4.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.41 100.71 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.508 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.21 -28.12 5.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.486 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.0 tp-100 -37.14 154.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.758 0.313 . . . . 0.0 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.4 m95 -98.7 90.99 4.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.508 ' CD2' ' C ' ' A' ' 163' ' ' LEU . 2.6 tt -85.06 -71.32 0.53 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.464 ' N ' HD21 ' A' ' 163' ' ' LEU . . . -122.24 118.25 3.6 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.456 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.93 -93.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.503 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.2 mtt85 -79.5 178.45 8.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.745 0.307 . . . . 0.0 110.862 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 86.2 mt-30 -79.96 178.85 7.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.417 ' O ' ' N ' ' A' ' 160' ' ' GLY . 32.1 pt -137.64 170.33 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.143 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 27.6 ttm-85 -133.68 154.98 50.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 5.7 p -138.87 147.27 42.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -157.63 151.86 24.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 76.9 m95 -72.44 130.1 39.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -114.61 117.69 31.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.077 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.6 t -145.94 147.28 31.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.156 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 19.2 ttp180 -72.13 115.92 11.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.867 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 8.3 pttt -64.55 123.96 84.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.617 0.723 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 148.55 65.52 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.654 2.236 . . . . 0.0 112.388 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.08 2.17 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.67 2.247 . . . . 0.0 112.367 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -43.97 150.0 0.63 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.562 0.696 . . . . 0.0 111.13 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 119.81 6.69 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.655 2.237 . . . . 0.0 112.332 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 7.1 t -51.98 168.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -111.19 73.0 0.21 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.455 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 151.57 69.47 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.65 2.234 . . . . 0.0 112.406 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 3.2 m -85.88 -58.06 2.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.861 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 60.5 p -60.24 -47.14 87.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.843 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.99 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.461 -0.255 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 27.4 t -52.55 143.82 14.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.847 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 43.7 t -44.27 -66.01 0.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 153.11 -85.75 0.14 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 p -89.82 40.21 0.99 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.871 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 38.6 m -147.8 129.7 15.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.856 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 133.98 -150.68 20.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 27.1 mm-40 -103.59 169.72 8.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.896 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.56 68.9 0.68 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.9 mmpt? -103.52 100.33 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -78.41 118.75 20.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.819 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 44.4 p -95.82 126.3 40.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.9 m -100.34 82.36 2.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.808 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.6 m120 62.45 41.39 9.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.861 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . 0.443 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 27.3 m170 -83.65 165.19 19.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.522 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 5.3 m-85 -99.81 133.91 43.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.846 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -95.35 135.67 36.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 78.8 t -121.43 121.22 64.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -85.02 145.9 27.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.7 t -135.45 128.1 47.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.15 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -118.08 -179.05 17.25 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.512 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 48.38 46.86 20.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.878 0.37 . . . . 0.0 110.845 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.431 ' O ' ' C ' ' A' ' 105' ' ' SER . 34.0 mt -88.13 105.35 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.936 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -36.09 153.39 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.654 0.74 . . . . 0.0 110.893 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -23.66 30.73 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.737 2.291 . . . . 0.0 112.327 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -79.3 -10.96 59.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.439 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 17.3 mm -65.69 143.8 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 65.2 p -126.14 164.32 21.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 66.8 m -63.72 -29.69 70.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.097 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -79.97 -34.2 38.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.429 ' O ' ' N ' ' A' ' 116' ' ' ALA . 98.1 m-20 -60.34 -55.53 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 mt -52.69 -40.12 33.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.462 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 62.7 mttt -64.34 -35.18 80.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.5 t -94.07 -9.71 35.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.429 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -95.14 -23.06 17.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.595 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 28.6 m-85 -105.92 -6.8 18.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.574 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.26 -45.98 99.68 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.559 0.695 . . . . 0.0 111.133 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.96 -17.1 0.7 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.653 2.235 . . . . 0.0 112.352 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.567 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 46.2 m-85 -90.66 -41.44 11.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.87 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 175.68 -174.16 46.69 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.7 tptm -71.46 138.43 49.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.751 0.31 . . . . 0.0 110.923 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.462 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 97.1 mt -104.01 139.34 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 5.8 t -116.49 -37.64 3.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -142.57 105.4 4.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -138.75 121.56 16.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.47 ' CZ ' ' HB3' ' A' ' 127' ' ' ARG . 2.4 ptp180 -153.11 154.71 35.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.88 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.4 p -107.72 100.05 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.148 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -50.04 133.87 9.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.436 ' HG2' ' N ' ' A' ' 137' ' ' SER . 20.5 mtmt -129.52 162.53 27.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.924 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -64.4 159.45 21.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 9.7 ttp -107.55 3.48 24.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -103.74 -45.67 4.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.121 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.3 p -110.52 -38.8 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.156 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 94.8 40.9 4.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.3 mttm -116.11 143.67 45.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.436 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 17.1 p -45.92 109.25 0.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 59.7 mttt -54.41 -35.67 63.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.99 19.35 4.02 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -161.2 146.69 14.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.909 0.385 . . . . 0.0 110.929 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.97 177.83 21.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -123.85 140.12 53.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.428 HG12 ' CE2' ' A' ' 145' ' ' PHE . 40.9 t -139.31 117.03 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 49.8 m -102.15 147.6 26.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.428 ' CE2' HG12 ' A' ' 143' ' ' VAL . 43.7 m-85 -123.49 145.13 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.884 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.443 ' HA ' ' CE1' ' A' ' 96' ' ' HIS . 19.2 m-85 -58.24 -36.65 73.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.952 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -121.34 174.26 6.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.869 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.522 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 44.6 tttt -85.01 -52.35 6.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.859 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.7 tp -47.68 -53.6 14.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.955 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -49.19 -44.36 43.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -62.53 -52.3 64.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -49.49 -43.11 45.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.903 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -48.24 -51.79 24.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.559 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.49 -65.89 0.62 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.057 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.441 ' C ' ' O ' ' A' ' 154' ' ' ALA . 80.9 mt -34.59 -34.79 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.124 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 154' ' ' ALA . 20.1 t -74.02 -63.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.163 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -69.44 -59.2 3.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.595 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 20.1 mmt -40.39 -51.11 2.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.15 102.33 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.491 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 87.94 -31.3 4.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.465 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.483 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.9 tp60 -34.27 150.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.561 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.3 m95 -96.96 91.03 5.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.937 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.418 ' CD1' ' CB ' ' A' ' 116' ' ' ALA . 5.9 tt -87.47 -70.56 0.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.907 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.439 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.52 117.35 3.67 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.475 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -91.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.457 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 15.0 mtp180 -79.55 -174.81 4.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.766 0.317 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.561 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 63.9 mt-30 -86.09 179.43 6.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.418 ' O ' ' N ' ' A' ' 160' ' ' GLY . 9.3 pt -136.84 169.31 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 30.2 ttp180 -129.25 162.87 26.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 32.6 p -141.38 150.5 42.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.091 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -163.02 164.32 25.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.437 ' CE2' HD11 ' A' ' 155' ' ' ILE . 94.2 m95 -93.65 107.95 19.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -84.11 37.64 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.064 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 30.0 m -132.04 132.33 43.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.126 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 26.1 ttt180 -109.45 148.11 31.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.14 145.95 49.76 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.602 0.715 . . . . 0.0 110.879 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 143.92 52.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.659 2.239 . . . . 0.0 112.376 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 143.81 52.04 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.683 2.256 . . . . 0.0 112.342 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -161.92 155.13 17.52 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.558 0.694 . . . . 0.0 111.078 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . 0.437 ' O ' ' C ' ' A' ' 181' ' ' SER . 54.2 Cg_endo -69.72 2.79 3.2 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.672 2.248 . . . . 0.0 112.376 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 180' ' ' PRO . 22.9 m -34.59 124.69 0.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.831 -179.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.405 ' HA2' ' HD2' ' A' ' 183' ' ' PRO . . . -99.43 101.14 2.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.491 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.405 ' HD2' ' HA2' ' A' ' 182' ' ' GLY . 54.4 Cg_endo -69.72 162.76 40.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.691 2.261 . . . . 0.0 112.338 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 44.5 p -152.56 146.35 25.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 29.6 m -152.44 144.59 23.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.838 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.464 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 13.7 t -97.57 114.3 26.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.888 0.375 . . . . 0.0 110.835 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.6 t -100.23 159.11 15.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.863 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.27 112.76 2.82 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.463 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.7 m -42.24 107.96 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.859 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.8 m -81.36 147.83 29.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.853 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 66.18 73.36 0.63 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.512 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 4.6 pm0 -78.12 161.46 27.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 0.0 110.913 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -133.34 90.28 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? 39.51 31.69 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.876 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -136.99 116.46 12.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 54.9 p -73.64 141.62 46.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.116 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.5 m -133.23 -53.46 0.9 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -102.17 31.76 3.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 36.1 m170 -119.4 156.54 29.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.532 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 74.5 m-85 -100.0 161.38 13.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.6 m-70 -114.22 134.35 54.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.427 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 97.9 t -124.58 118.25 52.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.137 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 16.5 t80 -88.47 129.73 35.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.18 111.99 36.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.113 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.83 -179.09 29.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 48.0 54.84 9.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.438 ' O ' ' C ' ' A' ' 105' ' ' SER . 33.8 mt -92.31 106.58 18.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.5 t -35.51 152.33 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.707 0.765 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -18.77 36.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.5 ' CG ' ' O ' ' A' ' 107' ' ' GLU . 9.3 tt0 -90.08 1.13 56.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.938 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 17.4 mm -74.72 147.38 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.128 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 51.3 p -132.04 163.58 28.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.086 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 25.5 m -58.71 -41.06 85.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.414 ' HG3' ' N ' ' A' ' 112' ' ' ASP . 0.3 OUTLIER -68.91 -35.4 76.8 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 179.978 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 116' ' ' ALA . 64.0 m-20 -60.17 -54.59 44.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.851 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.496 HG23 ' CD1' ' A' ' 117' ' ' PHE . 4.9 mt -57.99 -45.82 87.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.118 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.2 mtpp -57.44 -39.01 75.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.865 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 32.7 t -92.35 -9.15 42.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.839 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -95.64 -9.6 31.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.104 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.546 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.0 m-85 -120.26 -8.75 9.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.915 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.582 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.1 -45.97 98.9 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.639 0.733 . . . . 0.0 111.093 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.8 Cg_exo -47.98 -22.76 3.71 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.708 2.272 . . . . 0.0 112.321 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.498 ' CD2' ' HA ' ' A' ' 117' ' ' PHE . 39.7 m-85 -85.66 -35.62 20.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.863 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.59 174.7 34.63 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.453 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.646 ' CG ' ' CE1' ' A' ' 146' ' ' TYR . 0.8 OUTLIER -59.46 140.36 56.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.768 0.318 . . . . 0.0 110.877 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.445 ' CG2' ' HB1' ' A' ' 126' ' ' ALA . 82.7 mt -111.91 105.37 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 52.2 p -67.69 -32.15 72.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -159.67 123.93 3.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.445 ' HB1' ' CG2' ' A' ' 123' ' ' ILE . . . -146.51 125.45 12.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.097 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.2 ptm180 -149.12 166.76 27.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.3 p -120.36 99.85 8.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.173 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.46 HG12 ' CD ' ' A' ' 138' ' ' LYS . 43.3 t -51.18 119.77 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.412 ' CA ' ' HG3' ' A' ' 138' ' ' LYS . 29.0 mtmt -114.81 152.38 32.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -56.72 155.45 7.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.07 -6.79 31.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -102.82 -61.64 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.14 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.9 p -81.67 -34.57 30.65 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.12 33.46 26.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -117.68 152.12 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.8 m -43.34 108.95 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.46 ' CD ' HG12 ' A' ' 129' ' ' VAL . 6.4 mtpm? -51.41 -38.19 52.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 125.35 12.94 3.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.462 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 32.5 p90 -161.8 154.18 19.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.921 0.391 . . . . 0.0 110.919 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.06 -175.42 19.95 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.492 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -131.27 140.28 49.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.891 0.377 . . . . 0.0 110.858 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.8 t -144.86 109.58 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.12 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 73.7 m -86.71 141.92 28.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -120.61 140.43 51.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.646 ' CE1' ' CG ' ' A' ' 122' ' ' LYS . 4.4 m-85 -54.48 -50.38 67.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.933 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -115.59 171.02 8.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.532 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 59.0 tttt -80.28 -38.44 30.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.893 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.6 tp -57.35 -51.93 67.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.94 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -56.78 -41.47 77.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.896 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.427 ' HB1' ' CG2' ' A' ' 99' ' ' VAL . . . -66.3 -49.11 68.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.092 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -51.0 -43.91 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 62.9 m-20 -49.56 -48.93 48.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.483 ' HB1' ' CD2' ' A' ' 120' ' ' PHE . . . -66.09 -54.88 20.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.518 HD13 ' CZ2' ' A' ' 172' ' ' TRP . 97.5 mt -47.55 -35.29 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 77.5 t -82.24 -49.03 17.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.0 m-70 -71.51 -65.46 0.75 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.546 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 8.2 mmt -45.21 -46.52 12.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.48 103.6 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.458 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.41 -29.61 3.94 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.491 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.9 tp60 -40.98 149.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.926 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.438 ' N ' ' HG3' ' A' ' 161' ' ' GLN . 84.0 m95 -93.87 92.33 7.36 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.428 ' CD2' ' C ' ' A' ' 163' ' ' LEU . 5.5 tt -87.03 -72.34 0.52 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.487 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -120.33 117.11 3.43 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 56.09 -93.05 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.5 mpt_? -83.52 175.99 9.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.749 0.309 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.421 ' HG2' ' CE2' ' A' ' 162' ' ' TRP . 32.7 mt-30 -74.61 177.33 6.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.917 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 22.0 pt -136.23 165.09 30.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -129.56 152.33 49.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 29.8 p -130.07 160.46 33.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.166 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -169.81 163.35 9.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.518 ' CZ2' HD13 ' A' ' 155' ' ' ILE . 85.5 m95 -90.87 100.23 13.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -71.72 81.92 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.084 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.5 t -168.36 140.82 2.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.119 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.406 ' HD2' ' N ' ' A' ' 175' ' ' ARG . 10.8 mpt_? -103.63 133.54 48.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.47 143.24 31.75 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.523 0.677 . . . . 0.0 110.928 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . 0.406 ' HA ' ' HD2' ' A' ' 178' ' ' PRO . 53.6 Cg_endo -69.77 110.37 2.54 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.659 2.239 . . . . 0.0 112.366 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 177' ' ' PRO . 53.6 Cg_endo -69.76 103.32 1.14 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.713 2.275 . . . . 0.0 112.348 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -117.84 150.48 47.18 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.555 0.693 . . . . 0.0 111.112 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -164.46 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.718 2.279 . . . . 0.0 112.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 3.7 m -114.48 156.91 23.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.867 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -51.16 146.53 10.4 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 106.1 1.6 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.707 2.271 . . . . 0.0 112.304 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 8.7 m -161.14 146.14 13.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.877 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 8.2 m -71.65 -49.74 37.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.884 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.514 -179.971 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.3 p -77.68 143.55 38.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.9 0.381 . . . . 0.0 110.835 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.1 t -132.99 144.86 50.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.821 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.7 86.28 0.19 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.478 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 t -79.99 146.9 31.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 40.9 m -114.82 -59.02 2.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.851 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . 159.32 -125.86 1.56 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.477 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 88' ' ' GLY . 33.1 mt-30 -34.7 137.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 91' ' ' LYS . 42.6 mmtt -49.31 -30.14 7.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 90' ' ' LYS . 51.1 mmtt 36.32 53.17 0.97 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.846 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -99.26 92.76 5.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.896 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 18.8 p 43.96 29.46 0.32 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 88.5 p -68.45 -47.67 66.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 54.3 m-20 -77.52 -42.23 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 28.1 m170 -51.56 147.14 6.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.85 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.518 ' CD1' ' HD3' ' A' ' 148' ' ' LYS . 90.6 m-85 -102.44 145.09 30.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -100.27 138.68 37.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.846 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 25.2 t -124.23 130.23 73.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.184 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -91.77 138.09 31.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.7 118.31 46.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.62 172.05 17.95 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.513 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 54.53 53.37 10.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.407 ' O ' ' C ' ' A' ' 105' ' ' SER . 26.1 mt -87.93 104.48 16.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -38.03 153.57 0.13 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.702 0.763 . . . . 0.0 110.877 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -20.48 34.86 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.736 2.29 . . . . 0.0 112.31 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -83.21 -17.9 41.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 37.1 mm -57.61 156.95 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.123 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 40.5 p -143.87 170.61 15.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 56.9 m -66.13 -33.87 76.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -78.24 -35.21 48.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 67.1 m-20 -59.1 -55.89 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.841 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.422 HG22 ' CG2' ' A' ' 143' ' ' VAL . 7.8 mt -55.6 -42.68 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.11 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 17.7 mttp -61.64 -36.34 80.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.922 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.1 t -93.4 -10.41 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.848 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.47 ' CB ' HD12 ' A' ' 163' ' ' LEU . . . -94.02 -18.77 21.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 7.1 m-85 -111.57 -5.78 14.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.586 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.41 -45.71 99.89 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.593 0.711 . . . . 0.0 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.7 Cg_exo -48.04 -25.23 6.24 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.659 2.239 . . . . 0.0 112.382 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.554 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 54.0 m-85 -78.83 -38.84 37.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 168.02 179.13 40.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 35.2 tptt -59.41 142.21 52.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.77 0.319 . . . . 0.0 110.942 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.429 HG23 ' N ' ' A' ' 124' ' ' SER . 76.7 mt -114.33 137.1 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' SER . . . . . 0.429 ' N ' HG23 ' A' ' 123' ' ' ILE . 6.3 p -112.35 -23.6 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -154.02 143.31 21.41 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -174.77 123.62 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.06 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -148.2 159.35 44.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.6 p -112.55 99.9 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.165 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 80.5 t -51.32 126.59 6.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.152 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.467 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.2 mttm -125.84 159.94 31.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -62.52 159.51 15.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.873 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 ptp -102.38 -14.78 16.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.39 -38.02 8.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.076 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.6 p -105.78 -29.42 10.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.05 36.85 45.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.478 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mmtm -119.86 151.3 39.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.816 0.341 . . . . 0.0 110.893 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.467 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 56.2 p -45.97 113.26 0.59 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.873 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -59.57 -36.73 76.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.37 14.25 2.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.43 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 34.1 p90 -160.83 149.89 16.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.867 0.365 . . . . 0.0 110.937 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.28 -177.54 18.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -127.33 140.72 52.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.422 ' CG2' HG22 ' A' ' 113' ' ' ILE . 25.3 t -140.7 118.94 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.4 p -98.58 149.76 22.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -129.0 150.66 50.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -65.59 -40.73 93.03 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.88 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -125.24 162.81 23.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.526 ' HE3' ' CZ3' ' A' ' 172' ' ' TRP . 15.0 tptm -67.42 -58.5 4.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.9 tp -39.11 -51.03 1.9 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.924 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -51.92 -41.92 62.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -65.18 -53.31 46.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.062 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -49.46 -41.09 39.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -57.3 -52.68 64.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.471 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -61.76 -51.11 69.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.629 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 95.0 mt -43.96 -51.69 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 63.9 t -72.62 -59.76 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -50.92 -64.7 0.73 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 92.7 mmm -57.77 -39.24 77.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.97 94.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.46 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 91.87 -29.46 7.42 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.504 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.1 tp60 -36.3 152.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.761 0.315 . . . . 0.0 110.952 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.566 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.0 m95 -96.71 91.68 5.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.937 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.47 HD12 ' CB ' ' A' ' 116' ' ' ALA . 2.0 tt -88.64 -69.84 0.68 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.936 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -117.68 116.98 3.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 50.95 -90.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 164' ' ' GLY . 40.9 mtt180 -80.3 179.98 7.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.827 0.346 . . . . 0.0 110.836 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.566 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 45.7 mt-30 -81.77 179.84 7.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.466 ' CD1' ' HE3' ' A' ' 158' ' ' MET . 15.3 pt -139.14 163.52 26.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.117 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 46.9 ttt-85 -129.71 156.53 44.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.6 p -129.83 162.46 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -168.55 163.69 12.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.864 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.629 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 97.5 m95 -94.16 114.25 26.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -82.91 38.73 0.6 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.8 t -139.07 137.24 36.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.142 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 36.2 mtt180 -48.41 143.69 4.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.66 156.94 16.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.537 0.684 . . . . 0.0 110.904 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 116.43 4.56 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.65 2.233 . . . . 0.0 112.34 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.87 153.64 68.2 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.658 2.239 . . . . 0.0 112.328 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -154.81 145.19 15.92 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.575 0.702 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -45.91 1.41 Allowed 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.675 2.25 . . . . 0.0 112.348 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 18.8 m 59.19 45.76 13.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -98.79 146.33 18.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 141.32 45.13 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.658 2.238 . . . . 0.0 112.348 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 6.4 t -124.93 103.84 8.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.844 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.5 m -149.24 141.97 24.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.478 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 94.2 p -117.77 42.08 2.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.867 0.365 . . . . 0.0 110.86 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 15.3 m -66.94 118.89 11.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.814 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -105.18 -50.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 62.5 m 50.7 42.94 27.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.889 0.376 . . . . 0.0 110.891 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 3.0 m -68.56 96.25 0.69 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.47 -151.0 10.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 65.6 mt-30 -83.55 126.24 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.904 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -69.99 -47.68 61.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.99 120.77 28.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -81.08 -56.61 3.98 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.896 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 29.7 p -83.37 97.0 8.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.133 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.3 t -93.07 -47.97 6.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.853 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -58.94 -46.36 88.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 48.3 m170 -56.44 152.95 10.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.882 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.44 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 93.8 m-85 -90.65 135.37 33.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 82.4 m-70 -94.13 124.37 38.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 63.7 t -112.67 116.17 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.127 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.54 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 1.4 t80 -84.28 136.74 33.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.9 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.418 HG11 ' CD2' ' A' ' 104' ' ' LEU . 38.6 t -127.16 115.54 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.113 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.73 -174.48 25.8 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 46.29 50.74 11.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.903 0.382 . . . . 0.0 110.912 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.418 ' CD2' HG11 ' A' ' 101' ' ' VAL . 67.5 mt -91.28 110.61 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -42.41 153.68 0.3 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.696 0.76 . . . . 0.0 110.863 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -20.0 35.4 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.719 2.279 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -84.08 -14.02 51.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 20.4 mm -60.58 150.36 6.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.147 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.6 p -142.91 154.86 44.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.16 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 18.2 m -48.05 -42.18 27.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -65.47 -43.18 91.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.49 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.9 m-20 -59.22 -52.96 63.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.486 HG21 ' CE1' ' A' ' 117' ' ' PHE . 30.6 mt -60.96 -43.0 95.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 30.0 mttm -62.35 -36.17 81.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 38.6 t -94.01 -13.27 27.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.49 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -91.93 -13.21 31.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.507 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.1 m-85 -113.0 -9.8 13.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.03 -45.5 99.53 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.586 0.707 . . . . 0.0 111.06 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.97 -17.08 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.656 2.237 . . . . 0.0 112.341 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.555 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 38.9 m-85 -91.9 -40.36 11.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.14 174.56 44.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -67.54 120.9 14.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.812 0.339 . . . . 0.0 110.883 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 93.3 mt -85.77 140.08 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.118 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.5 p -110.58 -30.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -156.31 123.93 5.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -150.07 132.38 15.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.105 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 19.9 ptt180 -152.06 147.43 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -108.46 99.94 9.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.473 HG11 ' CG ' ' A' ' 138' ' ' LYS . 73.0 t -52.43 114.67 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 43.8 mttm -113.08 160.98 17.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -68.59 157.86 35.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.845 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 tpt -94.35 -27.86 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.65 -55.71 3.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 65.3 p -80.73 -38.78 28.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.136 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.43 18.62 61.91 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.479 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -105.75 146.9 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 110.906 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.1 t -39.03 114.26 0.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.473 ' CG ' HG11 ' A' ' 129' ' ' VAL . 12.3 mtpt -52.94 -38.79 62.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.97 20.65 1.44 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.525 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -171.39 154.04 3.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.96 0.41 . . . . 0.0 110.9 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.99 16.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.78 142.48 38.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.902 0.382 . . . . 0.0 110.831 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.48 HG12 ' CE2' ' A' ' 145' ' ' PHE . 43.3 t -147.3 108.97 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 44.3 m -92.25 149.27 21.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.48 ' CE2' HG12 ' A' ' 143' ' ' VAL . 36.6 m-85 -126.46 152.89 45.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -60.66 -45.66 93.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.908 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -127.72 160.14 32.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.896 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 151' ' ' ALA . 12.2 tptm -58.66 -60.3 4.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 49.0 tp -38.47 -47.4 1.27 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -57.94 -38.89 76.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.479 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -68.92 -57.07 6.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -43.32 -46.64 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -40.09 -47.48 2.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.555 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -76.93 -55.99 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.577 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 87.8 mt -42.93 -38.58 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 42.2 t -81.33 -48.7 18.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.118 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 -75.3 -67.11 0.69 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.507 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 23.2 mmt -42.17 -47.97 4.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.42 102.18 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.467 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.92 -34.51 3.55 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.479 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.445 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.4 tp60 -35.14 151.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.798 0.333 . . . . 0.0 110.927 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.556 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 86.1 m95 -98.15 91.36 5.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.418 ' CD2' ' C ' ' A' ' 163' ' ' LEU . 4.9 tt -85.41 -71.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.925 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.88 118.05 3.58 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.4 -93.05 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.514 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -82.13 170.35 15.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.759 0.314 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.556 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 80.8 mt-30 -71.3 -179.4 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 15.5 pt -136.98 168.77 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.5 ttp180 -131.88 158.71 40.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' THR . . . . . 0.424 ' CB ' ' HA ' ' A' ' 155' ' ' ILE . 0.9 OUTLIER -139.64 150.9 45.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.148 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 22.1 m-20 -166.96 158.46 12.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.577 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 98.0 m95 -85.48 100.54 11.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -56.06 -30.31 61.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 87.1 m -49.54 119.95 3.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.09 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 21.0 ttm180 -44.2 -62.46 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -147.03 134.4 10.27 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.546 0.689 . . . . 0.0 110.937 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 147.41 63.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.676 2.251 . . . . 0.0 112.372 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 140.08 41.8 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.692 2.261 . . . . 0.0 112.314 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -121.8 146.25 45.4 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 111.094 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 134.87 29.0 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.698 2.265 . . . . 0.0 112.329 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.9 p -86.61 131.58 34.12 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.885 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.58 -179.16 26.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 174.12 9.96 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.667 2.244 . . . . 0.0 112.308 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.5 t -115.14 -53.16 2.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.6 p -72.25 98.33 2.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.833 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.494 -179.991 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 64.4 m -106.59 115.25 29.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.897 0.38 . . . . 0.0 110.848 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 20.1 m -137.81 151.72 48.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.894 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -98.52 -145.9 19.56 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.7 t 69.09 42.4 1.26 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.885 0.374 . . . . 0.0 110.861 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 13.0 t -100.3 -46.3 5.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . 121.57 -82.7 0.35 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.507 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.402 ' C ' ' O ' ' A' ' 88' ' ' GLY . 9.8 tt0 -37.95 143.6 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.872 0.368 . . . . 0.0 110.962 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 47.6 mttt -101.65 42.61 1.12 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.06 83.26 1.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.881 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -49.78 6.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.0 p -93.94 96.57 9.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.15 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 t -101.41 -54.19 2.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.816 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -89.21 -41.77 12.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -40.43 153.28 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.849 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -91.03 133.0 35.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.928 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -96.58 122.3 39.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.861 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.5 t -109.81 126.04 66.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.2 t80 -90.48 138.49 31.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.461 HG12 ' CD2' ' A' ' 104' ' ' LEU . 92.7 t -128.7 124.55 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -115.65 -179.25 18.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 54.23 34.15 19.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.893 0.378 . . . . 0.0 110.917 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.461 ' CD2' HG12 ' A' ' 101' ' ' VAL . 40.5 mt -80.12 113.4 18.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -45.3 153.54 0.55 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.665 0.745 . . . . 0.0 110.832 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -25.88 28.44 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.671 2.248 . . . . 0.0 112.396 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -77.89 -7.72 57.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 6.4 mm -72.81 148.09 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.13 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.2 p -134.93 159.97 39.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.099 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 36.3 m -54.66 -44.65 73.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -63.05 -31.14 72.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.431 ' O ' ' N ' ' A' ' 116' ' ' ALA . 92.9 m-20 -69.7 -51.37 35.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.843 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 17.0 mt -58.49 -43.93 87.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.07 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 58.3 mttt -60.62 -34.9 74.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 28.1 t -93.96 -11.99 29.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.431 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -95.84 -13.72 23.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.088 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.494 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 13.3 m-85 -116.11 -11.56 11.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.588 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.5 -45.14 99.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.065 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -47.96 -17.14 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.313 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.568 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 59.5 m-85 -88.69 -41.34 12.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.855 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 173.59 148.98 6.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -40.96 128.92 2.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.0 110.866 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 58.4 mt -101.22 147.6 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 4.4 p -115.2 -36.59 4.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -140.92 133.81 29.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -164.2 128.76 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.088 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.422 ' HB2' ' NH1' ' A' ' 127' ' ' ARG . 0.3 OUTLIER -151.92 161.64 42.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.847 -179.926 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -118.48 99.85 8.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.144 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.408 HG12 ' NZ ' ' A' ' 138' ' ' LYS . 51.5 t -51.24 117.06 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.456 ' HG2' ' N ' ' A' ' 137' ' ' SER . 12.7 mttp -110.03 160.34 16.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.915 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -66.6 156.34 35.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.903 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 8.5 tpt -96.56 -10.41 27.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.66 -50.72 3.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.3 p -94.05 -29.26 15.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.65 17.89 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.438 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.1 mtpp -101.19 145.73 28.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.879 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.456 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 68.3 m -47.07 105.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.408 ' NZ ' HG12 ' A' ' 129' ' ' VAL . 12.6 mttp -44.03 -36.3 2.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 126.94 14.19 2.82 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.535 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -155.7 152.81 29.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.945 0.403 . . . . 0.0 110.901 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.459 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -148.43 -171.19 17.05 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -134.68 137.6 43.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.874 0.369 . . . . 0.0 110.868 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 92.5 t -137.47 118.05 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.134 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 88.8 p -98.08 152.85 18.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.41 ' CD2' ' HA ' ' A' ' 151' ' ' ALA . 26.7 m-85 -129.53 141.44 50.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.897 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -57.59 -40.86 79.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.862 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -117.7 178.81 4.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 45.7 tttt -87.18 -48.38 8.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 18.3 tp -48.02 -65.1 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -41.98 -51.32 4.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.41 ' HA ' ' CD2' ' A' ' 145' ' ' PHE . . . -55.52 -47.15 76.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -57.81 -42.1 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.914 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -51.3 -47.69 62.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.561 ' HB3' ' CD2' ' A' ' 120' ' ' PHE . . . -68.43 -53.97 20.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.062 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.429 ' CD1' ' CZ2' ' A' ' 172' ' ' TRP . 96.6 mt -41.37 -35.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 95.4 t -91.4 -47.43 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.148 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -63.82 -63.77 1.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 93.0 mmm -60.52 -37.99 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.929 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 94.06 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.58 -28.31 9.36 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.508 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . 73.3 tp60 -37.69 156.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.778 0.323 . . . . 0.0 110.92 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.556 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.6 m95 -98.95 90.99 4.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.403 ' C ' HD23 ' A' ' 163' ' ' LEU . 5.1 tt -86.15 -70.14 0.62 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.881 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.33 117.74 3.54 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.92 -92.7 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.3 mtt85 -80.89 179.66 7.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.314 . . . . 0.0 110.865 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.556 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 80.9 mt-30 -80.9 178.01 8.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.424 HD13 ' CE ' ' A' ' 158' ' ' MET . 29.4 pt -133.52 168.63 23.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 55.9 ttt180 -129.54 154.23 47.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.885 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 44.5 p -141.95 148.22 38.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.083 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -174.24 147.07 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.429 ' CZ2' ' CD1' ' A' ' 155' ' ' ILE . 96.5 m95 -61.7 122.72 16.02 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.959 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.63 -61.97 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 85.0 m -44.47 115.11 0.79 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.098 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 6.0 ptm180 -94.88 140.99 29.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.862 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -171.77 145.87 1.75 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.583 0.706 . . . . 0.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 148.7 66.2 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.712 2.275 . . . . 0.0 112.337 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 145.76 58.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.323 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -44.74 144.08 1.97 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 111.09 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 100.66 0.83 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.673 2.249 . . . . 0.0 112.354 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 13.9 t -88.72 108.67 19.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -39.04 146.19 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 131.92 22.2 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 0.0 112.326 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 20.7 t -160.84 157.72 27.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 41.4 m -42.28 -47.89 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.99 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.9 m 47.93 42.26 16.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.871 0.367 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 t -168.48 176.69 5.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.859 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -99.88 -177.92 30.71 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.3 p -165.44 177.87 7.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.918 0.39 . . . . 0.0 110.835 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 9.5 t -85.0 130.16 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.845 -179.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 164.01 -76.76 0.16 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.511 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -38.31 157.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.42 37.1 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.878 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 64.7 mttt -107.01 159.33 16.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -118.74 80.78 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 73.8 p -104.23 88.0 2.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.143 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.1 m -107.66 -59.62 1.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.85 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 96' ' ' HIS . 9.3 m120 -67.18 -51.85 48.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.919 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . 0.507 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 7.1 m170 -37.87 143.96 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.838 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.555 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 3.9 m-85 -91.14 139.61 30.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -93.16 131.86 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.926 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 48.2 t -124.05 129.34 74.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' ND2' ' A' ' 171' ' ' ASN . 1.8 t80 -99.42 149.86 22.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.5 t -137.41 130.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.25 173.29 16.27 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 139' ' ' GLY . 5.4 m-20 61.74 36.38 16.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.819 0.342 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 39.1 mt -80.18 110.87 16.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -38.66 153.06 0.16 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 121.634 0.731 . . . . 0.0 110.874 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -15.21 36.79 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.678 2.252 . . . . 0.0 112.307 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.416 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 7.6 tt0 -90.63 -6.19 54.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.909 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 25.5 mm -67.48 156.06 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 76.1 p -145.72 157.29 43.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 32.4 m -55.03 -39.06 68.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.074 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -71.58 -17.0 62.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -84.49 -46.32 11.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 7.7 mt -63.23 -38.76 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.4 mtpt -60.09 -36.12 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -92.84 -20.01 21.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.444 ' CB ' HD12 ' A' ' 163' ' ' LEU . . . -83.88 -16.92 42.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.8 m-85 -115.24 -7.55 12.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.581 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.72 -45.72 99.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.612 0.72 . . . . 0.0 111.114 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.0 Cg_exo -47.99 -18.1 1.04 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.654 2.236 . . . . 0.0 112.353 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.558 ' CD2' ' HB1' ' A' ' 154' ' ' ALA . 44.0 m-85 -89.77 -37.11 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . 0.422 ' HA3' ' CG ' ' A' ' 150' ' ' ASP . . . 172.97 -171.24 44.3 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.467 ' HD2' ' N ' ' A' ' 123' ' ' ILE . 0.0 OUTLIER -77.77 120.05 22.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.781 0.324 . . . . 0.0 110.929 179.97 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.467 ' N ' ' HD2' ' A' ' 122' ' ' LYS . 95.8 mt -91.91 101.12 12.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 93.1 p -67.84 -27.42 66.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.819 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -156.23 140.0 16.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -163.29 126.71 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.098 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -143.69 162.78 35.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.854 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.5 p -121.15 100.19 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.094 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.0 t -53.73 120.38 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.463 ' HG2' ' N ' ' A' ' 137' ' ' SER . 32.1 mttm -115.29 164.88 13.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -65.44 148.61 51.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -90.91 -3.44 57.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.856 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -111.5 -54.91 2.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.11 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 24.5 p -89.76 -27.19 20.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.59 28.13 59.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 pttt -108.58 138.83 44.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.78 0.324 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.463 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 14.6 t -41.85 109.17 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -51.19 -33.77 28.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.5 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 121.38 20.44 3.27 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.429 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -161.05 140.96 10.84 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.957 0.408 . . . . 0.0 110.924 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -136.61 -168.74 11.52 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -138.54 143.87 39.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.4 t -144.02 124.73 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.17 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.2 m -100.82 141.13 34.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.839 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -125.01 133.92 52.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.879 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.507 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.1 m-85 -53.35 -48.92 68.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -113.31 167.24 10.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.555 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 30.4 tttp -74.68 -42.29 58.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -46.86 -52.09 15.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.422 ' CG ' ' HA3' ' A' ' 121' ' ' GLY . 88.9 m-20 -54.42 -43.79 71.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -66.54 -61.12 2.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.072 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -41.16 -44.31 2.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 -55.29 -59.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.558 ' HB1' ' CD2' ' A' ' 120' ' ' PHE . . . -58.09 -54.25 49.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.508 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 85.4 mt -44.42 -35.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.75 -60.98 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.118 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.7 m-70 -56.68 -66.96 0.35 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.811 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.567 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 24.3 mmt -43.51 -47.12 7.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.93 95.22 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.458 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.77 -30.72 6.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.491 ' N ' ' O ' ' A' ' 158' ' ' MET . 7.5 tp60 -37.5 155.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.905 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.529 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 89.2 m95 -101.15 91.7 4.65 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.92 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.444 HD12 ' CB ' ' A' ' 116' ' ' ALA . 4.0 tt -86.18 -70.7 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.73 118.1 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.492 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -92.14 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.503 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -80.25 175.12 10.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.758 0.313 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.529 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 38.8 mt-30 -74.01 177.43 5.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 20.0 pt -135.31 164.62 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.134 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 29.7 ttp180 -128.01 154.13 45.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 22.4 p -142.68 154.05 43.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . 0.534 ' ND2' ' CD1' ' A' ' 100' ' ' PHE . 4.6 p30 -173.44 163.33 4.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.508 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 88.4 m95 -80.73 123.44 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.922 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -90.43 91.86 8.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.085 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 19.3 m -131.62 145.58 51.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -117.38 50.93 1.06 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.74 143.96 27.63 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.583 0.706 . . . . 0.0 110.913 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.86 153.93 67.92 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.669 2.246 . . . . 0.0 112.328 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 110.94 2.68 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.693 2.262 . . . . 0.0 112.333 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -114.4 146.07 35.09 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.533 0.682 . . . . 0.0 111.111 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 126.18 13.01 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.687 2.258 . . . . 0.0 112.317 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 11.5 m -96.75 127.53 42.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -72.87 144.62 35.38 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 132.99 24.55 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.685 2.257 . . . . 0.0 112.313 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 60.5 p -101.97 149.58 24.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.885 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.2 m -154.43 161.6 41.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 179.988 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 75.0 m -69.48 -52.77 23.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 5.3 t -172.56 154.98 3.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.812 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.29 -171.62 46.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.521 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.1 p -105.69 145.14 31.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.857 0.361 . . . . 0.0 110.848 -179.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 7.8 t -100.14 -64.26 1.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.852 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.24 -76.08 0.12 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.501 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -79.65 122.4 26.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.929 0.395 . . . . 0.0 110.908 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -149.41 -175.92 5.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.918 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? 50.75 49.4 21.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.906 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -87.37 58.37 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.9 p -96.04 73.81 3.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.136 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 35.7 t -110.35 -26.57 9.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.849 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 32.3 m120 -132.79 36.38 3.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . 0.491 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 28.2 m170 -96.0 160.35 14.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 26.9 m-85 -102.2 129.67 48.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -96.34 133.39 40.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 62.3 t -114.01 127.19 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -87.63 136.4 32.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.8 t -125.72 135.74 62.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.105 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.67 178.05 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 55.34 32.25 18.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 33.1 mt -78.85 118.84 21.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.6 t -50.36 152.47 3.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.82 23.45 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.678 2.252 . . . . 0.0 112.327 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -69.32 -13.2 62.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.466 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 14.6 mm -66.1 159.1 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.16 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 68.9 p -134.9 -175.82 4.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.178 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 97.3 m -78.97 -36.98 40.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.126 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -78.95 -16.35 57.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -72.29 -48.42 42.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.408 HG21 ' CG2' ' A' ' 143' ' ' VAL . 5.0 mt -62.25 -42.48 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.13 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 65.2 mttt -57.28 -35.26 69.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 6.9 t -93.83 -19.33 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.486 ' CB ' ' CD1' ' A' ' 163' ' ' LEU . . . -83.62 -20.09 34.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.089 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.559 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 12.9 m-85 -110.96 -7.16 14.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.53 -45.98 99.82 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.535 0.683 . . . . 0.0 111.076 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.01 -17.09 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.136 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.435 ' CD2' ' HA ' ' A' ' 117' ' ' PHE . 47.9 m-85 -90.69 -32.85 16.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.874 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.85 -165.6 37.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.512 ' HG2' ' CE1' ' A' ' 146' ' ' TYR . 72.4 tttt -78.84 131.71 36.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -104.44 113.64 41.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.105 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 3.2 t -79.46 -32.39 42.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -152.5 143.5 23.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -173.25 132.36 0.49 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.155 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -152.06 164.65 36.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -114.58 100.7 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -52.88 122.76 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.449 ' HG2' ' N ' ' A' ' 137' ' ' SER . 78.0 mttt -120.92 161.26 21.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -71.38 158.51 36.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.838 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -95.85 -15.83 22.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -94.63 -60.44 1.71 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 15.3 p -83.42 -31.19 26.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.16 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.2 25.6 63.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.3 mmtm -108.24 144.63 35.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.842 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.449 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 11.2 t -46.76 105.89 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -44.14 -37.82 3.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.22 10.08 3.52 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.8 p90 -153.56 153.13 31.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.946 0.403 . . . . 0.0 110.907 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -148.18 -171.73 17.42 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -130.97 142.12 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.897 0.38 . . . . 0.0 110.874 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.408 ' CG2' HG21 ' A' ' 113' ' ' ILE . 25.3 t -140.9 105.61 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.158 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 17.8 m -85.77 147.91 26.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.872 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.518 ' CD2' ' HA ' ' A' ' 151' ' ' ALA . 11.1 m-85 -129.23 129.21 44.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.512 ' CE1' ' HG2' ' A' ' 122' ' ' LYS . 21.1 m-85 -43.8 -46.96 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.95 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 23.7 m-20 -114.32 -178.87 3.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.853 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.545 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 25.9 tttm -87.1 -48.74 7.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.901 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.1 tp -50.11 -64.97 0.65 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 20.2 p-10 -39.73 -51.88 2.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.518 ' HA ' ' CD2' ' A' ' 145' ' ' PHE . . . -60.41 -58.37 8.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.082 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -43.58 -47.39 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -45.36 -50.64 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.461 ' O ' ' N ' ' A' ' 158' ' ' MET . . . -61.67 -52.34 64.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.098 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 92.1 mt -44.15 -39.54 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.8 t -77.29 -48.48 24.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 64.8 m-70 -72.05 -65.56 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.559 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.3 mmt -43.3 -49.61 6.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.2 96.6 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.455 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.59 -30.29 7.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.482 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.473 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.8 tp60 -40.16 154.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.915 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.56 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -98.92 91.17 4.92 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.486 ' CD1' ' CB ' ' A' ' 116' ' ' ALA . 5.6 tt -85.54 -73.14 0.46 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.466 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.94 117.17 3.57 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.477 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.69 -92.7 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.458 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -80.95 -177.29 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.861 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.56 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 33.3 mt-30 -82.5 177.15 8.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.492 ' CD1' ' SD ' ' A' ' 158' ' ' MET . 41.9 pt -134.4 173.95 13.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.138 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -136.76 158.46 44.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.04 156.1 47.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -163.88 168.25 19.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.879 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -94.83 105.68 17.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.951 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -72.27 103.88 3.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.1 t -145.85 128.84 16.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 66.6 mtm180 -84.38 133.85 34.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.884 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 15.8 ttpt -170.18 132.7 1.03 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.525 0.679 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 139.5 40.42 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.707 2.271 . . . . 0.0 112.368 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -178.93 2.55 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.653 2.235 . . . . 0.0 112.327 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -132.79 146.96 63.6 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.559 0.695 . . . . 0.0 111.084 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 131.23 20.79 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.633 2.222 . . . . 0.0 112.363 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 8.0 t -144.75 159.06 43.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.854 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 120.11 145.37 7.42 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -16.8 37.96 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.671 2.247 . . . . 0.0 112.352 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 23.0 t 51.3 36.15 15.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 5.0 t -111.54 -58.01 2.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.86 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.515 179.996 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 25.1 t -149.42 135.96 19.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 0.0 110.849 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 5.3 t -108.46 97.93 7.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.859 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.4 -118.96 0.23 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.0 m 46.85 51.52 12.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 110.887 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.0 p -118.51 142.72 47.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.11 -168.33 29.65 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.517 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -103.45 -2.11 27.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.893 0.378 . . . . 0.0 110.928 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 11.7 ttmt -84.23 110.69 18.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.3 mtmt -83.05 45.98 1.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.88 129.07 38.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 73.3 p -64.95 129.37 39.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.149 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.3 m -128.32 -49.8 1.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.83 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -127.21 36.98 4.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.887 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 38.5 m170 -105.3 155.41 19.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.527 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 85.3 m-85 -86.89 124.92 33.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -93.02 134.82 34.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 28.9 t -115.82 128.47 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.17 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -89.82 131.08 35.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.46 HG12 ' CD2' ' A' ' 104' ' ' LEU . 82.2 t -119.99 133.38 66.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.133 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -125.35 -178.43 15.31 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.526 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 47.4 43.58 15.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.883 0.373 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.46 ' CD2' HG12 ' A' ' 101' ' ' VAL . 45.1 mt -79.57 97.02 6.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -35.74 153.64 0.07 OUTLIER Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.684 0.754 . . . . 0.0 110.839 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.83 -14.6 36.09 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.622 2.215 . . . . 0.0 112.341 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -89.82 -3.62 58.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 15.1 mm -76.79 156.86 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.079 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 26.7 p -142.19 160.93 39.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.184 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 21.0 m -56.14 -33.43 65.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.173 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -74.6 -39.08 62.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.5 ' O ' ' N ' ' A' ' 116' ' ' ALA . 19.2 m-20 -55.06 -57.44 11.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.462 HG22 ' CG2' ' A' ' 143' ' ' VAL . 28.1 mt -52.77 -39.79 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.128 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.428 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 6.9 mtpm? -62.89 -41.86 99.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.6 t -90.53 -10.17 44.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.877 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.5 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -93.27 -23.44 18.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.128 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' PHE . . . . . 0.566 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.7 m-85 -105.05 -6.98 19.5 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.572 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -55.15 -46.43 99.68 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.553 0.692 . . . . 0.0 111.083 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.572 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.4 Cg_exo -47.96 -19.0 1.32 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.354 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.479 ' CE1' ' HA ' ' A' ' 154' ' ' ALA . 44.2 m-85 -89.41 -50.24 6.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.81 165.7 33.69 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.455 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -50.83 131.54 26.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.428 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 57.3 mt -99.44 117.48 44.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 57.8 p -86.93 -31.21 20.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -152.1 122.87 7.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.839 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -149.13 114.21 5.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.129 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.1 155.15 47.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.905 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 5.0 p -112.51 99.94 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.178 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 25.9 t -52.65 122.81 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.106 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.417 ' C ' ' HG3' ' A' ' 138' ' ' LYS . 4.3 mtmp? -117.16 156.76 27.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.886 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -58.16 151.36 19.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.894 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' MET . . . . . 0.403 ' O ' ' SD ' ' A' ' 132' ' ' MET . 0.0 OUTLIER -96.47 16.34 18.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -131.14 -56.38 1.03 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.1 p -84.53 -28.46 26.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.12 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.77 23.17 62.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.494 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.404 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 13.8 mmtp -108.48 167.35 10.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.777 0.322 . . . . 0.0 110.911 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 80.1 p -57.07 117.65 4.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.867 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.417 ' HG3' ' C ' ' A' ' 130' ' ' LYS . 41.5 mttt -60.54 -39.53 88.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.62 16.72 2.22 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.511 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -166.08 151.42 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.902 0.382 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.56 -171.9 14.09 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -138.69 139.33 38.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.462 ' CG2' HG22 ' A' ' 113' ' ' ILE . 54.4 t -145.09 108.22 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 6.0 m -86.05 154.75 21.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -130.7 141.46 50.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.874 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -60.42 -32.86 71.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -125.54 162.35 25.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.934 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.527 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 70.8 tttt -73.94 -47.87 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -52.04 -43.05 63.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -60.29 -34.26 73.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.836 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -74.51 -45.22 47.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.117 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 17.0 mt-10 -58.22 -42.14 85.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -53.14 -54.87 29.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.479 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . . . -62.42 -55.88 23.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.431 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 79.2 mt -42.0 -37.78 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 82.5 t -80.15 -58.84 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.173 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -59.64 -65.42 0.68 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' MET . . . . . 0.566 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.7 mmt -42.54 -48.12 5.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.54 104.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.484 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.81 -31.46 3.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.496 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . 0.499 ' N ' ' O ' ' A' ' 158' ' ' MET . 34.1 tp60 -37.28 149.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' TRP . . . . . 0.57 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 81.5 m95 -96.24 93.55 6.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.455 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.5 tt -86.36 -70.43 0.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.97 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -125.6 118.81 3.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 58.4 -95.28 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -84.86 170.26 13.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.57 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 39.0 mt-30 -68.7 172.28 6.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 14.9 pt -129.59 164.7 31.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.159 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . 0.437 ' HG3' ' N ' ' A' ' 170' ' ' THR . 21.0 tpp180 -125.05 156.44 38.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.922 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' THR . . . . . 0.437 ' N ' ' HG3' ' A' ' 169' ' ' ARG . 72.2 p -144.52 156.87 44.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -174.37 173.58 2.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' TRP . . . . . 0.431 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 98.2 m95 -90.91 108.55 19.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -44.99 -56.94 4.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.042 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.0 t -108.33 136.21 48.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -128.34 123.94 35.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.833 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -106.38 87.09 2.42 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.635 0.731 . . . . 0.0 110.928 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 125.79 12.56 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.67 2.247 . . . . 0.0 112.355 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 163.49 38.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.683 2.255 . . . . 0.0 112.38 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -91.59 157.02 42.61 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.6 0.714 . . . . 0.0 111.067 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.78 2.83 3.19 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.674 2.25 . . . . 0.0 112.379 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 35.4 t -82.05 143.36 31.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.76 146.53 4.35 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 168.67 20.92 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.368 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 m -139.5 161.24 37.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.83 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 4.1 m -129.75 137.68 50.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.829 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.455 -179.998 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 61.1 m170 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.822 0.344 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -107.86 121.53 44.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -84.09 123.97 30.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.0 t -112.3 122.86 67.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.105 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.522 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 2.1 t80 -83.02 141.21 32.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.854 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.493 HG22 HG22 ' A' ' 170' ' ' THR . 96.1 t -135.55 110.67 11.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.155 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.12 -174.25 30.26 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 45.73 52.6 9.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.429 ' O ' ' C ' ' A' ' 105' ' ' SER . 21.3 mt -91.41 100.28 13.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -36.19 153.56 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.692 0.758 . . . . 0.0 110.869 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -27.23 26.67 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.726 2.284 . . . . 0.0 112.317 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -75.97 -12.41 60.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.496 HG22 ' N ' ' A' ' 109' ' ' THR . 24.1 mm -63.45 157.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.157 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 108' ' ' ILE . 77.7 p -145.66 144.04 30.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.168 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.637 ' OG1' HG12 ' A' ' 128' ' ' VAL . 76.5 m -44.64 -38.08 4.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -70.89 -35.96 72.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 116' ' ' ALA . 27.1 m-20 -63.58 -52.14 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.431 HG23 ' CE1' ' A' ' 117' ' ' PHE . 51.9 mt -56.67 -46.04 82.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.599 ' O ' HD12 ' A' ' 123' ' ' ILE . 68.0 mttt -56.7 -33.87 66.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.963 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -94.01 -18.44 21.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.652 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -85.3 -13.05 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.12 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.47 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.7 m-85 -115.87 -6.55 12.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.852 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -57.68 -46.11 99.78 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.571 0.7 . . . . 0.0 111.118 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.93 -17.19 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.649 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 48.0 m-85 -90.47 -48.18 7.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -176.45 175.56 47.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.467 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.8 tptp -62.86 134.83 56.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.771 0.32 . . . . 0.0 110.882 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.599 HD12 ' O ' ' A' ' 114' ' ' LYS . 77.3 mt -101.31 133.04 45.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 39.8 t -106.76 -40.43 5.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -143.48 122.52 12.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -149.94 133.15 16.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.597 ' HA ' HG23 ' A' ' 110' ' ' THR . 22.2 ptt180 -155.41 153.15 29.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.637 HG12 ' OG1' ' A' ' 110' ' ' THR . 7.3 p -115.49 100.0 9.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.565 HG11 ' OH ' ' A' ' 140' ' ' TYR . 78.8 t -49.85 114.3 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.133 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.483 ' HG2' ' N ' ' A' ' 137' ' ' SER . 41.7 mttt -118.07 155.67 29.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.21 149.58 49.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 mmt -91.92 -8.73 45.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.71 -58.52 2.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.092 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 11.8 p -87.69 -38.54 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.11 34.38 14.9 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -118.3 138.96 52.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.77 0.319 . . . . 0.0 110.905 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.483 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 21.4 t -40.9 104.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.89 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 21.3 mttp -45.25 -36.76 4.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.926 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.31 23.37 2.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.501 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.565 ' OH ' HG11 ' A' ' 129' ' ' VAL . 52.4 p90 -165.52 143.06 5.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.929 0.395 . . . . 0.0 110.914 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.15 -173.37 19.73 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.442 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -133.24 141.16 47.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.907 0.384 . . . . 0.0 110.906 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.19 106.34 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 50.9 m -86.36 154.29 21.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -130.89 147.22 52.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -60.96 -40.72 94.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.94 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -122.76 176.23 6.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -83.54 -55.68 4.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 19.1 tp -42.75 -53.97 4.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -51.6 -45.78 63.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -61.0 -51.54 68.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -50.02 -42.62 49.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.891 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -52.2 -48.98 64.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.649 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.0 -52.34 36.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.09 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.625 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 88.5 mt -44.03 -38.78 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.146 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.92 -54.53 8.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.114 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -58.84 -64.16 1.04 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 89.5 mmm -57.54 -39.72 77.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.69 93.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 94.31 -29.5 8.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.493 ' N ' ' O ' ' A' ' 158' ' ' MET . 71.8 tp60 -38.86 148.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.361 . . . . 0.0 110.917 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.575 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 91.1 m95 -90.7 92.54 8.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.652 HD11 ' CB ' ' A' ' 116' ' ' ALA . 3.4 tt -88.7 -69.81 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.934 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.14 117.03 3.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.445 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.57 -91.3 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.494 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.3 mpt_? -83.14 175.73 9.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.859 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.575 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 51.0 mt-30 -77.08 177.43 7.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.502 HD11 ' HE3' ' A' ' 158' ' ' MET . 19.8 pt -137.35 162.69 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.07 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.3 mmt180 -118.98 165.07 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.493 HG22 HG22 ' A' ' 101' ' ' VAL . 3.8 p -149.81 141.4 23.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.108 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 -159.88 165.17 32.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.625 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 91.9 m95 -83.95 84.17 7.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.522 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.828 0.346 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -103.03 128.14 50.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 29.6 m-70 -83.4 131.85 35.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.831 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.415 HG21 ' HB1' ' A' ' 151' ' ' ALA . 58.6 t -118.51 124.37 73.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.099 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.436 ' CZ ' ' HB2' ' A' ' 140' ' ' TYR . 10.4 t80 -86.41 138.85 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.661 ' CG1' HD21 ' A' ' 104' ' ' LEU . 92.7 t -132.34 111.8 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.097 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.31 -175.32 26.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 49.35 41.66 20.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.661 HD21 ' CG1' ' A' ' 101' ' ' VAL . 67.9 mt -85.78 108.02 17.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.8 t -35.94 152.16 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.658 0.742 . . . . 0.0 110.855 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -19.43 35.88 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.684 2.256 . . . . 0.0 112.316 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -87.81 1.4 54.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 15.8 mm -75.38 146.34 9.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.123 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.6 p -139.59 145.79 39.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.175 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.409 ' OG1' HG12 ' A' ' 128' ' ' VAL . 88.6 m -39.01 -35.97 0.25 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.192 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -67.34 -48.89 66.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 116' ' ' ALA . 8.8 t0 -54.39 -52.72 60.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.457 HG23 ' CE1' ' A' ' 117' ' ' PHE . 64.6 mt -56.69 -42.68 77.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.159 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.439 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 36.0 mttt -63.51 -37.56 87.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.932 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -92.55 -8.93 42.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.841 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -97.4 -23.59 16.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.061 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 22.7 m-85 -105.29 -11.59 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.583 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -52.51 -45.9 95.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.603 0.716 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.3 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 0.0 112.336 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.625 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 58.7 m-85 -90.31 -51.19 5.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -178.46 158.64 23.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.498 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.4 tptt -48.64 128.7 15.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.712 0.291 . . . . 0.0 110.856 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.557 HG21 ' HB2' ' A' ' 126' ' ' ALA . 60.0 mt -96.39 137.76 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 10.6 t -112.88 -39.52 4.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.865 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -134.92 103.0 5.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.557 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -136.18 131.5 34.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 22.5 ptt180 -155.55 156.38 35.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.6 p -118.62 100.44 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.107 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.59 HG12 ' HG3' ' A' ' 138' ' ' LYS . 75.8 t -52.34 122.81 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.104 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -119.03 155.53 31.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.883 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.95 148.66 51.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 35.1 mtm -95.46 -9.41 32.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -91.13 -52.5 4.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.086 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.7 p -100.89 -40.38 7.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.152 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.59 26.25 8.21 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.48 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -109.3 149.27 29.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.915 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 11.9 m -43.09 114.65 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.824 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.59 ' HG3' HG12 ' A' ' 129' ' ' VAL . 13.2 mtpt -53.6 -39.82 65.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.927 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.77 19.34 1.83 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.555 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 44.2 p90 -167.53 150.28 6.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.899 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.65 -171.5 16.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.453 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -136.48 136.91 39.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.907 0.384 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 70.2 t -140.53 108.31 2.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.182 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.3 t -93.52 141.82 28.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -117.27 147.21 42.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -57.79 -38.22 75.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -124.95 155.64 39.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.87 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -61.43 -60.55 3.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 21.1 tp -40.01 -49.95 2.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -49.49 -40.68 38.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.845 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.415 ' HB1' HG21 ' A' ' 99' ' ' VAL . . . -69.3 -48.87 60.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.07 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -52.57 -38.89 60.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.924 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -56.53 -54.5 45.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.625 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.31 -61.62 2.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.533 HD13 ' CE2' ' A' ' 172' ' ' TRP . 68.3 mt -38.64 -39.73 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.159 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 20.3 t -70.55 -64.37 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.132 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 77.6 m-70 -63.63 -61.17 2.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 29.0 mmt -43.9 -48.44 8.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.44 92.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 97.68 -30.1 9.88 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.525 ' CD ' ' N ' ' A' ' 162' ' ' TRP . 9.3 tm0? -36.74 154.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.811 0.338 . . . . 0.0 110.863 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.586 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 77.1 m95 -101.43 91.24 4.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.978 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.549 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.2 tt -84.29 -70.89 0.54 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.921 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -125.58 120.33 3.82 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.458 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 57.37 -95.3 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -81.15 179.26 7.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.744 0.306 . . . . 0.0 110.921 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.586 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 53.9 mt-30 -79.57 -178.43 6.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.434 ' O ' ' N ' ' A' ' 160' ' ' GLY . 20.8 pt -136.66 162.19 35.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.7 ttm180 -126.4 144.07 50.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.519 HG21 ' HA ' ' A' ' 155' ' ' ILE . 1.3 p -121.6 153.18 38.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' ASN . . . . . 0.416 ' CG ' ' O ' ' A' ' 170' ' ' THR . 12.0 m120 -169.15 159.97 9.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.533 ' CE2' HD13 ' A' ' 155' ' ' ILE . 94.9 m95 -89.41 129.42 35.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.07 179.881 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 96' ' ' HIS . . . . . 0.441 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 38.1 m170 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.798 0.332 . . . . 0.0 110.885 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -104.72 121.4 43.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 5.2 m-70 -89.3 134.42 34.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.21 122.1 68.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 45.4 t80 -84.91 141.43 30.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.6 t -125.73 143.05 40.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.44 159.22 23.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.459 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 t0 68.06 33.77 4.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.88 0.372 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.49 HD12 ' C ' ' A' ' 140' ' ' TYR . 31.3 mt -70.91 99.06 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.4 t -35.85 153.22 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.739 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -18.93 36.6 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.335 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.452 ' CG ' ' O ' ' A' ' 107' ' ' GLU . 9.6 tt0 -87.71 -3.43 58.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.438 HG21 HD22 ' A' ' 104' ' ' LEU . 18.1 mm -69.36 144.59 13.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.6 p -134.49 148.8 50.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.118 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 88.4 m -50.87 -30.71 15.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.183 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -78.23 -23.16 47.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -78.91 -48.92 13.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.507 HG23 ' CD1' ' A' ' 117' ' ' PHE . 17.5 mt -57.85 -42.42 82.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.144 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.3 mttt -58.45 -43.98 89.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.7 t -81.94 -16.87 49.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.487 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -89.5 -20.11 24.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.066 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.3 m-85 -108.63 -10.59 15.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.855 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.585 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.12 -45.43 99.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.57 0.7 . . . . 0.0 111.042 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -47.98 -17.03 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.706 2.27 . . . . 0.0 112.33 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.65 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 34.6 m-85 -93.58 -32.13 14.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.16 178.79 36.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.579 ' HG3' ' CE1' ' A' ' 146' ' ' TYR . 32.0 tptt -62.82 143.68 57.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.802 0.334 . . . . 0.0 110.877 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.533 HG21 ' HB2' ' A' ' 126' ' ' ALA . 62.6 mt -113.57 126.24 70.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 1.7 t -93.77 -37.44 11.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -145.89 117.43 8.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.533 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -146.43 119.2 8.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -148.45 163.27 37.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.509 ' O ' HG13 ' A' ' 128' ' ' VAL . 3.9 p -115.76 104.26 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.128 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.0 t -57.49 124.65 11.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -122.36 157.98 30.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.912 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -64.83 158.23 25.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.932 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 42.7 mmm -101.92 -13.13 17.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.883 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.36 -47.69 7.59 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.119 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.8 p -102.55 -38.86 7.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.104 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.28 32.79 9.25 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.9 mttt -111.84 155.5 23.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.741 0.305 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.1 t -55.23 102.61 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 65.0 mttt -45.03 -39.0 5.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.892 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.92 16.96 2.87 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.455 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.49 ' C ' HD12 ' A' ' 104' ' ' LEU . 32.8 p90 -160.5 145.81 14.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.976 0.417 . . . . 0.0 110.927 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -141.55 -176.17 15.64 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -129.82 142.15 50.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.869 0.366 . . . . 0.0 110.924 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 19.8 t -149.35 106.03 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.155 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 48.9 m -92.0 142.1 27.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.652 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 23.7 m-85 -112.42 144.67 41.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.579 ' CE1' ' HG3' ' A' ' 122' ' ' LYS . 8.5 m-85 -56.98 -35.75 69.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.557 ' ND2' ' N ' ' A' ' 147' ' ' ASN . 0.0 OUTLIER -127.15 179.7 5.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.901 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -86.98 -40.96 14.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 55.9 tp -52.44 -65.07 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.456 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 14.6 p-10 -43.8 -53.63 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.844 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.652 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -55.0 -57.16 12.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.066 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.441 ' O ' HG23 ' A' ' 156' ' ' VAL . 26.8 mt-10 -46.38 -47.21 18.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 64.6 m-20 -49.8 -55.09 15.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.65 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -57.05 -60.73 3.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.081 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.623 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 83.3 mt -39.31 -37.72 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.152 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 152' ' ' GLU . 90.4 t -77.76 -48.6 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.139 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -75.56 -62.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 23.2 mmt -45.31 -47.27 13.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.45 94.96 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.446 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 96.59 -30.69 8.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.474 ' N ' ' O ' ' A' ' 158' ' ' MET . 6.2 tm0? -38.25 157.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 110.923 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 87.1 m95 -102.56 95.0 5.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.958 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.522 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.3 tt -90.88 -70.5 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.414 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.09 116.77 3.53 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.505 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.42 -91.53 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -82.07 178.81 8.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.839 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 43.9 mt-30 -80.63 177.83 8.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 7.7 pt -137.3 170.19 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.111 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.4 ttm-85 -131.29 149.57 52.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.9 p -126.67 150.85 48.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -168.77 154.56 6.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.623 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.2 m95 -81.05 113.24 19.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.111 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 7.6 m-70 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.862 0.363 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -94.12 130.24 40.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' HIS . . . . . 0.507 ' CB ' ' HB3' ' A' ' 173' ' ' ALA . 54.6 m-70 -88.28 128.12 35.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 95.6 t -116.44 124.65 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -89.57 141.86 28.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 169' ' ' ARG . 61.2 t -131.59 134.89 60.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.46 17.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.479 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.96 36.09 23.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.879 0.371 . . . . 0.0 110.836 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.492 HD21 HG11 ' A' ' 101' ' ' VAL . 31.2 mt -81.1 110.03 16.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -41.61 153.31 0.27 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -23.64 30.52 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.336 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -75.84 -18.53 59.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.646 HD12 HD22 ' A' ' 163' ' ' LEU . 20.2 mm -66.33 133.09 31.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 60.8 p -121.21 151.42 39.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 52.9 m -43.98 -34.54 1.74 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.136 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -70.93 -43.81 67.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.4 m-20 -58.76 -53.83 53.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.608 HG23 ' CE1' ' A' ' 117' ' ' PHE . 43.3 mt -56.34 -38.68 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.542 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 7.0 mtpt -63.58 -39.13 93.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.3 t -93.3 -11.92 31.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.836 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.748 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.72 -20.94 21.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.09 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.608 ' CE1' HG23 ' A' ' 113' ' ' ILE . 19.6 m-85 -107.4 -8.65 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.73 -45.66 99.8 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.589 0.709 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -48.0 -17.07 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.283 . . . . 0.0 112.361 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.631 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.7 m-85 -90.73 -38.84 12.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.896 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.97 167.29 31.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -54.54 126.63 24.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.445 HD12 ' O ' ' A' ' 114' ' ' LYS . 85.7 mt -95.76 132.85 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.147 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 92.1 p -99.99 -44.92 5.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.1 120.65 13.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.542 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -143.21 128.32 18.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.099 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 -156.44 151.75 26.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.718 HG13 ' HE2' ' A' ' 130' ' ' LYS . 7.2 p -108.59 100.08 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 68.7 t -49.49 130.37 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.077 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.718 ' HE2' HG13 ' A' ' 128' ' ' VAL . 29.9 mtmt -125.55 167.75 14.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 30.3 t0 -68.53 157.33 36.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -94.57 -12.53 27.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.58 -62.55 1.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.6 p -81.08 -28.38 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.131 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.26 33.45 53.71 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.411 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 7.1 mmpt? -106.03 158.33 16.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.307 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.412 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 16.5 m -65.47 100.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 37.4 mttt -44.21 -36.77 2.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 121.17 18.58 3.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.485 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -156.71 142.45 17.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.908 0.385 . . . . 0.0 110.952 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.1 -169.76 12.26 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -134.23 142.38 47.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 73.1 t -144.83 110.55 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.136 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 15.8 m -89.67 145.01 25.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -121.88 149.18 43.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -58.63 -46.64 86.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -128.66 165.23 21.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' A' ' 151' ' ' ALA . 14.3 ttmt -62.13 -62.22 1.92 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 65.0 tp -38.19 -50.88 1.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -55.68 -39.62 71.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.907 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.602 ' HB3' ' HH2' ' A' ' 172' ' ' TRP . . . -67.02 -51.19 57.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.149 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.423 ' O ' HG23 ' A' ' 156' ' ' VAL . 5.5 mm-40 -50.14 -48.04 53.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -42.03 -36.59 1.16 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.631 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -86.0 -54.53 4.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.095 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.629 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 76.1 mt -47.67 -34.31 3.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.16 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 152' ' ' GLU . 46.7 t -81.37 -46.33 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.129 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -74.92 -65.26 0.89 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.892 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.72 ' HB2' HG21 ' A' ' 170' ' ' THR . 8.1 mmt -42.33 -48.66 5.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -35.51 103.04 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.467 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 82.08 -32.53 2.74 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.3 tp-100 -34.32 149.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.756 0.312 . . . . 0.0 110.966 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 90.8 m95 -99.89 92.51 5.32 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.926 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.748 HD11 ' CB ' ' A' ' 116' ' ' ALA . 7.0 tt -87.24 -71.04 0.58 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.583 ' HA3' HD11 ' A' ' 108' ' ' ILE . . . -120.63 117.67 3.59 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.483 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.94 -92.78 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.504 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.735 0.302 . . . . 0.0 110.864 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 71.5 mt-30 -77.15 -178.96 5.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 25.0 pt -137.96 163.68 29.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.724 ' O ' HG13 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -126.45 152.14 46.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.944 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.72 HG21 ' HB2' ' A' ' 158' ' ' MET . 16.4 p -134.16 158.46 43.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.156 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 171' ' ' ASN . . . . . 0.413 ' HB2' ' NH1' ' A' ' 169' ' ' ARG . 24.4 t-20 -172.07 173.18 4.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.843 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.629 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 83.8 m95 -95.04 106.97 19.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.507 ' HB3' ' CB ' ' A' ' 98' ' ' HIS . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.828 0.347 . . . . 0.0 110.866 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.532 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 58.2 m-85 -113.48 134.24 54.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -91.29 128.35 37.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 98.3 t -111.59 135.48 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.508 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 2.7 t80 -100.24 139.38 36.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 54.7 t -131.39 114.78 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.42 172.83 19.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 139' ' ' GLY . 1.6 m-20 58.71 37.73 25.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.359 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.508 HD12 ' C ' ' A' ' 140' ' ' TYR . 31.7 mt -71.88 101.08 2.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 104' ' ' LEU . 0.7 OUTLIER -36.64 155.23 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.663 0.744 . . . . 0.0 110.88 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -13.11 34.14 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -89.9 -16.72 29.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.894 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.483 HG21 HD22 ' A' ' 104' ' ' LEU . 10.7 mm -66.93 144.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 80.4 p -142.55 145.93 34.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.183 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 49.2 m -39.75 -37.49 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.101 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -68.27 -45.35 73.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.487 ' O ' ' N ' ' A' ' 116' ' ' ALA . 75.4 m-20 -64.32 -50.72 66.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CD1' ' A' ' 117' ' ' PHE . 13.1 mt -53.52 -45.4 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.475 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 13.3 mtpt -61.35 -35.64 77.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.2 t -91.54 -13.59 31.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.76 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.71 -17.59 21.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.058 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.578 ' CE1' ' SD ' ' A' ' 158' ' ' MET . 25.5 m-85 -108.34 -11.03 15.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.845 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.591 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.16 -44.79 99.06 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 0.0 111.106 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -48.06 -16.75 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.261 . . . . 0.0 112.341 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -94.31 -41.47 9.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 174.5 147.94 6.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -43.89 126.89 5.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 62.5 mt -91.63 134.33 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.9 p -100.29 -42.92 6.46 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -145.39 107.31 4.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.858 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HB1' HG22 ' A' ' 143' ' ' VAL . . . -137.34 135.46 37.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.077 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -157.6 165.99 34.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 128' ' ' VAL . 3.8 p -123.07 100.04 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.142 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 41.9 t -53.4 128.04 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.403 ' HG2' ' C ' ' A' ' 136' ' ' LYS . 49.6 mttt -121.26 171.31 8.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.82 159.29 31.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.85 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.424 ' N ' ' SD ' ' A' ' 132' ' ' MET . 0.3 OUTLIER -101.95 9.55 40.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.994 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -122.72 -44.01 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.5 p -98.92 -31.23 11.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.98 30.09 56.2 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.403 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 51.5 mmtt -114.06 155.14 26.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.1 t -50.67 110.9 0.46 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.852 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -53.32 -34.74 58.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.935 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 123.99 11.17 4.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.508 ' C ' HD12 ' A' ' 104' ' ' LEU . 48.8 p90 -154.97 159.24 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.892 0.377 . . . . 0.0 110.966 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -160.06 -167.95 21.35 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.476 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -141.37 152.39 44.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.38 . . . . 0.0 110.902 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.599 HG22 ' HB1' ' A' ' 126' ' ' ALA . 43.0 t -153.91 109.52 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.182 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 70.8 m -85.07 150.89 24.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -129.89 149.15 51.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.859 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -63.3 -43.55 97.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.927 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -120.06 157.96 27.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.532 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 57.3 tttt -65.51 -49.99 66.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.5 tp -47.65 -56.08 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -45.83 -39.46 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.407 ' HB1' ' CG2' ' A' ' 99' ' ' VAL . . . -67.8 -49.58 61.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.125 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.446 ' O ' HG23 ' A' ' 156' ' ' VAL . 23.6 mt-10 -51.47 -46.31 63.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.918 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -52.68 -47.9 66.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.875 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.27 -55.93 18.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.588 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 96.4 mt -50.0 -35.01 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 152' ' ' GLU . 74.3 t -78.98 -49.33 20.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.135 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.7 m-70 -72.67 -67.07 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.578 ' SD ' ' CE1' ' A' ' 117' ' ' PHE . 14.9 mmt -44.86 -47.28 11.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.53 101.22 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 84.5 -31.57 3.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.527 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.9 tp-100 -34.78 151.51 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.819 0.342 . . . . 0.0 110.91 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.58 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.9 m95 -97.02 90.63 5.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.92 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.76 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.5 tt -85.31 -70.08 0.61 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.1 117.94 3.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.506 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.78 -93.68 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 27.7 mtt85 -80.47 -179.73 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.733 0.302 . . . . 0.0 110.897 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.58 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 40.1 mt-30 -83.77 176.16 9.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.935 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.424 ' O ' ' N ' ' A' ' 160' ' ' GLY . 18.9 pt -131.81 167.79 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -130.91 149.23 52.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 20.1 p -126.54 162.09 26.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -173.0 156.9 3.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.913 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.588 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.0 m95 -87.07 119.19 27.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.139 179.884 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.0 m170 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.881 0.372 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.544 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 88.7 m-85 -89.43 154.35 20.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -111.77 135.77 51.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.421 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 60.7 t -126.65 121.07 57.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.156 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.405 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 87.6 t80 -86.14 139.34 31.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.903 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 169' ' ' ARG . 47.0 t -130.11 120.17 48.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.178 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -111.43 -175.36 20.09 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 46.34 43.64 11.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.871 0.367 . . . . 0.0 110.838 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.517 HD21 HG11 ' A' ' 101' ' ' VAL . 39.5 mt -85.0 110.1 18.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -39.67 153.44 0.19 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.686 0.755 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.408 ' HA ' ' HB2' ' A' ' 137' ' ' SER . 54.0 Cg_endo -69.75 -20.01 35.44 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 0.0 112.345 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -82.98 -20.62 34.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.876 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 46.8 mm -50.0 151.02 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.127 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 37.3 p -139.14 148.29 43.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.157 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.587 ' OG1' HG12 ' A' ' 128' ' ' VAL . 27.7 m -48.91 -38.11 21.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.153 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -71.89 -32.7 67.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.496 ' O ' ' N ' ' A' ' 116' ' ' ALA . 10.9 m-20 -65.21 -53.59 42.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 31.6 mt -56.25 -48.01 80.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.091 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.9 mttm -56.41 -39.32 72.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.913 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.4 t -92.37 -8.98 43.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.635 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -94.21 -13.9 26.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.121 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.581 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.6 m-85 -115.49 -11.6 11.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.595 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -49.82 -46.63 80.63 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.603 0.716 . . . . 0.0 111.157 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.595 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 63.8 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.695 2.263 . . . . 0.0 112.31 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.582 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 50.0 m-85 -92.42 -33.05 14.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.921 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.06 157.84 9.18 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.527 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 18.5 tptp -49.09 145.29 4.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.88 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 53.6 mt -115.21 143.42 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 51.4 p -108.26 -33.98 6.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.76 136.35 22.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -164.68 129.12 2.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.478 ' HA ' HG23 ' A' ' 110' ' ' THR . 9.0 ptp85 -150.42 154.23 37.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.723 HG13 ' HE2' ' A' ' 130' ' ' LYS . 7.4 p -113.12 100.08 9.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.423 HG11 ' OH ' ' A' ' 140' ' ' TYR . 47.1 t -51.74 114.26 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.723 ' HE2' HG13 ' A' ' 128' ' ' VAL . 32.3 mtmt -109.09 163.14 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 158.3 7.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.865 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 ttt -98.93 -8.52 25.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -108.06 -48.79 3.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.11 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.9 p -96.96 -24.45 15.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.089 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.92 19.97 78.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.468 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -95.99 143.29 27.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.47 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 37.3 m -47.61 106.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -50.15 -45.1 52.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 133.26 29.99 0.48 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.427 ' C ' HD12 ' A' ' 104' ' ' LEU . 41.3 p90 -171.98 144.68 1.74 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.956 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.446 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -145.96 -172.01 15.95 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.498 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -131.57 140.78 49.54 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.897 0.38 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.8 t -140.78 122.15 14.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.089 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 63.6 p -101.68 147.67 26.17 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.873 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.65 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 11.1 m-85 -125.36 148.68 48.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.833 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -64.5 -35.99 82.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.934 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -130.62 154.39 47.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.916 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.544 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 11.3 ttmt -60.1 -66.74 0.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.906 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 148' ' ' LYS . 14.9 tp -35.3 -59.49 0.52 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -47.47 -41.86 21.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.65 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -71.52 -54.07 11.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.5 ' HA ' HD12 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -47.82 -39.39 18.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.911 -179.948 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -52.3 -46.39 65.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.489 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.64 -53.21 44.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.5 HD12 ' HA ' ' A' ' 152' ' ' GLU . 81.9 mt -41.01 -35.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.123 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.4 t -89.23 -53.74 8.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -59.27 -62.45 1.88 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.838 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.582 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 83.7 mmm -64.04 -36.36 83.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.37 92.03 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.91 -28.58 12.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.7 tp-100 -38.61 155.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.882 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.604 ' CZ2' ' NE2' ' A' ' 167' ' ' GLN . 92.1 m95 -95.64 90.91 5.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.959 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.635 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.9 tt -87.09 -69.83 0.66 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.888 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.72 116.97 3.44 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.94 -91.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.8 mtt180 -82.63 178.14 8.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.838 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.604 ' NE2' ' CZ2' ' A' ' 162' ' ' TRP . 78.3 mt-30 -78.14 175.47 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.929 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.463 HD11 ' HB3' ' A' ' 158' ' ' MET . 32.9 pt -132.64 168.64 23.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.127 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.559 ' O ' HG13 ' A' ' 101' ' ' VAL . 65.2 ttt180 -126.39 160.87 29.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.899 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 31.7 p -146.8 147.58 31.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.134 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -160.77 164.05 31.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 11.7 m95 -79.14 83.37 5.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.951 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.123 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.1 m170 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.791 0.329 . . . . 0.0 110.846 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -96.96 128.97 44.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -87.71 119.6 28.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.412 HG13 HG12 ' A' ' 155' ' ' ILE . 65.6 t -109.79 119.75 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.13 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.425 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 3.2 t80 -84.14 145.4 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.469 HG13 ' O ' ' A' ' 169' ' ' ARG . 61.9 t -132.76 140.79 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -130.23 -169.37 12.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.501 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 44.9 36.71 2.0 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.831 0.348 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 40.9 mt -78.74 106.15 10.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.961 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -40.44 153.6 0.21 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.685 0.755 . . . . 0.0 110.844 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -28.31 25.51 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.733 2.289 . . . . 0.0 112.325 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -77.41 -7.4 56.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.862 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.568 HG22 ' N ' ' A' ' 109' ' ' THR . 9.5 mm -68.56 161.96 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.568 ' N ' HG22 ' A' ' 108' ' ' ILE . 56.4 p -142.96 172.1 13.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.474 ' OG1' HG12 ' A' ' 128' ' ' VAL . 15.5 m -69.0 -39.15 79.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -74.0 -17.95 60.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.93 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 17.9 m-20 -75.32 -54.54 6.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CE1' ' A' ' 117' ' ' PHE . 14.5 mt -53.62 -48.18 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.62 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 16.8 mtpp -54.57 -41.78 70.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -87.32 -15.88 36.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.881 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.604 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.28 -14.8 32.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.067 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.598 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 16.4 m-85 -114.65 -8.82 12.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.581 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.0 -46.28 98.69 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.594 0.712 . . . . 0.0 111.105 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.581 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.4 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.658 2.238 . . . . 0.0 112.388 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.572 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 56.6 m-85 -89.98 -32.87 16.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.81 171.14 26.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.492 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.576 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 0.0 OUTLIER -55.86 132.62 50.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.762 0.315 . . . . 0.0 110.872 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.409 HD13 ' HA ' ' A' ' 114' ' ' LYS . 96.5 mt -102.52 123.84 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.14 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 83.9 p -86.02 -49.69 7.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.841 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -143.84 117.6 9.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.852 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.62 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -141.75 134.31 28.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.473 ' CZ ' ' HB3' ' A' ' 127' ' ' ARG . 1.7 ptp180 -158.81 164.93 35.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.474 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.3 p -112.94 100.06 9.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.093 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -49.68 126.5 4.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.192 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -121.46 171.99 8.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -76.76 156.96 31.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.89 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 17.2 ttp -94.89 -11.79 28.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.92 -62.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 71.1 p -82.9 -30.69 28.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.98 28.45 60.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.5 mmtp -106.32 152.3 23.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.829 0.347 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 50.6 p -45.99 109.59 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.846 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -53.95 -36.3 62.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.97 12.81 4.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.503 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 30.8 p90 -162.64 146.73 11.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.907 0.384 . . . . 0.0 110.922 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -133.97 -169.59 12.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.479 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -136.99 141.87 42.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 41.4 t -145.04 108.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 13.3 t -88.48 150.98 22.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.49 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 57.6 m-85 -127.54 151.62 48.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.576 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 14.3 m-85 -69.38 -42.42 75.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -115.23 178.96 4.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.908 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.8 tttm -87.15 -41.59 13.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 14.4 tp -53.49 -65.06 0.63 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.459 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 12.4 p-10 -41.81 -53.97 3.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -53.95 -51.11 64.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.123 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -53.39 -44.81 68.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -50.25 -48.58 54.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.857 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.572 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -67.07 -60.56 2.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.101 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.586 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 97.4 mt -38.32 -41.26 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.3 t -79.66 -58.48 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 30.2 m-70 -57.81 -65.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.897 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.598 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 15.8 mmt -46.59 -45.84 19.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -40.16 91.77 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 99.77 -32.08 7.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.506 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.444 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.2 tp-100 -39.06 149.02 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.835 0.35 . . . . 0.0 110.92 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.563 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 78.9 m95 -95.31 91.65 6.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.632 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.1 tt -87.34 -71.71 0.55 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.497 ' HA3' HD11 ' A' ' 108' ' ' ILE . . . -119.89 119.26 4.18 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.476 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.39 -92.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.497 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -85.42 169.3 13.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.756 0.312 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.563 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 85.7 mt-30 -68.65 177.18 2.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 29.1 pt -135.8 169.87 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.469 ' O ' HG13 ' A' ' 101' ' ' VAL . 2.6 ptp180 -137.23 163.43 30.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.832 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 101' ' ' VAL . 42.8 p -140.18 163.51 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -162.86 157.77 21.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.586 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 82.6 m95 -88.69 96.96 10.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.925 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.847 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 8.8 m-70 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.566 ' CE1' ' HE3' ' A' ' 148' ' ' LYS . 85.2 m-85 -89.6 131.86 35.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -93.25 124.82 37.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.819 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 65.5 t -111.26 130.96 63.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.491 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 1.9 t80 -98.9 140.74 32.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.534 HG13 ' O ' ' A' ' 169' ' ' ARG . 21.5 t -130.55 134.99 61.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.114 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.75 172.79 16.45 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.534 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.0 t0 58.63 40.3 23.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 110.877 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.477 HD13 HG23 ' A' ' 128' ' ' VAL . 35.6 mt -77.28 97.58 4.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.912 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.6 t -35.0 152.45 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.655 0.74 . . . . 0.0 110.882 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 -14.13 35.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.728 2.286 . . . . 0.0 112.37 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -93.42 1.68 56.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 9.4 mm -76.77 146.82 8.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.109 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 57.6 p -134.43 158.99 42.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 90.0 m -57.22 -33.69 67.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.142 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -75.93 -17.67 59.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' CB ' ' A' ' 116' ' ' ALA . 11.9 m-20 -81.78 -48.08 12.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.475 HG23 ' CE1' ' A' ' 117' ' ' PHE . 30.9 mt -64.39 -39.58 86.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.142 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.42 ' O ' HD12 ' A' ' 123' ' ' ILE . 57.8 mttt -63.83 -42.83 97.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 1.3 t -86.08 -16.47 37.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 112' ' ' ASP . . . -85.51 -29.63 24.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.508 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 9.0 m-85 -100.39 -8.3 23.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.58 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.71 -46.45 99.36 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.569 0.7 . . . . 0.0 111.108 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.58 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.2 Cg_exo -47.98 -17.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.642 2.228 . . . . 0.0 112.358 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.514 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 46.4 m-85 -91.56 -36.4 13.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.09 176.9 40.02 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.3 tttt -68.5 121.2 15.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.758 0.313 . . . . 0.0 110.92 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.42 HD12 ' O ' ' A' ' 114' ' ' LYS . 56.8 mt -91.89 127.77 43.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.128 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.6 t -92.45 -42.34 9.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.882 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -142.66 124.56 15.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.892 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -154.73 126.81 7.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.7 ptm180 -150.55 156.32 41.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.6 p -108.59 99.95 9.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.115 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.6 t -51.84 122.55 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.459 ' HG2' ' N ' ' A' ' 137' ' ' SER . 69.4 mttt -115.92 172.45 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.901 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -75.25 143.51 43.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.893 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 25.3 tpp -89.28 3.41 52.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -106.64 -62.94 1.33 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.119 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.7 p -91.94 -27.53 17.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.144 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.38 30.34 22.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 137' ' ' SER . 49.1 mtmt -112.03 135.71 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.76 0.314 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.459 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 67.4 m -37.24 119.31 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.803 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -60.75 -42.35 97.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.46 26.91 0.64 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.443 ' C ' HD12 ' A' ' 104' ' ' LEU . 16.4 p90 -169.82 144.77 2.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.944 0.402 . . . . 0.0 110.904 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -138.4 -177.99 15.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.486 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -134.2 139.7 45.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 53.5 t -141.85 127.9 18.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.5 m -104.92 144.45 31.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 150' ' ' ASP . 19.6 m-85 -124.1 145.1 49.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.855 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -62.0 -46.95 86.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.966 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -118.45 165.8 13.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.566 ' HE3' ' CE1' ' A' ' 97' ' ' PHE . 10.9 ttmt -67.52 -56.19 10.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.945 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.7 tp -39.26 -53.9 1.87 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.403 ' HB3' ' CD1' ' A' ' 145' ' ' PHE . 65.0 m-20 -51.28 -39.44 56.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -70.24 -58.03 4.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -46.88 -47.48 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 28.1 m-20 -51.01 -47.38 61.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.482 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -69.08 -49.71 54.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.61 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 91.8 mt -48.54 -34.53 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.136 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 88.1 t -89.41 -55.8 5.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -57.01 -63.01 1.35 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.622 ' CE ' HD11 ' A' ' 168' ' ' ILE . 92.0 mmm -57.53 -40.03 77.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 92.25 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.529 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.48 -29.35 9.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.482 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.2 tp-100 -37.3 153.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.796 0.332 . . . . 0.0 110.888 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.566 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 90.7 m95 -96.82 91.02 5.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.965 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.481 HD12 ' HE1' ' A' ' 158' ' ' MET . 4.8 tt -85.47 -70.22 0.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.11 118.02 3.43 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.04 -93.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.52 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -82.25 174.31 11.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.842 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.566 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 84.5 mt-30 -76.16 178.23 6.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.622 HD11 ' CE ' ' A' ' 158' ' ' MET . 9.2 pt -139.91 166.99 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.534 ' O ' HG13 ' A' ' 101' ' ' VAL . 51.8 mtt180 -126.71 167.74 15.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 4.2 p -147.76 143.76 27.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.165 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -153.67 166.95 31.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.61 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 97.0 m95 -88.11 109.87 20.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.12 179.869 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.7 m170 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.838 0.351 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.569 ' CE1' ' HD3' ' A' ' 148' ' ' LYS . 90.5 m-85 -93.45 157.64 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.904 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -112.66 129.12 56.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.455 HG22 HD11 ' A' ' 155' ' ' ILE . 49.5 t -119.88 117.63 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.46 132.52 34.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.73 HG22 HG22 ' A' ' 170' ' ' THR . 91.1 t -124.11 120.49 59.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -110.46 177.78 19.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 53.83 46.35 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 110.913 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.496 HD12 ' N ' ' A' ' 141' ' ' GLY . 28.1 mt -90.85 113.81 26.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -45.53 152.73 0.65 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.715 0.769 . . . . 0.0 110.847 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -33.96 15.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.658 2.239 . . . . 0.0 112.317 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -66.41 -22.95 66.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.902 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.401 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 22.6 mm -55.41 150.31 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.157 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 44.3 p -130.74 164.01 26.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.185 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.703 HG23 ' HA ' ' A' ' 127' ' ' ARG . 90.6 m -64.63 -32.64 74.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.11 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -79.95 -11.84 59.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -83.53 -50.53 8.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.881 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.603 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.6 mt -57.84 -39.57 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.157 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 58.7 mttt -60.43 -35.77 76.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.4 t -92.48 -16.18 26.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.845 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.718 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -89.34 -16.27 31.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.085 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.603 ' CE1' HG23 ' A' ' 113' ' ' ILE . 21.1 m-85 -112.19 -9.5 13.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.64 -46.09 99.38 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.548 0.689 . . . . 0.0 111.102 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.1 Cg_exo -48.01 -17.08 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.71 2.273 . . . . 0.0 112.335 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.633 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 49.3 m-85 -91.27 -31.95 15.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 159.67 172.49 26.92 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.9 tttt -58.37 140.07 54.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 110.912 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.46 HG21 ' HB2' ' A' ' 126' ' ' ALA . 89.6 mt -109.92 131.02 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 79.3 p -96.57 -26.0 15.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -159.81 125.04 4.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.46 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -150.16 124.4 9.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.703 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.0 OUTLIER -151.32 155.56 38.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.591 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.0 p -108.22 100.06 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.123 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.4 t -49.03 122.67 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.168 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 38.4 mttt -119.1 168.9 10.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -73.34 145.69 45.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 tpt -87.41 15.72 6.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -130.19 -55.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.134 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 7.5 p -85.93 -28.47 24.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.122 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.03 22.69 70.81 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.3 mmpt? -106.59 150.11 26.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 44.6 m -54.2 109.27 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.865 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -49.35 -35.29 18.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.45 15.25 2.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -160.91 144.34 13.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.934 0.397 . . . . 0.0 110.92 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.496 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -136.13 -176.0 14.12 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -129.29 136.44 50.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.16 119.07 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.133 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 11.4 m -99.18 145.3 27.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -124.51 148.99 47.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -65.1 -46.33 81.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -119.77 150.56 40.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.569 ' HD3' ' CE1' ' A' ' 97' ' ' PHE . 20.8 tptt -55.88 -56.66 17.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' LYS . 28.8 tp -37.36 -49.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.944 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 1.0 OUTLIER -57.26 -42.09 80.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.809 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.458 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -64.85 -47.02 79.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -58.15 -46.43 85.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -48.78 -46.85 42.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.916 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.633 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -70.72 -60.44 2.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.586 HD13 ' CE2' ' A' ' 172' ' ' TRP . 66.6 mt -39.03 -36.78 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.116 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 69.2 t -78.7 -60.76 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -62.88 -66.13 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.851 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.581 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 29.4 mmt -37.8 -50.63 1.25 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.926 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.14 102.43 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.525 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 88.58 -30.66 5.21 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 51.0 tp60 -35.27 152.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.759 0.314 . . . . 0.0 110.923 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.567 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 84.8 m95 -100.76 91.42 4.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.937 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.718 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.4 tt -87.42 -70.36 0.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.401 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.22 118.72 3.97 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.532 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.29 -92.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.442 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.6 mtt180 -80.4 178.07 8.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.567 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 22.4 mt-30 -79.24 -178.79 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 23.2 pt -138.33 171.17 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 101' ' ' VAL . 12.5 ttm180 -136.45 141.95 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.73 HG22 HG22 ' A' ' 101' ' ' VAL . 24.0 p -127.11 148.69 50.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.129 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -159.94 166.41 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.586 ' CE2' HD13 ' A' ' 155' ' ' ILE . 85.8 m95 -82.7 107.01 15.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 179.87 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.846 0.355 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.533 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 25.4 m-85 -107.19 133.33 51.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -87.88 129.02 35.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.877 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.0 t -120.39 122.83 69.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.551 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 0.6 OUTLIER -86.46 145.47 26.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.577 ' CG1' HD21 ' A' ' 104' ' ' LEU . 98.7 t -137.53 110.74 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -102.05 -172.77 27.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.503 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 45.78 46.34 11.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.577 HD21 ' CG1' ' A' ' 101' ' ' VAL . 65.7 mt -87.69 109.49 19.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.4 t -43.12 153.23 0.35 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.627 0.727 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -18.23 36.92 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.662 2.241 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -87.4 -4.41 59.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.434 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 24.5 mm -69.19 147.82 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 70.3 p -136.49 144.6 44.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.157 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.428 ' OG1' HG12 ' A' ' 128' ' ' VAL . 89.6 m -46.77 -35.71 6.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -72.29 -31.57 65.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -69.49 -49.18 57.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.45 HG23 ' CE1' ' A' ' 117' ' ' PHE . 17.6 mt -58.44 -47.25 88.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.134 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.492 ' CG ' ' HB3' ' A' ' 126' ' ' ALA . 27.8 mtpt -60.09 -35.2 74.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.942 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 30.0 t -90.74 -8.67 49.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.64 -24.91 14.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.068 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.9 m-85 -100.59 -8.68 22.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.07 -46.19 98.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.729 . . . . 0.0 111.107 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -48.0 -17.16 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.658 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 52.2 m-85 -90.99 -38.31 12.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.39 179.28 41.74 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.455 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.469 ' HG2' ' CZ ' ' A' ' 146' ' ' TYR . 20.9 tptt -66.1 133.26 50.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.727 0.299 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.4 HD13 ' HA ' ' A' ' 114' ' ' LYS . 67.9 mt -106.4 128.42 60.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.6 t -100.57 -27.82 13.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -148.43 138.76 22.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.824 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.492 ' HB3' ' CG ' ' A' ' 114' ' ' LYS . . . -168.08 123.4 0.99 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 14.6 ptp180 -148.07 156.6 42.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.873 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.594 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.5 p -116.39 100.61 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.101 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.713 HG11 ' OH ' ' A' ' 140' ' ' TYR . 23.0 t -53.25 119.44 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.069 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.471 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.6 mttm -119.62 157.8 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -64.07 153.95 35.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.884 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 48.2 tpp -95.52 -13.32 24.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.85 -56.39 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -87.83 -34.91 18.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.165 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.56 29.98 31.22 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 14.5 mmtp -112.18 147.68 35.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.882 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.471 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 39.1 t -49.09 104.8 0.07 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 58.0 mttt -44.75 -36.13 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.904 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.21 27.67 1.32 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.713 ' OH ' HG11 ' A' ' 129' ' ' VAL . 49.2 p90 -167.37 151.64 6.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.935 0.398 . . . . 0.0 110.904 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -150.13 -177.81 24.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -133.9 141.22 47.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.882 0.372 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 90.4 t -143.64 116.57 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 67.6 m -94.04 139.11 31.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.47 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 12.2 m-85 -117.65 138.44 51.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.469 ' CZ ' ' HG2' ' A' ' 122' ' ' LYS . 6.5 m-85 -51.79 -45.52 63.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.7 168.9 11.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.91 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.533 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 53.0 tttt -74.58 -59.26 2.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.1 tp -39.69 -49.02 2.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -58.97 -40.24 84.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.47 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -67.99 -43.93 77.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -56.66 -44.73 81.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -52.26 -46.47 65.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.658 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.97 -51.89 34.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.685 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 96.9 mt -46.0 -37.27 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.4 t -86.58 -54.94 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -57.31 -60.74 3.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.588 ' HE1' HD12 ' A' ' 163' ' ' LEU . 94.2 mmm -60.5 -38.93 85.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.13 94.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.0 -31.59 5.86 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.518 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.4 tp-100 -35.21 152.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.807 0.337 . . . . 0.0 110.888 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.569 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -93.99 91.01 6.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.588 HD12 ' HE1' ' A' ' 158' ' ' MET . 4.9 tt -87.57 -70.26 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -118.5 116.62 3.45 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.55 -91.11 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -83.84 174.19 10.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.793 0.33 . . . . 0.0 110.819 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.569 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 58.9 mt-30 -75.51 170.69 15.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.963 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.587 HD11 ' HE3' ' A' ' 158' ' ' MET . 15.7 pt -129.03 167.27 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.118 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 8.6 mmt85 -121.59 165.4 15.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.868 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 2.6 p -149.77 128.28 12.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.166 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -144.47 157.78 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.685 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 79.0 m95 -81.01 107.24 13.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.914 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.416 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.114 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 21.9 m170 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.451 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 94.8 m-85 -103.34 136.88 42.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 60.0 m-70 -96.07 127.0 41.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.416 HG21 ' HB1' ' A' ' 151' ' ' ALA . 25.2 t -117.19 131.95 68.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' OD1' ' A' ' 171' ' ' ASN . 2.2 t80 -97.64 138.78 34.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.516 HG22 HG22 ' A' ' 170' ' ' THR . 88.4 t -125.05 115.42 44.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.152 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.03 -178.72 30.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 45.78 47.02 12.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.831 0.348 . . . . 0.0 110.903 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.562 HD12 ' C ' ' A' ' 140' ' ' TYR . 32.7 mt -78.88 100.49 7.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -40.81 155.2 0.2 Allowed Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.634 0.73 . . . . 0.0 110.882 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -19.01 36.51 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.698 2.265 . . . . 0.0 112.292 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -82.02 -22.44 36.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.848 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.633 HD12 HD22 ' A' ' 163' ' ' LEU . 6.8 mm -60.91 137.97 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.111 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.437 ' O ' ' N ' ' A' ' 111' ' ' GLU . 52.8 p -133.0 140.5 47.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.44 ' OG1' HG12 ' A' ' 128' ' ' VAL . 91.2 m -36.74 -32.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.159 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 109' ' ' THR . 15.0 tt0 -73.74 -48.96 27.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.466 ' O ' ' N ' ' A' ' 116' ' ' ALA . 77.1 m-20 -58.6 -51.33 70.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.2 mt -50.76 -38.8 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.112 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.493 ' O ' HD12 ' A' ' 123' ' ' ILE . 22.3 mttp -67.18 -35.34 79.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 22.9 t -92.95 -11.1 34.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.835 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.922 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.85 -32.89 15.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.083 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.56 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.7 m-85 -95.85 -5.02 42.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.582 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -57.67 -46.64 99.74 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.603 0.715 . . . . 0.0 111.087 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.582 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.696 2.264 . . . . 0.0 112.32 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.689 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 36.0 m-85 -93.2 -30.67 15.09 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.848 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.18 179.93 36.23 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.515 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.548 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 41.1 tptt -63.82 140.24 58.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.761 0.315 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.493 HD12 ' O ' ' A' ' 114' ' ' LYS . 97.7 mt -108.34 130.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.9 p -98.31 -50.76 4.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.863 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -136.44 118.83 15.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -142.11 124.82 15.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.091 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -148.09 156.15 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.44 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.1 p -113.13 100.11 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.126 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.794 HG11 ' CE1' ' A' ' 140' ' ' TYR . 46.1 t -49.12 127.52 4.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -130.53 151.87 50.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.82 155.88 5.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 5.2 ptp -97.62 -17.79 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.857 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.75 -57.54 2.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.147 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.7 p -81.51 -32.78 32.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.123 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.43 28.38 61.77 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.474 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -101.88 162.62 12.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.804 0.335 . . . . 0.0 110.877 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 77.7 p -58.86 98.45 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.849 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.516 ' HB3' ' CE2' ' A' ' 140' ' ' TYR . 20.5 mmtt -42.95 -42.98 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.87 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.41 19.18 4.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.794 ' CE1' HG11 ' A' ' 129' ' ' VAL . 47.7 p90 -163.37 153.45 15.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.892 0.377 . . . . 0.0 110.951 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -151.22 -172.01 19.78 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -135.54 140.16 44.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.875 0.369 . . . . 0.0 110.875 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 28.6 t -145.52 107.64 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 3.5 t -89.19 154.06 20.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.531 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 13.6 m-85 -129.46 150.34 50.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.865 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.548 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 16.0 m-85 -66.37 -33.52 75.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.895 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -129.52 165.44 21.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.451 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . 22.9 tttm -69.35 -61.97 1.57 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.7 tp -39.4 -63.19 0.58 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -40.77 -45.31 2.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -69.76 -60.75 2.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -40.41 -47.06 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 17.7 m-80 -47.66 -56.97 6.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.689 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -56.72 -53.72 54.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.474 HD13 ' CE2' ' A' ' 172' ' ' TRP . 47.7 mt -41.86 -35.39 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.8 t -84.5 -56.64 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 66.3 m-70 -62.09 -64.67 0.86 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.579 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 11.9 mmt -44.86 -47.01 11.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.56 102.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.74 -28.67 3.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.484 ' N ' ' O ' ' A' ' 158' ' ' MET . 62.7 tp60 -35.8 152.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.79 0.328 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.589 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 85.2 m95 -99.16 91.02 4.79 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.922 HD11 ' CB ' ' A' ' 116' ' ' ALA . 6.6 tt -86.77 -70.45 0.61 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.902 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.18 118.43 3.78 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.461 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.65 -92.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.488 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 14.7 mtt-85 -79.41 -178.38 6.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.759 0.314 . . . . 0.0 110.87 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.589 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 30.1 mt-30 -84.14 179.82 7.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.419 ' O ' ' N ' ' A' ' 160' ' ' GLY . 19.7 pt -136.87 171.95 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.486 ' O ' HG13 ' A' ' 101' ' ' VAL . 41.3 ttt180 -134.64 160.5 37.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.858 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.516 HG22 HG22 ' A' ' 101' ' ' VAL . 17.1 p -145.12 152.54 40.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' ASN . . . . . 0.576 ' OD1' ' CD1' ' A' ' 100' ' ' PHE . 3.0 p30 -172.96 149.9 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.474 ' CE2' HD13 ' A' ' 155' ' ' ILE . 99.2 m95 -68.98 133.14 47.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.089 179.871 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 56.7 m170 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.856 0.36 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.431 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 66.9 m-85 -96.68 140.95 30.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.888 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -100.57 131.89 46.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.401 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 58.5 t -122.27 124.48 71.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -91.2 140.02 30.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.482 HG11 HD21 ' A' ' 104' ' ' LEU . 77.7 t -127.6 126.78 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -121.93 -178.45 15.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.475 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 50.87 39.63 22.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.83 0.348 . . . . 0.0 110.852 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.482 HD21 HG11 ' A' ' 101' ' ' VAL . 44.0 mt -84.21 126.03 32.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 t -50.51 152.15 3.48 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.678 0.751 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 -14.18 35.83 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -91.8 -6.73 51.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.29 153.1 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 40.5 p -139.09 -179.96 6.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.8 m -69.92 -40.42 75.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.094 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -70.65 -36.74 73.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 116' ' ' ALA . 5.0 m-20 -58.09 -52.31 66.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.509 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.5 mt -60.69 -42.41 91.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.412 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 14.2 mtpt -59.69 -36.6 76.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.883 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.5 t -94.03 -17.4 22.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.549 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -84.62 -18.31 35.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.564 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.3 m-85 -111.63 -5.49 14.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.569 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.1 -46.2 99.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.559 0.695 . . . . 0.0 111.09 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.569 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.02 -19.57 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.578 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 45.0 m-85 -87.96 -36.93 16.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.96 -161.95 34.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.496 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.9 tmtt? -87.17 124.64 33.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.883 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.401 HD12 ' O ' ' A' ' 114' ' ' LYS . 46.6 mt -96.54 134.28 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.107 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.6 p -100.13 -45.88 5.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -134.41 122.02 21.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.837 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -151.16 122.61 7.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.414 ' NE ' ' HB2' ' A' ' 142' ' ' PHE . 0.0 OUTLIER -146.62 159.49 43.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -114.15 99.95 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.143 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 23.5 t -51.73 134.14 13.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.11 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.46 ' HG2' ' N ' ' A' ' 137' ' ' SER . 35.5 mttt -124.98 168.15 13.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -75.73 152.11 37.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 mpp? -97.49 16.71 19.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -123.67 -38.26 2.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 13.7 p -111.25 -24.15 10.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 78.33 20.61 71.84 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 20.0 mmtp -106.63 154.19 21.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.761 0.315 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.46 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 28.3 m -51.18 120.11 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.852 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -60.18 -36.77 78.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.52 13.9 2.47 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.497 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -158.74 145.59 17.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 0.0 110.905 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -137.7 -175.85 14.11 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.414 ' HB2' ' NE ' ' A' ' 127' ' ' ARG . 41.6 m-85 -133.4 143.24 48.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.949 0.404 . . . . 0.0 110.888 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.0 t -145.51 127.38 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 32.2 t -105.13 151.15 24.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.498 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 73.6 m-85 -129.32 138.99 51.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -50.43 -42.47 53.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.941 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -127.27 164.55 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.914 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.475 ' O ' ' N ' ' A' ' 151' ' ' ALA . 13.7 ttmt -62.41 -62.37 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 148' ' ' LYS . 58.5 tp -34.58 -58.29 0.5 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.963 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -48.5 -42.47 33.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.498 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -70.69 -50.44 36.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.088 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -53.75 -46.12 70.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -45.99 -47.84 16.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.496 ' HB1' ' HG3' ' A' ' 158' ' ' MET . . . -66.08 -63.18 1.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 154' ' ' ALA . 45.6 mt -34.76 -46.53 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.77 -61.19 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.164 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -65.8 -64.66 0.81 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.835 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.578 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 18.5 mmt -42.11 -48.6 4.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.41 100.71 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.508 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.21 -28.12 5.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.486 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.0 tp-100 -37.14 154.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.758 0.313 . . . . 0.0 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.577 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.4 m95 -98.7 90.99 4.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.587 ' C ' HD23 ' A' ' 163' ' ' LEU . 2.6 tt -85.06 -71.32 0.53 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -122.24 118.25 3.6 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.456 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.93 -93.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.503 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.2 mtt85 -79.5 178.45 8.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.745 0.307 . . . . 0.0 110.862 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 86.2 mt-30 -79.96 178.85 7.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.431 HG22 HD23 ' A' ' 104' ' ' LEU . 32.1 pt -137.64 170.33 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.143 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 27.6 ttm-85 -133.68 154.98 50.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.441 HG22 HG22 ' A' ' 101' ' ' VAL . 5.7 p -138.87 147.27 42.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -157.63 151.86 24.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 76.9 m95 -72.44 130.1 39.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.077 179.904 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 96' ' ' HIS . . . . . 0.524 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.836 0.351 . . . . 0.0 110.85 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.522 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 5.3 m-85 -99.81 133.91 43.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.846 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -95.35 135.67 36.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.448 HG22 HD11 ' A' ' 155' ' ' ILE . 78.8 t -121.43 121.22 64.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -85.02 145.9 27.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.59 HG13 ' O ' ' A' ' 169' ' ' ARG . 17.7 t -135.45 128.1 47.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.15 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -118.08 -179.05 17.25 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.512 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 48.38 46.86 20.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.878 0.37 . . . . 0.0 110.845 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.617 HD23 HG22 ' A' ' 168' ' ' ILE . 34.0 mt -88.13 105.35 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.936 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -36.09 153.39 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.654 0.74 . . . . 0.0 110.893 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -23.66 30.73 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.737 2.291 . . . . 0.0 112.327 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -79.3 -10.96 59.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.438 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 17.3 mm -65.69 143.8 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.472 ' HG1' ' CG ' ' A' ' 112' ' ' ASP . 65.2 p -126.14 164.32 21.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.468 ' OG1' HG12 ' A' ' 128' ' ' VAL . 66.8 m -63.72 -29.69 70.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.097 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -79.97 -34.2 38.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.472 ' CG ' ' HG1' ' A' ' 109' ' ' THR . 98.1 m-20 -60.34 -55.53 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.468 HG23 ' CE1' ' A' ' 117' ' ' PHE . 11.7 mt -52.69 -40.12 33.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.474 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 62.7 mttt -64.34 -35.18 80.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.5 t -94.07 -9.71 35.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.79 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.14 -23.06 17.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.595 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 28.6 m-85 -105.92 -6.8 18.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.575 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -58.26 -45.98 99.68 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.559 0.695 . . . . 0.0 111.133 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.575 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.96 -17.1 0.7 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.653 2.235 . . . . 0.0 112.352 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.584 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 46.2 m-85 -90.66 -41.44 11.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.87 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 175.68 -174.16 46.69 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.7 tptm -71.46 138.43 49.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.751 0.31 . . . . 0.0 110.923 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 97.1 mt -104.01 139.34 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 5.8 t -116.49 -37.64 3.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -142.57 105.4 4.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -138.75 121.56 16.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.476 ' CZ ' ' HB3' ' A' ' 127' ' ' ARG . 2.4 ptp180 -153.11 154.71 35.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.88 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.614 HG13 ' HE2' ' A' ' 130' ' ' LYS . 2.4 p -107.72 100.05 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.148 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -50.04 133.87 9.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.614 ' HE2' HG13 ' A' ' 128' ' ' VAL . 20.5 mtmt -129.52 162.53 27.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.924 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -64.4 159.45 21.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 9.7 ttp -107.55 3.48 24.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -103.74 -45.67 4.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.121 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.3 p -110.52 -38.8 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.156 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 94.8 40.9 4.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.3 mttm -116.11 143.67 45.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.455 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 17.1 p -45.92 109.25 0.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 59.7 mttt -54.41 -35.67 63.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.99 19.35 4.02 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -161.2 146.69 14.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.909 0.385 . . . . 0.0 110.929 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.97 177.83 21.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -123.85 140.12 53.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.9 t -139.31 117.03 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.139 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 49.8 m -102.15 147.6 26.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -123.49 145.13 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.524 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 19.2 m-85 -58.24 -36.65 73.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.952 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -121.34 174.26 6.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.869 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.522 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 44.6 tttt -85.01 -52.35 6.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.859 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.7 tp -47.68 -53.6 14.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.955 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -49.19 -44.36 43.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -62.53 -52.3 64.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -49.49 -43.11 45.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.903 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -48.24 -51.79 24.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.562 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.49 -65.89 0.62 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.057 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.448 HD11 HG22 ' A' ' 99' ' ' VAL . 80.9 mt -34.59 -34.79 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.124 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 154' ' ' ALA . 20.1 t -74.02 -63.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.163 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -69.44 -59.2 3.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.595 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 20.1 mmt -40.39 -51.11 2.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.15 102.33 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.491 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 87.94 -31.3 4.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.465 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.483 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.9 tp60 -34.27 150.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.573 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.3 m95 -96.96 91.03 5.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.937 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.79 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.9 tt -87.47 -70.56 0.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.907 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.52 117.35 3.67 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.475 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -91.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.457 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 15.0 mtp180 -79.55 -174.81 4.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.766 0.317 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.573 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 63.9 mt-30 -86.09 179.43 6.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.617 HG22 HD23 ' A' ' 104' ' ' LEU . 9.3 pt -136.84 169.31 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.59 ' O ' HG13 ' A' ' 101' ' ' VAL . 30.2 ttp180 -129.25 162.87 26.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 32.6 p -141.38 150.5 42.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.091 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -163.02 164.32 25.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 94.2 m95 -93.65 107.95 19.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.064 179.889 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 4.9 m-70 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.817 0.342 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.538 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 74.5 m-85 -100.0 161.38 13.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.6 m-70 -114.22 134.35 54.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -124.58 118.25 52.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.137 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.612 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 16.5 t80 -88.47 129.73 35.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.18 111.99 36.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.113 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.83 -179.09 29.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 48.0 54.84 9.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.451 HD12 ' C ' ' A' ' 140' ' ' TYR . 33.8 mt -92.31 106.58 18.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.5 t -35.51 152.33 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.707 0.765 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -18.77 36.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.5 ' CG ' ' O ' ' A' ' 107' ' ' GLU . 9.3 tt0 -90.08 1.13 56.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.938 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 17.4 mm -74.72 147.38 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.128 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 51.3 p -132.04 163.58 28.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.086 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 25.5 m -58.71 -41.06 85.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.91 -35.4 76.8 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 116' ' ' ALA . 64.0 m-20 -60.17 -54.59 44.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.851 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mt -57.99 -45.82 87.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.118 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.825 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 13.2 mtpp -57.44 -39.01 75.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.865 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 32.7 t -92.35 -9.15 42.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.839 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.533 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.64 -9.6 31.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.104 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.54 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.0 m-85 -120.26 -8.75 9.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.915 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.582 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.1 -45.97 98.9 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.639 0.733 . . . . 0.0 111.093 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.8 Cg_exo -47.98 -22.76 3.71 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.708 2.272 . . . . 0.0 112.321 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.685 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 39.7 m-85 -85.66 -35.62 20.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.863 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.59 174.7 34.63 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.453 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.646 ' CG ' ' CE1' ' A' ' 146' ' ' TYR . 0.8 OUTLIER -59.46 140.36 56.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.768 0.318 . . . . 0.0 110.877 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.763 HG21 ' HB2' ' A' ' 126' ' ' ALA . 82.7 mt -111.91 105.37 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 52.2 p -67.69 -32.15 72.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -159.67 123.93 3.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.825 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -146.51 125.45 12.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.097 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.2 ptm180 -149.12 166.76 27.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.568 ' O ' HG13 ' A' ' 128' ' ' VAL . 6.3 p -120.36 99.85 8.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.173 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.3 t -51.18 119.77 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.431 ' CA ' ' HG3' ' A' ' 138' ' ' LYS . 29.0 mtmt -114.81 152.38 32.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -56.72 155.45 7.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.07 -6.79 31.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -102.82 -61.64 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.14 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.9 p -81.67 -34.57 30.65 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.12 33.46 26.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -117.68 152.12 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.8 m -43.34 108.95 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.431 ' HG3' ' CA ' ' A' ' 130' ' ' LYS . 6.4 mtpm? -51.41 -38.19 52.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 125.35 12.94 3.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.462 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.451 ' C ' HD12 ' A' ' 104' ' ' LEU . 32.5 p90 -161.8 154.18 19.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.921 0.391 . . . . 0.0 110.919 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.06 -175.42 19.95 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.492 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -131.27 140.28 49.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.891 0.377 . . . . 0.0 110.858 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.8 t -144.86 109.58 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.12 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 73.7 m -86.71 141.92 28.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.594 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 17.8 m-85 -120.61 140.43 51.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.646 ' CE1' ' CG ' ' A' ' 122' ' ' LYS . 4.4 m-85 -54.48 -50.38 67.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.933 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -115.59 171.02 8.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.538 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 59.0 tttt -80.28 -38.44 30.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.893 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.6 tp -57.35 -51.93 67.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.94 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -56.78 -41.47 77.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.896 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.594 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -66.3 -49.11 68.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.092 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -51.0 -43.91 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -49.56 -48.93 48.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.685 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -66.09 -54.88 20.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.5 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 97.5 mt -47.55 -35.29 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 77.5 t -82.24 -49.03 17.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.0 m-70 -71.51 -65.46 0.75 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.54 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 8.2 mmt -45.21 -46.52 12.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.48 103.6 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.458 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.41 -29.61 3.94 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.491 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.9 tp60 -40.98 149.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.926 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.439 ' CE2' ' HG2' ' A' ' 167' ' ' GLN . 84.0 m95 -93.87 92.33 7.36 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.622 ' C ' HD23 ' A' ' 163' ' ' LEU . 5.5 tt -87.03 -72.34 0.52 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.487 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -120.33 117.11 3.43 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 56.09 -93.05 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.5 mpt_? -83.52 175.99 9.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.749 0.309 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.439 ' HG2' ' CE2' ' A' ' 162' ' ' TRP . 32.7 mt-30 -74.61 177.33 6.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.917 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 22.0 pt -136.23 165.09 30.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -129.56 152.33 49.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 29.8 p -130.07 160.46 33.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.166 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -169.81 163.35 9.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.5 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 85.5 m95 -90.87 100.23 13.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.612 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.084 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 28.1 m170 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.847 0.356 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.533 ' CD1' ' HD3' ' A' ' 148' ' ' LYS . 90.6 m-85 -102.44 145.09 30.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -100.27 138.68 37.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.846 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 25.2 t -124.23 130.23 73.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.184 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -91.77 138.09 31.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.7 118.31 46.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.62 172.05 17.95 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.513 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 54.53 53.37 10.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.41 HD23 ' HA ' ' A' ' 104' ' ' LEU . 26.1 mt -87.93 104.48 16.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -38.03 153.57 0.13 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.702 0.763 . . . . 0.0 110.877 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -20.48 34.86 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.736 2.29 . . . . 0.0 112.31 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -83.21 -17.9 41.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.475 HG22 ' N ' ' A' ' 109' ' ' THR . 37.1 mm -57.61 156.95 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.123 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.475 ' N ' HG22 ' A' ' 108' ' ' ILE . 40.5 p -143.87 170.61 15.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.437 ' OG1' HG12 ' A' ' 128' ' ' VAL . 56.9 m -66.13 -33.87 76.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -78.24 -35.21 48.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 67.1 m-20 -59.1 -55.89 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.841 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.457 HG23 ' CE1' ' A' ' 117' ' ' PHE . 7.8 mt -55.6 -42.68 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.11 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 17.7 mttp -61.64 -36.34 80.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.922 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.1 t -93.4 -10.41 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.848 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.512 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -94.02 -18.77 21.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.575 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 7.1 m-85 -111.57 -5.78 14.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.586 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.41 -45.71 99.89 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.593 0.711 . . . . 0.0 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.7 Cg_exo -48.04 -25.23 6.24 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.659 2.239 . . . . 0.0 112.382 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.557 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 54.0 m-85 -78.83 -38.84 37.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 168.02 179.13 40.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 35.2 tptt -59.41 142.21 52.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.77 0.319 . . . . 0.0 110.942 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.7 mt -114.33 137.1 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 6.3 p -112.35 -23.6 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -154.02 143.31 21.41 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -174.77 123.62 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.06 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -148.2 159.35 44.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.441 ' O ' HG13 ' A' ' 128' ' ' VAL . 2.6 p -112.55 99.9 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.165 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.514 HG11 ' CZ ' ' A' ' 140' ' ' TYR . 80.5 t -51.32 126.59 6.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.485 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.2 mttm -125.84 159.94 31.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -62.52 159.51 15.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.873 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 ptp -102.38 -14.78 16.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.39 -38.02 8.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.076 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.6 p -105.78 -29.42 10.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.05 36.85 45.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.478 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mmtm -119.86 151.3 39.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.816 0.341 . . . . 0.0 110.893 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.485 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 56.2 p -45.97 113.26 0.59 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.873 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -59.57 -36.73 76.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.37 14.25 2.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.43 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.514 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 34.1 p90 -160.83 149.89 16.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.867 0.365 . . . . 0.0 110.937 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.28 -177.54 18.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -127.33 140.72 52.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 25.3 t -140.7 118.94 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.4 p -98.58 149.76 22.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -129.0 150.66 50.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -65.59 -40.73 93.03 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.88 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -125.24 162.81 23.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.541 ' HE3' ' CZ3' ' A' ' 172' ' ' TRP . 15.0 tptm -67.42 -58.5 4.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.9 tp -39.11 -51.03 1.9 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.924 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -51.92 -41.92 62.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -65.18 -53.31 46.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.062 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -49.46 -41.09 39.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -57.3 -52.68 64.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.53 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.76 -51.11 69.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.657 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 95.0 mt -43.96 -51.69 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 63.9 t -72.62 -59.76 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -50.92 -64.7 0.73 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.575 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 92.7 mmm -57.77 -39.24 77.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.97 94.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.46 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 91.87 -29.46 7.42 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.504 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.1 tp60 -36.3 152.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.761 0.315 . . . . 0.0 110.952 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.573 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.0 m95 -96.71 91.68 5.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.937 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.512 HD11 ' CB ' ' A' ' 116' ' ' ALA . 2.0 tt -88.64 -69.84 0.68 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.936 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -117.68 116.98 3.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 50.95 -90.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 164' ' ' GLY . 40.9 mtt180 -80.3 179.98 7.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.827 0.346 . . . . 0.0 110.836 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.573 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 45.7 mt-30 -81.77 179.84 7.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.565 HD11 ' CE ' ' A' ' 158' ' ' MET . 15.3 pt -139.14 163.52 26.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.117 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 46.9 ttt-85 -129.71 156.53 44.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.6 p -129.83 162.46 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -168.55 163.69 12.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.864 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.657 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.5 m95 -94.16 114.25 26.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.109 179.898 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 48.3 m170 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.858 0.361 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 93.8 m-85 -90.65 135.37 33.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 82.4 m-70 -94.13 124.37 38.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 63.7 t -112.67 116.17 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.127 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.54 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 1.4 t80 -84.28 136.74 33.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.9 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 169' ' ' ARG . 38.6 t -127.16 115.54 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.113 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.73 -174.48 25.8 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 46.29 50.74 11.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.903 0.382 . . . . 0.0 110.912 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.5 mt -91.28 110.61 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -42.41 153.68 0.3 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.696 0.76 . . . . 0.0 110.863 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -20.0 35.4 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.719 2.279 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -84.08 -14.02 51.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 20.4 mm -60.58 150.36 6.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.147 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.6 p -142.91 154.86 44.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.16 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 18.2 m -48.05 -42.18 27.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -65.47 -43.18 91.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.49 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.9 m-20 -59.22 -52.96 63.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.462 HG23 ' CE1' ' A' ' 117' ' ' PHE . 30.6 mt -60.96 -43.0 95.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.463 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 30.0 mttm -62.35 -36.17 81.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 38.6 t -94.01 -13.27 27.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.531 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -91.93 -13.21 31.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.503 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.1 m-85 -113.0 -9.8 13.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.03 -45.5 99.53 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.586 0.707 . . . . 0.0 111.06 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.97 -17.08 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.656 2.237 . . . . 0.0 112.341 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.484 ' CD2' ' HA ' ' A' ' 117' ' ' PHE . 38.9 m-85 -91.9 -40.36 11.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.14 174.56 44.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -67.54 120.9 14.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.812 0.339 . . . . 0.0 110.883 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 93.3 mt -85.77 140.08 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.118 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.5 p -110.58 -30.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -156.31 123.93 5.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.463 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -150.07 132.38 15.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.105 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 19.9 ptt180 -152.06 147.43 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -108.46 99.94 9.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.653 HG12 ' CG ' ' A' ' 138' ' ' LYS . 73.0 t -52.43 114.67 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 43.8 mttm -113.08 160.98 17.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -68.59 157.86 35.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.845 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 tpt -94.35 -27.86 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.65 -55.71 3.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 65.3 p -80.73 -38.78 28.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.136 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.43 18.62 61.91 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.479 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -105.75 146.9 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 110.906 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.1 t -39.03 114.26 0.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.653 ' CG ' HG12 ' A' ' 129' ' ' VAL . 12.3 mtpt -52.94 -38.79 62.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.97 20.65 1.44 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.525 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.47 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 9.1 p90 -171.39 154.04 3.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.96 0.41 . . . . 0.0 110.9 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.99 16.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.78 142.48 38.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.902 0.382 . . . . 0.0 110.831 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 43.3 t -147.3 108.97 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 44.3 m -92.25 149.27 21.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -126.46 152.89 45.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -60.66 -45.66 93.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.908 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -127.72 160.14 32.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.896 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 151' ' ' ALA . 12.2 tptm -58.66 -60.3 4.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 49.0 tp -38.47 -47.4 1.27 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -57.94 -38.89 76.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.479 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -68.92 -57.07 6.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.415 ' O ' HG23 ' A' ' 156' ' ' VAL . 4.6 mm-40 -43.32 -46.64 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -40.09 -47.48 2.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.555 ' HB1' ' HG3' ' A' ' 158' ' ' MET . . . -76.93 -55.99 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.676 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 87.8 mt -42.93 -38.58 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 152' ' ' GLU . 42.2 t -81.33 -48.7 18.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.118 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 -75.3 -67.11 0.69 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.555 ' HG3' ' HB1' ' A' ' 154' ' ' ALA . 23.2 mmt -42.17 -47.97 4.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.42 102.18 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.467 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.92 -34.51 3.55 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.479 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.445 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.4 tp60 -35.14 151.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.798 0.333 . . . . 0.0 110.927 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.562 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.1 m95 -98.15 91.36 5.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.58 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.9 tt -85.41 -71.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.925 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.88 118.05 3.58 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.4 -93.05 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.514 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -82.13 170.35 15.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.759 0.314 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.562 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 80.8 mt-30 -71.3 -179.4 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 15.5 pt -136.98 168.77 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.603 ' O ' HG13 ' A' ' 101' ' ' VAL . 36.5 ttp180 -131.88 158.71 40.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.429 ' CB ' ' HA ' ' A' ' 155' ' ' ILE . 0.9 OUTLIER -139.64 150.9 45.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.148 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 22.1 m-20 -166.96 158.46 12.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.676 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.0 m95 -85.48 100.54 11.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.919 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.9 m170 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.851 0.357 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -91.03 133.0 35.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.928 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -96.58 122.3 39.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.861 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.5 t -109.81 126.04 66.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.2 t80 -90.48 138.49 31.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 169' ' ' ARG . 92.7 t -128.7 124.55 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -115.65 -179.25 18.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 54.23 34.15 19.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.893 0.378 . . . . 0.0 110.917 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.493 HD12 ' N ' ' A' ' 141' ' ' GLY . 40.5 mt -80.12 113.4 18.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -45.3 153.54 0.55 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.665 0.745 . . . . 0.0 110.832 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -25.88 28.44 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.671 2.248 . . . . 0.0 112.396 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -77.89 -7.72 57.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 6.4 mm -72.81 148.09 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.13 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.2 p -134.93 159.97 39.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.099 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.668 ' OG1' HG12 ' A' ' 128' ' ' VAL . 36.3 m -54.66 -44.65 73.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -63.05 -31.14 72.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.431 ' O ' ' N ' ' A' ' 116' ' ' ALA . 92.9 m-20 -69.7 -51.37 35.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.843 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.448 HG23 ' CE1' ' A' ' 117' ' ' PHE . 17.0 mt -58.49 -43.93 87.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 118' ' ' ALA . 58.3 mttt -60.62 -34.9 74.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 28.1 t -93.96 -11.99 29.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.597 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.84 -13.72 23.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.088 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.501 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 13.3 m-85 -116.11 -11.56 11.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.588 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.5 -45.14 99.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.065 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -47.96 -17.14 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.313 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.617 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 59.5 m-85 -88.69 -41.34 12.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.855 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 173.59 148.98 6.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -40.96 128.92 2.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.0 110.866 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 58.4 mt -101.22 147.6 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 4.4 p -115.2 -36.59 4.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -140.92 133.81 29.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.406 ' HB3' ' HE3' ' A' ' 114' ' ' LYS . . . -164.2 128.76 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.088 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.496 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.3 OUTLIER -151.92 161.64 42.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.847 -179.926 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.668 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.1 p -118.48 99.85 8.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.144 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 51.5 t -51.24 117.06 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.468 ' HG2' ' N ' ' A' ' 137' ' ' SER . 12.7 mttp -110.03 160.34 16.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.915 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -66.6 156.34 35.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.903 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 8.5 tpt -96.56 -10.41 27.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.66 -50.72 3.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.3 p -94.05 -29.26 15.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.65 17.89 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.438 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.1 mtpp -101.19 145.73 28.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.879 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.468 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 68.3 m -47.07 105.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 12.6 mttp -44.03 -36.3 2.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 126.94 14.19 2.82 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.535 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -155.7 152.81 29.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.945 0.403 . . . . 0.0 110.901 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.493 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -148.43 -171.19 17.05 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -134.68 137.6 43.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.874 0.369 . . . . 0.0 110.868 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 92.5 t -137.47 118.05 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.134 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 88.8 p -98.08 152.85 18.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.586 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 26.7 m-85 -129.53 141.44 50.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.897 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -57.59 -40.86 79.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.862 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -117.7 178.81 4.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 45.7 tttt -87.18 -48.38 8.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 18.3 tp -48.02 -65.1 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -41.98 -51.32 4.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.586 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -55.52 -47.15 76.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -57.81 -42.1 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.914 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -51.3 -47.69 62.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.617 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.43 -53.97 20.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.062 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.429 ' CD1' ' CZ2' ' A' ' 172' ' ' TRP . 96.6 mt -41.37 -35.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 95.4 t -91.4 -47.43 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.148 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -63.82 -63.77 1.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.581 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 93.0 mmm -60.52 -37.99 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.929 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 94.06 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.58 -28.31 9.36 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.508 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . 11.9 tp-100 -37.69 156.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.778 0.323 . . . . 0.0 110.92 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.568 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.6 m95 -98.95 90.99 4.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.597 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.1 tt -86.15 -70.14 0.62 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.881 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.33 117.74 3.54 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.92 -92.7 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.3 mtt85 -80.89 179.66 7.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.314 . . . . 0.0 110.865 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.568 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 80.9 mt-30 -80.9 178.01 8.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.412 HD11 ' HE3' ' A' ' 158' ' ' MET . 29.4 pt -133.52 168.63 23.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.71 ' O ' HG13 ' A' ' 101' ' ' VAL . 55.9 ttt180 -129.54 154.23 47.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.885 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.606 HG22 HG22 ' A' ' 101' ' ' VAL . 44.5 p -141.95 148.22 38.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.083 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -174.24 147.07 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.429 ' CZ2' ' CD1' ' A' ' 155' ' ' ILE . 96.5 m95 -61.7 122.72 16.02 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.959 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.931 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 96' ' ' HIS . . . . . 0.517 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 7.1 m170 . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.843 0.354 . . . . 0.0 110.838 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.558 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 3.9 m-85 -91.14 139.61 30.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -93.16 131.86 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.926 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 48.2 t -124.05 129.34 74.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' ND2' ' A' ' 171' ' ' ASN . 1.8 t80 -99.42 149.86 22.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.604 HG13 ' O ' ' A' ' 169' ' ' ARG . 43.5 t -137.41 130.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.25 173.29 16.27 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 139' ' ' GLY . 5.4 m-20 61.74 36.38 16.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.819 0.342 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.422 HD13 HD11 ' A' ' 113' ' ' ILE . 39.1 mt -80.18 110.87 16.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -38.66 153.06 0.16 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 121.634 0.731 . . . . 0.0 110.874 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -15.21 36.79 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.678 2.252 . . . . 0.0 112.307 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.416 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 7.6 tt0 -90.63 -6.19 54.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.909 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 109' ' ' THR . 25.5 mm -67.48 156.06 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.448 ' N ' HG22 ' A' ' 108' ' ' ILE . 76.1 p -145.72 157.29 43.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.631 ' OG1' HG12 ' A' ' 128' ' ' VAL . 32.4 m -55.03 -39.06 68.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.074 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -71.58 -17.0 62.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -84.49 -46.32 11.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.51 HG23 ' CE1' ' A' ' 117' ' ' PHE . 7.7 mt -63.23 -38.76 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.462 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 19.4 mtpt -60.09 -36.12 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -92.84 -20.01 21.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.509 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -83.88 -16.92 42.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.8 m-85 -115.24 -7.55 12.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.581 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.72 -45.72 99.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.612 0.72 . . . . 0.0 111.114 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.0 Cg_exo -47.99 -18.1 1.04 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.654 2.236 . . . . 0.0 112.353 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.644 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 44.0 m-85 -89.77 -37.11 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.439 ' HA3' ' CG ' ' A' ' 150' ' ' ASP . . . 172.97 -171.24 44.3 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.456 ' HD2' ' N ' ' A' ' 123' ' ' ILE . 0.0 OUTLIER -77.77 120.05 22.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.781 0.324 . . . . 0.0 110.929 179.97 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.598 HG21 ' HB2' ' A' ' 126' ' ' ALA . 95.8 mt -91.91 101.12 12.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 93.1 p -67.84 -27.42 66.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.819 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -156.23 140.0 16.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.598 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -163.29 126.71 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.098 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.519 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.8 OUTLIER -143.69 162.78 35.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.854 -179.895 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.631 HG12 ' OG1' ' A' ' 110' ' ' THR . 6.5 p -121.15 100.19 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.0 t -53.73 120.38 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.481 ' HG2' ' N ' ' A' ' 137' ' ' SER . 32.1 mttm -115.29 164.88 13.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -65.44 148.61 51.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -90.91 -3.44 57.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.856 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -111.5 -54.91 2.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.11 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 24.5 p -89.76 -27.19 20.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.59 28.13 59.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 pttt -108.58 138.83 44.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.78 0.324 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.481 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 14.6 t -41.85 109.17 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -51.19 -33.77 28.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.5 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 121.38 20.44 3.27 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.429 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -161.05 140.96 10.84 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.957 0.408 . . . . 0.0 110.924 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -136.61 -168.74 11.52 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -138.54 143.87 39.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.4 t -144.02 124.73 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.17 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.2 m -100.82 141.13 34.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.839 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -125.01 133.92 52.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.879 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.517 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.1 m-85 -53.35 -48.92 68.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -113.31 167.24 10.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.558 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 30.4 tttp -74.68 -42.29 58.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -46.86 -52.09 15.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.439 ' CG ' ' HA3' ' A' ' 121' ' ' GLY . 88.9 m-20 -54.42 -43.79 71.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -66.54 -61.12 2.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.072 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -41.16 -44.31 2.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 -55.29 -59.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.644 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -58.09 -54.25 49.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.615 HD13 ' CE2' ' A' ' 172' ' ' TRP . 85.4 mt -44.42 -35.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.75 -60.98 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.118 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.7 m-70 -56.68 -66.96 0.35 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.811 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 24.3 mmt -43.51 -47.12 7.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.93 95.22 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.458 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.77 -30.72 6.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.488 ' N ' ' O ' ' A' ' 158' ' ' MET . 7.5 tp60 -37.5 155.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.905 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.546 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 89.2 m95 -101.15 91.7 4.65 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.92 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.542 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.0 tt -86.18 -70.7 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.416 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.73 118.1 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.492 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -92.14 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.503 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -80.25 175.12 10.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.758 0.313 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.546 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 38.8 mt-30 -74.01 177.43 5.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 20.0 pt -135.31 164.62 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.134 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.604 ' O ' HG13 ' A' ' 101' ' ' VAL . 29.7 ttp180 -128.01 154.13 45.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.566 HG22 HG22 ' A' ' 101' ' ' VAL . 22.4 p -142.68 154.05 43.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' ASN . . . . . 0.534 ' ND2' ' CD1' ' A' ' 100' ' ' PHE . 4.6 p30 -173.44 163.33 4.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.615 ' CE2' HD13 ' A' ' 155' ' ' ILE . 88.4 m95 -80.73 123.44 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.922 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.085 179.886 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 96' ' ' HIS . . . . . 0.518 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.838 0.352 . . . . 0.0 110.877 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.557 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 26.9 m-85 -102.2 129.67 48.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -96.34 133.39 40.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.465 HG22 HD11 ' A' ' 155' ' ' ILE . 62.3 t -114.01 127.19 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.115 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 24.4 t80 -87.63 136.4 32.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.426 HG13 ' O ' ' A' ' 169' ' ' ARG . 43.8 t -125.72 135.74 62.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.105 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.67 178.05 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 55.34 32.25 18.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 33.1 mt -78.85 118.84 21.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.6 t -50.36 152.47 3.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.82 23.45 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.678 2.252 . . . . 0.0 112.327 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -69.32 -13.2 62.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.532 HD12 HD22 ' A' ' 163' ' ' LEU . 14.6 mm -66.1 159.1 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.16 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.494 ' N ' HG22 ' A' ' 108' ' ' ILE . 68.9 p -134.9 -175.82 4.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.178 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 97.3 m -78.97 -36.98 40.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.126 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -78.95 -16.35 57.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -72.29 -48.42 42.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.0 mt -62.25 -42.48 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.13 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 65.2 mttt -57.28 -35.26 69.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 6.9 t -93.83 -19.33 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.685 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -83.62 -20.09 34.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.089 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.556 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 12.9 m-85 -110.96 -7.16 14.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.53 -45.98 99.82 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.535 0.683 . . . . 0.0 111.076 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.01 -17.09 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.136 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.637 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.9 m-85 -90.69 -32.85 16.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.874 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.85 -165.6 37.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.51 ' HG2' ' CE1' ' A' ' 146' ' ' TYR . 72.4 tttt -78.84 131.71 36.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -104.44 113.64 41.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.105 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 3.2 t -79.46 -32.39 42.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -152.5 143.5 23.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -173.25 132.36 0.49 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.155 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -152.06 164.65 36.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.607 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.6 p -114.58 100.7 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -52.88 122.76 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.467 ' HG2' ' N ' ' A' ' 137' ' ' SER . 78.0 mttt -120.92 161.26 21.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -71.38 158.51 36.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.838 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -95.85 -15.83 22.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -94.63 -60.44 1.71 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 15.3 p -83.42 -31.19 26.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.16 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.2 25.6 63.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.3 mmtm -108.24 144.63 35.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.842 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.467 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 11.2 t -46.76 105.89 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -44.14 -37.82 3.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.22 10.08 3.52 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.8 p90 -153.56 153.13 31.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.946 0.403 . . . . 0.0 110.907 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -148.18 -171.73 17.42 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -130.97 142.12 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.897 0.38 . . . . 0.0 110.874 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 25.3 t -140.9 105.61 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.158 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 17.8 m -85.77 147.91 26.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.872 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.9 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 11.1 m-85 -129.23 129.21 44.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.518 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 21.1 m-85 -43.8 -46.96 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.95 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 23.7 m-20 -114.32 -178.87 3.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.853 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.557 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 25.9 tttm -87.1 -48.74 7.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.901 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.1 tp -50.11 -64.97 0.65 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 20.2 p-10 -39.73 -51.88 2.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.9 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -60.41 -58.37 8.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.082 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -43.58 -47.39 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -45.36 -50.64 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.637 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.67 -52.34 64.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.098 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.465 HD11 HG22 ' A' ' 99' ' ' VAL . 92.1 mt -44.15 -39.54 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.8 t -77.29 -48.48 24.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 64.8 m-70 -72.05 -65.56 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.556 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.3 mmt -43.3 -49.61 6.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.2 96.6 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.455 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.59 -30.29 7.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.482 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.473 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.8 tp60 -40.16 154.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.915 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.577 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -98.92 91.17 4.92 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.685 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.6 tt -85.54 -73.14 0.46 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.462 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.94 117.17 3.57 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.477 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.69 -92.7 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.458 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -80.95 -177.29 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.861 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 33.3 mt-30 -82.5 177.15 8.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.492 ' CD1' ' SD ' ' A' ' 158' ' ' MET . 41.9 pt -134.4 173.95 13.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.138 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.426 ' O ' HG13 ' A' ' 101' ' ' VAL . 21.2 ttm180 -136.76 158.46 44.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.04 156.1 47.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -163.88 168.25 19.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.879 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -94.83 105.68 17.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.951 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 38.5 m170 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.803 0.335 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.526 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 85.3 m-85 -86.89 124.92 33.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -93.02 134.82 34.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.498 HG22 HD11 ' A' ' 155' ' ' ILE . 28.9 t -115.82 128.47 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.17 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -89.82 131.08 35.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.783 HG11 HD21 ' A' ' 104' ' ' LEU . 82.2 t -119.99 133.38 66.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.133 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -125.35 -178.43 15.31 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.526 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 47.4 43.58 15.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.883 0.373 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.783 HD21 HG11 ' A' ' 101' ' ' VAL . 45.1 mt -79.57 97.02 6.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -35.74 153.64 0.07 OUTLIER Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.684 0.754 . . . . 0.0 110.839 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.83 -14.6 36.09 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.622 2.215 . . . . 0.0 112.341 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -89.82 -3.62 58.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 109' ' ' THR . 15.1 mm -76.79 156.86 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.426 ' N ' HG22 ' A' ' 108' ' ' ILE . 26.7 p -142.19 160.93 39.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.184 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.785 ' OG1' HG12 ' A' ' 128' ' ' VAL . 21.0 m -56.14 -33.43 65.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.173 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -74.6 -39.08 62.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.5 ' O ' ' N ' ' A' ' 116' ' ' ALA . 19.2 m-20 -55.06 -57.44 11.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.545 HG23 ' CE1' ' A' ' 117' ' ' PHE . 28.1 mt -52.77 -39.79 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.128 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.64 ' HA ' HD13 ' A' ' 123' ' ' ILE . 6.9 mtpm? -62.89 -41.86 99.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.6 t -90.53 -10.17 44.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.877 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.567 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -93.27 -23.44 18.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.128 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' PHE . . . . . 0.565 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.7 m-85 -105.05 -6.98 19.5 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.574 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -55.15 -46.43 99.68 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.553 0.692 . . . . 0.0 111.083 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.574 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.4 Cg_exo -47.96 -19.0 1.32 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.354 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.688 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 44.2 m-85 -89.41 -50.24 6.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.81 165.7 33.69 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.455 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -50.83 131.54 26.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.64 HD13 ' HA ' ' A' ' 114' ' ' LYS . 57.3 mt -99.44 117.48 44.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 57.8 p -86.93 -31.21 20.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -152.1 122.87 7.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.839 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.567 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -149.13 114.21 5.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.129 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.1 155.15 47.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.905 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.785 HG12 ' OG1' ' A' ' 110' ' ' THR . 5.0 p -112.51 99.94 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.178 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 25.9 t -52.65 122.81 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.106 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.512 ' HE3' HG13 ' A' ' 128' ' ' VAL . 4.3 mtmp? -117.16 156.76 27.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.886 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -58.16 151.36 19.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.894 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' MET . . . . . 0.403 ' O ' ' SD ' ' A' ' 132' ' ' MET . 0.0 OUTLIER -96.47 16.34 18.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -131.14 -56.38 1.03 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.1 p -84.53 -28.46 26.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.12 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.77 23.17 62.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.494 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.407 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 13.8 mmtp -108.48 167.35 10.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.777 0.322 . . . . 0.0 110.911 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 80.1 p -57.07 117.65 4.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.867 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.429 ' HG3' ' C ' ' A' ' 130' ' ' LYS . 41.5 mttt -60.54 -39.53 88.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.62 16.72 2.22 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.511 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -166.08 151.42 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.902 0.382 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.56 -171.9 14.09 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -138.69 139.33 38.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.517 HG21 ' CG2' ' A' ' 113' ' ' ILE . 54.4 t -145.09 108.22 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 6.0 m -86.05 154.75 21.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -130.7 141.46 50.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.874 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -60.42 -32.86 71.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -125.54 162.35 25.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.934 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.526 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 70.8 tttt -73.94 -47.87 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -52.04 -43.05 63.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -60.29 -34.26 73.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.836 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -74.51 -45.22 47.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.117 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.524 ' O ' HG23 ' A' ' 156' ' ' VAL . 17.0 mt-10 -58.22 -42.14 85.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.894 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -53.14 -54.87 29.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ALA . . . . . 0.688 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -62.42 -55.88 23.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.498 HD11 HG22 ' A' ' 99' ' ' VAL . 79.2 mt -42.0 -37.78 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 152' ' ' GLU . 82.5 t -80.15 -58.84 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.173 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -59.64 -65.42 0.68 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' MET . . . . . 0.565 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.7 mmt -42.54 -48.12 5.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.54 104.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.484 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.81 -31.46 3.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.496 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 161' ' ' GLN . . . . . 0.499 ' N ' ' O ' ' A' ' 158' ' ' MET . 34.1 tp60 -37.28 149.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 81.5 m95 -96.24 93.55 6.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.567 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.5 tt -86.36 -70.43 0.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.97 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.406 ' HA3' HD13 ' A' ' 108' ' ' ILE . . . -125.6 118.81 3.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 58.4 -95.28 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -84.86 170.26 13.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 167' ' ' GLN . . . . . 0.581 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 39.0 mt-30 -68.7 172.28 6.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 14.9 pt -129.59 164.7 31.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.159 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.421 ' HG3' ' N ' ' A' ' 170' ' ' THR . 21.0 tpp180 -125.05 156.44 38.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.922 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 170' ' ' THR . . . . . 0.467 HG21 ' HB2' ' A' ' 158' ' ' MET . 72.2 p -144.52 156.87 44.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -174.37 173.58 2.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' TRP . . . . . 0.474 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.2 m95 -90.91 108.55 19.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.042 179.9 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.5 t -79.28 153.4 29.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.922 0.391 . . . . 0.0 110.809 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.1 m -98.4 173.67 6.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.9 -161.27 10.3 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.1 m -81.9 151.94 27.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.876 0.369 . . . . 0.0 110.845 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 45.9 t -68.8 96.99 0.78 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.841 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -103.81 44.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -70.03 169.23 13.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 110.876 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 15.2 tptm -92.79 -55.1 3.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -128.3 133.47 48.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -61.13 108.87 0.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 37.4 p -56.58 131.14 47.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -82.61 72.91 9.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.882 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 58.93 42.79 18.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 61.1 m170 -82.84 170.47 14.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.858 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -107.86 121.53 44.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -84.09 123.97 30.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.0 t -112.3 122.86 67.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.105 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.522 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 2.1 t80 -83.02 141.21 32.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.854 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.493 HG22 HG22 ' A' ' 170' ' ' THR . 96.1 t -135.55 110.67 11.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.155 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.12 -174.25 30.26 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 45.73 52.6 9.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.429 ' O ' ' C ' ' A' ' 105' ' ' SER . 21.3 mt -91.41 100.28 13.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -36.19 153.56 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.692 0.758 . . . . 0.0 110.869 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -27.23 26.67 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.726 2.284 . . . . 0.0 112.317 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -75.97 -12.41 60.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.496 HG22 ' N ' ' A' ' 109' ' ' THR . 24.1 mm -63.45 157.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.157 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 108' ' ' ILE . 77.7 p -145.66 144.04 30.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.168 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.637 ' OG1' HG12 ' A' ' 128' ' ' VAL . 76.5 m -44.64 -38.08 4.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -70.89 -35.96 72.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 116' ' ' ALA . 27.1 m-20 -63.58 -52.14 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.431 HG23 ' CE1' ' A' ' 117' ' ' PHE . 51.9 mt -56.67 -46.04 82.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.599 ' O ' HD12 ' A' ' 123' ' ' ILE . 68.0 mttt -56.7 -33.87 66.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.963 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -94.01 -18.44 21.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.652 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -85.3 -13.05 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.12 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.47 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.7 m-85 -115.87 -6.55 12.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.852 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -57.68 -46.11 99.78 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.571 0.7 . . . . 0.0 111.118 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.93 -17.19 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.649 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 48.0 m-85 -90.47 -48.18 7.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -176.45 175.56 47.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.467 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.8 tptp -62.86 134.83 56.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.771 0.32 . . . . 0.0 110.882 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.599 HD12 ' O ' ' A' ' 114' ' ' LYS . 77.3 mt -101.31 133.04 45.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 39.8 t -106.76 -40.43 5.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -143.48 122.52 12.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -149.94 133.15 16.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.597 ' HA ' HG23 ' A' ' 110' ' ' THR . 22.2 ptt180 -155.41 153.15 29.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.637 HG12 ' OG1' ' A' ' 110' ' ' THR . 7.3 p -115.49 100.0 9.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.565 HG11 ' OH ' ' A' ' 140' ' ' TYR . 78.8 t -49.85 114.3 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.133 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.483 ' HG2' ' N ' ' A' ' 137' ' ' SER . 41.7 mttt -118.07 155.67 29.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.21 149.58 49.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 mmt -91.92 -8.73 45.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.71 -58.52 2.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.092 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 11.8 p -87.69 -38.54 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.11 34.38 14.9 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -118.3 138.96 52.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.77 0.319 . . . . 0.0 110.905 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.483 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 21.4 t -40.9 104.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.89 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 21.3 mttp -45.25 -36.76 4.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.926 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.31 23.37 2.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.501 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.565 ' OH ' HG11 ' A' ' 129' ' ' VAL . 52.4 p90 -165.52 143.06 5.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.929 0.395 . . . . 0.0 110.914 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.15 -173.37 19.73 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.442 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -133.24 141.16 47.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.907 0.384 . . . . 0.0 110.906 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.19 106.34 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 50.9 m -86.36 154.29 21.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -130.89 147.22 52.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -60.96 -40.72 94.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.94 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -122.76 176.23 6.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -83.54 -55.68 4.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 19.1 tp -42.75 -53.97 4.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -51.6 -45.78 63.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -61.0 -51.54 68.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -50.02 -42.62 49.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.891 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -52.2 -48.98 64.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.649 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.0 -52.34 36.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.09 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.625 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 88.5 mt -44.03 -38.78 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.146 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.92 -54.53 8.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.114 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -58.84 -64.16 1.04 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 89.5 mmm -57.54 -39.72 77.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.69 93.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 94.31 -29.5 8.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.493 ' N ' ' O ' ' A' ' 158' ' ' MET . 71.8 tp60 -38.86 148.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.361 . . . . 0.0 110.917 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.575 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 91.1 m95 -90.7 92.54 8.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.652 HD11 ' CB ' ' A' ' 116' ' ' ALA . 3.4 tt -88.7 -69.81 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.934 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.14 117.03 3.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.445 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.57 -91.3 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.494 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.3 mpt_? -83.14 175.73 9.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.859 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.575 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 51.0 mt-30 -77.08 177.43 7.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.502 HD11 ' HE3' ' A' ' 158' ' ' MET . 19.8 pt -137.35 162.69 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.07 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.3 mmt180 -118.98 165.07 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.493 HG22 HG22 ' A' ' 101' ' ' VAL . 3.8 p -149.81 141.4 23.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.108 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 -159.88 165.17 32.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.625 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 91.9 m95 -83.95 84.17 7.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.522 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -41.06 -38.79 1.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 26.4 m -63.87 137.31 57.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.157 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 16.4 ttt85 -121.74 135.67 54.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 67.9 mttt -118.09 141.68 29.77 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.531 0.681 . . . . 0.0 110.927 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 143.11 50.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.687 2.258 . . . . 0.0 112.366 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 141.94 46.59 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.711 2.274 . . . . 0.0 112.352 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -74.61 144.07 79.94 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.576 0.703 . . . . 0.0 111.108 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 179.47 3.68 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 25.0 p -129.01 175.78 8.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -139.44 71.42 0.44 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 173.4 11.01 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.674 2.249 . . . . 0.0 112.361 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 78.3 p -170.78 130.4 0.82 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 86.1 p -155.01 169.88 23.06 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.86 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.487 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 68.9 m -125.62 177.41 6.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.955 0.407 . . . . 0.0 110.834 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 26.1 m -114.97 177.38 4.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.846 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 85.99 72.18 1.29 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 78.0 p -113.41 129.99 56.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.7 t -72.37 -60.37 2.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -104.66 158.77 16.25 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.526 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -92.04 158.5 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.884 0.373 . . . . 0.0 110.903 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -110.76 167.0 10.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.882 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.2 mtmm -94.28 40.61 1.09 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.918 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -165.18 141.39 5.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.936 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 41.8 p -60.18 124.07 19.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.149 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 40.7 t -117.52 -60.78 1.78 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.841 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -110.85 41.97 1.7 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.93 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.432 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 44.5 m170 -110.76 155.93 21.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -103.03 128.14 50.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 29.6 m-70 -83.4 131.85 35.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.831 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.415 HG21 ' HB1' ' A' ' 151' ' ' ALA . 58.6 t -118.51 124.37 73.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.099 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.436 ' CZ ' ' HB2' ' A' ' 140' ' ' TYR . 10.4 t80 -86.41 138.85 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.661 ' CG1' HD21 ' A' ' 104' ' ' LEU . 92.7 t -132.34 111.8 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.097 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.31 -175.32 26.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 49.35 41.66 20.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.661 HD21 ' CG1' ' A' ' 101' ' ' VAL . 67.9 mt -85.78 108.02 17.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.8 t -35.94 152.16 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.658 0.742 . . . . 0.0 110.855 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -19.43 35.88 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.684 2.256 . . . . 0.0 112.316 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -87.81 1.4 54.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 15.8 mm -75.38 146.34 9.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.123 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.6 p -139.59 145.79 39.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.175 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.409 ' OG1' HG12 ' A' ' 128' ' ' VAL . 88.6 m -39.01 -35.97 0.25 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.192 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -67.34 -48.89 66.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 116' ' ' ALA . 8.8 t0 -54.39 -52.72 60.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.457 HG23 ' CE1' ' A' ' 117' ' ' PHE . 64.6 mt -56.69 -42.68 77.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.159 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.439 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 36.0 mttt -63.51 -37.56 87.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.932 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -92.55 -8.93 42.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.841 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -97.4 -23.59 16.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.061 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 22.7 m-85 -105.29 -11.59 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.583 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -52.51 -45.9 95.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.603 0.716 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.3 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 0.0 112.336 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.625 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 58.7 m-85 -90.31 -51.19 5.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -178.46 158.64 23.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.498 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.4 tptt -48.64 128.7 15.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.712 0.291 . . . . 0.0 110.856 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.557 HG21 ' HB2' ' A' ' 126' ' ' ALA . 60.0 mt -96.39 137.76 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 10.6 t -112.88 -39.52 4.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.865 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -134.92 103.0 5.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.557 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -136.18 131.5 34.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 22.5 ptt180 -155.55 156.38 35.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.6 p -118.62 100.44 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.107 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.59 HG12 ' HG3' ' A' ' 138' ' ' LYS . 75.8 t -52.34 122.81 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.104 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -119.03 155.53 31.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.883 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.95 148.66 51.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 35.1 mtm -95.46 -9.41 32.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -91.13 -52.5 4.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.086 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.7 p -100.89 -40.38 7.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.152 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.59 26.25 8.21 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.48 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -109.3 149.27 29.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.915 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 11.9 m -43.09 114.65 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.824 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.59 ' HG3' HG12 ' A' ' 129' ' ' VAL . 13.2 mtpt -53.6 -39.82 65.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.927 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.77 19.34 1.83 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.555 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 44.2 p90 -167.53 150.28 6.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.899 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.65 -171.5 16.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.453 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -136.48 136.91 39.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.907 0.384 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 70.2 t -140.53 108.31 2.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.182 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.3 t -93.52 141.82 28.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -117.27 147.21 42.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.432 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 10.1 m-85 -57.79 -38.22 75.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -124.95 155.64 39.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.87 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -61.43 -60.55 3.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 21.1 tp -40.01 -49.95 2.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -49.49 -40.68 38.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.845 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.415 ' HB1' HG21 ' A' ' 99' ' ' VAL . . . -69.3 -48.87 60.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.07 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -52.57 -38.89 60.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.924 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -56.53 -54.5 45.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.625 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.31 -61.62 2.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.533 HD13 ' CE2' ' A' ' 172' ' ' TRP . 68.3 mt -38.64 -39.73 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.159 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 20.3 t -70.55 -64.37 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.132 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 77.6 m-70 -63.63 -61.17 2.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 29.0 mmt -43.9 -48.44 8.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.44 92.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 97.68 -30.1 9.88 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.525 ' CD ' ' N ' ' A' ' 162' ' ' TRP . 9.3 tm0? -36.74 154.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.811 0.338 . . . . 0.0 110.863 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.586 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 77.1 m95 -101.43 91.24 4.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.978 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.549 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.2 tt -84.29 -70.89 0.54 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.921 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -125.58 120.33 3.82 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.458 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 57.37 -95.3 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -81.15 179.26 7.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.744 0.306 . . . . 0.0 110.921 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.586 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 53.9 mt-30 -79.57 -178.43 6.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.434 ' O ' ' N ' ' A' ' 160' ' ' GLY . 20.8 pt -136.66 162.19 35.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.7 ttm180 -126.4 144.07 50.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.519 HG21 ' HA ' ' A' ' 155' ' ' ILE . 1.3 p -121.6 153.18 38.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' ASN . . . . . 0.416 ' CG ' ' O ' ' A' ' 170' ' ' THR . 12.0 m120 -169.15 159.97 9.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.533 ' CE2' HD13 ' A' ' 155' ' ' ILE . 94.9 m95 -89.41 129.42 35.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -94.21 -44.19 8.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.07 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 39.8 m -52.89 103.58 0.07 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.094 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 34.0 mtt-85 -134.94 147.07 49.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 17.4 ttmt 65.55 52.4 0.93 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.522 0.677 . . . . 0.0 110.925 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.7 Cg_endo -69.72 149.23 66.87 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.362 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 130.71 19.79 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.655 2.237 . . . . 0.0 112.33 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -169.11 145.13 2.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.594 0.711 . . . . 0.0 111.079 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 139.17 39.33 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.696 2.264 . . . . 0.0 112.323 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 55.7 m -85.36 90.61 7.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 67.92 81.38 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 136.63 33.46 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.712 2.275 . . . . 0.0 112.34 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 17.9 t -105.9 99.08 8.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.842 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 54.5 p -58.98 141.69 53.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.864 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.498 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 32.0 m -122.37 -53.46 1.91 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.894 0.378 . . . . 0.0 110.9 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 13.8 t -63.71 169.3 4.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.836 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.24 110.12 3.45 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 15.4 m -122.02 123.89 42.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 0.0 110.844 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 47.5 t -68.9 117.66 10.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 61.95 101.62 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 54.1 mt-30 -81.6 102.55 10.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.857 0.36 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 16.3 ttmt -110.49 125.19 53.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.915 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -94.14 28.61 2.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.914 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.436 ' O ' ' C ' ' A' ' 93' ' ' THR . 1.1 m-20 53.0 50.75 17.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.453 ' O ' ' N ' ' A' ' 95' ' ' ASN . 41.1 p 34.17 53.03 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.154 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 95' ' ' ASN . 1.3 t -44.96 92.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.843 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.453 ' N ' ' O ' ' A' ' 93' ' ' THR . 24.5 p30 34.43 36.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.441 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 38.1 m170 -50.66 174.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -104.72 121.4 43.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 5.2 m-70 -89.3 134.42 34.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.21 122.1 68.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 45.4 t80 -84.91 141.43 30.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.6 t -125.73 143.05 40.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.44 159.22 23.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.459 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 t0 68.06 33.77 4.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.88 0.372 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.49 HD12 ' C ' ' A' ' 140' ' ' TYR . 31.3 mt -70.91 99.06 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.4 t -35.85 153.22 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.739 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -18.93 36.6 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.335 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.452 ' CG ' ' O ' ' A' ' 107' ' ' GLU . 9.6 tt0 -87.71 -3.43 58.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.438 HG21 HD22 ' A' ' 104' ' ' LEU . 18.1 mm -69.36 144.59 13.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.6 p -134.49 148.8 50.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.118 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 88.4 m -50.87 -30.71 15.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.183 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -78.23 -23.16 47.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -78.91 -48.92 13.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.507 HG23 ' CD1' ' A' ' 117' ' ' PHE . 17.5 mt -57.85 -42.42 82.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.144 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.3 mttt -58.45 -43.98 89.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.7 t -81.94 -16.87 49.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.487 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -89.5 -20.11 24.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.066 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.3 m-85 -108.63 -10.59 15.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.855 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.585 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.12 -45.43 99.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.57 0.7 . . . . 0.0 111.042 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -47.98 -17.03 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.706 2.27 . . . . 0.0 112.33 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.65 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 34.6 m-85 -93.58 -32.13 14.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.16 178.79 36.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.579 ' HG3' ' CE1' ' A' ' 146' ' ' TYR . 32.0 tptt -62.82 143.68 57.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.802 0.334 . . . . 0.0 110.877 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.533 HG21 ' HB2' ' A' ' 126' ' ' ALA . 62.6 mt -113.57 126.24 70.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 1.7 t -93.77 -37.44 11.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -145.89 117.43 8.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.533 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -146.43 119.2 8.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -148.45 163.27 37.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.509 ' O ' HG13 ' A' ' 128' ' ' VAL . 3.9 p -115.76 104.26 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.128 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.0 t -57.49 124.65 11.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -122.36 157.98 30.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.912 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -64.83 158.23 25.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.932 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 42.7 mmm -101.92 -13.13 17.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.883 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.36 -47.69 7.59 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.119 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.8 p -102.55 -38.86 7.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.104 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.28 32.79 9.25 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.9 mttt -111.84 155.5 23.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.741 0.305 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.1 t -55.23 102.61 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 65.0 mttt -45.03 -39.0 5.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.892 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.92 16.96 2.87 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.455 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.49 ' C ' HD12 ' A' ' 104' ' ' LEU . 32.8 p90 -160.5 145.81 14.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.976 0.417 . . . . 0.0 110.927 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -141.55 -176.17 15.64 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -129.82 142.15 50.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.869 0.366 . . . . 0.0 110.924 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 19.8 t -149.35 106.03 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.155 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 48.9 m -92.0 142.1 27.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.652 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 23.7 m-85 -112.42 144.67 41.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.579 ' CE1' ' HG3' ' A' ' 122' ' ' LYS . 8.5 m-85 -56.98 -35.75 69.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.557 ' ND2' ' N ' ' A' ' 147' ' ' ASN . 0.0 OUTLIER -127.15 179.7 5.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.901 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -86.98 -40.96 14.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 55.9 tp -52.44 -65.07 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.456 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 14.6 p-10 -43.8 -53.63 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.844 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.652 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -55.0 -57.16 12.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.066 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.441 ' O ' HG23 ' A' ' 156' ' ' VAL . 26.8 mt-10 -46.38 -47.21 18.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 64.6 m-20 -49.8 -55.09 15.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.65 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -57.05 -60.73 3.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.081 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.623 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 83.3 mt -39.31 -37.72 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.152 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 152' ' ' GLU . 90.4 t -77.76 -48.6 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.139 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -75.56 -62.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 23.2 mmt -45.31 -47.27 13.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.45 94.96 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.446 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 96.59 -30.69 8.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.474 ' N ' ' O ' ' A' ' 158' ' ' MET . 6.2 tm0? -38.25 157.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 110.923 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 87.1 m95 -102.56 95.0 5.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.958 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.522 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.3 tt -90.88 -70.5 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.414 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.09 116.77 3.53 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.505 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.42 -91.53 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -82.07 178.81 8.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.839 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 43.9 mt-30 -80.63 177.83 8.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 7.7 pt -137.3 170.19 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.111 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.4 ttm-85 -131.29 149.57 52.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.9 p -126.67 150.85 48.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -168.77 154.56 6.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.623 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.2 m95 -81.05 113.24 19.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -52.45 -52.24 55.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.111 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 13.1 t -100.59 152.76 20.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.101 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.427 ' HB2' ' NH1' ' A' ' 175' ' ' ARG . 22.4 mtm105 -117.01 146.14 43.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.404 ' HD3' ' C ' ' A' ' 176' ' ' LYS . 0.0 OUTLIER -107.62 146.59 33.67 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.567 0.699 . . . . 0.0 110.92 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 158.89 55.41 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.712 2.275 . . . . 0.0 112.314 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 100.76 0.85 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.688 2.259 . . . . 0.0 112.35 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -53.82 151.71 11.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.555 0.693 . . . . 0.0 111.144 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -44.53 2.05 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.701 2.267 . . . . 0.0 112.349 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 84.4 p -59.3 175.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.825 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 155.86 76.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.48 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 148.53 65.5 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.726 2.284 . . . . 0.0 112.364 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 t -146.67 120.21 9.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 10.7 t -168.04 152.77 6.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.836 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.453 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.3 m -154.67 158.28 39.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.869 0.366 . . . . 0.0 110.897 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.6 m -119.58 128.67 54.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 70.0 173.03 10.98 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.502 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -108.31 -57.32 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.891 0.377 . . . . 0.0 110.859 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 29.0 m -55.93 -49.62 72.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 115.9 159.4 11.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.515 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -99.16 -55.74 2.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -95.29 46.78 1.12 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -53.23 106.3 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 93' ' ' THR . 0.4 OUTLIER -67.85 119.04 11.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.852 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 92' ' ' ASP . 22.5 p -35.29 125.79 0.61 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.1 t -128.33 -50.35 1.29 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -117.27 43.15 2.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.899 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.405 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 30.6 m170 -122.88 153.03 40.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.817 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -94.12 130.24 40.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' HIS . . . . . 0.507 ' CB ' ' HB3' ' A' ' 173' ' ' ALA . 54.6 m-70 -88.28 128.12 35.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 95.6 t -116.44 124.65 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -89.57 141.86 28.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 169' ' ' ARG . 61.2 t -131.59 134.89 60.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.46 17.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.479 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.96 36.09 23.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.879 0.371 . . . . 0.0 110.836 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.492 HD21 HG11 ' A' ' 101' ' ' VAL . 31.2 mt -81.1 110.03 16.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -41.61 153.31 0.27 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -23.64 30.52 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.336 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -75.84 -18.53 59.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.646 HD12 HD22 ' A' ' 163' ' ' LEU . 20.2 mm -66.33 133.09 31.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 60.8 p -121.21 151.42 39.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 52.9 m -43.98 -34.54 1.74 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.136 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -70.93 -43.81 67.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.4 m-20 -58.76 -53.83 53.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.608 HG23 ' CE1' ' A' ' 117' ' ' PHE . 43.3 mt -56.34 -38.68 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.542 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 7.0 mtpt -63.58 -39.13 93.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.3 t -93.3 -11.92 31.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.836 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.748 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.72 -20.94 21.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.09 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.608 ' CE1' HG23 ' A' ' 113' ' ' ILE . 19.6 m-85 -107.4 -8.65 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.73 -45.66 99.8 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.589 0.709 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -48.0 -17.07 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.283 . . . . 0.0 112.361 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.631 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.7 m-85 -90.73 -38.84 12.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.896 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.97 167.29 31.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -54.54 126.63 24.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.445 HD12 ' O ' ' A' ' 114' ' ' LYS . 85.7 mt -95.76 132.85 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.147 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 92.1 p -99.99 -44.92 5.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.1 120.65 13.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.542 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -143.21 128.32 18.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.099 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 -156.44 151.75 26.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.718 HG13 ' HE2' ' A' ' 130' ' ' LYS . 7.2 p -108.59 100.08 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 68.7 t -49.49 130.37 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.077 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.718 ' HE2' HG13 ' A' ' 128' ' ' VAL . 29.9 mtmt -125.55 167.75 14.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 30.3 t0 -68.53 157.33 36.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -94.57 -12.53 27.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.58 -62.55 1.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.6 p -81.08 -28.38 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.131 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.26 33.45 53.71 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.411 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 7.1 mmpt? -106.03 158.33 16.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.307 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.412 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 16.5 m -65.47 100.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 37.4 mttt -44.21 -36.77 2.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 121.17 18.58 3.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.485 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -156.71 142.45 17.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.908 0.385 . . . . 0.0 110.952 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.1 -169.76 12.26 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -134.23 142.38 47.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 73.1 t -144.83 110.55 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.136 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 15.8 m -89.67 145.01 25.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -121.88 149.18 43.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.405 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 10.1 m-85 -58.63 -46.64 86.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -128.66 165.23 21.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' A' ' 151' ' ' ALA . 14.3 ttmt -62.13 -62.22 1.92 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 65.0 tp -38.19 -50.88 1.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -55.68 -39.62 71.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.907 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.602 ' HB3' ' HH2' ' A' ' 172' ' ' TRP . . . -67.02 -51.19 57.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.149 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.423 ' O ' HG23 ' A' ' 156' ' ' VAL . 5.5 mm-40 -50.14 -48.04 53.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -42.03 -36.59 1.16 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.631 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -86.0 -54.53 4.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.095 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.629 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 76.1 mt -47.67 -34.31 3.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.16 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 152' ' ' GLU . 46.7 t -81.37 -46.33 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.129 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -74.92 -65.26 0.89 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.892 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.72 ' HB2' HG21 ' A' ' 170' ' ' THR . 8.1 mmt -42.33 -48.66 5.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -35.51 103.04 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.467 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 82.08 -32.53 2.74 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.3 tp-100 -34.32 149.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.756 0.312 . . . . 0.0 110.966 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 90.8 m95 -99.89 92.51 5.32 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.926 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.748 HD11 ' CB ' ' A' ' 116' ' ' ALA . 7.0 tt -87.24 -71.04 0.58 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.583 ' HA3' HD11 ' A' ' 108' ' ' ILE . . . -120.63 117.67 3.59 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.483 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.94 -92.78 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.504 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.735 0.302 . . . . 0.0 110.864 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 71.5 mt-30 -77.15 -178.96 5.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 25.0 pt -137.96 163.68 29.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.724 ' O ' HG13 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -126.45 152.14 46.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.944 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.72 HG21 ' HB2' ' A' ' 158' ' ' MET . 16.4 p -134.16 158.46 43.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.156 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 171' ' ' ASN . . . . . 0.413 ' HB2' ' NH1' ' A' ' 169' ' ' ARG . 24.4 t-20 -172.07 173.18 4.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.843 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.629 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 83.8 m95 -95.04 106.97 19.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.507 ' HB3' ' CB ' ' A' ' 98' ' ' HIS . . . -53.84 -57.43 10.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 10.0 t -85.19 143.97 28.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.099 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.412 ' HD3' ' C ' ' A' ' 175' ' ' ARG . 0.0 OUTLIER -137.68 117.22 12.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 32.1 mttp -86.74 144.36 37.07 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.559 0.695 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 147.07 62.34 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.721 2.281 . . . . 0.0 112.346 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 151.03 68.9 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -134.22 142.6 43.7 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.577 0.704 . . . . 0.0 111.068 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 143.92 52.43 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.662 2.242 . . . . 0.0 112.373 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 8.4 t -79.19 172.9 13.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.826 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -132.85 152.88 20.45 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.484 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 163.59 37.72 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.715 2.277 . . . . 0.0 112.379 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 19.6 m -72.31 -56.26 5.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 46.8 p -89.65 134.74 34.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.966 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 20.2 m -143.44 144.54 32.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.9 0.381 . . . . 0.0 110.858 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 20.2 t -154.66 139.32 17.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.838 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 79.15 50.55 5.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.9 m -91.88 132.53 36.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.838 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 85.4 p -161.35 129.72 4.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.815 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -92.92 -114.17 2.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.419 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -105.45 91.12 3.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.882 0.373 . . . . 0.0 110.912 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -129.95 100.5 5.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.2 44.77 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.945 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -105.46 106.71 17.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.824 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.42 ' CG2' ' HB2' ' A' ' 124' ' ' SER . 69.1 p -96.49 105.9 18.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.5 m -124.32 -59.13 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -98.94 43.4 1.06 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -106.12 164.02 12.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.866 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.532 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 58.2 m-85 -113.48 134.24 54.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -91.29 128.35 37.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 98.3 t -111.59 135.48 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.508 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 2.7 t80 -100.24 139.38 36.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 54.7 t -131.39 114.78 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.42 172.83 19.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 139' ' ' GLY . 1.6 m-20 58.71 37.73 25.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.359 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.508 HD12 ' C ' ' A' ' 140' ' ' TYR . 31.7 mt -71.88 101.08 2.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 104' ' ' LEU . 0.7 OUTLIER -36.64 155.23 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.663 0.744 . . . . 0.0 110.88 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -13.11 34.14 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -89.9 -16.72 29.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.894 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.483 HG21 HD22 ' A' ' 104' ' ' LEU . 10.7 mm -66.93 144.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 80.4 p -142.55 145.93 34.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.183 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 49.2 m -39.75 -37.49 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.101 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -68.27 -45.35 73.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.487 ' O ' ' N ' ' A' ' 116' ' ' ALA . 75.4 m-20 -64.32 -50.72 66.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CD1' ' A' ' 117' ' ' PHE . 13.1 mt -53.52 -45.4 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.475 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 13.3 mtpt -61.35 -35.64 77.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.2 t -91.54 -13.59 31.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.76 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.71 -17.59 21.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.058 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.578 ' CE1' ' SD ' ' A' ' 158' ' ' MET . 25.5 m-85 -108.34 -11.03 15.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.845 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.591 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.16 -44.79 99.06 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 0.0 111.106 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -48.06 -16.75 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.261 . . . . 0.0 112.341 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -94.31 -41.47 9.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 174.5 147.94 6.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -43.89 126.89 5.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 62.5 mt -91.63 134.33 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' SER . . . . . 0.42 ' HB2' ' CG2' ' A' ' 93' ' ' THR . 87.9 p -100.29 -42.92 6.46 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.859 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -145.39 107.31 4.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.858 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HB1' HG22 ' A' ' 143' ' ' VAL . . . -137.34 135.46 37.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.077 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -157.6 165.99 34.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 128' ' ' VAL . 3.8 p -123.07 100.04 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.142 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 41.9 t -53.4 128.04 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.403 ' HG2' ' C ' ' A' ' 136' ' ' LYS . 49.6 mttt -121.26 171.31 8.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.82 159.29 31.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.85 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.424 ' N ' ' SD ' ' A' ' 132' ' ' MET . 0.3 OUTLIER -101.95 9.55 40.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.994 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -122.72 -44.01 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.5 p -98.92 -31.23 11.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.98 30.09 56.2 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.403 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 51.5 mmtt -114.06 155.14 26.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.1 t -50.67 110.9 0.46 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.852 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -53.32 -34.74 58.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.935 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 123.99 11.17 4.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.508 ' C ' HD12 ' A' ' 104' ' ' LEU . 48.8 p90 -154.97 159.24 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.892 0.377 . . . . 0.0 110.966 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -160.06 -167.95 21.35 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.476 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -141.37 152.39 44.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.38 . . . . 0.0 110.902 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.599 HG22 ' HB1' ' A' ' 126' ' ' ALA . 43.0 t -153.91 109.52 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.182 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 70.8 m -85.07 150.89 24.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -129.89 149.15 51.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.859 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -63.3 -43.55 97.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.927 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -120.06 157.96 27.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.532 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 57.3 tttt -65.51 -49.99 66.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.5 tp -47.65 -56.08 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -45.83 -39.46 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.407 ' HB1' ' CG2' ' A' ' 99' ' ' VAL . . . -67.8 -49.58 61.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.125 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.446 ' O ' HG23 ' A' ' 156' ' ' VAL . 23.6 mt-10 -51.47 -46.31 63.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.918 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -52.68 -47.9 66.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.875 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.27 -55.93 18.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.588 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 96.4 mt -50.0 -35.01 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 152' ' ' GLU . 74.3 t -78.98 -49.33 20.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.135 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.7 m-70 -72.67 -67.07 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.578 ' SD ' ' CE1' ' A' ' 117' ' ' PHE . 14.9 mmt -44.86 -47.28 11.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.53 101.22 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 84.5 -31.57 3.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.527 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.9 tp-100 -34.78 151.51 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.819 0.342 . . . . 0.0 110.91 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.58 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.9 m95 -97.02 90.63 5.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.92 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.76 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.5 tt -85.31 -70.08 0.61 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.1 117.94 3.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.506 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.78 -93.68 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 27.7 mtt85 -80.47 -179.73 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.733 0.302 . . . . 0.0 110.897 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.58 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 40.1 mt-30 -83.77 176.16 9.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.935 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.424 ' O ' ' N ' ' A' ' 160' ' ' GLY . 18.9 pt -131.81 167.79 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -130.91 149.23 52.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 20.1 p -126.54 162.09 26.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -173.0 156.9 3.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.913 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.588 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.0 m95 -87.07 119.19 27.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -87.53 42.97 1.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.139 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -115.47 142.45 46.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 50.3 mtt-85 -124.84 144.03 50.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.858 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.439 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 0.8 OUTLIER 43.97 54.74 11.89 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.585 0.707 . . . . 0.0 110.89 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 177' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.5 Cg_endo -69.76 159.74 52.28 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 157.58 59.94 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 0.0 112.354 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -158.38 152.53 20.02 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.732 . . . . 0.0 111.095 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 170.99 15.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.728 2.285 . . . . 0.0 112.308 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 5.6 t -117.73 105.39 11.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.877 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 86.85 178.71 49.09 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.474 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 128.43 16.03 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.707 2.271 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 1.8 m -132.05 121.87 24.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.852 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 24.8 t -140.25 131.0 25.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.833 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.383 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.9 t -71.24 135.32 47.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.881 0.372 . . . . 0.0 110.889 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 73.4 p -137.72 148.49 45.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.845 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 137.22 -142.58 13.63 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.522 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 t -133.49 146.3 50.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 110.904 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 22.0 m -76.84 97.97 4.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 50.82 93.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.502 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -79.31 115.83 19.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.901 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.8 pttt -98.26 -39.46 8.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -47.55 111.07 0.37 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -53.3 -60.68 2.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 37.3 p -46.96 132.39 11.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.133 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.1 t -129.93 -56.1 1.12 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 -61.21 -60.03 4.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.0 m170 -42.28 152.92 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.544 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 88.7 m-85 -89.43 154.35 20.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -111.77 135.77 51.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.421 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 60.7 t -126.65 121.07 57.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.156 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.405 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 87.6 t80 -86.14 139.34 31.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.903 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 169' ' ' ARG . 47.0 t -130.11 120.17 48.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.178 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -111.43 -175.36 20.09 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 46.34 43.64 11.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.871 0.367 . . . . 0.0 110.838 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.517 HD21 HG11 ' A' ' 101' ' ' VAL . 39.5 mt -85.0 110.1 18.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -39.67 153.44 0.19 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.686 0.755 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.408 ' HA ' ' HB2' ' A' ' 137' ' ' SER . 54.0 Cg_endo -69.75 -20.01 35.44 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 0.0 112.345 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -82.98 -20.62 34.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.876 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 46.8 mm -50.0 151.02 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.127 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 37.3 p -139.14 148.29 43.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.157 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.587 ' OG1' HG12 ' A' ' 128' ' ' VAL . 27.7 m -48.91 -38.11 21.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.153 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -71.89 -32.7 67.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.496 ' O ' ' N ' ' A' ' 116' ' ' ALA . 10.9 m-20 -65.21 -53.59 42.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 31.6 mt -56.25 -48.01 80.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.091 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.9 mttm -56.41 -39.32 72.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.913 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.4 t -92.37 -8.98 43.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.635 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -94.21 -13.9 26.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.121 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.581 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.6 m-85 -115.49 -11.6 11.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.595 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -49.82 -46.63 80.63 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.603 0.716 . . . . 0.0 111.157 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.595 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 63.8 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.695 2.263 . . . . 0.0 112.31 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.582 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 50.0 m-85 -92.42 -33.05 14.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.921 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.06 157.84 9.18 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.527 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 18.5 tptp -49.09 145.29 4.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.88 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 53.6 mt -115.21 143.42 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 51.4 p -108.26 -33.98 6.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.76 136.35 22.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -164.68 129.12 2.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.478 ' HA ' HG23 ' A' ' 110' ' ' THR . 9.0 ptp85 -150.42 154.23 37.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.723 HG13 ' HE2' ' A' ' 130' ' ' LYS . 7.4 p -113.12 100.08 9.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.423 HG11 ' OH ' ' A' ' 140' ' ' TYR . 47.1 t -51.74 114.26 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.723 ' HE2' HG13 ' A' ' 128' ' ' VAL . 32.3 mtmt -109.09 163.14 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 158.3 7.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.865 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 ttt -98.93 -8.52 25.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -108.06 -48.79 3.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.11 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.9 p -96.96 -24.45 15.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.089 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.92 19.97 78.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.468 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -95.99 143.29 27.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.47 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 37.3 m -47.61 106.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -50.15 -45.1 52.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 133.26 29.99 0.48 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.427 ' C ' HD12 ' A' ' 104' ' ' LEU . 41.3 p90 -171.98 144.68 1.74 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.956 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.446 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -145.96 -172.01 15.95 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.498 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -131.57 140.78 49.54 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.897 0.38 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.8 t -140.78 122.15 14.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.089 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 63.6 p -101.68 147.67 26.17 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.873 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.65 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 11.1 m-85 -125.36 148.68 48.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.833 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -64.5 -35.99 82.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.934 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -130.62 154.39 47.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.916 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.544 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 11.3 ttmt -60.1 -66.74 0.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.906 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 148' ' ' LYS . 14.9 tp -35.3 -59.49 0.52 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -47.47 -41.86 21.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.65 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -71.52 -54.07 11.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.5 ' HA ' HD12 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -47.82 -39.39 18.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.911 -179.948 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -52.3 -46.39 65.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.489 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.64 -53.21 44.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.5 HD12 ' HA ' ' A' ' 152' ' ' GLU . 81.9 mt -41.01 -35.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.123 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.4 t -89.23 -53.74 8.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -59.27 -62.45 1.88 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.838 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.582 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 83.7 mmm -64.04 -36.36 83.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.37 92.03 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.91 -28.58 12.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.7 tp-100 -38.61 155.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.882 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.604 ' CZ2' ' NE2' ' A' ' 167' ' ' GLN . 92.1 m95 -95.64 90.91 5.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.959 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.635 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.9 tt -87.09 -69.83 0.66 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.888 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.72 116.97 3.44 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.94 -91.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.8 mtt180 -82.63 178.14 8.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.838 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.604 ' NE2' ' CZ2' ' A' ' 162' ' ' TRP . 78.3 mt-30 -78.14 175.47 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.929 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.463 HD11 ' HB3' ' A' ' 158' ' ' MET . 32.9 pt -132.64 168.64 23.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.127 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.559 ' O ' HG13 ' A' ' 101' ' ' VAL . 65.2 ttt180 -126.39 160.87 29.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.899 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 31.7 p -146.8 147.58 31.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.134 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -160.77 164.05 31.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 11.7 m95 -79.14 83.37 5.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.951 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -39.52 -37.83 0.52 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.123 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 m -127.38 108.75 11.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.142 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 -82.03 -43.01 18.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.448 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 24.9 ttmt 40.94 53.64 6.65 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.534 0.683 . . . . 0.0 110.939 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.9 Cg_endo -69.75 164.04 36.0 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.688 2.259 . . . . 0.0 112.352 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 144.12 53.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.32 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -121.58 145.21 42.28 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.553 0.692 . . . . 0.0 111.081 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 181' ' ' SER . 53.5 Cg_endo -69.77 -14.2 35.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.677 2.252 . . . . 0.0 112.37 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 181' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 180' ' ' PRO . 7.7 t -36.42 120.6 0.68 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 93.33 73.31 1.22 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.43 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -19.03 36.58 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.694 2.262 . . . . 0.0 112.311 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 34.8 m -69.94 138.48 52.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.6 m -72.86 -45.23 59.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.855 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.483 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.9 p -116.21 161.84 18.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.885 0.374 . . . . 0.0 110.833 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 97.6 p -87.39 12.36 12.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.855 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -176.42 -84.19 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.492 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 63.5 p -156.56 157.9 36.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.89 0.376 . . . . 0.0 110.853 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 32.8 t -94.87 119.9 34.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.878 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -150.23 116.84 0.8 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.476 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -105.85 79.11 1.39 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 0.0 110.896 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 20.7 pttt -169.0 145.47 3.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.3 mttt -153.86 110.49 3.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -57.15 -69.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 60.6 p -69.44 112.16 5.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.137 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.5 m -111.76 -65.98 1.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -50.67 -41.81 56.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 4.3 m-70 -57.48 151.76 16.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -96.96 128.97 44.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 10.0 m170 -87.71 119.6 28.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.412 HG13 HG12 ' A' ' 155' ' ' ILE . 65.6 t -109.79 119.75 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.13 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.425 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 3.2 t80 -84.14 145.4 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.469 HG13 ' O ' ' A' ' 169' ' ' ARG . 61.9 t -132.76 140.79 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -130.23 -169.37 12.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.501 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 44.9 36.71 2.0 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.831 0.348 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 40.9 mt -78.74 106.15 10.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.961 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -40.44 153.6 0.21 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.685 0.755 . . . . 0.0 110.844 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -28.31 25.51 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.733 2.289 . . . . 0.0 112.325 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -77.41 -7.4 56.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.862 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.568 HG22 ' N ' ' A' ' 109' ' ' THR . 9.5 mm -68.56 161.96 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.568 ' N ' HG22 ' A' ' 108' ' ' ILE . 56.4 p -142.96 172.1 13.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.474 ' OG1' HG12 ' A' ' 128' ' ' VAL . 15.5 m -69.0 -39.15 79.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -74.0 -17.95 60.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.93 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 17.9 m-20 -75.32 -54.54 6.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CE1' ' A' ' 117' ' ' PHE . 14.5 mt -53.62 -48.18 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.62 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 16.8 mtpp -54.57 -41.78 70.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -87.32 -15.88 36.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.881 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.604 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.28 -14.8 32.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.067 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.598 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 16.4 m-85 -114.65 -8.82 12.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.581 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.0 -46.28 98.69 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.594 0.712 . . . . 0.0 111.105 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.581 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.4 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.658 2.238 . . . . 0.0 112.388 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.572 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 56.6 m-85 -89.98 -32.87 16.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.81 171.14 26.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.492 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.576 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 0.0 OUTLIER -55.86 132.62 50.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.762 0.315 . . . . 0.0 110.872 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.409 HD13 ' HA ' ' A' ' 114' ' ' LYS . 96.5 mt -102.52 123.84 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.14 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 83.9 p -86.02 -49.69 7.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.841 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -143.84 117.6 9.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.852 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.62 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -141.75 134.31 28.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.473 ' CZ ' ' HB3' ' A' ' 127' ' ' ARG . 1.7 ptp180 -158.81 164.93 35.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.474 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.3 p -112.94 100.06 9.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.093 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -49.68 126.5 4.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.192 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -121.46 171.99 8.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -76.76 156.96 31.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.89 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 17.2 ttp -94.89 -11.79 28.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.92 -62.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 71.1 p -82.9 -30.69 28.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.98 28.45 60.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.5 mmtp -106.32 152.3 23.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.829 0.347 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 50.6 p -45.99 109.59 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.846 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -53.95 -36.3 62.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.97 12.81 4.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.503 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 30.8 p90 -162.64 146.73 11.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.907 0.384 . . . . 0.0 110.922 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -133.97 -169.59 12.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.479 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -136.99 141.87 42.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 41.4 t -145.04 108.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 13.3 t -88.48 150.98 22.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.49 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 57.6 m-85 -127.54 151.62 48.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.576 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 14.3 m-85 -69.38 -42.42 75.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -115.23 178.96 4.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.908 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.8 tttm -87.15 -41.59 13.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 14.4 tp -53.49 -65.06 0.63 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.459 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 12.4 p-10 -41.81 -53.97 3.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -53.95 -51.11 64.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.123 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -53.39 -44.81 68.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -50.25 -48.58 54.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.857 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.572 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -67.07 -60.56 2.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.101 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.586 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 97.4 mt -38.32 -41.26 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.3 t -79.66 -58.48 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 30.2 m-70 -57.81 -65.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.897 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.598 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 15.8 mmt -46.59 -45.84 19.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -40.16 91.77 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 99.77 -32.08 7.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.506 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.444 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.2 tp-100 -39.06 149.02 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.835 0.35 . . . . 0.0 110.92 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.563 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 78.9 m95 -95.31 91.65 6.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.632 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.1 tt -87.34 -71.71 0.55 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.497 ' HA3' HD11 ' A' ' 108' ' ' ILE . . . -119.89 119.26 4.18 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.476 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.39 -92.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.497 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -85.42 169.3 13.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.756 0.312 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.563 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 85.7 mt-30 -68.65 177.18 2.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 29.1 pt -135.8 169.87 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.469 ' O ' HG13 ' A' ' 101' ' ' VAL . 2.6 ptp180 -137.23 163.43 30.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.832 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 101' ' ' VAL . 42.8 p -140.18 163.51 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -162.86 157.77 21.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.586 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 82.6 m95 -88.69 96.96 10.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.925 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.88 37.81 0.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.7 t -128.56 142.74 50.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.17 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -117.4 126.9 53.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.53 144.34 45.89 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 110.879 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 147.42 62.67 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.673 2.248 . . . . 0.0 112.299 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 145.95 58.49 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.641 2.227 . . . . 0.0 112.343 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -139.27 144.67 41.32 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.619 0.723 . . . . 0.0 111.109 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 176.98 6.08 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.719 2.279 . . . . 0.0 112.365 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 22.8 m -94.94 -45.27 7.34 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 116.72 166.39 14.28 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 166.31 27.98 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.712 2.275 . . . . 0.0 112.357 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.3 m -130.86 95.33 3.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 6.2 t -66.53 148.32 52.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.824 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.986 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 54.5 p -62.35 155.21 25.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.861 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 -44.09 2.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 66.43 0.74 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.515 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.2 t -97.77 148.49 23.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.86 0.362 . . . . 0.0 110.851 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 23.4 m -156.0 155.35 32.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.87 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.17 43.04 2.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.477 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -126.38 152.72 45.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.872 0.368 . . . . 0.0 110.923 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 33.8 mmtm -106.43 143.2 34.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.9 mmtp -150.82 143.47 24.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.85 174.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 70.6 p -82.73 125.56 31.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.159 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 23.6 t -102.53 87.43 3.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.858 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 46.46 43.52 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 8.8 m-70 -77.39 162.11 27.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.855 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.566 ' CE1' ' HE3' ' A' ' 148' ' ' LYS . 85.2 m-85 -89.6 131.86 35.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -93.25 124.82 37.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.819 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 65.5 t -111.26 130.96 63.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.491 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 1.9 t80 -98.9 140.74 32.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.534 HG13 ' O ' ' A' ' 169' ' ' ARG . 21.5 t -130.55 134.99 61.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.114 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.75 172.79 16.45 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.534 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.0 t0 58.63 40.3 23.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 110.877 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.477 HD13 HG23 ' A' ' 128' ' ' VAL . 35.6 mt -77.28 97.58 4.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.912 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.6 t -35.0 152.45 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.655 0.74 . . . . 0.0 110.882 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 -14.13 35.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.728 2.286 . . . . 0.0 112.37 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -93.42 1.68 56.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 9.4 mm -76.77 146.82 8.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.109 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 57.6 p -134.43 158.99 42.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 90.0 m -57.22 -33.69 67.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.142 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -75.93 -17.67 59.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' CB ' ' A' ' 116' ' ' ALA . 11.9 m-20 -81.78 -48.08 12.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.475 HG23 ' CE1' ' A' ' 117' ' ' PHE . 30.9 mt -64.39 -39.58 86.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.142 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.42 ' O ' HD12 ' A' ' 123' ' ' ILE . 57.8 mttt -63.83 -42.83 97.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 1.3 t -86.08 -16.47 37.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 112' ' ' ASP . . . -85.51 -29.63 24.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.508 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 9.0 m-85 -100.39 -8.3 23.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.58 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.71 -46.45 99.36 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.569 0.7 . . . . 0.0 111.108 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.58 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.2 Cg_exo -47.98 -17.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.642 2.228 . . . . 0.0 112.358 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.514 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 46.4 m-85 -91.56 -36.4 13.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.09 176.9 40.02 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.3 tttt -68.5 121.2 15.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.758 0.313 . . . . 0.0 110.92 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.42 HD12 ' O ' ' A' ' 114' ' ' LYS . 56.8 mt -91.89 127.77 43.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.128 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.6 t -92.45 -42.34 9.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.882 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -142.66 124.56 15.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.892 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -154.73 126.81 7.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.7 ptm180 -150.55 156.32 41.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.6 p -108.59 99.95 9.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.115 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.6 t -51.84 122.55 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.459 ' HG2' ' N ' ' A' ' 137' ' ' SER . 69.4 mttt -115.92 172.45 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.901 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -75.25 143.51 43.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.893 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 25.3 tpp -89.28 3.41 52.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -106.64 -62.94 1.33 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.119 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.7 p -91.94 -27.53 17.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.144 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.38 30.34 22.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 137' ' ' SER . 49.1 mtmt -112.03 135.71 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.76 0.314 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.459 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 67.4 m -37.24 119.31 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.803 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -60.75 -42.35 97.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.46 26.91 0.64 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.443 ' C ' HD12 ' A' ' 104' ' ' LEU . 16.4 p90 -169.82 144.77 2.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.944 0.402 . . . . 0.0 110.904 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -138.4 -177.99 15.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.486 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -134.2 139.7 45.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 53.5 t -141.85 127.9 18.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.5 m -104.92 144.45 31.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 150' ' ' ASP . 19.6 m-85 -124.1 145.1 49.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.855 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -62.0 -46.95 86.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.966 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -118.45 165.8 13.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.566 ' HE3' ' CE1' ' A' ' 97' ' ' PHE . 10.9 ttmt -67.52 -56.19 10.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.945 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.7 tp -39.26 -53.9 1.87 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.403 ' HB3' ' CD1' ' A' ' 145' ' ' PHE . 65.0 m-20 -51.28 -39.44 56.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -70.24 -58.03 4.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -46.88 -47.48 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 28.1 m-20 -51.01 -47.38 61.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.482 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -69.08 -49.71 54.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.61 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 91.8 mt -48.54 -34.53 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.136 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 88.1 t -89.41 -55.8 5.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -57.01 -63.01 1.35 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.622 ' CE ' HD11 ' A' ' 168' ' ' ILE . 92.0 mmm -57.53 -40.03 77.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 92.25 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.529 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.48 -29.35 9.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.482 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.2 tp-100 -37.3 153.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.796 0.332 . . . . 0.0 110.888 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.566 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 90.7 m95 -96.82 91.02 5.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.965 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.481 HD12 ' HE1' ' A' ' 158' ' ' MET . 4.8 tt -85.47 -70.22 0.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.11 118.02 3.43 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.04 -93.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.52 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -82.25 174.31 11.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.842 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.566 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 84.5 mt-30 -76.16 178.23 6.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.622 HD11 ' CE ' ' A' ' 158' ' ' MET . 9.2 pt -139.91 166.99 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.534 ' O ' HG13 ' A' ' 101' ' ' VAL . 51.8 mtt180 -126.71 167.74 15.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 4.2 p -147.76 143.76 27.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.165 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -153.67 166.95 31.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.61 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 97.0 m95 -88.11 109.87 20.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -81.55 62.71 5.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.12 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 79.4 m -132.98 122.6 24.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.152 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -100.71 85.72 2.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.2 ttpm? -167.32 137.49 2.36 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.581 0.705 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 151.92 68.8 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.707 2.271 . . . . 0.0 112.298 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 107.06 1.77 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.694 2.263 . . . . 0.0 112.349 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -61.86 144.86 93.16 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.63 0.729 . . . . 0.0 111.083 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 139.4 40.1 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.339 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 94.8 p -116.92 173.68 6.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -121.22 169.69 14.45 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 113.86 3.51 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.666 2.244 . . . . 0.0 112.381 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 50.8 m -91.37 166.4 12.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 15.7 m -115.22 167.93 10.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.484 179.997 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 88.8 p -166.31 124.65 1.47 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.359 . . . . 0.0 110.861 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 85.9 p -115.44 155.75 26.88 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.74 -79.05 0.63 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.49 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 9.8 t -71.02 144.99 50.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.83 0.348 . . . . 0.0 110.89 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -172.99 168.84 4.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.809 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -126.05 70.13 0.49 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.457 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -58.24 -35.78 72.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.811 0.339 . . . . 0.0 110.854 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -81.26 -32.42 33.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.92 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.3 tmtm? -163.5 108.72 1.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -79.38 146.85 32.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 41.4 p -108.27 123.1 48.27 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.117 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.5 p -130.04 -36.78 1.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.837 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -111.42 27.1 9.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.7 m170 -119.91 155.9 31.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.906 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.569 ' CE1' ' HD3' ' A' ' 148' ' ' LYS . 90.5 m-85 -93.45 157.64 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.904 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -112.66 129.12 56.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.455 HG22 HD11 ' A' ' 155' ' ' ILE . 49.5 t -119.88 117.63 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.46 132.52 34.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.73 HG22 HG22 ' A' ' 170' ' ' THR . 91.1 t -124.11 120.49 59.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -110.46 177.78 19.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 53.83 46.35 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 110.913 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.496 HD12 ' N ' ' A' ' 141' ' ' GLY . 28.1 mt -90.85 113.81 26.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -45.53 152.73 0.65 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.715 0.769 . . . . 0.0 110.847 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -33.96 15.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.658 2.239 . . . . 0.0 112.317 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -66.41 -22.95 66.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.902 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.401 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 22.6 mm -55.41 150.31 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.157 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 44.3 p -130.74 164.01 26.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.185 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.703 HG23 ' HA ' ' A' ' 127' ' ' ARG . 90.6 m -64.63 -32.64 74.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.11 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -79.95 -11.84 59.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -83.53 -50.53 8.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.881 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.603 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.6 mt -57.84 -39.57 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.157 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 58.7 mttt -60.43 -35.77 76.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.4 t -92.48 -16.18 26.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.845 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.718 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -89.34 -16.27 31.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.085 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.603 ' CE1' HG23 ' A' ' 113' ' ' ILE . 21.1 m-85 -112.19 -9.5 13.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.64 -46.09 99.38 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.548 0.689 . . . . 0.0 111.102 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.1 Cg_exo -48.01 -17.08 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.71 2.273 . . . . 0.0 112.335 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.633 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 49.3 m-85 -91.27 -31.95 15.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 159.67 172.49 26.92 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.9 tttt -58.37 140.07 54.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 110.912 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.46 HG21 ' HB2' ' A' ' 126' ' ' ALA . 89.6 mt -109.92 131.02 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 79.3 p -96.57 -26.0 15.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -159.81 125.04 4.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.46 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -150.16 124.4 9.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.703 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.0 OUTLIER -151.32 155.56 38.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.591 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.0 p -108.22 100.06 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.123 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.4 t -49.03 122.67 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.168 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 38.4 mttt -119.1 168.9 10.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -73.34 145.69 45.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 tpt -87.41 15.72 6.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -130.19 -55.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.134 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 7.5 p -85.93 -28.47 24.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.122 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.03 22.69 70.81 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.3 mmpt? -106.59 150.11 26.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 44.6 m -54.2 109.27 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.865 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -49.35 -35.29 18.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.45 15.25 2.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -160.91 144.34 13.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.934 0.397 . . . . 0.0 110.92 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.496 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -136.13 -176.0 14.12 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -129.29 136.44 50.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.16 119.07 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.133 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 11.4 m -99.18 145.3 27.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -124.51 148.99 47.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -65.1 -46.33 81.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -119.77 150.56 40.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.569 ' HD3' ' CE1' ' A' ' 97' ' ' PHE . 20.8 tptt -55.88 -56.66 17.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' LYS . 28.8 tp -37.36 -49.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.944 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 1.0 OUTLIER -57.26 -42.09 80.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.809 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.458 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -64.85 -47.02 79.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -58.15 -46.43 85.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -48.78 -46.85 42.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.916 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.633 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -70.72 -60.44 2.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.586 HD13 ' CE2' ' A' ' 172' ' ' TRP . 66.6 mt -39.03 -36.78 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.116 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 69.2 t -78.7 -60.76 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -62.88 -66.13 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.851 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.581 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 29.4 mmt -37.8 -50.63 1.25 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.926 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.14 102.43 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.525 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 88.58 -30.66 5.21 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 51.0 tp60 -35.27 152.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.759 0.314 . . . . 0.0 110.923 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.567 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 84.8 m95 -100.76 91.42 4.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.937 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.718 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.4 tt -87.42 -70.36 0.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.401 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.22 118.72 3.97 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.532 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.29 -92.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.442 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.6 mtt180 -80.4 178.07 8.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.567 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 22.4 mt-30 -79.24 -178.79 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 23.2 pt -138.33 171.17 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 101' ' ' VAL . 12.5 ttm180 -136.45 141.95 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.73 HG22 HG22 ' A' ' 101' ' ' VAL . 24.0 p -127.11 148.69 50.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.129 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -159.94 166.41 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.586 ' CE2' HD13 ' A' ' 155' ' ' ILE . 85.8 m95 -82.7 107.01 15.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -53.86 89.98 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.4 ' N ' ' O ' ' A' ' 172' ' ' TRP . 39.2 m -124.19 140.56 52.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.124 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -122.65 142.42 50.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -134.09 136.4 26.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.522 0.677 . . . . 0.0 110.913 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 157.89 58.88 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.688 2.258 . . . . 0.0 112.352 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 81.45 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.7 2.267 . . . . 0.0 112.345 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -141.73 144.16 31.88 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.578 0.704 . . . . 0.0 111.077 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 131.13 20.61 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.711 2.274 . . . . 0.0 112.373 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 73.9 m -103.87 -46.32 4.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.802 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 139.92 173.92 13.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.514 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 -46.52 1.19 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.372 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 t -75.36 162.23 28.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.831 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 8.4 t -64.7 -48.95 72.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.831 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.471 -179.994 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 23.4 m -57.68 132.76 54.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.857 0.36 . . . . 0.0 110.872 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.0 p -153.13 156.37 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.842 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.38 130.99 1.18 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.515 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.5 m -149.73 174.36 12.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.879 0.371 . . . . 0.0 110.826 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 9.4 t -114.89 123.41 49.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.834 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 90' ' ' LYS . . . 167.51 114.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.506 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -48.02 93.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.842 0.353 . . . . 0.0 110.901 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' GLY . 35.8 mmtm -141.91 135.19 29.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.9 mtmt 43.61 26.57 0.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.918 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -106.03 108.33 19.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 5.0 p -91.99 140.58 29.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -130.77 -47.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.873 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -74.15 -28.41 61.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.508 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 60.0 m170 -65.52 172.92 2.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.533 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 25.4 m-85 -107.19 133.33 51.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -87.88 129.02 35.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.877 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.0 t -120.39 122.83 69.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.551 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 0.6 OUTLIER -86.46 145.47 26.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.577 ' CG1' HD21 ' A' ' 104' ' ' LEU . 98.7 t -137.53 110.74 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -102.05 -172.77 27.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.503 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 45.78 46.34 11.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.577 HD21 ' CG1' ' A' ' 101' ' ' VAL . 65.7 mt -87.69 109.49 19.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.4 t -43.12 153.23 0.35 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.627 0.727 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -18.23 36.92 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.662 2.241 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -87.4 -4.41 59.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.434 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 24.5 mm -69.19 147.82 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 70.3 p -136.49 144.6 44.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.157 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.428 ' OG1' HG12 ' A' ' 128' ' ' VAL . 89.6 m -46.77 -35.71 6.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -72.29 -31.57 65.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -69.49 -49.18 57.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.45 HG23 ' CE1' ' A' ' 117' ' ' PHE . 17.6 mt -58.44 -47.25 88.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.134 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.492 ' CG ' ' HB3' ' A' ' 126' ' ' ALA . 27.8 mtpt -60.09 -35.2 74.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.942 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 30.0 t -90.74 -8.67 49.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.64 -24.91 14.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.068 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.9 m-85 -100.59 -8.68 22.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.07 -46.19 98.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.729 . . . . 0.0 111.107 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -48.0 -17.16 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.658 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 52.2 m-85 -90.99 -38.31 12.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.39 179.28 41.74 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.455 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.469 ' HG2' ' CZ ' ' A' ' 146' ' ' TYR . 20.9 tptt -66.1 133.26 50.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.727 0.299 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.4 HD13 ' HA ' ' A' ' 114' ' ' LYS . 67.9 mt -106.4 128.42 60.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.6 t -100.57 -27.82 13.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -148.43 138.76 22.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.824 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.492 ' HB3' ' CG ' ' A' ' 114' ' ' LYS . . . -168.08 123.4 0.99 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 14.6 ptp180 -148.07 156.6 42.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.873 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.594 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.5 p -116.39 100.61 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.101 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.713 HG11 ' OH ' ' A' ' 140' ' ' TYR . 23.0 t -53.25 119.44 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.069 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.471 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.6 mttm -119.62 157.8 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -64.07 153.95 35.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.884 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 48.2 tpp -95.52 -13.32 24.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.85 -56.39 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -87.83 -34.91 18.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.165 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.56 29.98 31.22 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 14.5 mmtp -112.18 147.68 35.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.882 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.471 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 39.1 t -49.09 104.8 0.07 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 58.0 mttt -44.75 -36.13 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.904 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.21 27.67 1.32 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.713 ' OH ' HG11 ' A' ' 129' ' ' VAL . 49.2 p90 -167.37 151.64 6.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.935 0.398 . . . . 0.0 110.904 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -150.13 -177.81 24.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -133.9 141.22 47.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.882 0.372 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 90.4 t -143.64 116.57 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 67.6 m -94.04 139.11 31.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.47 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 12.2 m-85 -117.65 138.44 51.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.508 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 6.5 m-85 -51.79 -45.52 63.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.7 168.9 11.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.91 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.533 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 53.0 tttt -74.58 -59.26 2.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.1 tp -39.69 -49.02 2.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -58.97 -40.24 84.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.47 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -67.99 -43.93 77.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -56.66 -44.73 81.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -52.26 -46.47 65.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.658 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.97 -51.89 34.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.685 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 96.9 mt -46.0 -37.27 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.4 t -86.58 -54.94 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -57.31 -60.74 3.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.588 ' HE1' HD12 ' A' ' 163' ' ' LEU . 94.2 mmm -60.5 -38.93 85.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.13 94.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.0 -31.59 5.86 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.518 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.4 tp-100 -35.21 152.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.807 0.337 . . . . 0.0 110.888 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.569 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -93.99 91.01 6.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.588 HD12 ' HE1' ' A' ' 158' ' ' MET . 4.9 tt -87.57 -70.26 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -118.5 116.62 3.45 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.55 -91.11 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -83.84 174.19 10.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.793 0.33 . . . . 0.0 110.819 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.569 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 58.9 mt-30 -75.51 170.69 15.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.963 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.587 HD11 ' HE3' ' A' ' 158' ' ' MET . 15.7 pt -129.03 167.27 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.118 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 8.6 mmt85 -121.59 165.4 15.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.868 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 2.6 p -149.77 128.28 12.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.166 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -144.47 157.78 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.685 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 79.0 m95 -81.01 107.24 13.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.914 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.416 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -89.12 80.12 7.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.114 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.4 t -159.3 144.03 15.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.173 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 1.3 tpm_? -86.11 148.97 25.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -93.71 129.73 37.28 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.556 0.693 . . . . 0.0 110.893 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 148.86 65.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.662 2.241 . . . . 0.0 112.328 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 163.98 36.23 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.64 2.226 . . . . 0.0 112.349 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -157.91 144.18 12.81 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.613 0.721 . . . . 0.0 111.064 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 108.01 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.645 2.23 . . . . 0.0 112.352 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 83.7 p -110.79 102.66 11.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -170.95 70.31 0.12 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 159.6 52.83 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.392 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 1.4 t -71.24 124.54 24.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.838 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 26.4 m 49.08 41.83 20.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.818 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.502 179.976 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.2 t -125.89 -51.43 1.57 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.831 0.348 . . . . 0.0 110.832 -179.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 78.0 p -93.42 147.67 22.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.915 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -135.14 -72.87 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.501 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.7 m -148.56 114.0 5.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.918 0.389 . . . . 0.0 110.871 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 29.4 t -41.75 156.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.856 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.12 -75.75 0.12 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.47 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -126.8 37.91 4.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.892 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -99.03 163.94 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -140.04 157.59 45.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.88 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.429 ' O ' ' CE1' ' A' ' 96' ' ' HIS . 25.6 t70 -89.09 108.14 19.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 26.8 p -121.13 72.67 0.99 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.9 m -95.34 -38.24 10.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.819 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -116.58 19.73 14.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.86 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.429 ' CE1' ' O ' ' A' ' 92' ' ' ASP . 21.9 m170 -99.35 157.46 16.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.886 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.451 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 94.8 m-85 -103.34 136.88 42.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 60.0 m-70 -96.07 127.0 41.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.416 HG21 ' HB1' ' A' ' 151' ' ' ALA . 25.2 t -117.19 131.95 68.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' OD1' ' A' ' 171' ' ' ASN . 2.2 t80 -97.64 138.78 34.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.516 HG22 HG22 ' A' ' 170' ' ' THR . 88.4 t -125.05 115.42 44.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.152 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.03 -178.72 30.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 45.78 47.02 12.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.831 0.348 . . . . 0.0 110.903 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.562 HD12 ' C ' ' A' ' 140' ' ' TYR . 32.7 mt -78.88 100.49 7.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -40.81 155.2 0.2 Allowed Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.634 0.73 . . . . 0.0 110.882 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -19.01 36.51 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.698 2.265 . . . . 0.0 112.292 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -82.02 -22.44 36.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.848 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.633 HD12 HD22 ' A' ' 163' ' ' LEU . 6.8 mm -60.91 137.97 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.111 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.437 ' O ' ' N ' ' A' ' 111' ' ' GLU . 52.8 p -133.0 140.5 47.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.44 ' OG1' HG12 ' A' ' 128' ' ' VAL . 91.2 m -36.74 -32.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.159 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 109' ' ' THR . 15.0 tt0 -73.74 -48.96 27.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.466 ' O ' ' N ' ' A' ' 116' ' ' ALA . 77.1 m-20 -58.6 -51.33 70.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.2 mt -50.76 -38.8 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.112 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.493 ' O ' HD12 ' A' ' 123' ' ' ILE . 22.3 mttp -67.18 -35.34 79.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 22.9 t -92.95 -11.1 34.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.835 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.922 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.85 -32.89 15.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.083 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.56 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.7 m-85 -95.85 -5.02 42.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.582 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -57.67 -46.64 99.74 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.603 0.715 . . . . 0.0 111.087 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.582 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.696 2.264 . . . . 0.0 112.32 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.689 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 36.0 m-85 -93.2 -30.67 15.09 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.848 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.18 179.93 36.23 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.515 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.548 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 41.1 tptt -63.82 140.24 58.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.761 0.315 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.493 HD12 ' O ' ' A' ' 114' ' ' LYS . 97.7 mt -108.34 130.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.9 p -98.31 -50.76 4.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.863 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -136.44 118.83 15.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -142.11 124.82 15.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.091 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -148.09 156.15 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.44 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.1 p -113.13 100.11 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.126 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.794 HG11 ' CE1' ' A' ' 140' ' ' TYR . 46.1 t -49.12 127.52 4.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -130.53 151.87 50.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.82 155.88 5.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 5.2 ptp -97.62 -17.79 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.857 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.75 -57.54 2.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.147 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.7 p -81.51 -32.78 32.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.123 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.43 28.38 61.77 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.474 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -101.88 162.62 12.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.804 0.335 . . . . 0.0 110.877 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 77.7 p -58.86 98.45 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.849 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.516 ' HB3' ' CE2' ' A' ' 140' ' ' TYR . 20.5 mmtt -42.95 -42.98 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.87 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.41 19.18 4.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.794 ' CE1' HG11 ' A' ' 129' ' ' VAL . 47.7 p90 -163.37 153.45 15.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.892 0.377 . . . . 0.0 110.951 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -151.22 -172.01 19.78 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -135.54 140.16 44.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.875 0.369 . . . . 0.0 110.875 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 28.6 t -145.52 107.64 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 3.5 t -89.19 154.06 20.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.531 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 13.6 m-85 -129.46 150.34 50.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.865 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.548 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 16.0 m-85 -66.37 -33.52 75.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.895 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -129.52 165.44 21.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.451 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . 22.9 tttm -69.35 -61.97 1.57 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.7 tp -39.4 -63.19 0.58 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -40.77 -45.31 2.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -69.76 -60.75 2.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -40.41 -47.06 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 17.7 m-80 -47.66 -56.97 6.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.689 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -56.72 -53.72 54.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.474 HD13 ' CE2' ' A' ' 172' ' ' TRP . 47.7 mt -41.86 -35.39 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.8 t -84.5 -56.64 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 66.3 m-70 -62.09 -64.67 0.86 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.579 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 11.9 mmt -44.86 -47.01 11.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.56 102.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.74 -28.67 3.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.484 ' N ' ' O ' ' A' ' 158' ' ' MET . 62.7 tp60 -35.8 152.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.79 0.328 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.589 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 85.2 m95 -99.16 91.02 4.79 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.922 HD11 ' CB ' ' A' ' 116' ' ' ALA . 6.6 tt -86.77 -70.45 0.61 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.902 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.18 118.43 3.78 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.461 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.65 -92.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.488 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 14.7 mtt-85 -79.41 -178.38 6.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.759 0.314 . . . . 0.0 110.87 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.589 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 30.1 mt-30 -84.14 179.82 7.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.419 ' O ' ' N ' ' A' ' 160' ' ' GLY . 19.7 pt -136.87 171.95 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.486 ' O ' HG13 ' A' ' 101' ' ' VAL . 41.3 ttt180 -134.64 160.5 37.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.858 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.516 HG22 HG22 ' A' ' 101' ' ' VAL . 17.1 p -145.12 152.54 40.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' ASN . . . . . 0.576 ' OD1' ' CD1' ' A' ' 100' ' ' PHE . 3.0 p30 -172.96 149.9 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.474 ' CE2' HD13 ' A' ' 155' ' ' ILE . 99.2 m95 -68.98 133.14 47.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.89 61.13 6.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.089 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 2.2 m -149.46 151.47 34.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.163 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.1 56.23 1.34 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -165.15 136.09 3.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.589 0.709 . . . . 0.0 110.944 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 140.37 42.42 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.648 2.232 . . . . 0.0 112.329 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 145.32 56.77 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.741 2.294 . . . . 0.0 112.342 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -65.58 144.04 98.8 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 0.0 111.097 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 119.38 6.34 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.73 2.287 . . . . 0.0 112.359 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 3.7 m -44.38 168.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.85 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -156.19 83.22 0.15 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.441 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 150.7 68.32 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.346 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 29.2 t -118.64 128.03 54.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 16.1 t -139.69 168.45 19.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.845 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.482 179.975 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.5 t -48.88 -46.39 42.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.844 0.354 . . . . 0.0 110.845 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -49.72 -47.31 50.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.838 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.29 145.04 44.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 3.1 t -88.38 153.41 21.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.849 0.357 . . . . 0.0 110.857 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 16.2 m -83.8 128.13 34.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.68 120.24 0.89 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 29.4 mt-30 -111.32 148.87 32.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.85 0.357 . . . . 0.0 110.926 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -113.3 41.65 2.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt 45.5 39.63 4.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.883 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -148.99 125.28 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 34.6 p -84.51 96.97 9.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 27.8 t -117.21 -49.25 2.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 t30 -64.22 -50.8 66.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -44.47 165.56 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.835 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.431 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 66.9 m-85 -96.68 140.95 30.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.888 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -100.57 131.89 46.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.401 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 58.5 t -122.27 124.48 71.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -91.2 140.02 30.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.482 HG11 HD21 ' A' ' 104' ' ' LEU . 77.7 t -127.6 126.78 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -121.93 -178.45 15.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.475 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 50.87 39.63 22.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.83 0.348 . . . . 0.0 110.852 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.482 HD21 HG11 ' A' ' 101' ' ' VAL . 44.0 mt -84.21 126.03 32.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 t -50.51 152.15 3.48 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.678 0.751 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 -14.18 35.83 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -91.8 -6.73 51.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.29 153.1 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 40.5 p -139.09 -179.96 6.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.8 m -69.92 -40.42 75.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.094 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -70.65 -36.74 73.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 116' ' ' ALA . 5.0 m-20 -58.09 -52.31 66.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.509 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.5 mt -60.69 -42.41 91.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.412 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 14.2 mtpt -59.69 -36.6 76.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.883 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.5 t -94.03 -17.4 22.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.549 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -84.62 -18.31 35.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.564 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.3 m-85 -111.63 -5.49 14.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.569 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.1 -46.2 99.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.559 0.695 . . . . 0.0 111.09 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.569 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.02 -19.57 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.578 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 45.0 m-85 -87.96 -36.93 16.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.96 -161.95 34.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.496 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.9 tmtt? -87.17 124.64 33.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.883 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.401 HD12 ' O ' ' A' ' 114' ' ' LYS . 46.6 mt -96.54 134.28 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.107 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.6 p -100.13 -45.88 5.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -134.41 122.02 21.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.837 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -151.16 122.61 7.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.414 ' NE ' ' HB2' ' A' ' 142' ' ' PHE . 0.0 OUTLIER -146.62 159.49 43.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -114.15 99.95 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.143 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 23.5 t -51.73 134.14 13.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.11 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.46 ' HG2' ' N ' ' A' ' 137' ' ' SER . 35.5 mttt -124.98 168.15 13.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -75.73 152.11 37.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 mpp? -97.49 16.71 19.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -123.67 -38.26 2.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 13.7 p -111.25 -24.15 10.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 78.33 20.61 71.84 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 20.0 mmtp -106.63 154.19 21.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.761 0.315 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.46 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 28.3 m -51.18 120.11 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.852 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -60.18 -36.77 78.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.52 13.9 2.47 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.497 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -158.74 145.59 17.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 0.0 110.905 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -137.7 -175.85 14.11 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.414 ' HB2' ' NE ' ' A' ' 127' ' ' ARG . 41.6 m-85 -133.4 143.24 48.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.949 0.404 . . . . 0.0 110.888 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.0 t -145.51 127.38 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 32.2 t -105.13 151.15 24.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.498 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 73.6 m-85 -129.32 138.99 51.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -50.43 -42.47 53.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.941 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -127.27 164.55 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.914 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.475 ' O ' ' N ' ' A' ' 151' ' ' ALA . 13.7 ttmt -62.41 -62.37 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 148' ' ' LYS . 58.5 tp -34.58 -58.29 0.5 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.963 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -48.5 -42.47 33.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.498 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -70.69 -50.44 36.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.088 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -53.75 -46.12 70.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -45.99 -47.84 16.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.496 ' HB1' ' HG3' ' A' ' 158' ' ' MET . . . -66.08 -63.18 1.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 154' ' ' ALA . 45.6 mt -34.76 -46.53 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.77 -61.19 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.164 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -65.8 -64.66 0.81 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.835 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.578 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 18.5 mmt -42.11 -48.6 4.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.41 100.71 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.508 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.21 -28.12 5.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.486 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.0 tp-100 -37.14 154.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.758 0.313 . . . . 0.0 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.577 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.4 m95 -98.7 90.99 4.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.587 ' C ' HD23 ' A' ' 163' ' ' LEU . 2.6 tt -85.06 -71.32 0.53 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -122.24 118.25 3.6 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.456 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.93 -93.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.503 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.2 mtt85 -79.5 178.45 8.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.745 0.307 . . . . 0.0 110.862 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 86.2 mt-30 -79.96 178.85 7.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.431 HG22 HD23 ' A' ' 104' ' ' LEU . 32.1 pt -137.64 170.33 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.143 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 27.6 ttm-85 -133.68 154.98 50.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.441 HG22 HG22 ' A' ' 101' ' ' VAL . 5.7 p -138.87 147.27 42.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -157.63 151.86 24.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 76.9 m95 -72.44 130.1 39.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -114.61 117.69 31.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.077 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.6 t -145.94 147.28 31.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.156 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 19.2 ttp180 -72.13 115.92 11.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.867 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 8.3 pttt -64.55 123.96 84.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.617 0.723 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 148.55 65.52 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.654 2.236 . . . . 0.0 112.388 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.08 2.17 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.67 2.247 . . . . 0.0 112.367 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -43.97 150.0 0.63 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.562 0.696 . . . . 0.0 111.13 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 119.81 6.69 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.655 2.237 . . . . 0.0 112.332 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 7.1 t -51.98 168.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -111.19 73.0 0.21 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.455 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 151.57 69.47 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.65 2.234 . . . . 0.0 112.406 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 3.2 m -85.88 -58.06 2.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.861 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 60.5 p -60.24 -47.14 87.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.843 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.99 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.461 -0.255 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 27.4 t -52.55 143.82 14.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.847 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 43.7 t -44.27 -66.01 0.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 153.11 -85.75 0.14 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 p -89.82 40.21 0.99 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.871 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 38.6 m -147.8 129.7 15.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.856 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 133.98 -150.68 20.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 27.1 mm-40 -103.59 169.72 8.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.896 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.56 68.9 0.68 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.9 mmpt? -103.52 100.33 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -78.41 118.75 20.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.819 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 44.4 p -95.82 126.3 40.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.9 m -100.34 82.36 2.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.808 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.6 m120 62.45 41.39 9.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.861 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.524 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 0.9 OUTLIER -83.65 165.19 19.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.945 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.522 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 5.3 m-85 -99.81 133.91 43.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.846 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -95.35 135.67 36.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.448 HG22 HD11 ' A' ' 155' ' ' ILE . 78.8 t -121.43 121.22 64.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -85.02 145.9 27.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.59 HG13 ' O ' ' A' ' 169' ' ' ARG . 17.7 t -135.45 128.1 47.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.15 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -118.08 -179.05 17.25 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.512 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 48.38 46.86 20.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.878 0.37 . . . . 0.0 110.845 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.617 HD23 HG22 ' A' ' 168' ' ' ILE . 34.0 mt -88.13 105.35 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.936 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -36.09 153.39 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.654 0.74 . . . . 0.0 110.893 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -23.66 30.73 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.737 2.291 . . . . 0.0 112.327 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -79.3 -10.96 59.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.438 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 17.3 mm -65.69 143.8 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.472 ' HG1' ' CG ' ' A' ' 112' ' ' ASP . 65.2 p -126.14 164.32 21.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.468 ' OG1' HG12 ' A' ' 128' ' ' VAL . 66.8 m -63.72 -29.69 70.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.097 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -79.97 -34.2 38.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.472 ' CG ' ' HG1' ' A' ' 109' ' ' THR . 98.1 m-20 -60.34 -55.53 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.468 HG23 ' CE1' ' A' ' 117' ' ' PHE . 11.7 mt -52.69 -40.12 33.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.474 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 62.7 mttt -64.34 -35.18 80.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.5 t -94.07 -9.71 35.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.79 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.14 -23.06 17.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.595 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 28.6 m-85 -105.92 -6.8 18.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.575 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -58.26 -45.98 99.68 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.559 0.695 . . . . 0.0 111.133 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.575 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.96 -17.1 0.7 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.653 2.235 . . . . 0.0 112.352 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.584 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 46.2 m-85 -90.66 -41.44 11.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.87 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 175.68 -174.16 46.69 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.7 tptm -71.46 138.43 49.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.751 0.31 . . . . 0.0 110.923 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 97.1 mt -104.01 139.34 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 5.8 t -116.49 -37.64 3.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -142.57 105.4 4.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -138.75 121.56 16.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.476 ' CZ ' ' HB3' ' A' ' 127' ' ' ARG . 2.4 ptp180 -153.11 154.71 35.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.88 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.614 HG13 ' HE2' ' A' ' 130' ' ' LYS . 2.4 p -107.72 100.05 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.148 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -50.04 133.87 9.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.614 ' HE2' HG13 ' A' ' 128' ' ' VAL . 20.5 mtmt -129.52 162.53 27.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.924 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -64.4 159.45 21.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 9.7 ttp -107.55 3.48 24.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -103.74 -45.67 4.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.121 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.3 p -110.52 -38.8 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.156 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 94.8 40.9 4.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.3 mttm -116.11 143.67 45.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.455 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 17.1 p -45.92 109.25 0.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 59.7 mttt -54.41 -35.67 63.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.99 19.35 4.02 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -161.2 146.69 14.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.909 0.385 . . . . 0.0 110.929 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.97 177.83 21.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -123.85 140.12 53.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.9 t -139.31 117.03 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.139 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 49.8 m -102.15 147.6 26.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -123.49 145.13 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.524 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 19.2 m-85 -58.24 -36.65 73.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.952 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -121.34 174.26 6.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.869 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.522 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 44.6 tttt -85.01 -52.35 6.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.859 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.7 tp -47.68 -53.6 14.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.955 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -49.19 -44.36 43.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -62.53 -52.3 64.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -49.49 -43.11 45.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.903 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -48.24 -51.79 24.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.562 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.49 -65.89 0.62 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.057 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.448 HD11 HG22 ' A' ' 99' ' ' VAL . 80.9 mt -34.59 -34.79 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.124 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 154' ' ' ALA . 20.1 t -74.02 -63.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.163 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -69.44 -59.2 3.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.595 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 20.1 mmt -40.39 -51.11 2.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.15 102.33 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.491 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 87.94 -31.3 4.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.465 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.483 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.9 tp60 -34.27 150.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.573 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.3 m95 -96.96 91.03 5.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.937 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.79 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.9 tt -87.47 -70.56 0.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.907 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.52 117.35 3.67 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.475 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -91.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.457 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 15.0 mtp180 -79.55 -174.81 4.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.766 0.317 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.573 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 63.9 mt-30 -86.09 179.43 6.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.617 HG22 HD23 ' A' ' 104' ' ' LEU . 9.3 pt -136.84 169.31 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.59 ' O ' HG13 ' A' ' 101' ' ' VAL . 30.2 ttp180 -129.25 162.87 26.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 32.6 p -141.38 150.5 42.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.091 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -163.02 164.32 25.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 94.2 m95 -93.65 107.95 19.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -84.11 37.64 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.064 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 30.0 m -132.04 132.33 43.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.126 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 26.1 ttt180 -109.45 148.11 31.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.14 145.95 49.76 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.602 0.715 . . . . 0.0 110.879 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 143.92 52.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.659 2.239 . . . . 0.0 112.376 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 143.81 52.04 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.683 2.256 . . . . 0.0 112.342 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' ALA . . . . . 0.41 ' HB1' ' HD2' ' A' ' 180' ' ' PRO . . . -161.92 155.13 17.52 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.558 0.694 . . . . 0.0 111.078 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 180' ' ' PRO . . . . . 0.437 ' O ' ' C ' ' A' ' 181' ' ' SER . 54.2 Cg_endo -69.72 2.79 3.2 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.672 2.248 . . . . 0.0 112.376 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 181' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 180' ' ' PRO . 22.9 m -34.59 124.69 0.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.831 -179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.419 ' HA2' ' HD2' ' A' ' 183' ' ' PRO . . . -99.43 101.14 2.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.491 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.419 ' HD2' ' HA2' ' A' ' 182' ' ' GLY . 54.4 Cg_endo -69.72 162.76 40.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.691 2.261 . . . . 0.0 112.338 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 44.5 p -152.56 146.35 25.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 29.6 m -152.44 144.59 23.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.838 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.464 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 13.7 t -97.57 114.3 26.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.888 0.375 . . . . 0.0 110.835 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.6 t -100.23 159.11 15.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.863 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.27 112.76 2.82 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.463 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.7 m -42.24 107.96 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.859 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.8 m -81.36 147.83 29.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.853 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 66.18 73.36 0.63 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.512 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 4.6 pm0 -78.12 161.46 27.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 0.0 110.913 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -133.34 90.28 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? 39.51 31.69 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.876 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -136.99 116.46 12.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 54.9 p -73.64 141.62 46.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.116 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.5 m -133.23 -53.46 0.9 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -102.17 31.76 3.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 4.9 m-70 -119.4 156.54 29.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.538 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 74.5 m-85 -100.0 161.38 13.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.6 m-70 -114.22 134.35 54.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -124.58 118.25 52.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.137 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.612 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 16.5 t80 -88.47 129.73 35.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.18 111.99 36.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.113 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.83 -179.09 29.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 48.0 54.84 9.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.451 HD12 ' C ' ' A' ' 140' ' ' TYR . 33.8 mt -92.31 106.58 18.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.5 t -35.51 152.33 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.707 0.765 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -18.77 36.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.5 ' CG ' ' O ' ' A' ' 107' ' ' GLU . 9.3 tt0 -90.08 1.13 56.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.938 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 17.4 mm -74.72 147.38 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.128 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 51.3 p -132.04 163.58 28.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.086 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 25.5 m -58.71 -41.06 85.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.91 -35.4 76.8 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 116' ' ' ALA . 64.0 m-20 -60.17 -54.59 44.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.851 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mt -57.99 -45.82 87.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.118 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.825 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 13.2 mtpp -57.44 -39.01 75.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.865 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 32.7 t -92.35 -9.15 42.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.839 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.533 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.64 -9.6 31.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.104 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.54 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.0 m-85 -120.26 -8.75 9.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.915 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.582 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.1 -45.97 98.9 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.639 0.733 . . . . 0.0 111.093 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.8 Cg_exo -47.98 -22.76 3.71 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.708 2.272 . . . . 0.0 112.321 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.685 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 39.7 m-85 -85.66 -35.62 20.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.863 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.59 174.7 34.63 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.453 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.646 ' CG ' ' CE1' ' A' ' 146' ' ' TYR . 0.8 OUTLIER -59.46 140.36 56.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.768 0.318 . . . . 0.0 110.877 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.763 HG21 ' HB2' ' A' ' 126' ' ' ALA . 82.7 mt -111.91 105.37 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 52.2 p -67.69 -32.15 72.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -159.67 123.93 3.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.825 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -146.51 125.45 12.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.097 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.2 ptm180 -149.12 166.76 27.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.568 ' O ' HG13 ' A' ' 128' ' ' VAL . 6.3 p -120.36 99.85 8.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.173 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.3 t -51.18 119.77 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.431 ' CA ' ' HG3' ' A' ' 138' ' ' LYS . 29.0 mtmt -114.81 152.38 32.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -56.72 155.45 7.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.07 -6.79 31.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -102.82 -61.64 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.14 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.9 p -81.67 -34.57 30.65 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.12 33.46 26.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -117.68 152.12 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.8 m -43.34 108.95 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.431 ' HG3' ' CA ' ' A' ' 130' ' ' LYS . 6.4 mtpm? -51.41 -38.19 52.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 125.35 12.94 3.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.462 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.451 ' C ' HD12 ' A' ' 104' ' ' LEU . 32.5 p90 -161.8 154.18 19.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.921 0.391 . . . . 0.0 110.919 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.06 -175.42 19.95 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.492 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -131.27 140.28 49.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.891 0.377 . . . . 0.0 110.858 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.8 t -144.86 109.58 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.12 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 73.7 m -86.71 141.92 28.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.594 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 17.8 m-85 -120.61 140.43 51.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.646 ' CE1' ' CG ' ' A' ' 122' ' ' LYS . 4.4 m-85 -54.48 -50.38 67.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.933 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -115.59 171.02 8.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.538 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 59.0 tttt -80.28 -38.44 30.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.893 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.6 tp -57.35 -51.93 67.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.94 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -56.78 -41.47 77.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.896 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.594 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -66.3 -49.11 68.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.092 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -51.0 -43.91 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -49.56 -48.93 48.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.685 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -66.09 -54.88 20.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.5 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 97.5 mt -47.55 -35.29 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 77.5 t -82.24 -49.03 17.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.0 m-70 -71.51 -65.46 0.75 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.54 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 8.2 mmt -45.21 -46.52 12.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.48 103.6 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.458 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.41 -29.61 3.94 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.491 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.9 tp60 -40.98 149.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.926 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.439 ' CE2' ' HG2' ' A' ' 167' ' ' GLN . 84.0 m95 -93.87 92.33 7.36 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.622 ' C ' HD23 ' A' ' 163' ' ' LEU . 5.5 tt -87.03 -72.34 0.52 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.487 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -120.33 117.11 3.43 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 56.09 -93.05 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.5 mpt_? -83.52 175.99 9.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.749 0.309 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.439 ' HG2' ' CE2' ' A' ' 162' ' ' TRP . 32.7 mt-30 -74.61 177.33 6.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.917 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 22.0 pt -136.23 165.09 30.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -129.56 152.33 49.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 29.8 p -130.07 160.46 33.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.166 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -169.81 163.35 9.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.5 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 85.5 m95 -90.87 100.23 13.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.612 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -71.72 81.92 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.084 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.5 t -168.36 140.82 2.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.119 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.418 ' HD2' ' N ' ' A' ' 175' ' ' ARG . 10.8 mpt_? -103.63 133.54 48.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.47 143.24 31.75 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.523 0.677 . . . . 0.0 110.928 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' PRO . . . . . 0.473 ' HA ' ' HD2' ' A' ' 178' ' ' PRO . 53.6 Cg_endo -69.77 110.37 2.54 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.659 2.239 . . . . 0.0 112.366 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 178' ' ' PRO . . . . . 0.473 ' HD2' ' HA ' ' A' ' 177' ' ' PRO . 53.6 Cg_endo -69.76 103.32 1.14 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.713 2.275 . . . . 0.0 112.348 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -117.84 150.48 47.18 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.555 0.693 . . . . 0.0 111.112 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -164.46 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.718 2.279 . . . . 0.0 112.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 3.7 m -114.48 156.91 23.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.867 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -51.16 146.53 10.4 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 106.1 1.6 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.707 2.271 . . . . 0.0 112.304 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 8.7 m -161.14 146.14 13.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.877 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 8.2 m -71.65 -49.74 37.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.884 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.514 -179.971 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.3 p -77.68 143.55 38.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.9 0.381 . . . . 0.0 110.835 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.1 t -132.99 144.86 50.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.821 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.7 86.28 0.19 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.478 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 t -79.99 146.9 31.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 40.9 m -114.82 -59.02 2.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.851 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . 159.32 -125.86 1.56 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.477 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 88' ' ' GLY . 33.1 mt-30 -34.7 137.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 91' ' ' LYS . 42.6 mmtt -49.31 -30.14 7.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 90' ' ' LYS . 51.1 mmtt 36.32 53.17 0.97 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.846 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -99.26 92.76 5.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.896 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 18.8 p 43.96 29.46 0.32 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 88.5 p -68.45 -47.67 66.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 54.3 m-20 -77.52 -42.23 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 28.1 m170 -51.56 147.14 6.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.85 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.533 ' CD1' ' HD3' ' A' ' 148' ' ' LYS . 90.6 m-85 -102.44 145.09 30.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -100.27 138.68 37.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.846 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 25.2 t -124.23 130.23 73.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.184 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -91.77 138.09 31.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.7 118.31 46.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.62 172.05 17.95 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.513 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 54.53 53.37 10.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.41 HD23 ' HA ' ' A' ' 104' ' ' LEU . 26.1 mt -87.93 104.48 16.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -38.03 153.57 0.13 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.702 0.763 . . . . 0.0 110.877 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -20.48 34.86 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.736 2.29 . . . . 0.0 112.31 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -83.21 -17.9 41.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.475 HG22 ' N ' ' A' ' 109' ' ' THR . 37.1 mm -57.61 156.95 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.123 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.475 ' N ' HG22 ' A' ' 108' ' ' ILE . 40.5 p -143.87 170.61 15.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.437 ' OG1' HG12 ' A' ' 128' ' ' VAL . 56.9 m -66.13 -33.87 76.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -78.24 -35.21 48.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 67.1 m-20 -59.1 -55.89 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.841 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.457 HG23 ' CE1' ' A' ' 117' ' ' PHE . 7.8 mt -55.6 -42.68 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.11 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 17.7 mttp -61.64 -36.34 80.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.922 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.1 t -93.4 -10.41 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.848 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.512 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -94.02 -18.77 21.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.575 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 7.1 m-85 -111.57 -5.78 14.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.586 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.41 -45.71 99.89 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.593 0.711 . . . . 0.0 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.7 Cg_exo -48.04 -25.23 6.24 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.659 2.239 . . . . 0.0 112.382 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.557 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 54.0 m-85 -78.83 -38.84 37.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 168.02 179.13 40.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 35.2 tptt -59.41 142.21 52.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.77 0.319 . . . . 0.0 110.942 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.7 mt -114.33 137.1 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 6.3 p -112.35 -23.6 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -154.02 143.31 21.41 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -174.77 123.62 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.06 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -148.2 159.35 44.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.441 ' O ' HG13 ' A' ' 128' ' ' VAL . 2.6 p -112.55 99.9 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.165 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.514 HG11 ' CZ ' ' A' ' 140' ' ' TYR . 80.5 t -51.32 126.59 6.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.485 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.2 mttm -125.84 159.94 31.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -62.52 159.51 15.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.873 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 ptp -102.38 -14.78 16.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.39 -38.02 8.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.076 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.6 p -105.78 -29.42 10.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.05 36.85 45.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.478 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mmtm -119.86 151.3 39.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.816 0.341 . . . . 0.0 110.893 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.485 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 56.2 p -45.97 113.26 0.59 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.873 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -59.57 -36.73 76.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.37 14.25 2.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.43 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.514 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 34.1 p90 -160.83 149.89 16.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.867 0.365 . . . . 0.0 110.937 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.28 -177.54 18.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -127.33 140.72 52.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 25.3 t -140.7 118.94 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.4 p -98.58 149.76 22.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -129.0 150.66 50.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -65.59 -40.73 93.03 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.88 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -125.24 162.81 23.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.541 ' HE3' ' CZ3' ' A' ' 172' ' ' TRP . 15.0 tptm -67.42 -58.5 4.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.9 tp -39.11 -51.03 1.9 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.924 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -51.92 -41.92 62.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -65.18 -53.31 46.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.062 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -49.46 -41.09 39.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -57.3 -52.68 64.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.53 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.76 -51.11 69.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.657 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 95.0 mt -43.96 -51.69 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 63.9 t -72.62 -59.76 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -50.92 -64.7 0.73 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.575 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 92.7 mmm -57.77 -39.24 77.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.97 94.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.46 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 91.87 -29.46 7.42 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.504 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.1 tp60 -36.3 152.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.761 0.315 . . . . 0.0 110.952 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.573 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.0 m95 -96.71 91.68 5.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.937 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.512 HD11 ' CB ' ' A' ' 116' ' ' ALA . 2.0 tt -88.64 -69.84 0.68 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.936 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -117.68 116.98 3.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 50.95 -90.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 164' ' ' GLY . 40.9 mtt180 -80.3 179.98 7.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.827 0.346 . . . . 0.0 110.836 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.573 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 45.7 mt-30 -81.77 179.84 7.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.565 HD11 ' CE ' ' A' ' 158' ' ' MET . 15.3 pt -139.14 163.52 26.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.117 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 46.9 ttt-85 -129.71 156.53 44.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.6 p -129.83 162.46 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -168.55 163.69 12.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.864 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.657 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.5 m95 -94.16 114.25 26.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -82.91 38.73 0.6 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.8 t -139.07 137.24 36.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.142 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 36.2 mtt180 -48.41 143.69 4.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.66 156.94 16.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.537 0.684 . . . . 0.0 110.904 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' PRO . . . . . 0.432 ' HA ' ' HD2' ' A' ' 178' ' ' PRO . 53.8 Cg_endo -69.78 116.43 4.56 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.65 2.233 . . . . 0.0 112.34 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 178' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 177' ' ' PRO . 53.8 Cg_endo -69.87 153.64 68.2 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.658 2.239 . . . . 0.0 112.328 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -154.81 145.19 15.92 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.575 0.702 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -45.91 1.41 Allowed 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.675 2.25 . . . . 0.0 112.348 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 18.8 m 59.19 45.76 13.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -98.79 146.33 18.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 141.32 45.13 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.658 2.238 . . . . 0.0 112.348 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 6.4 t -124.93 103.84 8.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.844 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.5 m -149.24 141.97 24.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.478 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 94.2 p -117.77 42.08 2.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.867 0.365 . . . . 0.0 110.86 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 15.3 m -66.94 118.89 11.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.814 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -105.18 -50.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 62.5 m 50.7 42.94 27.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.889 0.376 . . . . 0.0 110.891 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 3.0 m -68.56 96.25 0.69 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.47 -151.0 10.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 65.6 mt-30 -83.55 126.24 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.904 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -69.99 -47.68 61.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.99 120.77 28.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -81.08 -56.61 3.98 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.896 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 29.7 p -83.37 97.0 8.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.133 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.3 t -93.07 -47.97 6.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.853 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -58.94 -46.36 88.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 48.3 m170 -56.44 152.95 10.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.882 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 93.8 m-85 -90.65 135.37 33.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 82.4 m-70 -94.13 124.37 38.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 63.7 t -112.67 116.17 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.127 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.54 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 1.4 t80 -84.28 136.74 33.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.9 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 169' ' ' ARG . 38.6 t -127.16 115.54 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.113 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.73 -174.48 25.8 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 46.29 50.74 11.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.903 0.382 . . . . 0.0 110.912 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.5 mt -91.28 110.61 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -42.41 153.68 0.3 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.696 0.76 . . . . 0.0 110.863 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -20.0 35.4 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.719 2.279 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -84.08 -14.02 51.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 20.4 mm -60.58 150.36 6.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.147 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.6 p -142.91 154.86 44.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.16 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 18.2 m -48.05 -42.18 27.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -65.47 -43.18 91.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.49 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.9 m-20 -59.22 -52.96 63.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.462 HG23 ' CE1' ' A' ' 117' ' ' PHE . 30.6 mt -60.96 -43.0 95.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.463 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 30.0 mttm -62.35 -36.17 81.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 38.6 t -94.01 -13.27 27.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.531 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -91.93 -13.21 31.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.503 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.1 m-85 -113.0 -9.8 13.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.03 -45.5 99.53 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.586 0.707 . . . . 0.0 111.06 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.97 -17.08 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.656 2.237 . . . . 0.0 112.341 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.484 ' CD2' ' HA ' ' A' ' 117' ' ' PHE . 38.9 m-85 -91.9 -40.36 11.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.14 174.56 44.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -67.54 120.9 14.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.812 0.339 . . . . 0.0 110.883 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 93.3 mt -85.77 140.08 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.118 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.5 p -110.58 -30.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -156.31 123.93 5.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.463 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -150.07 132.38 15.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.105 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 19.9 ptt180 -152.06 147.43 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -108.46 99.94 9.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.653 HG12 ' CG ' ' A' ' 138' ' ' LYS . 73.0 t -52.43 114.67 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 43.8 mttm -113.08 160.98 17.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -68.59 157.86 35.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.845 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 tpt -94.35 -27.86 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.65 -55.71 3.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 65.3 p -80.73 -38.78 28.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.136 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.43 18.62 61.91 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.479 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -105.75 146.9 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 110.906 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.1 t -39.03 114.26 0.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.653 ' CG ' HG12 ' A' ' 129' ' ' VAL . 12.3 mtpt -52.94 -38.79 62.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.97 20.65 1.44 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.525 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.47 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 9.1 p90 -171.39 154.04 3.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.96 0.41 . . . . 0.0 110.9 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.99 16.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.78 142.48 38.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.902 0.382 . . . . 0.0 110.831 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 43.3 t -147.3 108.97 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 44.3 m -92.25 149.27 21.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -126.46 152.89 45.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -60.66 -45.66 93.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.908 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -127.72 160.14 32.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.896 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 151' ' ' ALA . 12.2 tptm -58.66 -60.3 4.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 49.0 tp -38.47 -47.4 1.27 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -57.94 -38.89 76.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.479 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -68.92 -57.07 6.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.415 ' O ' HG23 ' A' ' 156' ' ' VAL . 4.6 mm-40 -43.32 -46.64 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -40.09 -47.48 2.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.555 ' HB1' ' HG3' ' A' ' 158' ' ' MET . . . -76.93 -55.99 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.676 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 87.8 mt -42.93 -38.58 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 152' ' ' GLU . 42.2 t -81.33 -48.7 18.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.118 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 -75.3 -67.11 0.69 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.555 ' HG3' ' HB1' ' A' ' 154' ' ' ALA . 23.2 mmt -42.17 -47.97 4.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.42 102.18 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.467 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.92 -34.51 3.55 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.479 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.445 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.4 tp60 -35.14 151.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.798 0.333 . . . . 0.0 110.927 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.562 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.1 m95 -98.15 91.36 5.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.58 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.9 tt -85.41 -71.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.925 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.88 118.05 3.58 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.4 -93.05 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.514 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -82.13 170.35 15.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.759 0.314 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.562 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 80.8 mt-30 -71.3 -179.4 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 15.5 pt -136.98 168.77 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.603 ' O ' HG13 ' A' ' 101' ' ' VAL . 36.5 ttp180 -131.88 158.71 40.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.429 ' CB ' ' HA ' ' A' ' 155' ' ' ILE . 0.9 OUTLIER -139.64 150.9 45.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.148 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 22.1 m-20 -166.96 158.46 12.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.676 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.0 m95 -85.48 100.54 11.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -56.06 -30.31 61.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 87.1 m -49.54 119.95 3.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.09 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 21.0 ttm180 -44.2 -62.46 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -147.03 134.4 10.27 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.546 0.689 . . . . 0.0 110.937 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 147.41 63.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.676 2.251 . . . . 0.0 112.372 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 140.08 41.8 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.692 2.261 . . . . 0.0 112.314 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -121.8 146.25 45.4 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 111.094 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 134.87 29.0 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.698 2.265 . . . . 0.0 112.329 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.9 p -86.61 131.58 34.12 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.885 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.58 -179.16 26.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 174.12 9.96 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.667 2.244 . . . . 0.0 112.308 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.5 t -115.14 -53.16 2.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.6 p -72.25 98.33 2.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.833 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.494 -179.991 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 64.4 m -106.59 115.25 29.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.897 0.38 . . . . 0.0 110.848 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 20.1 m -137.81 151.72 48.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.894 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -98.52 -145.9 19.56 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.7 t 69.09 42.4 1.26 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.885 0.374 . . . . 0.0 110.861 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 13.0 t -100.3 -46.3 5.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . 121.57 -82.7 0.35 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.507 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.402 ' C ' ' O ' ' A' ' 88' ' ' GLY . 9.8 tt0 -37.95 143.6 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.872 0.368 . . . . 0.0 110.962 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 47.6 mttt -101.65 42.61 1.12 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.06 83.26 1.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.881 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -49.78 6.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.0 p -93.94 96.57 9.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.15 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 t -101.41 -54.19 2.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.816 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -89.21 -41.77 12.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -40.43 153.28 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.849 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -91.03 133.0 35.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.928 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -96.58 122.3 39.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.861 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.5 t -109.81 126.04 66.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.2 t80 -90.48 138.49 31.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 169' ' ' ARG . 92.7 t -128.7 124.55 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -115.65 -179.25 18.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 54.23 34.15 19.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.893 0.378 . . . . 0.0 110.917 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.493 HD12 ' N ' ' A' ' 141' ' ' GLY . 40.5 mt -80.12 113.4 18.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -45.3 153.54 0.55 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.665 0.745 . . . . 0.0 110.832 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -25.88 28.44 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.671 2.248 . . . . 0.0 112.396 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -77.89 -7.72 57.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 6.4 mm -72.81 148.09 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.13 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.2 p -134.93 159.97 39.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.099 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.668 ' OG1' HG12 ' A' ' 128' ' ' VAL . 36.3 m -54.66 -44.65 73.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -63.05 -31.14 72.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.431 ' O ' ' N ' ' A' ' 116' ' ' ALA . 92.9 m-20 -69.7 -51.37 35.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.843 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.448 HG23 ' CE1' ' A' ' 117' ' ' PHE . 17.0 mt -58.49 -43.93 87.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 118' ' ' ALA . 58.3 mttt -60.62 -34.9 74.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 28.1 t -93.96 -11.99 29.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.597 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.84 -13.72 23.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.088 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.501 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 13.3 m-85 -116.11 -11.56 11.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.588 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.5 -45.14 99.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.065 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -47.96 -17.14 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.313 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.617 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 59.5 m-85 -88.69 -41.34 12.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.855 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 173.59 148.98 6.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -40.96 128.92 2.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.0 110.866 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 58.4 mt -101.22 147.6 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 4.4 p -115.2 -36.59 4.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -140.92 133.81 29.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.406 ' HB3' ' HE3' ' A' ' 114' ' ' LYS . . . -164.2 128.76 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.088 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.496 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.3 OUTLIER -151.92 161.64 42.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.847 -179.926 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.668 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.1 p -118.48 99.85 8.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.144 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 51.5 t -51.24 117.06 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.468 ' HG2' ' N ' ' A' ' 137' ' ' SER . 12.7 mttp -110.03 160.34 16.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.915 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -66.6 156.34 35.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.903 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 8.5 tpt -96.56 -10.41 27.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.66 -50.72 3.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.3 p -94.05 -29.26 15.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.65 17.89 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.438 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.1 mtpp -101.19 145.73 28.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.879 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.468 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 68.3 m -47.07 105.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 12.6 mttp -44.03 -36.3 2.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 126.94 14.19 2.82 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.535 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -155.7 152.81 29.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.945 0.403 . . . . 0.0 110.901 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.493 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -148.43 -171.19 17.05 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -134.68 137.6 43.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.874 0.369 . . . . 0.0 110.868 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 92.5 t -137.47 118.05 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.134 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 88.8 p -98.08 152.85 18.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.586 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 26.7 m-85 -129.53 141.44 50.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.897 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -57.59 -40.86 79.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.862 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -117.7 178.81 4.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 45.7 tttt -87.18 -48.38 8.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 18.3 tp -48.02 -65.1 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -41.98 -51.32 4.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.586 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -55.52 -47.15 76.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -57.81 -42.1 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.914 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -51.3 -47.69 62.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.617 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.43 -53.97 20.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.062 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.429 ' CD1' ' CZ2' ' A' ' 172' ' ' TRP . 96.6 mt -41.37 -35.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 95.4 t -91.4 -47.43 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.148 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -63.82 -63.77 1.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.581 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 93.0 mmm -60.52 -37.99 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.929 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 94.06 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.58 -28.31 9.36 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.508 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . 11.9 tp-100 -37.69 156.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.778 0.323 . . . . 0.0 110.92 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.568 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.6 m95 -98.95 90.99 4.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.597 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.1 tt -86.15 -70.14 0.62 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.881 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.33 117.74 3.54 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.92 -92.7 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.3 mtt85 -80.89 179.66 7.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.314 . . . . 0.0 110.865 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.568 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 80.9 mt-30 -80.9 178.01 8.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.412 HD11 ' HE3' ' A' ' 158' ' ' MET . 29.4 pt -133.52 168.63 23.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.71 ' O ' HG13 ' A' ' 101' ' ' VAL . 55.9 ttt180 -129.54 154.23 47.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.885 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.606 HG22 HG22 ' A' ' 101' ' ' VAL . 44.5 p -141.95 148.22 38.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.083 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -174.24 147.07 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.429 ' CZ2' ' CD1' ' A' ' 155' ' ' ILE . 96.5 m95 -61.7 122.72 16.02 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.959 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.63 -61.97 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 85.0 m -44.47 115.11 0.79 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.098 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 6.0 ptm180 -94.88 140.99 29.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.862 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -171.77 145.87 1.75 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.583 0.706 . . . . 0.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 148.7 66.2 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.712 2.275 . . . . 0.0 112.337 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 145.76 58.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.323 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -44.74 144.08 1.97 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 111.09 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 100.66 0.83 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.673 2.249 . . . . 0.0 112.354 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 13.9 t -88.72 108.67 19.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -39.04 146.19 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 131.92 22.2 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 0.0 112.326 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 20.7 t -160.84 157.72 27.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 41.4 m -42.28 -47.89 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.99 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.9 m 47.93 42.26 16.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.871 0.367 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 t -168.48 176.69 5.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.859 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -99.88 -177.92 30.71 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.3 p -165.44 177.87 7.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.918 0.39 . . . . 0.0 110.835 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 9.5 t -85.0 130.16 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.845 -179.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 164.01 -76.76 0.16 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.511 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -38.31 157.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.42 37.1 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.878 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 64.7 mttt -107.01 159.33 16.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -118.74 80.78 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 73.8 p -104.23 88.0 2.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.143 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.1 m -107.66 -59.62 1.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.85 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 96' ' ' HIS . 9.3 m120 -67.18 -51.85 48.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.919 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.517 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 7.1 m170 -37.87 143.96 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.838 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.558 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 3.9 m-85 -91.14 139.61 30.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -93.16 131.86 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.926 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 48.2 t -124.05 129.34 74.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' ND2' ' A' ' 171' ' ' ASN . 1.8 t80 -99.42 149.86 22.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.604 HG13 ' O ' ' A' ' 169' ' ' ARG . 43.5 t -137.41 130.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.25 173.29 16.27 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 139' ' ' GLY . 5.4 m-20 61.74 36.38 16.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.819 0.342 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.422 HD13 HD11 ' A' ' 113' ' ' ILE . 39.1 mt -80.18 110.87 16.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -38.66 153.06 0.16 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 121.634 0.731 . . . . 0.0 110.874 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -15.21 36.79 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.678 2.252 . . . . 0.0 112.307 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.416 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 7.6 tt0 -90.63 -6.19 54.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.909 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 109' ' ' THR . 25.5 mm -67.48 156.06 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.448 ' N ' HG22 ' A' ' 108' ' ' ILE . 76.1 p -145.72 157.29 43.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.631 ' OG1' HG12 ' A' ' 128' ' ' VAL . 32.4 m -55.03 -39.06 68.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.074 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -71.58 -17.0 62.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -84.49 -46.32 11.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.51 HG23 ' CE1' ' A' ' 117' ' ' PHE . 7.7 mt -63.23 -38.76 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.462 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 19.4 mtpt -60.09 -36.12 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -92.84 -20.01 21.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.509 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -83.88 -16.92 42.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.8 m-85 -115.24 -7.55 12.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.581 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.72 -45.72 99.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.612 0.72 . . . . 0.0 111.114 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.0 Cg_exo -47.99 -18.1 1.04 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.654 2.236 . . . . 0.0 112.353 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.644 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 44.0 m-85 -89.77 -37.11 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.439 ' HA3' ' CG ' ' A' ' 150' ' ' ASP . . . 172.97 -171.24 44.3 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.456 ' HD2' ' N ' ' A' ' 123' ' ' ILE . 0.0 OUTLIER -77.77 120.05 22.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.781 0.324 . . . . 0.0 110.929 179.97 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.598 HG21 ' HB2' ' A' ' 126' ' ' ALA . 95.8 mt -91.91 101.12 12.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 93.1 p -67.84 -27.42 66.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.819 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -156.23 140.0 16.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.598 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -163.29 126.71 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.098 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.519 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.8 OUTLIER -143.69 162.78 35.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.854 -179.895 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.631 HG12 ' OG1' ' A' ' 110' ' ' THR . 6.5 p -121.15 100.19 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.0 t -53.73 120.38 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.481 ' HG2' ' N ' ' A' ' 137' ' ' SER . 32.1 mttm -115.29 164.88 13.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -65.44 148.61 51.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -90.91 -3.44 57.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.856 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -111.5 -54.91 2.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.11 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 24.5 p -89.76 -27.19 20.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.59 28.13 59.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 pttt -108.58 138.83 44.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.78 0.324 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.481 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 14.6 t -41.85 109.17 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -51.19 -33.77 28.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.5 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 121.38 20.44 3.27 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.429 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -161.05 140.96 10.84 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.957 0.408 . . . . 0.0 110.924 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -136.61 -168.74 11.52 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -138.54 143.87 39.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.4 t -144.02 124.73 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.17 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.2 m -100.82 141.13 34.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.839 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -125.01 133.92 52.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.879 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.517 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.1 m-85 -53.35 -48.92 68.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -113.31 167.24 10.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.558 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 30.4 tttp -74.68 -42.29 58.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -46.86 -52.09 15.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.439 ' CG ' ' HA3' ' A' ' 121' ' ' GLY . 88.9 m-20 -54.42 -43.79 71.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -66.54 -61.12 2.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.072 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -41.16 -44.31 2.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 -55.29 -59.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.644 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -58.09 -54.25 49.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.615 HD13 ' CE2' ' A' ' 172' ' ' TRP . 85.4 mt -44.42 -35.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.75 -60.98 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.118 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.7 m-70 -56.68 -66.96 0.35 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.811 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 24.3 mmt -43.51 -47.12 7.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.93 95.22 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.458 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.77 -30.72 6.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.488 ' N ' ' O ' ' A' ' 158' ' ' MET . 7.5 tp60 -37.5 155.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.905 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.546 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 89.2 m95 -101.15 91.7 4.65 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.92 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.542 ' C ' HD23 ' A' ' 163' ' ' LEU . 4.0 tt -86.18 -70.7 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.416 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.73 118.1 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.492 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -92.14 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.503 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -80.25 175.12 10.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.758 0.313 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.546 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 38.8 mt-30 -74.01 177.43 5.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 20.0 pt -135.31 164.62 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.134 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.604 ' O ' HG13 ' A' ' 101' ' ' VAL . 29.7 ttp180 -128.01 154.13 45.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.566 HG22 HG22 ' A' ' 101' ' ' VAL . 22.4 p -142.68 154.05 43.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' ASN . . . . . 0.534 ' ND2' ' CD1' ' A' ' 100' ' ' PHE . 4.6 p30 -173.44 163.33 4.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.615 ' CE2' HD13 ' A' ' 155' ' ' ILE . 88.4 m95 -80.73 123.44 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.922 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -90.43 91.86 8.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.085 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 19.3 m -131.62 145.58 51.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -117.38 50.93 1.06 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.74 143.96 27.63 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.583 0.706 . . . . 0.0 110.913 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.86 153.93 67.92 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.669 2.246 . . . . 0.0 112.328 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 110.94 2.68 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.693 2.262 . . . . 0.0 112.333 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -114.4 146.07 35.09 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.533 0.682 . . . . 0.0 111.111 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 126.18 13.01 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.687 2.258 . . . . 0.0 112.317 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 11.5 m -96.75 127.53 42.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -72.87 144.62 35.38 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 132.99 24.55 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.685 2.257 . . . . 0.0 112.313 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 60.5 p -101.97 149.58 24.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.885 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.2 m -154.43 161.6 41.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 179.988 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 75.0 m -69.48 -52.77 23.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 5.3 t -172.56 154.98 3.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.812 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.29 -171.62 46.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.521 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.1 p -105.69 145.14 31.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.857 0.361 . . . . 0.0 110.848 -179.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 7.8 t -100.14 -64.26 1.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.852 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.24 -76.08 0.12 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.501 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -79.65 122.4 26.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.929 0.395 . . . . 0.0 110.908 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -149.41 -175.92 5.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.918 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? 50.75 49.4 21.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.906 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -87.37 58.37 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.9 p -96.04 73.81 3.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.136 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 35.7 t -110.35 -26.57 9.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.849 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 32.3 m120 -132.79 36.38 3.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.497 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 28.2 m170 -96.0 160.35 14.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.557 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 26.9 m-85 -102.2 129.67 48.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -96.34 133.39 40.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.465 HG22 HD11 ' A' ' 155' ' ' ILE . 62.3 t -114.01 127.19 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.115 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 24.4 t80 -87.63 136.4 32.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.426 HG13 ' O ' ' A' ' 169' ' ' ARG . 43.8 t -125.72 135.74 62.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.105 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.67 178.05 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 55.34 32.25 18.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 33.1 mt -78.85 118.84 21.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.6 t -50.36 152.47 3.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.82 23.45 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.678 2.252 . . . . 0.0 112.327 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -69.32 -13.2 62.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.532 HD12 HD22 ' A' ' 163' ' ' LEU . 14.6 mm -66.1 159.1 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.16 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.494 ' N ' HG22 ' A' ' 108' ' ' ILE . 68.9 p -134.9 -175.82 4.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.178 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 97.3 m -78.97 -36.98 40.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.126 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -78.95 -16.35 57.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -72.29 -48.42 42.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.0 mt -62.25 -42.48 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.13 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 65.2 mttt -57.28 -35.26 69.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 6.9 t -93.83 -19.33 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.685 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -83.62 -20.09 34.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.089 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.556 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 12.9 m-85 -110.96 -7.16 14.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.53 -45.98 99.82 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.535 0.683 . . . . 0.0 111.076 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.01 -17.09 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.136 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.637 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.9 m-85 -90.69 -32.85 16.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.874 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.85 -165.6 37.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.51 ' HG2' ' CE1' ' A' ' 146' ' ' TYR . 72.4 tttt -78.84 131.71 36.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -104.44 113.64 41.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.105 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 3.2 t -79.46 -32.39 42.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -152.5 143.5 23.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -173.25 132.36 0.49 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.155 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -152.06 164.65 36.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.607 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.6 p -114.58 100.7 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -52.88 122.76 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.467 ' HG2' ' N ' ' A' ' 137' ' ' SER . 78.0 mttt -120.92 161.26 21.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -71.38 158.51 36.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.838 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -95.85 -15.83 22.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -94.63 -60.44 1.71 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 15.3 p -83.42 -31.19 26.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.16 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.2 25.6 63.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.3 mmtm -108.24 144.63 35.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.842 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.467 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 11.2 t -46.76 105.89 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -44.14 -37.82 3.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.22 10.08 3.52 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.8 p90 -153.56 153.13 31.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.946 0.403 . . . . 0.0 110.907 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -148.18 -171.73 17.42 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -130.97 142.12 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.897 0.38 . . . . 0.0 110.874 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 25.3 t -140.9 105.61 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.158 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 17.8 m -85.77 147.91 26.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.872 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.9 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 11.1 m-85 -129.23 129.21 44.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.51 ' CE1' ' HG2' ' A' ' 122' ' ' LYS . 21.1 m-85 -43.8 -46.96 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.95 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 23.7 m-20 -114.32 -178.87 3.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.853 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.557 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 25.9 tttm -87.1 -48.74 7.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.901 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.1 tp -50.11 -64.97 0.65 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 20.2 p-10 -39.73 -51.88 2.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.9 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -60.41 -58.37 8.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.082 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -43.58 -47.39 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -45.36 -50.64 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.637 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.67 -52.34 64.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.098 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.465 HD11 HG22 ' A' ' 99' ' ' VAL . 92.1 mt -44.15 -39.54 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.8 t -77.29 -48.48 24.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 64.8 m-70 -72.05 -65.56 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.556 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.3 mmt -43.3 -49.61 6.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.2 96.6 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.455 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.59 -30.29 7.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.482 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.473 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.8 tp60 -40.16 154.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.915 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.577 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -98.92 91.17 4.92 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.685 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.6 tt -85.54 -73.14 0.46 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.462 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.94 117.17 3.57 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.477 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.69 -92.7 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.458 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -80.95 -177.29 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.861 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 33.3 mt-30 -82.5 177.15 8.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.492 ' CD1' ' SD ' ' A' ' 158' ' ' MET . 41.9 pt -134.4 173.95 13.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.138 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.426 ' O ' HG13 ' A' ' 101' ' ' VAL . 21.2 ttm180 -136.76 158.46 44.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.04 156.1 47.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -163.88 168.25 19.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.879 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -94.83 105.68 17.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.951 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -72.27 103.88 3.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.414 ' O ' HG23 ' A' ' 174' ' ' THR . 15.1 t -145.85 128.84 16.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 66.6 mtm180 -84.38 133.85 34.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.884 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 15.8 ttpt -170.18 132.7 1.03 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.525 0.679 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 139.5 40.42 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.707 2.271 . . . . 0.0 112.368 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -178.93 2.55 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.653 2.235 . . . . 0.0 112.327 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -132.79 146.96 63.6 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.559 0.695 . . . . 0.0 111.084 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 131.23 20.79 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.633 2.222 . . . . 0.0 112.363 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 8.0 t -144.75 159.06 43.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.854 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 120.11 145.37 7.42 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -16.8 37.96 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.671 2.247 . . . . 0.0 112.352 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 23.0 t 51.3 36.15 15.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 5.0 t -111.54 -58.01 2.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.86 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.515 179.996 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 25.1 t -149.42 135.96 19.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 0.0 110.849 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 5.3 t -108.46 97.93 7.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.859 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.4 -118.96 0.23 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.0 m 46.85 51.52 12.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 110.887 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.0 p -118.51 142.72 47.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.11 -168.33 29.65 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.517 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -103.45 -2.11 27.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.893 0.378 . . . . 0.0 110.928 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 11.7 ttmt -84.23 110.69 18.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.3 mtmt -83.05 45.98 1.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.88 129.07 38.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 73.3 p -64.95 129.37 39.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.149 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.3 m -128.32 -49.8 1.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.83 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -127.21 36.98 4.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.887 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 38.5 m170 -105.3 155.41 19.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.526 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 85.3 m-85 -86.89 124.92 33.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -93.02 134.82 34.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.498 HG22 HD11 ' A' ' 155' ' ' ILE . 28.9 t -115.82 128.47 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.17 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -89.82 131.08 35.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.783 HG11 HD21 ' A' ' 104' ' ' LEU . 82.2 t -119.99 133.38 66.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.133 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -125.35 -178.43 15.31 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.526 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 47.4 43.58 15.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.883 0.373 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.783 HD21 HG11 ' A' ' 101' ' ' VAL . 45.1 mt -79.57 97.02 6.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -35.74 153.64 0.07 OUTLIER Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.684 0.754 . . . . 0.0 110.839 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.83 -14.6 36.09 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.622 2.215 . . . . 0.0 112.341 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -89.82 -3.62 58.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 109' ' ' THR . 15.1 mm -76.79 156.86 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.426 ' N ' HG22 ' A' ' 108' ' ' ILE . 26.7 p -142.19 160.93 39.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.184 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.785 ' OG1' HG12 ' A' ' 128' ' ' VAL . 21.0 m -56.14 -33.43 65.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.173 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -74.6 -39.08 62.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.5 ' O ' ' N ' ' A' ' 116' ' ' ALA . 19.2 m-20 -55.06 -57.44 11.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.545 HG23 ' CE1' ' A' ' 117' ' ' PHE . 28.1 mt -52.77 -39.79 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.128 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.64 ' HA ' HD13 ' A' ' 123' ' ' ILE . 6.9 mtpm? -62.89 -41.86 99.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.6 t -90.53 -10.17 44.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.877 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.567 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -93.27 -23.44 18.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.128 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' PHE . . . . . 0.565 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.7 m-85 -105.05 -6.98 19.5 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.574 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -55.15 -46.43 99.68 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.553 0.692 . . . . 0.0 111.083 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.574 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.4 Cg_exo -47.96 -19.0 1.32 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.354 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.688 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 44.2 m-85 -89.41 -50.24 6.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.81 165.7 33.69 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.455 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -50.83 131.54 26.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.64 HD13 ' HA ' ' A' ' 114' ' ' LYS . 57.3 mt -99.44 117.48 44.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 57.8 p -86.93 -31.21 20.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -152.1 122.87 7.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.839 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.567 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -149.13 114.21 5.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.129 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.1 155.15 47.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.905 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.785 HG12 ' OG1' ' A' ' 110' ' ' THR . 5.0 p -112.51 99.94 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.178 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 25.9 t -52.65 122.81 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.106 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.512 ' HE3' HG13 ' A' ' 128' ' ' VAL . 4.3 mtmp? -117.16 156.76 27.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.886 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -58.16 151.36 19.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.894 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' MET . . . . . 0.403 ' O ' ' SD ' ' A' ' 132' ' ' MET . 0.0 OUTLIER -96.47 16.34 18.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -131.14 -56.38 1.03 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.1 p -84.53 -28.46 26.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.12 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.77 23.17 62.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.494 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.407 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 13.8 mmtp -108.48 167.35 10.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.777 0.322 . . . . 0.0 110.911 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 80.1 p -57.07 117.65 4.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.867 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.429 ' HG3' ' C ' ' A' ' 130' ' ' LYS . 41.5 mttt -60.54 -39.53 88.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.62 16.72 2.22 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.511 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -166.08 151.42 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.902 0.382 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.56 -171.9 14.09 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -138.69 139.33 38.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.517 HG21 ' CG2' ' A' ' 113' ' ' ILE . 54.4 t -145.09 108.22 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 6.0 m -86.05 154.75 21.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -130.7 141.46 50.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.874 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -60.42 -32.86 71.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -125.54 162.35 25.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.934 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.526 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 70.8 tttt -73.94 -47.87 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -52.04 -43.05 63.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -60.29 -34.26 73.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.836 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -74.51 -45.22 47.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.117 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.524 ' O ' HG23 ' A' ' 156' ' ' VAL . 17.0 mt-10 -58.22 -42.14 85.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.894 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -53.14 -54.87 29.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.688 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -62.42 -55.88 23.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.498 HD11 HG22 ' A' ' 99' ' ' VAL . 79.2 mt -42.0 -37.78 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 152' ' ' GLU . 82.5 t -80.15 -58.84 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.173 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -59.64 -65.42 0.68 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' MET . . . . . 0.565 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.7 mmt -42.54 -48.12 5.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.54 104.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.484 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.81 -31.46 3.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.496 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 161' ' ' GLN . . . . . 0.499 ' N ' ' O ' ' A' ' 158' ' ' MET . 34.1 tp60 -37.28 149.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 81.5 m95 -96.24 93.55 6.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.567 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.5 tt -86.36 -70.43 0.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.97 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.406 ' HA3' HD13 ' A' ' 108' ' ' ILE . . . -125.6 118.81 3.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 58.4 -95.28 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -84.86 170.26 13.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.581 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 39.0 mt-30 -68.7 172.28 6.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 14.9 pt -129.59 164.7 31.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.159 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.421 ' HG3' ' N ' ' A' ' 170' ' ' THR . 21.0 tpp180 -125.05 156.44 38.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.922 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' THR . . . . . 0.467 HG21 ' HB2' ' A' ' 158' ' ' MET . 72.2 p -144.52 156.87 44.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -174.37 173.58 2.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' TRP . . . . . 0.474 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.2 m95 -90.91 108.55 19.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -44.99 -56.94 4.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.042 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.0 t -108.33 136.21 48.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -128.34 123.94 35.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.833 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -106.38 87.09 2.42 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.635 0.731 . . . . 0.0 110.928 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 125.79 12.56 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.67 2.247 . . . . 0.0 112.355 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 163.49 38.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.683 2.255 . . . . 0.0 112.38 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' ALA . . . . . 0.474 ' HB1' ' HD2' ' A' ' 180' ' ' PRO . . . -91.59 157.02 42.61 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.6 0.714 . . . . 0.0 111.067 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 180' ' ' PRO . . . . . 0.474 ' HD2' ' HB1' ' A' ' 179' ' ' ALA . 54.4 Cg_endo -69.78 2.83 3.19 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.674 2.25 . . . . 0.0 112.379 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 35.4 t -82.05 143.36 31.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.76 146.53 4.35 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 168.67 20.92 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.368 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 m -139.5 161.24 37.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.83 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 4.1 m -129.75 137.68 50.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.829 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.455 -179.998 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 61.1 m170 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.822 0.344 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -107.86 121.53 44.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -84.09 123.97 30.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.0 t -112.3 122.86 67.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.105 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.522 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 2.1 t80 -83.02 141.21 32.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.854 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.493 HG22 HG22 ' A' ' 170' ' ' THR . 96.1 t -135.55 110.67 11.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.155 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.12 -174.25 30.26 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 45.73 52.6 9.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.429 ' O ' ' C ' ' A' ' 105' ' ' SER . 21.3 mt -91.41 100.28 13.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -36.19 153.56 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.692 0.758 . . . . 0.0 110.869 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -27.23 26.67 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.726 2.284 . . . . 0.0 112.317 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -75.97 -12.41 60.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.496 HG22 ' N ' ' A' ' 109' ' ' THR . 24.1 mm -63.45 157.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.157 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 108' ' ' ILE . 77.7 p -145.66 144.04 30.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.168 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.637 ' OG1' HG12 ' A' ' 128' ' ' VAL . 76.5 m -44.64 -38.08 4.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -70.89 -35.96 72.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 116' ' ' ALA . 27.1 m-20 -63.58 -52.14 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.431 HG23 ' CE1' ' A' ' 117' ' ' PHE . 51.9 mt -56.67 -46.04 82.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.599 ' O ' HD12 ' A' ' 123' ' ' ILE . 68.0 mttt -56.7 -33.87 66.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.963 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -94.01 -18.44 21.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.652 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -85.3 -13.05 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.12 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.47 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.7 m-85 -115.87 -6.55 12.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.852 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -57.68 -46.11 99.78 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.571 0.7 . . . . 0.0 111.118 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.93 -17.19 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.649 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 48.0 m-85 -90.47 -48.18 7.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -176.45 175.56 47.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.467 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.8 tptp -62.86 134.83 56.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.771 0.32 . . . . 0.0 110.882 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.599 HD12 ' O ' ' A' ' 114' ' ' LYS . 77.3 mt -101.31 133.04 45.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 39.8 t -106.76 -40.43 5.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -143.48 122.52 12.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -149.94 133.15 16.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.597 ' HA ' HG23 ' A' ' 110' ' ' THR . 22.2 ptt180 -155.41 153.15 29.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.637 HG12 ' OG1' ' A' ' 110' ' ' THR . 7.3 p -115.49 100.0 9.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.565 HG11 ' OH ' ' A' ' 140' ' ' TYR . 78.8 t -49.85 114.3 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.133 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.483 ' HG2' ' N ' ' A' ' 137' ' ' SER . 41.7 mttt -118.07 155.67 29.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.21 149.58 49.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 mmt -91.92 -8.73 45.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.71 -58.52 2.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.092 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 11.8 p -87.69 -38.54 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.11 34.38 14.9 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -118.3 138.96 52.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.77 0.319 . . . . 0.0 110.905 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.483 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 21.4 t -40.9 104.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.89 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 21.3 mttp -45.25 -36.76 4.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.926 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.31 23.37 2.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.501 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.565 ' OH ' HG11 ' A' ' 129' ' ' VAL . 52.4 p90 -165.52 143.06 5.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.929 0.395 . . . . 0.0 110.914 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.15 -173.37 19.73 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.442 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -133.24 141.16 47.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.907 0.384 . . . . 0.0 110.906 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.19 106.34 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 50.9 m -86.36 154.29 21.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -130.89 147.22 52.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -60.96 -40.72 94.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.94 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -122.76 176.23 6.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -83.54 -55.68 4.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 19.1 tp -42.75 -53.97 4.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -51.6 -45.78 63.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -61.0 -51.54 68.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -50.02 -42.62 49.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.891 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -52.2 -48.98 64.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.649 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.0 -52.34 36.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.09 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.625 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 88.5 mt -44.03 -38.78 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.146 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.92 -54.53 8.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.114 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -58.84 -64.16 1.04 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 89.5 mmm -57.54 -39.72 77.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.69 93.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 94.31 -29.5 8.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.493 ' N ' ' O ' ' A' ' 158' ' ' MET . 71.8 tp60 -38.86 148.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.361 . . . . 0.0 110.917 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.575 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 91.1 m95 -90.7 92.54 8.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.652 HD11 ' CB ' ' A' ' 116' ' ' ALA . 3.4 tt -88.7 -69.81 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.934 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.14 117.03 3.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.445 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.57 -91.3 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.494 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.3 mpt_? -83.14 175.73 9.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.859 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.575 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 51.0 mt-30 -77.08 177.43 7.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.502 HD11 ' HE3' ' A' ' 158' ' ' MET . 19.8 pt -137.35 162.69 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.07 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.3 mmt180 -118.98 165.07 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.493 HG22 HG22 ' A' ' 101' ' ' VAL . 3.8 p -149.81 141.4 23.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.108 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . 0.451 ' ND2' ' O ' ' A' ' 170' ' ' THR . 35.0 m120 -159.88 165.17 32.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.625 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 91.9 m95 -83.95 84.17 7.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.522 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . 0.432 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 44.5 m170 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.828 0.346 . . . . 0.0 110.888 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -103.03 128.14 50.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 29.6 m-70 -83.4 131.85 35.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.831 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.415 HG21 ' HB1' ' A' ' 151' ' ' ALA . 58.6 t -118.51 124.37 73.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.099 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.436 ' CZ ' ' HB2' ' A' ' 140' ' ' TYR . 10.4 t80 -86.41 138.85 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.661 ' CG1' HD21 ' A' ' 104' ' ' LEU . 92.7 t -132.34 111.8 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.097 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.31 -175.32 26.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 49.35 41.66 20.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.661 HD21 ' CG1' ' A' ' 101' ' ' VAL . 67.9 mt -85.78 108.02 17.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.8 t -35.94 152.16 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.658 0.742 . . . . 0.0 110.855 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -19.43 35.88 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.684 2.256 . . . . 0.0 112.316 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -87.81 1.4 54.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 15.8 mm -75.38 146.34 9.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.123 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.6 p -139.59 145.79 39.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.175 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.409 ' OG1' HG12 ' A' ' 128' ' ' VAL . 88.6 m -39.01 -35.97 0.25 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.192 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -67.34 -48.89 66.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 116' ' ' ALA . 8.8 t0 -54.39 -52.72 60.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.457 HG23 ' CE1' ' A' ' 117' ' ' PHE . 64.6 mt -56.69 -42.68 77.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.159 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.439 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 36.0 mttt -63.51 -37.56 87.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.932 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -92.55 -8.93 42.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.841 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -97.4 -23.59 16.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.061 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 22.7 m-85 -105.29 -11.59 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.583 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -52.51 -45.9 95.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.603 0.716 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.3 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 0.0 112.336 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.625 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 58.7 m-85 -90.31 -51.19 5.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -178.46 158.64 23.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.498 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.4 tptt -48.64 128.7 15.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.712 0.291 . . . . 0.0 110.856 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.557 HG21 ' HB2' ' A' ' 126' ' ' ALA . 60.0 mt -96.39 137.76 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 10.6 t -112.88 -39.52 4.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.865 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -134.92 103.0 5.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.557 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -136.18 131.5 34.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 22.5 ptt180 -155.55 156.38 35.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.597 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.6 p -118.62 100.44 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.107 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.59 HG12 ' HG3' ' A' ' 138' ' ' LYS . 75.8 t -52.34 122.81 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.104 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -119.03 155.53 31.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.883 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.95 148.66 51.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 35.1 mtm -95.46 -9.41 32.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -91.13 -52.5 4.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.086 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.7 p -100.89 -40.38 7.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.152 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.59 26.25 8.21 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.48 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -109.3 149.27 29.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.915 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 11.9 m -43.09 114.65 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.824 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.59 ' HG3' HG12 ' A' ' 129' ' ' VAL . 13.2 mtpt -53.6 -39.82 65.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.927 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.77 19.34 1.83 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.555 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 44.2 p90 -167.53 150.28 6.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.899 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.65 -171.5 16.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.453 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -136.48 136.91 39.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.907 0.384 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 70.2 t -140.53 108.31 2.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.182 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.3 t -93.52 141.82 28.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -117.27 147.21 42.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.432 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 10.1 m-85 -57.79 -38.22 75.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -124.95 155.64 39.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.87 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -61.43 -60.55 3.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 21.1 tp -40.01 -49.95 2.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -49.49 -40.68 38.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.845 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.415 ' HB1' HG21 ' A' ' 99' ' ' VAL . . . -69.3 -48.87 60.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.07 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -52.57 -38.89 60.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.924 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -56.53 -54.5 45.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.625 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.31 -61.62 2.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.533 HD13 ' CE2' ' A' ' 172' ' ' TRP . 68.3 mt -38.64 -39.73 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.159 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 20.3 t -70.55 -64.37 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.132 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 77.6 m-70 -63.63 -61.17 2.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 29.0 mmt -43.9 -48.44 8.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.44 92.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 97.68 -30.1 9.88 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.525 ' CD ' ' N ' ' A' ' 162' ' ' TRP . 1.0 OUTLIER -36.74 154.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.811 0.338 . . . . 0.0 110.863 -179.851 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.586 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 77.1 m95 -101.43 91.24 4.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.978 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.549 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.2 tt -84.29 -70.89 0.54 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.921 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -125.58 120.33 3.82 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.458 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 57.37 -95.3 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -81.15 179.26 7.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.744 0.306 . . . . 0.0 110.921 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.586 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 53.9 mt-30 -79.57 -178.43 6.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.434 ' O ' ' N ' ' A' ' 160' ' ' GLY . 20.8 pt -136.66 162.19 35.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.7 ttm180 -126.4 144.07 50.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.519 HG21 ' HA ' ' A' ' 155' ' ' ILE . 1.3 p -121.6 153.18 38.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . 0.416 ' CG ' ' O ' ' A' ' 170' ' ' THR . 12.0 m120 -169.15 159.97 9.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.533 ' CE2' HD13 ' A' ' 155' ' ' ILE . 94.9 m95 -89.41 129.42 35.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.07 179.881 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . 0.441 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 38.1 m170 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.798 0.332 . . . . 0.0 110.885 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -104.72 121.4 43.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 5.2 m-70 -89.3 134.42 34.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.21 122.1 68.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 45.4 t80 -84.91 141.43 30.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.6 t -125.73 143.05 40.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.44 159.22 23.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.459 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 t0 68.06 33.77 4.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.88 0.372 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.49 HD12 ' C ' ' A' ' 140' ' ' TYR . 31.3 mt -70.91 99.06 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.4 t -35.85 153.22 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.739 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -18.93 36.6 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.335 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.452 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 9.6 tt0 -87.71 -3.43 58.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.438 HG21 HD22 ' A' ' 104' ' ' LEU . 18.1 mm -69.36 144.59 13.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.6 p -134.49 148.8 50.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.118 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 88.4 m -50.87 -30.71 15.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.183 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -78.23 -23.16 47.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -78.91 -48.92 13.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.507 HG23 ' CD1' ' A' ' 117' ' ' PHE . 17.5 mt -57.85 -42.42 82.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.144 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.3 mttt -58.45 -43.98 89.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.7 t -81.94 -16.87 49.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.487 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -89.5 -20.11 24.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.066 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.3 m-85 -108.63 -10.59 15.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.855 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.585 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.12 -45.43 99.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.57 0.7 . . . . 0.0 111.042 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -47.98 -17.03 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.706 2.27 . . . . 0.0 112.33 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.65 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 34.6 m-85 -93.58 -32.13 14.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.16 178.79 36.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.579 ' HG3' ' CE1' ' A' ' 146' ' ' TYR . 32.0 tptt -62.82 143.68 57.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.802 0.334 . . . . 0.0 110.877 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.533 HG21 ' HB2' ' A' ' 126' ' ' ALA . 62.6 mt -113.57 126.24 70.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 1.7 t -93.77 -37.44 11.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -145.89 117.43 8.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.533 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -146.43 119.2 8.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -148.45 163.27 37.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.509 HG13 ' O ' ' A' ' 128' ' ' VAL . 3.9 p -115.76 104.26 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.128 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.0 t -57.49 124.65 11.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -122.36 157.98 30.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.912 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -64.83 158.23 25.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.932 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 42.7 mmm -101.92 -13.13 17.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.883 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.36 -47.69 7.59 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.119 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.8 p -102.55 -38.86 7.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.104 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.28 32.79 9.25 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.9 mttt -111.84 155.5 23.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.741 0.305 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.1 t -55.23 102.61 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 65.0 mttt -45.03 -39.0 5.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.892 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.92 16.96 2.87 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.455 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.49 ' C ' HD12 ' A' ' 104' ' ' LEU . 32.8 p90 -160.5 145.81 14.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.976 0.417 . . . . 0.0 110.927 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -141.55 -176.17 15.64 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -129.82 142.15 50.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.869 0.366 . . . . 0.0 110.924 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 19.8 t -149.35 106.03 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.155 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 48.9 m -92.0 142.1 27.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.652 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 23.7 m-85 -112.42 144.67 41.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.579 ' CE1' ' HG3' ' A' ' 122' ' ' LYS . 8.5 m-85 -56.98 -35.75 69.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.557 ' ND2' ' N ' ' A' ' 147' ' ' ASN . 0.0 OUTLIER -127.15 179.7 5.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.901 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -86.98 -40.96 14.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 55.9 tp -52.44 -65.07 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.456 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 14.6 p-10 -43.8 -53.63 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.844 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.652 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -55.0 -57.16 12.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.066 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.441 ' O ' HG23 ' A' ' 156' ' ' VAL . 26.8 mt-10 -46.38 -47.21 18.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 64.6 m-20 -49.8 -55.09 15.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.65 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -57.05 -60.73 3.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.081 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.623 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 83.3 mt -39.31 -37.72 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.152 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 152' ' ' GLU . 90.4 t -77.76 -48.6 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.139 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -75.56 -62.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 23.2 mmt -45.31 -47.27 13.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.45 94.96 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.446 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 96.59 -30.69 8.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.474 ' N ' ' O ' ' A' ' 158' ' ' MET . 6.2 tm0? -38.25 157.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 110.923 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 87.1 m95 -102.56 95.0 5.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.958 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.522 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.3 tt -90.88 -70.5 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.414 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.09 116.77 3.53 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.505 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.42 -91.53 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -82.07 178.81 8.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.839 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 43.9 mt-30 -80.63 177.83 8.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 7.7 pt -137.3 170.19 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.111 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.4 ttm-85 -131.29 149.57 52.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.9 p -126.67 150.85 48.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -168.77 154.56 6.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.623 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.2 m95 -81.05 113.24 19.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.111 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . 0.405 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 30.6 m170 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.862 0.363 . . . . 0.0 110.817 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -94.12 130.24 40.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . 0.507 ' CB ' ' HB3' ' A' ' 173' ' ' ALA . 54.6 m-70 -88.28 128.12 35.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 95.6 t -116.44 124.65 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -89.57 141.86 28.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 169' ' ' ARG . 61.2 t -131.59 134.89 60.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.46 17.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.479 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.96 36.09 23.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.879 0.371 . . . . 0.0 110.836 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.492 HD21 HG11 ' A' ' 101' ' ' VAL . 31.2 mt -81.1 110.03 16.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -41.61 153.31 0.27 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -23.64 30.52 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.336 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -75.84 -18.53 59.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.646 HD12 HD22 ' A' ' 163' ' ' LEU . 20.2 mm -66.33 133.09 31.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 60.8 p -121.21 151.42 39.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 52.9 m -43.98 -34.54 1.74 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.136 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -70.93 -43.81 67.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.4 m-20 -58.76 -53.83 53.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.608 HG23 ' CE1' ' A' ' 117' ' ' PHE . 43.3 mt -56.34 -38.68 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.542 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 7.0 mtpt -63.58 -39.13 93.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.3 t -93.3 -11.92 31.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.836 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.748 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.72 -20.94 21.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.09 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.608 ' CE1' HG23 ' A' ' 113' ' ' ILE . 19.6 m-85 -107.4 -8.65 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.73 -45.66 99.8 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.589 0.709 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -48.0 -17.07 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.283 . . . . 0.0 112.361 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.631 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.7 m-85 -90.73 -38.84 12.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.896 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.97 167.29 31.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -54.54 126.63 24.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.445 HD12 ' O ' ' A' ' 114' ' ' LYS . 85.7 mt -95.76 132.85 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.147 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 92.1 p -99.99 -44.92 5.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.1 120.65 13.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.542 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -143.21 128.32 18.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.099 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 -156.44 151.75 26.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.718 HG13 ' HE2' ' A' ' 130' ' ' LYS . 7.2 p -108.59 100.08 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 68.7 t -49.49 130.37 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.077 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.718 ' HE2' HG13 ' A' ' 128' ' ' VAL . 29.9 mtmt -125.55 167.75 14.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 30.3 t0 -68.53 157.33 36.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -94.57 -12.53 27.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.58 -62.55 1.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.6 p -81.08 -28.38 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.131 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.26 33.45 53.71 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.411 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 7.1 mmpt? -106.03 158.33 16.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.307 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.412 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 16.5 m -65.47 100.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 37.4 mttt -44.21 -36.77 2.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 121.17 18.58 3.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.485 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -156.71 142.45 17.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.908 0.385 . . . . 0.0 110.952 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.1 -169.76 12.26 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -134.23 142.38 47.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 73.1 t -144.83 110.55 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.136 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 15.8 m -89.67 145.01 25.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -121.88 149.18 43.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.405 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 10.1 m-85 -58.63 -46.64 86.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -128.66 165.23 21.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' A' ' 151' ' ' ALA . 14.3 ttmt -62.13 -62.22 1.92 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 65.0 tp -38.19 -50.88 1.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -55.68 -39.62 71.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.907 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.602 ' HB3' ' HH2' ' A' ' 172' ' ' TRP . . . -67.02 -51.19 57.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.149 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.423 ' O ' HG23 ' A' ' 156' ' ' VAL . 5.5 mm-40 -50.14 -48.04 53.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -42.03 -36.59 1.16 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.631 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -86.0 -54.53 4.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.095 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.629 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 76.1 mt -47.67 -34.31 3.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.16 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 152' ' ' GLU . 46.7 t -81.37 -46.33 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.129 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -74.92 -65.26 0.89 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.892 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.72 ' HB2' HG21 ' A' ' 170' ' ' THR . 8.1 mmt -42.33 -48.66 5.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -35.51 103.04 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.467 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 82.08 -32.53 2.74 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.3 tp-100 -34.32 149.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.756 0.312 . . . . 0.0 110.966 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 90.8 m95 -99.89 92.51 5.32 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.926 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.748 HD11 ' CB ' ' A' ' 116' ' ' ALA . 7.0 tt -87.24 -71.04 0.58 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.583 ' HA3' HD11 ' A' ' 108' ' ' ILE . . . -120.63 117.67 3.59 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.483 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.94 -92.78 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.504 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.735 0.302 . . . . 0.0 110.864 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 71.5 mt-30 -77.15 -178.96 5.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 25.0 pt -137.96 163.68 29.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.724 ' O ' HG13 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -126.45 152.14 46.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.944 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.72 HG21 ' HB2' ' A' ' 158' ' ' MET . 16.4 p -134.16 158.46 43.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.156 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . 0.413 ' HB2' ' NH1' ' A' ' 169' ' ' ARG . 24.4 t-20 -172.07 173.18 4.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.843 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.629 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 83.8 m95 -95.04 106.97 19.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.507 ' HB3' ' CB ' ' A' ' 98' ' ' HIS . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 19.4 m170 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.828 0.347 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.532 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 58.2 m-85 -113.48 134.24 54.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -91.29 128.35 37.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 98.3 t -111.59 135.48 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.508 ' C ' ' CD1' ' A' ' 100' ' ' PHE . 2.7 t80 -100.24 139.38 36.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 54.7 t -131.39 114.78 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.42 172.83 19.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 139' ' ' GLY . 1.6 m-20 58.71 37.73 25.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.359 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.508 HD12 ' C ' ' A' ' 140' ' ' TYR . 31.7 mt -71.88 101.08 2.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 104' ' ' LEU . 0.7 OUTLIER -36.64 155.23 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.663 0.744 . . . . 0.0 110.88 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -13.11 34.14 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -89.9 -16.72 29.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.894 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.483 HG21 HD22 ' A' ' 104' ' ' LEU . 10.7 mm -66.93 144.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 80.4 p -142.55 145.93 34.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.183 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 49.2 m -39.75 -37.49 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.101 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -68.27 -45.35 73.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.487 ' O ' ' N ' ' A' ' 116' ' ' ALA . 75.4 m-20 -64.32 -50.72 66.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CD1' ' A' ' 117' ' ' PHE . 13.1 mt -53.52 -45.4 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.475 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 13.3 mtpt -61.35 -35.64 77.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.2 t -91.54 -13.59 31.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.76 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.71 -17.59 21.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.058 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.578 ' CE1' ' SD ' ' A' ' 158' ' ' MET . 25.5 m-85 -108.34 -11.03 15.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.845 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.591 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.16 -44.79 99.06 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 0.0 111.106 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -48.06 -16.75 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.261 . . . . 0.0 112.341 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -94.31 -41.47 9.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 174.5 147.94 6.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -43.89 126.89 5.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 62.5 mt -91.63 134.33 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.9 p -100.29 -42.92 6.46 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -145.39 107.31 4.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.858 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HB1' HG22 ' A' ' 143' ' ' VAL . . . -137.34 135.46 37.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.077 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -157.6 165.99 34.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.514 HG13 ' O ' ' A' ' 128' ' ' VAL . 3.8 p -123.07 100.04 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.142 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 41.9 t -53.4 128.04 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.403 ' HG2' ' C ' ' A' ' 136' ' ' LYS . 49.6 mttt -121.26 171.31 8.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.82 159.29 31.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.85 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.424 ' N ' ' SD ' ' A' ' 132' ' ' MET . 0.3 OUTLIER -101.95 9.55 40.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -122.72 -44.01 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.5 p -98.92 -31.23 11.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.98 30.09 56.2 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.403 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 51.5 mmtt -114.06 155.14 26.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.1 t -50.67 110.9 0.46 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.852 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -53.32 -34.74 58.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.935 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 123.99 11.17 4.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.508 ' C ' HD12 ' A' ' 104' ' ' LEU . 48.8 p90 -154.97 159.24 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.892 0.377 . . . . 0.0 110.966 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -160.06 -167.95 21.35 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.476 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -141.37 152.39 44.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.38 . . . . 0.0 110.902 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.599 HG22 ' HB1' ' A' ' 126' ' ' ALA . 43.0 t -153.91 109.52 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.182 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 70.8 m -85.07 150.89 24.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -129.89 149.15 51.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.859 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -63.3 -43.55 97.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.927 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -120.06 157.96 27.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.532 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 57.3 tttt -65.51 -49.99 66.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.5 tp -47.65 -56.08 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -45.83 -39.46 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.407 ' HB1' ' CG2' ' A' ' 99' ' ' VAL . . . -67.8 -49.58 61.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.125 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.446 ' O ' HG23 ' A' ' 156' ' ' VAL . 23.6 mt-10 -51.47 -46.31 63.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.918 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -52.68 -47.9 66.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.875 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.27 -55.93 18.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.588 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 96.4 mt -50.0 -35.01 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 152' ' ' GLU . 74.3 t -78.98 -49.33 20.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.135 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.7 m-70 -72.67 -67.07 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.578 ' SD ' ' CE1' ' A' ' 117' ' ' PHE . 14.9 mmt -44.86 -47.28 11.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.53 101.22 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 84.5 -31.57 3.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.527 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.9 tp-100 -34.78 151.51 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.819 0.342 . . . . 0.0 110.91 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.58 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.9 m95 -97.02 90.63 5.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.92 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.76 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.5 tt -85.31 -70.08 0.61 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.1 117.94 3.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.506 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.78 -93.68 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 27.7 mtt85 -80.47 -179.73 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.733 0.302 . . . . 0.0 110.897 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.58 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 40.1 mt-30 -83.77 176.16 9.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.935 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.424 ' O ' ' N ' ' A' ' 160' ' ' GLY . 18.9 pt -131.81 167.79 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -130.91 149.23 52.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 20.1 p -126.54 162.09 26.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -173.0 156.9 3.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.913 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.588 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.0 m95 -87.07 119.19 27.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.139 179.884 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.0 m170 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.881 0.372 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.544 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 88.7 m-85 -89.43 154.35 20.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -111.77 135.77 51.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.421 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 60.7 t -126.65 121.07 57.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.156 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.405 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 87.6 t80 -86.14 139.34 31.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.903 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 169' ' ' ARG . 47.0 t -130.11 120.17 48.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.178 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -111.43 -175.36 20.09 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 46.34 43.64 11.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.871 0.367 . . . . 0.0 110.838 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.517 HD21 HG11 ' A' ' 101' ' ' VAL . 39.5 mt -85.0 110.1 18.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -39.67 153.44 0.19 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.686 0.755 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.408 ' HA ' ' HB2' ' A' ' 137' ' ' SER . 54.0 Cg_endo -69.75 -20.01 35.44 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 0.0 112.345 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -82.98 -20.62 34.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.876 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 46.8 mm -50.0 151.02 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.127 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 37.3 p -139.14 148.29 43.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.157 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.587 ' OG1' HG12 ' A' ' 128' ' ' VAL . 27.7 m -48.91 -38.11 21.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.153 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -71.89 -32.7 67.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.496 ' O ' ' N ' ' A' ' 116' ' ' ALA . 10.9 m-20 -65.21 -53.59 42.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 31.6 mt -56.25 -48.01 80.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.091 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.9 mttm -56.41 -39.32 72.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.913 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.4 t -92.37 -8.98 43.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.635 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -94.21 -13.9 26.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.121 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.581 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.6 m-85 -115.49 -11.6 11.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.595 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -49.82 -46.63 80.63 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.603 0.716 . . . . 0.0 111.157 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.595 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 63.8 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.695 2.263 . . . . 0.0 112.31 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.582 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 50.0 m-85 -92.42 -33.05 14.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.921 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.06 157.84 9.18 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.527 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 18.5 tptp -49.09 145.29 4.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.88 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 53.6 mt -115.21 143.42 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 51.4 p -108.26 -33.98 6.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.76 136.35 22.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -164.68 129.12 2.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.478 ' HA ' HG23 ' A' ' 110' ' ' THR . 9.0 ptp85 -150.42 154.23 37.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.723 HG13 ' HE2' ' A' ' 130' ' ' LYS . 7.4 p -113.12 100.08 9.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.423 HG11 ' OH ' ' A' ' 140' ' ' TYR . 47.1 t -51.74 114.26 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.723 ' HE2' HG13 ' A' ' 128' ' ' VAL . 32.3 mtmt -109.09 163.14 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 158.3 7.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.865 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 ttt -98.93 -8.52 25.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -108.06 -48.79 3.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.11 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.9 p -96.96 -24.45 15.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.089 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.92 19.97 78.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.468 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -95.99 143.29 27.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.47 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 37.3 m -47.61 106.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -50.15 -45.1 52.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 133.26 29.99 0.48 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.427 ' C ' HD12 ' A' ' 104' ' ' LEU . 41.3 p90 -171.98 144.68 1.74 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.956 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.446 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -145.96 -172.01 15.95 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.498 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -131.57 140.78 49.54 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.897 0.38 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.8 t -140.78 122.15 14.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.089 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 63.6 p -101.68 147.67 26.17 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.873 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.65 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 11.1 m-85 -125.36 148.68 48.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.833 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -64.5 -35.99 82.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.934 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -130.62 154.39 47.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.916 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.544 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 11.3 ttmt -60.1 -66.74 0.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.906 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 148' ' ' LYS . 14.9 tp -35.3 -59.49 0.52 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -47.47 -41.86 21.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.65 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -71.52 -54.07 11.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.5 ' HA ' HD12 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -47.82 -39.39 18.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.911 -179.948 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -52.3 -46.39 65.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.489 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.64 -53.21 44.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.5 HD12 ' HA ' ' A' ' 152' ' ' GLU . 81.9 mt -41.01 -35.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.123 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.4 t -89.23 -53.74 8.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -59.27 -62.45 1.88 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.838 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.582 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 83.7 mmm -64.04 -36.36 83.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.37 92.03 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.91 -28.58 12.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.7 tp-100 -38.61 155.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.882 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.575 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.1 m95 -95.64 90.91 5.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.959 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.635 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.9 tt -87.09 -69.83 0.66 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.888 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.72 116.97 3.44 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.94 -91.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.8 mtt180 -82.63 178.14 8.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.838 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.575 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 34.0 mt-30 -78.14 175.47 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.929 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.463 HD11 ' HB3' ' A' ' 158' ' ' MET . 32.9 pt -132.64 168.64 23.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.127 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.559 ' O ' HG13 ' A' ' 101' ' ' VAL . 65.2 ttt180 -126.39 160.87 29.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.899 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 31.7 p -146.8 147.58 31.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.134 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -160.77 164.05 31.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 11.7 m95 -79.14 83.37 5.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.951 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.123 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.1 m170 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.791 0.329 . . . . 0.0 110.846 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -96.96 128.97 44.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -87.71 119.6 28.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.412 HG13 HG12 ' A' ' 155' ' ' ILE . 65.6 t -109.79 119.75 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.13 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.425 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 3.2 t80 -84.14 145.4 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.469 HG13 ' O ' ' A' ' 169' ' ' ARG . 61.9 t -132.76 140.79 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -130.23 -169.37 12.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.501 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 44.9 36.71 2.0 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.831 0.348 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 40.9 mt -78.74 106.15 10.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.961 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -40.44 153.6 0.21 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.685 0.755 . . . . 0.0 110.844 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -28.31 25.51 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.733 2.289 . . . . 0.0 112.325 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -77.41 -7.4 56.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.862 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.568 HG22 ' N ' ' A' ' 109' ' ' THR . 9.5 mm -68.56 161.96 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.568 ' N ' HG22 ' A' ' 108' ' ' ILE . 56.4 p -142.96 172.1 13.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.474 ' OG1' HG12 ' A' ' 128' ' ' VAL . 15.5 m -69.0 -39.15 79.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -74.0 -17.95 60.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.93 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 17.9 m-20 -75.32 -54.54 6.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CE1' ' A' ' 117' ' ' PHE . 14.5 mt -53.62 -48.18 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.62 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 16.8 mtpp -54.57 -41.78 70.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -87.32 -15.88 36.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.881 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.604 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.28 -14.8 32.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.067 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.598 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 16.4 m-85 -114.65 -8.82 12.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.581 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.0 -46.28 98.69 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.594 0.712 . . . . 0.0 111.105 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.581 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.4 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.658 2.238 . . . . 0.0 112.388 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.572 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 56.6 m-85 -89.98 -32.87 16.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.81 171.14 26.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.492 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.576 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 0.0 OUTLIER -55.86 132.62 50.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.762 0.315 . . . . 0.0 110.872 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.409 HD13 ' HA ' ' A' ' 114' ' ' LYS . 96.5 mt -102.52 123.84 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.14 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 83.9 p -86.02 -49.69 7.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.841 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -143.84 117.6 9.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.852 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.62 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -141.75 134.31 28.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.473 ' HB3' ' CZ ' ' A' ' 127' ' ' ARG . 1.7 ptp180 -158.81 164.93 35.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.474 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.3 p -112.94 100.06 9.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.093 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -49.68 126.5 4.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.192 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -121.46 171.99 8.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -76.76 156.96 31.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.89 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 17.2 ttp -94.89 -11.79 28.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.92 -62.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 71.1 p -82.9 -30.69 28.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.98 28.45 60.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.5 mmtp -106.32 152.3 23.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.829 0.347 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 50.6 p -45.99 109.59 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.846 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -53.95 -36.3 62.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.97 12.81 4.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.503 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 30.8 p90 -162.64 146.73 11.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.907 0.384 . . . . 0.0 110.922 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -133.97 -169.59 12.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.479 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -136.99 141.87 42.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 41.4 t -145.04 108.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 13.3 t -88.48 150.98 22.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.49 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 57.6 m-85 -127.54 151.62 48.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.576 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 14.3 m-85 -69.38 -42.42 75.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -115.23 178.96 4.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.908 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.8 tttm -87.15 -41.59 13.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 14.4 tp -53.49 -65.06 0.63 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.459 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 12.4 p-10 -41.81 -53.97 3.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -53.95 -51.11 64.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.123 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -53.39 -44.81 68.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -50.25 -48.58 54.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.857 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.572 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -67.07 -60.56 2.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.101 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.586 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 97.4 mt -38.32 -41.26 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.3 t -79.66 -58.48 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 30.2 m-70 -57.81 -65.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.897 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.598 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 15.8 mmt -46.59 -45.84 19.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -40.16 91.77 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 99.77 -32.08 7.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.506 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.444 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.2 tp-100 -39.06 149.02 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.835 0.35 . . . . 0.0 110.92 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.563 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 78.9 m95 -95.31 91.65 6.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.632 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.1 tt -87.34 -71.71 0.55 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.497 ' HA3' HD11 ' A' ' 108' ' ' ILE . . . -119.89 119.26 4.18 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.476 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.39 -92.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.497 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -85.42 169.3 13.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.756 0.312 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.563 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 85.7 mt-30 -68.65 177.18 2.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 29.1 pt -135.8 169.87 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.469 ' O ' HG13 ' A' ' 101' ' ' VAL . 2.6 ptp180 -137.23 163.43 30.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.832 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 101' ' ' VAL . 42.8 p -140.18 163.51 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -162.86 157.77 21.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.586 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 82.6 m95 -88.69 96.96 10.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.925 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.847 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . 0.516 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 48.6 m170 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.566 ' CE1' ' HE3' ' A' ' 148' ' ' LYS . 85.2 m-85 -89.6 131.86 35.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -93.25 124.82 37.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.819 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 65.5 t -111.26 130.96 63.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.491 ' C ' ' CD1' ' A' ' 100' ' ' PHE . 1.9 t80 -98.9 140.74 32.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.534 HG13 ' O ' ' A' ' 169' ' ' ARG . 21.5 t -130.55 134.99 61.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.114 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.75 172.79 16.45 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.534 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.0 t0 58.63 40.3 23.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 110.877 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.477 HD13 HG23 ' A' ' 128' ' ' VAL . 35.6 mt -77.28 97.58 4.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.912 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.6 t -35.0 152.45 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.655 0.74 . . . . 0.0 110.882 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 -14.13 35.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.728 2.286 . . . . 0.0 112.37 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -93.42 1.68 56.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 9.4 mm -76.77 146.82 8.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.109 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 57.6 p -134.43 158.99 42.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 90.0 m -57.22 -33.69 67.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.142 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -75.93 -17.67 59.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' CB ' ' A' ' 116' ' ' ALA . 11.9 m-20 -81.78 -48.08 12.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.475 HG23 ' CE1' ' A' ' 117' ' ' PHE . 30.9 mt -64.39 -39.58 86.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.142 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.42 ' O ' HD12 ' A' ' 123' ' ' ILE . 57.8 mttt -63.83 -42.83 97.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 1.3 t -86.08 -16.47 37.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 112' ' ' ASP . . . -85.51 -29.63 24.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.508 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 9.0 m-85 -100.39 -8.3 23.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.58 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.71 -46.45 99.36 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.569 0.7 . . . . 0.0 111.108 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.58 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.2 Cg_exo -47.98 -17.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.642 2.228 . . . . 0.0 112.358 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.514 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 46.4 m-85 -91.56 -36.4 13.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.09 176.9 40.02 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.3 tttt -68.5 121.2 15.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.758 0.313 . . . . 0.0 110.92 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.42 HD12 ' O ' ' A' ' 114' ' ' LYS . 56.8 mt -91.89 127.77 43.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.128 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.6 t -92.45 -42.34 9.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.882 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -142.66 124.56 15.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.892 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -154.73 126.81 7.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.7 ptm180 -150.55 156.32 41.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.6 p -108.59 99.95 9.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.115 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.6 t -51.84 122.55 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.459 ' HG2' ' N ' ' A' ' 137' ' ' SER . 69.4 mttt -115.92 172.45 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.901 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -75.25 143.51 43.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.893 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 25.3 tpp -89.28 3.41 52.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -106.64 -62.94 1.33 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.119 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.7 p -91.94 -27.53 17.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.144 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.38 30.34 22.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 137' ' ' SER . 49.1 mtmt -112.03 135.71 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.76 0.314 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.459 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 67.4 m -37.24 119.31 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.803 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -60.75 -42.35 97.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.46 26.91 0.64 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.443 ' C ' HD12 ' A' ' 104' ' ' LEU . 16.4 p90 -169.82 144.77 2.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.944 0.402 . . . . 0.0 110.904 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -138.4 -177.99 15.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.486 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -134.2 139.7 45.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 53.5 t -141.85 127.9 18.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.5 m -104.92 144.45 31.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 150' ' ' ASP . 19.6 m-85 -124.1 145.1 49.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.855 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.516 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.7 m-85 -62.0 -46.95 86.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.966 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -118.45 165.8 13.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.566 ' HE3' ' CE1' ' A' ' 97' ' ' PHE . 10.9 ttmt -67.52 -56.19 10.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.945 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.7 tp -39.26 -53.9 1.87 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.403 ' HB3' ' CD1' ' A' ' 145' ' ' PHE . 65.0 m-20 -51.28 -39.44 56.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -70.24 -58.03 4.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -46.88 -47.48 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 28.1 m-20 -51.01 -47.38 61.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.482 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -69.08 -49.71 54.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.61 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 91.8 mt -48.54 -34.53 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.136 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 88.1 t -89.41 -55.8 5.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -57.01 -63.01 1.35 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.622 ' CE ' HD11 ' A' ' 168' ' ' ILE . 92.0 mmm -57.53 -40.03 77.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 92.25 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.529 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.48 -29.35 9.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.482 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.2 tp-100 -37.3 153.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.796 0.332 . . . . 0.0 110.888 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.566 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 90.7 m95 -96.82 91.02 5.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.965 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.481 HD12 ' HE1' ' A' ' 158' ' ' MET . 4.8 tt -85.47 -70.22 0.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.11 118.02 3.43 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.04 -93.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.52 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -82.25 174.31 11.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.842 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.566 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 84.5 mt-30 -76.16 178.23 6.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.622 HD11 ' CE ' ' A' ' 158' ' ' MET . 9.2 pt -139.91 166.99 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.534 ' O ' HG13 ' A' ' 101' ' ' VAL . 51.8 mtt180 -126.71 167.74 15.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 4.2 p -147.76 143.76 27.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.165 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -153.67 166.95 31.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.61 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 97.0 m95 -88.11 109.87 20.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.12 179.869 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.7 m170 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.838 0.351 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.569 ' CE1' ' HD3' ' A' ' 148' ' ' LYS . 90.5 m-85 -93.45 157.64 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.904 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -112.66 129.12 56.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.455 HG22 HD11 ' A' ' 155' ' ' ILE . 49.5 t -119.88 117.63 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.46 132.52 34.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.73 HG22 HG22 ' A' ' 170' ' ' THR . 91.1 t -124.11 120.49 59.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -110.46 177.78 19.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 53.83 46.35 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 110.913 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.496 HD12 ' N ' ' A' ' 141' ' ' GLY . 28.1 mt -90.85 113.81 26.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -45.53 152.73 0.65 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.715 0.769 . . . . 0.0 110.847 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -33.96 15.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.658 2.239 . . . . 0.0 112.317 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -66.41 -22.95 66.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.902 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.401 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 22.6 mm -55.41 150.31 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.157 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 44.3 p -130.74 164.01 26.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.185 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.703 HG23 ' HA ' ' A' ' 127' ' ' ARG . 90.6 m -64.63 -32.64 74.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.11 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -79.95 -11.84 59.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -83.53 -50.53 8.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.881 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.603 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.6 mt -57.84 -39.57 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.157 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 58.7 mttt -60.43 -35.77 76.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.4 t -92.48 -16.18 26.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.845 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.718 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -89.34 -16.27 31.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.085 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.603 ' CE1' HG23 ' A' ' 113' ' ' ILE . 21.1 m-85 -112.19 -9.5 13.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.64 -46.09 99.38 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.548 0.689 . . . . 0.0 111.102 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.1 Cg_exo -48.01 -17.08 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.71 2.273 . . . . 0.0 112.335 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.633 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 49.3 m-85 -91.27 -31.95 15.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 159.67 172.49 26.92 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.9 tttt -58.37 140.07 54.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 110.912 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.46 HG21 ' HB2' ' A' ' 126' ' ' ALA . 89.6 mt -109.92 131.02 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 79.3 p -96.57 -26.0 15.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -159.81 125.04 4.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.46 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -150.16 124.4 9.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.703 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.0 OUTLIER -151.32 155.56 38.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.591 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.0 p -108.22 100.06 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.123 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.4 t -49.03 122.67 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.168 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 38.4 mttt -119.1 168.9 10.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -73.34 145.69 45.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 tpt -87.41 15.72 6.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -130.19 -55.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.134 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 7.5 p -85.93 -28.47 24.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.122 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.03 22.69 70.81 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.3 mmpt? -106.59 150.11 26.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 44.6 m -54.2 109.27 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.865 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -49.35 -35.29 18.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.45 15.25 2.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -160.91 144.34 13.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.934 0.397 . . . . 0.0 110.92 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.496 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -136.13 -176.0 14.12 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -129.29 136.44 50.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.16 119.07 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.133 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 11.4 m -99.18 145.3 27.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -124.51 148.99 47.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -65.1 -46.33 81.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -119.77 150.56 40.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.569 ' HD3' ' CE1' ' A' ' 97' ' ' PHE . 20.8 tptt -55.88 -56.66 17.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' LYS . 28.8 tp -37.36 -49.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.944 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 1.0 OUTLIER -57.26 -42.09 80.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.809 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.458 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -64.85 -47.02 79.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -58.15 -46.43 85.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -48.78 -46.85 42.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.916 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.633 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -70.72 -60.44 2.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.586 HD13 ' CE2' ' A' ' 172' ' ' TRP . 66.6 mt -39.03 -36.78 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.116 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 69.2 t -78.7 -60.76 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -62.88 -66.13 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.851 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.581 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 29.4 mmt -37.8 -50.63 1.25 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.926 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.14 102.43 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.525 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 88.58 -30.66 5.21 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 51.0 tp60 -35.27 152.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.759 0.314 . . . . 0.0 110.923 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.567 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 84.8 m95 -100.76 91.42 4.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.937 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.718 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.4 tt -87.42 -70.36 0.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.401 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.22 118.72 3.97 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.532 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.29 -92.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.442 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.6 mtt180 -80.4 178.07 8.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.567 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 22.4 mt-30 -79.24 -178.79 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 23.2 pt -138.33 171.17 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 101' ' ' VAL . 12.5 ttm180 -136.45 141.95 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.73 HG22 HG22 ' A' ' 101' ' ' VAL . 24.0 p -127.11 148.69 50.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.129 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -159.94 166.41 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.586 ' CE2' HD13 ' A' ' 155' ' ' ILE . 85.8 m95 -82.7 107.01 15.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 179.87 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . 0.508 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 60.0 m170 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.846 0.355 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.533 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 25.4 m-85 -107.19 133.33 51.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -87.88 129.02 35.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.877 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.0 t -120.39 122.83 69.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.551 ' C ' ' CD1' ' A' ' 100' ' ' PHE . 0.6 OUTLIER -86.46 145.47 26.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.577 ' CG1' HD21 ' A' ' 104' ' ' LEU . 98.7 t -137.53 110.74 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -102.05 -172.77 27.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.503 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 45.78 46.34 11.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.577 HD21 ' CG1' ' A' ' 101' ' ' VAL . 65.7 mt -87.69 109.49 19.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.4 t -43.12 153.23 0.35 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.627 0.727 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -18.23 36.92 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.662 2.241 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -87.4 -4.41 59.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.434 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 24.5 mm -69.19 147.82 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 70.3 p -136.49 144.6 44.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.157 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.428 ' OG1' HG12 ' A' ' 128' ' ' VAL . 89.6 m -46.77 -35.71 6.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -72.29 -31.57 65.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -69.49 -49.18 57.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.45 HG23 ' CE1' ' A' ' 117' ' ' PHE . 17.6 mt -58.44 -47.25 88.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.134 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.492 ' CG ' ' HB3' ' A' ' 126' ' ' ALA . 27.8 mtpt -60.09 -35.2 74.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.942 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 30.0 t -90.74 -8.67 49.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.64 -24.91 14.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.068 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.9 m-85 -100.59 -8.68 22.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.578 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.07 -46.19 98.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.729 . . . . 0.0 111.107 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -48.0 -17.16 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.658 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 52.2 m-85 -90.99 -38.31 12.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.39 179.28 41.74 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.455 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.469 ' HG2' ' CZ ' ' A' ' 146' ' ' TYR . 20.9 tptt -66.1 133.26 50.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.727 0.299 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.4 HD13 ' HA ' ' A' ' 114' ' ' LYS . 67.9 mt -106.4 128.42 60.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.6 t -100.57 -27.82 13.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -148.43 138.76 22.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.824 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.492 ' HB3' ' CG ' ' A' ' 114' ' ' LYS . . . -168.08 123.4 0.99 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 14.6 ptp180 -148.07 156.6 42.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.873 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.5 p -116.39 100.61 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.101 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.713 HG11 ' OH ' ' A' ' 140' ' ' TYR . 23.0 t -53.25 119.44 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.069 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.471 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.6 mttm -119.62 157.8 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -64.07 153.95 35.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.884 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 48.2 tpp -95.52 -13.32 24.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.85 -56.39 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -87.83 -34.91 18.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.165 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.56 29.98 31.22 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 14.5 mmtp -112.18 147.68 35.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.882 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.471 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 39.1 t -49.09 104.8 0.07 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 58.0 mttt -44.75 -36.13 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.904 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.21 27.67 1.32 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.713 ' OH ' HG11 ' A' ' 129' ' ' VAL . 49.2 p90 -167.37 151.64 6.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.935 0.398 . . . . 0.0 110.904 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -150.13 -177.81 24.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -133.9 141.22 47.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.882 0.372 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 90.4 t -143.64 116.57 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 67.6 m -94.04 139.11 31.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.47 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 12.2 m-85 -117.65 138.44 51.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.508 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 6.5 m-85 -51.79 -45.52 63.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.7 168.9 11.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.91 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.533 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 53.0 tttt -74.58 -59.26 2.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.1 tp -39.69 -49.02 2.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -58.97 -40.24 84.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.47 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -67.99 -43.93 77.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -56.66 -44.73 81.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -52.26 -46.47 65.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.658 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.97 -51.89 34.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.685 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 96.9 mt -46.0 -37.27 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.4 t -86.58 -54.94 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -57.31 -60.74 3.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.588 ' HE1' HD12 ' A' ' 163' ' ' LEU . 94.2 mmm -60.5 -38.93 85.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.13 94.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.0 -31.59 5.86 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.518 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.4 tp-100 -35.21 152.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.807 0.337 . . . . 0.0 110.888 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.569 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -93.99 91.01 6.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.588 HD12 ' HE1' ' A' ' 158' ' ' MET . 4.9 tt -87.57 -70.26 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -118.5 116.62 3.45 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.55 -91.11 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -83.84 174.19 10.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.793 0.33 . . . . 0.0 110.819 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.569 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 58.9 mt-30 -75.51 170.69 15.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.963 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.587 HD11 ' HE3' ' A' ' 158' ' ' MET . 15.7 pt -129.03 167.27 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.118 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 8.6 mmt85 -121.59 165.4 15.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.868 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 2.6 p -149.77 128.28 12.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.166 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -144.47 157.78 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.685 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 79.0 m95 -81.01 107.24 13.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.914 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.416 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.114 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 21.9 m170 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.451 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 94.8 m-85 -103.34 136.88 42.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 60.0 m-70 -96.07 127.0 41.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.416 HG21 ' HB1' ' A' ' 151' ' ' ALA . 25.2 t -117.19 131.95 68.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' OD1' ' A' ' 171' ' ' ASN . 2.2 t80 -97.64 138.78 34.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.516 HG22 HG22 ' A' ' 170' ' ' THR . 88.4 t -125.05 115.42 44.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.152 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.03 -178.72 30.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 45.78 47.02 12.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.831 0.348 . . . . 0.0 110.903 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.562 HD12 ' C ' ' A' ' 140' ' ' TYR . 32.7 mt -78.88 100.49 7.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -40.81 155.2 0.2 Allowed Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.634 0.73 . . . . 0.0 110.882 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -19.01 36.51 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.698 2.265 . . . . 0.0 112.292 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -82.02 -22.44 36.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.848 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.633 HD12 HD22 ' A' ' 163' ' ' LEU . 6.8 mm -60.91 137.97 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.111 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.437 ' O ' ' N ' ' A' ' 111' ' ' GLU . 52.8 p -133.0 140.5 47.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.44 ' OG1' HG12 ' A' ' 128' ' ' VAL . 91.2 m -36.74 -32.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.159 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 109' ' ' THR . 15.0 tt0 -73.74 -48.96 27.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.466 ' O ' ' N ' ' A' ' 116' ' ' ALA . 77.1 m-20 -58.6 -51.33 70.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.2 mt -50.76 -38.8 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.112 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.493 ' O ' HD12 ' A' ' 123' ' ' ILE . 22.3 mttp -67.18 -35.34 79.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 22.9 t -92.95 -11.1 34.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.835 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.922 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.85 -32.89 15.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.083 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.56 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.7 m-85 -95.85 -5.02 42.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.582 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -57.67 -46.64 99.74 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.603 0.715 . . . . 0.0 111.087 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.582 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.696 2.264 . . . . 0.0 112.32 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.689 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 36.0 m-85 -93.2 -30.67 15.09 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.848 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.18 179.93 36.23 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.515 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.548 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 41.1 tptt -63.82 140.24 58.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.761 0.315 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.493 HD12 ' O ' ' A' ' 114' ' ' LYS . 97.7 mt -108.34 130.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.9 p -98.31 -50.76 4.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.863 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -136.44 118.83 15.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -142.11 124.82 15.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.091 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -148.09 156.15 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.44 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.1 p -113.13 100.11 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.126 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.794 HG11 ' CE1' ' A' ' 140' ' ' TYR . 46.1 t -49.12 127.52 4.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -130.53 151.87 50.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.82 155.88 5.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 5.2 ptp -97.62 -17.79 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.857 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.75 -57.54 2.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.147 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.7 p -81.51 -32.78 32.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.123 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.43 28.38 61.77 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.474 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -101.88 162.62 12.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.804 0.335 . . . . 0.0 110.877 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 77.7 p -58.86 98.45 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.849 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.516 ' HB3' ' CE2' ' A' ' 140' ' ' TYR . 20.5 mmtt -42.95 -42.98 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.87 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.41 19.18 4.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.794 ' CE1' HG11 ' A' ' 129' ' ' VAL . 47.7 p90 -163.37 153.45 15.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.892 0.377 . . . . 0.0 110.951 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -151.22 -172.01 19.78 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -135.54 140.16 44.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.875 0.369 . . . . 0.0 110.875 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 28.6 t -145.52 107.64 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 3.5 t -89.19 154.06 20.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.531 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 13.6 m-85 -129.46 150.34 50.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.865 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.548 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 16.0 m-85 -66.37 -33.52 75.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.895 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -129.52 165.44 21.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.451 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . 22.9 tttm -69.35 -61.97 1.57 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.7 tp -39.4 -63.19 0.58 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -40.77 -45.31 2.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -69.76 -60.75 2.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -40.41 -47.06 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 17.7 m-80 -47.66 -56.97 6.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.689 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -56.72 -53.72 54.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.474 HD13 ' CE2' ' A' ' 172' ' ' TRP . 47.7 mt -41.86 -35.39 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.8 t -84.5 -56.64 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 66.3 m-70 -62.09 -64.67 0.86 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.579 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 11.9 mmt -44.86 -47.01 11.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.56 102.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.74 -28.67 3.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.484 ' N ' ' O ' ' A' ' 158' ' ' MET . 62.7 tp60 -35.8 152.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.79 0.328 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.589 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 85.2 m95 -99.16 91.02 4.79 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.922 HD11 ' CB ' ' A' ' 116' ' ' ALA . 6.6 tt -86.77 -70.45 0.61 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.902 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.18 118.43 3.78 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.461 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.65 -92.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.488 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 14.7 mtt-85 -79.41 -178.38 6.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.759 0.314 . . . . 0.0 110.87 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.589 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 30.1 mt-30 -84.14 179.82 7.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.419 ' O ' ' N ' ' A' ' 160' ' ' GLY . 19.7 pt -136.87 171.95 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.486 ' O ' HG13 ' A' ' 101' ' ' VAL . 41.3 ttt180 -134.64 160.5 37.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.858 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.516 HG22 HG22 ' A' ' 101' ' ' VAL . 17.1 p -145.12 152.54 40.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . 0.576 ' OD1' ' CD1' ' A' ' 100' ' ' PHE . 3.0 p30 -172.96 149.9 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.474 ' CE2' HD13 ' A' ' 155' ' ' ILE . 99.2 m95 -68.98 133.14 47.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.089 179.871 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 56.7 m170 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.856 0.36 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.431 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 66.9 m-85 -96.68 140.95 30.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.888 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -100.57 131.89 46.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.401 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 58.5 t -122.27 124.48 71.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -91.2 140.02 30.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.482 HG11 HD21 ' A' ' 104' ' ' LEU . 77.7 t -127.6 126.78 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -121.93 -178.45 15.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.475 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 50.87 39.63 22.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.83 0.348 . . . . 0.0 110.852 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.482 HD21 HG11 ' A' ' 101' ' ' VAL . 44.0 mt -84.21 126.03 32.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 t -50.51 152.15 3.48 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.678 0.751 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 -14.18 35.83 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -91.8 -6.73 51.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.29 153.1 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 40.5 p -139.09 -179.96 6.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.8 m -69.92 -40.42 75.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.094 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -70.65 -36.74 73.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 116' ' ' ALA . 5.0 m-20 -58.09 -52.31 66.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.509 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.5 mt -60.69 -42.41 91.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.412 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 14.2 mtpt -59.69 -36.6 76.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.883 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.5 t -94.03 -17.4 22.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.549 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -84.62 -18.31 35.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.564 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.3 m-85 -111.63 -5.49 14.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.569 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.1 -46.2 99.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.559 0.695 . . . . 0.0 111.09 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.569 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.02 -19.57 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.578 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 45.0 m-85 -87.96 -36.93 16.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.96 -161.95 34.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.496 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.9 tmtt? -87.17 124.64 33.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.883 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.401 HD12 ' O ' ' A' ' 114' ' ' LYS . 46.6 mt -96.54 134.28 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.107 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.6 p -100.13 -45.88 5.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -134.41 122.02 21.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.837 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -151.16 122.61 7.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.414 ' NE ' ' HB2' ' A' ' 142' ' ' PHE . 0.0 OUTLIER -146.62 159.49 43.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -114.15 99.95 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.143 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 23.5 t -51.73 134.14 13.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.11 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.46 ' HG2' ' N ' ' A' ' 137' ' ' SER . 35.5 mttt -124.98 168.15 13.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -75.73 152.11 37.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 mpp? -97.49 16.71 19.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -123.67 -38.26 2.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 13.7 p -111.25 -24.15 10.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 78.33 20.61 71.84 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 20.0 mmtp -106.63 154.19 21.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.761 0.315 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.46 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 28.3 m -51.18 120.11 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.852 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -60.18 -36.77 78.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.52 13.9 2.47 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.497 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -158.74 145.59 17.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 0.0 110.905 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -137.7 -175.85 14.11 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.414 ' HB2' ' NE ' ' A' ' 127' ' ' ARG . 41.6 m-85 -133.4 143.24 48.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.949 0.404 . . . . 0.0 110.888 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.0 t -145.51 127.38 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 32.2 t -105.13 151.15 24.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.498 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 73.6 m-85 -129.32 138.99 51.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -50.43 -42.47 53.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.941 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -127.27 164.55 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.914 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.475 ' O ' ' N ' ' A' ' 151' ' ' ALA . 13.7 ttmt -62.41 -62.37 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 148' ' ' LYS . 58.5 tp -34.58 -58.29 0.5 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.963 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -48.5 -42.47 33.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.498 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -70.69 -50.44 36.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.088 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -53.75 -46.12 70.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -45.99 -47.84 16.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.496 ' HB1' ' HG3' ' A' ' 158' ' ' MET . . . -66.08 -63.18 1.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 154' ' ' ALA . 45.6 mt -34.76 -46.53 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.77 -61.19 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.164 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -65.8 -64.66 0.81 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.835 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.578 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 18.5 mmt -42.11 -48.6 4.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.41 100.71 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.508 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.21 -28.12 5.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.486 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.0 tp-100 -37.14 154.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.758 0.313 . . . . 0.0 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.577 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.4 m95 -98.7 90.99 4.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.587 HD23 ' C ' ' A' ' 163' ' ' LEU . 2.6 tt -85.06 -71.32 0.53 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -122.24 118.25 3.6 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.456 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.93 -93.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.503 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.2 mtt85 -79.5 178.45 8.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.745 0.307 . . . . 0.0 110.862 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 86.2 mt-30 -79.96 178.85 7.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.431 HG22 HD23 ' A' ' 104' ' ' LEU . 32.1 pt -137.64 170.33 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.143 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 27.6 ttm-85 -133.68 154.98 50.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.441 HG22 HG22 ' A' ' 101' ' ' VAL . 5.7 p -138.87 147.27 42.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -157.63 151.86 24.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 76.9 m95 -72.44 130.1 39.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.077 179.904 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . 0.449 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 27.3 m170 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.836 0.351 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.522 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 5.3 m-85 -99.81 133.91 43.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.846 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -95.35 135.67 36.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.448 HG22 HD11 ' A' ' 155' ' ' ILE . 78.8 t -121.43 121.22 64.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -85.02 145.9 27.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.59 HG13 ' O ' ' A' ' 169' ' ' ARG . 17.7 t -135.45 128.1 47.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.15 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -118.08 -179.05 17.25 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.512 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 48.38 46.86 20.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.878 0.37 . . . . 0.0 110.845 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.617 HD23 HG22 ' A' ' 168' ' ' ILE . 34.0 mt -88.13 105.35 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.936 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -36.09 153.39 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.654 0.74 . . . . 0.0 110.893 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -23.66 30.73 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.737 2.291 . . . . 0.0 112.327 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -79.3 -10.96 59.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.438 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 17.3 mm -65.69 143.8 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.472 ' HG1' ' CG ' ' A' ' 112' ' ' ASP . 65.2 p -126.14 164.32 21.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.468 ' OG1' HG12 ' A' ' 128' ' ' VAL . 66.8 m -63.72 -29.69 70.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.097 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -79.97 -34.2 38.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.472 ' CG ' ' HG1' ' A' ' 109' ' ' THR . 98.1 m-20 -60.34 -55.53 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.468 HG23 ' CE1' ' A' ' 117' ' ' PHE . 11.7 mt -52.69 -40.12 33.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.474 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 62.7 mttt -64.34 -35.18 80.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.5 t -94.07 -9.71 35.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.79 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.14 -23.06 17.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.595 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 28.6 m-85 -105.92 -6.8 18.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.575 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -58.26 -45.98 99.68 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.559 0.695 . . . . 0.0 111.133 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.575 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.96 -17.1 0.7 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.653 2.235 . . . . 0.0 112.352 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.584 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 46.2 m-85 -90.66 -41.44 11.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.87 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 175.68 -174.16 46.69 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.7 tptm -71.46 138.43 49.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.751 0.31 . . . . 0.0 110.923 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 97.1 mt -104.01 139.34 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 5.8 t -116.49 -37.64 3.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -142.57 105.4 4.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -138.75 121.56 16.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.476 ' HB3' ' CZ ' ' A' ' 127' ' ' ARG . 2.4 ptp180 -153.11 154.71 35.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.88 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.614 HG13 ' HE2' ' A' ' 130' ' ' LYS . 2.4 p -107.72 100.05 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.148 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -50.04 133.87 9.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.614 ' HE2' HG13 ' A' ' 128' ' ' VAL . 20.5 mtmt -129.52 162.53 27.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.924 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -64.4 159.45 21.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 9.7 ttp -107.55 3.48 24.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -103.74 -45.67 4.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.121 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.3 p -110.52 -38.8 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.156 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 94.8 40.9 4.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.3 mttm -116.11 143.67 45.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.455 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 17.1 p -45.92 109.25 0.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 59.7 mttt -54.41 -35.67 63.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.99 19.35 4.02 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -161.2 146.69 14.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.909 0.385 . . . . 0.0 110.929 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.97 177.83 21.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -123.85 140.12 53.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.9 t -139.31 117.03 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.139 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 49.8 m -102.15 147.6 26.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -123.49 145.13 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.449 ' HA ' ' CE1' ' A' ' 96' ' ' HIS . 19.2 m-85 -58.24 -36.65 73.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.952 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -121.34 174.26 6.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.869 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.522 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 44.6 tttt -85.01 -52.35 6.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.859 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.7 tp -47.68 -53.6 14.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.955 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -49.19 -44.36 43.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -62.53 -52.3 64.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -49.49 -43.11 45.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.903 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -48.24 -51.79 24.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.562 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.49 -65.89 0.62 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.057 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.448 HD11 HG22 ' A' ' 99' ' ' VAL . 80.9 mt -34.59 -34.79 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.124 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 154' ' ' ALA . 20.1 t -74.02 -63.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.163 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -69.44 -59.2 3.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.595 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 20.1 mmt -40.39 -51.11 2.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.15 102.33 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.491 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 87.94 -31.3 4.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.465 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.483 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.9 tp60 -34.27 150.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.573 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.3 m95 -96.96 91.03 5.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.937 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.79 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.9 tt -87.47 -70.56 0.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.907 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.52 117.35 3.67 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.475 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -91.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.457 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 15.0 mtp180 -79.55 -174.81 4.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.766 0.317 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.573 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 63.9 mt-30 -86.09 179.43 6.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.617 HG22 HD23 ' A' ' 104' ' ' LEU . 9.3 pt -136.84 169.31 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.59 ' O ' HG13 ' A' ' 101' ' ' VAL . 30.2 ttp180 -129.25 162.87 26.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 32.6 p -141.38 150.5 42.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.091 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -163.02 164.32 25.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 94.2 m95 -93.65 107.95 19.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.064 179.889 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 36.1 m170 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.817 0.342 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.538 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 74.5 m-85 -100.0 161.38 13.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.6 m-70 -114.22 134.35 54.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -124.58 118.25 52.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.137 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.612 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 16.5 t80 -88.47 129.73 35.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.18 111.99 36.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.113 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.83 -179.09 29.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 48.0 54.84 9.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.451 HD12 ' C ' ' A' ' 140' ' ' TYR . 33.8 mt -92.31 106.58 18.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.5 t -35.51 152.33 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.707 0.765 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -18.77 36.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.5 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 9.3 tt0 -90.08 1.13 56.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.938 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 17.4 mm -74.72 147.38 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.128 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 51.3 p -132.04 163.58 28.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.086 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 25.5 m -58.71 -41.06 85.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.91 -35.4 76.8 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 116' ' ' ALA . 64.0 m-20 -60.17 -54.59 44.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.851 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mt -57.99 -45.82 87.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.118 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.825 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 13.2 mtpp -57.44 -39.01 75.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.865 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 32.7 t -92.35 -9.15 42.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.839 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.533 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.64 -9.6 31.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.104 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.54 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.0 m-85 -120.26 -8.75 9.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.915 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.582 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.1 -45.97 98.9 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.639 0.733 . . . . 0.0 111.093 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.8 Cg_exo -47.98 -22.76 3.71 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.708 2.272 . . . . 0.0 112.321 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.685 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 39.7 m-85 -85.66 -35.62 20.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.863 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.59 174.7 34.63 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.453 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.646 ' CG ' ' CE1' ' A' ' 146' ' ' TYR . 0.8 OUTLIER -59.46 140.36 56.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.768 0.318 . . . . 0.0 110.877 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.763 HG21 ' HB2' ' A' ' 126' ' ' ALA . 82.7 mt -111.91 105.37 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 52.2 p -67.69 -32.15 72.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -159.67 123.93 3.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.825 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -146.51 125.45 12.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.097 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.2 ptm180 -149.12 166.76 27.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.568 HG13 ' O ' ' A' ' 128' ' ' VAL . 6.3 p -120.36 99.85 8.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.173 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.3 t -51.18 119.77 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.431 ' CA ' ' HG3' ' A' ' 138' ' ' LYS . 29.0 mtmt -114.81 152.38 32.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -56.72 155.45 7.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.07 -6.79 31.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -102.82 -61.64 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.14 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.9 p -81.67 -34.57 30.65 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.12 33.46 26.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -117.68 152.12 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.8 m -43.34 108.95 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.431 ' HG3' ' CA ' ' A' ' 130' ' ' LYS . 6.4 mtpm? -51.41 -38.19 52.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 125.35 12.94 3.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.462 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.451 ' C ' HD12 ' A' ' 104' ' ' LEU . 32.5 p90 -161.8 154.18 19.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.921 0.391 . . . . 0.0 110.919 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.06 -175.42 19.95 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.492 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -131.27 140.28 49.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.891 0.377 . . . . 0.0 110.858 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.8 t -144.86 109.58 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.12 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 73.7 m -86.71 141.92 28.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.594 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 17.8 m-85 -120.61 140.43 51.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.646 ' CE1' ' CG ' ' A' ' 122' ' ' LYS . 4.4 m-85 -54.48 -50.38 67.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.933 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -115.59 171.02 8.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.538 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 59.0 tttt -80.28 -38.44 30.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.893 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.6 tp -57.35 -51.93 67.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.94 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -56.78 -41.47 77.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.896 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.594 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -66.3 -49.11 68.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.092 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -51.0 -43.91 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 62.9 m-20 -49.56 -48.93 48.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.685 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -66.09 -54.88 20.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.5 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 97.5 mt -47.55 -35.29 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 77.5 t -82.24 -49.03 17.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.0 m-70 -71.51 -65.46 0.75 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.54 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 8.2 mmt -45.21 -46.52 12.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.48 103.6 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.458 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.41 -29.61 3.94 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.491 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.9 tp60 -40.98 149.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.926 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.439 ' CE2' ' HG2' ' A' ' 167' ' ' GLN . 84.0 m95 -93.87 92.33 7.36 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.622 HD23 ' C ' ' A' ' 163' ' ' LEU . 5.5 tt -87.03 -72.34 0.52 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.487 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -120.33 117.11 3.43 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 56.09 -93.05 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.5 mpt_? -83.52 175.99 9.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.749 0.309 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.439 ' HG2' ' CE2' ' A' ' 162' ' ' TRP . 32.7 mt-30 -74.61 177.33 6.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.917 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 22.0 pt -136.23 165.09 30.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -129.56 152.33 49.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 29.8 p -130.07 160.46 33.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.166 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -169.81 163.35 9.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.5 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 85.5 m95 -90.87 100.23 13.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.612 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.084 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 28.1 m170 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.847 0.356 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.533 ' CD1' ' HD3' ' A' ' 148' ' ' LYS . 90.6 m-85 -102.44 145.09 30.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -100.27 138.68 37.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.846 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 25.2 t -124.23 130.23 73.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.184 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -91.77 138.09 31.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.7 118.31 46.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.62 172.05 17.95 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.513 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 54.53 53.37 10.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.41 HD23 ' HA ' ' A' ' 104' ' ' LEU . 26.1 mt -87.93 104.48 16.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -38.03 153.57 0.13 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.702 0.763 . . . . 0.0 110.877 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -20.48 34.86 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.736 2.29 . . . . 0.0 112.31 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -83.21 -17.9 41.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.475 HG22 ' N ' ' A' ' 109' ' ' THR . 37.1 mm -57.61 156.95 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.123 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.475 ' N ' HG22 ' A' ' 108' ' ' ILE . 40.5 p -143.87 170.61 15.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.437 ' OG1' HG12 ' A' ' 128' ' ' VAL . 56.9 m -66.13 -33.87 76.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -78.24 -35.21 48.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 67.1 m-20 -59.1 -55.89 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.841 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.457 HG23 ' CE1' ' A' ' 117' ' ' PHE . 7.8 mt -55.6 -42.68 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.11 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 17.7 mttp -61.64 -36.34 80.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.922 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.1 t -93.4 -10.41 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.848 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.512 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -94.02 -18.77 21.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.575 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 7.1 m-85 -111.57 -5.78 14.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.586 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.41 -45.71 99.89 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.593 0.711 . . . . 0.0 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.7 Cg_exo -48.04 -25.23 6.24 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.659 2.239 . . . . 0.0 112.382 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.557 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 54.0 m-85 -78.83 -38.84 37.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 168.02 179.13 40.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 35.2 tptt -59.41 142.21 52.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.77 0.319 . . . . 0.0 110.942 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.7 mt -114.33 137.1 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 6.3 p -112.35 -23.6 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -154.02 143.31 21.41 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -174.77 123.62 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.06 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -148.2 159.35 44.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.441 HG13 ' O ' ' A' ' 128' ' ' VAL . 2.6 p -112.55 99.9 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.165 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.514 HG11 ' CZ ' ' A' ' 140' ' ' TYR . 80.5 t -51.32 126.59 6.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.485 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.2 mttm -125.84 159.94 31.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -62.52 159.51 15.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.873 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 ptp -102.38 -14.78 16.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.39 -38.02 8.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.076 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.6 p -105.78 -29.42 10.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.05 36.85 45.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.478 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mmtm -119.86 151.3 39.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.816 0.341 . . . . 0.0 110.893 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.485 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 56.2 p -45.97 113.26 0.59 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.873 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -59.57 -36.73 76.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.37 14.25 2.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.43 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.514 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 34.1 p90 -160.83 149.89 16.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.867 0.365 . . . . 0.0 110.937 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.28 -177.54 18.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -127.33 140.72 52.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 25.3 t -140.7 118.94 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.4 p -98.58 149.76 22.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -129.0 150.66 50.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -65.59 -40.73 93.03 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.88 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -125.24 162.81 23.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.541 ' HE3' ' CZ3' ' A' ' 172' ' ' TRP . 15.0 tptm -67.42 -58.5 4.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.9 tp -39.11 -51.03 1.9 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.924 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -51.92 -41.92 62.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -65.18 -53.31 46.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.062 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -49.46 -41.09 39.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -57.3 -52.68 64.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.53 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.76 -51.11 69.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.657 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 95.0 mt -43.96 -51.69 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 63.9 t -72.62 -59.76 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -50.92 -64.7 0.73 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.575 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 92.7 mmm -57.77 -39.24 77.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.97 94.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.46 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 91.87 -29.46 7.42 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.504 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.1 tp60 -36.3 152.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.761 0.315 . . . . 0.0 110.952 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.573 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.0 m95 -96.71 91.68 5.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.937 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.512 HD11 ' CB ' ' A' ' 116' ' ' ALA . 2.0 tt -88.64 -69.84 0.68 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.936 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -117.68 116.98 3.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 50.95 -90.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 164' ' ' GLY . 40.9 mtt180 -80.3 179.98 7.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.827 0.346 . . . . 0.0 110.836 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.573 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 45.7 mt-30 -81.77 179.84 7.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.565 HD11 ' CE ' ' A' ' 158' ' ' MET . 15.3 pt -139.14 163.52 26.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.117 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 46.9 ttt-85 -129.71 156.53 44.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.6 p -129.83 162.46 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -168.55 163.69 12.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.864 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.657 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.5 m95 -94.16 114.25 26.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.109 179.898 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 48.3 m170 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.858 0.361 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 93.8 m-85 -90.65 135.37 33.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 82.4 m-70 -94.13 124.37 38.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 63.7 t -112.67 116.17 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.127 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.54 ' C ' ' CD1' ' A' ' 100' ' ' PHE . 1.4 t80 -84.28 136.74 33.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.9 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 169' ' ' ARG . 38.6 t -127.16 115.54 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.113 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.73 -174.48 25.8 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 46.29 50.74 11.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.903 0.382 . . . . 0.0 110.912 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.5 mt -91.28 110.61 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -42.41 153.68 0.3 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.696 0.76 . . . . 0.0 110.863 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -20.0 35.4 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.719 2.279 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -84.08 -14.02 51.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 20.4 mm -60.58 150.36 6.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.147 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.6 p -142.91 154.86 44.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.16 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 18.2 m -48.05 -42.18 27.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -65.47 -43.18 91.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.49 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.9 m-20 -59.22 -52.96 63.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.462 HG23 ' CE1' ' A' ' 117' ' ' PHE . 30.6 mt -60.96 -43.0 95.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.463 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 30.0 mttm -62.35 -36.17 81.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 38.6 t -94.01 -13.27 27.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.531 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -91.93 -13.21 31.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.503 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.1 m-85 -113.0 -9.8 13.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.03 -45.5 99.53 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.586 0.707 . . . . 0.0 111.06 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.97 -17.08 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.656 2.237 . . . . 0.0 112.341 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.484 ' CE2' ' HA ' ' A' ' 117' ' ' PHE . 38.9 m-85 -91.9 -40.36 11.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.14 174.56 44.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -67.54 120.9 14.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.812 0.339 . . . . 0.0 110.883 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 93.3 mt -85.77 140.08 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.118 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.5 p -110.58 -30.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -156.31 123.93 5.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.463 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -150.07 132.38 15.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.105 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 19.9 ptt180 -152.06 147.43 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -108.46 99.94 9.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.653 HG12 ' CG ' ' A' ' 138' ' ' LYS . 73.0 t -52.43 114.67 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 43.8 mttm -113.08 160.98 17.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -68.59 157.86 35.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.845 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 tpt -94.35 -27.86 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.65 -55.71 3.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 65.3 p -80.73 -38.78 28.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.136 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.43 18.62 61.91 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.479 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -105.75 146.9 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 110.906 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.1 t -39.03 114.26 0.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.653 ' CG ' HG12 ' A' ' 129' ' ' VAL . 12.3 mtpt -52.94 -38.79 62.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.97 20.65 1.44 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.525 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.47 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 9.1 p90 -171.39 154.04 3.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.96 0.41 . . . . 0.0 110.9 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.99 16.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.78 142.48 38.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.902 0.382 . . . . 0.0 110.831 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 43.3 t -147.3 108.97 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 44.3 m -92.25 149.27 21.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -126.46 152.89 45.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -60.66 -45.66 93.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.908 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -127.72 160.14 32.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.896 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 151' ' ' ALA . 12.2 tptm -58.66 -60.3 4.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 49.0 tp -38.47 -47.4 1.27 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -57.94 -38.89 76.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.479 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -68.92 -57.07 6.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.415 ' O ' HG23 ' A' ' 156' ' ' VAL . 4.6 mm-40 -43.32 -46.64 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -40.09 -47.48 2.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.555 ' HB1' ' HG3' ' A' ' 158' ' ' MET . . . -76.93 -55.99 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.676 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 87.8 mt -42.93 -38.58 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 152' ' ' GLU . 42.2 t -81.33 -48.7 18.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.118 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 -75.3 -67.11 0.69 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.555 ' HG3' ' HB1' ' A' ' 154' ' ' ALA . 23.2 mmt -42.17 -47.97 4.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.42 102.18 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.467 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.92 -34.51 3.55 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.479 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.445 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.4 tp60 -35.14 151.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.798 0.333 . . . . 0.0 110.927 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.562 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.1 m95 -98.15 91.36 5.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.58 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.9 tt -85.41 -71.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.925 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.88 118.05 3.58 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.4 -93.05 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.514 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -82.13 170.35 15.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.759 0.314 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.562 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 80.8 mt-30 -71.3 -179.4 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 15.5 pt -136.98 168.77 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.603 ' O ' HG13 ' A' ' 101' ' ' VAL . 36.5 ttp180 -131.88 158.71 40.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.429 ' CB ' ' HA ' ' A' ' 155' ' ' ILE . 0.9 OUTLIER -139.64 150.9 45.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.148 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 22.1 m-20 -166.96 158.46 12.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.676 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.0 m95 -85.48 100.54 11.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.919 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.9 m170 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.851 0.357 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -91.03 133.0 35.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.928 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -96.58 122.3 39.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.861 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.5 t -109.81 126.04 66.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.2 t80 -90.48 138.49 31.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 169' ' ' ARG . 92.7 t -128.7 124.55 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -115.65 -179.25 18.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 54.23 34.15 19.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.893 0.378 . . . . 0.0 110.917 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.493 HD12 ' N ' ' A' ' 141' ' ' GLY . 40.5 mt -80.12 113.4 18.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -45.3 153.54 0.55 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.665 0.745 . . . . 0.0 110.832 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -25.88 28.44 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.671 2.248 . . . . 0.0 112.396 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -77.89 -7.72 57.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 6.4 mm -72.81 148.09 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.13 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.2 p -134.93 159.97 39.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.099 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.668 ' OG1' HG12 ' A' ' 128' ' ' VAL . 36.3 m -54.66 -44.65 73.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -63.05 -31.14 72.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.431 ' O ' ' N ' ' A' ' 116' ' ' ALA . 92.9 m-20 -69.7 -51.37 35.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.843 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.448 HG23 ' CE1' ' A' ' 117' ' ' PHE . 17.0 mt -58.49 -43.93 87.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 118' ' ' ALA . 58.3 mttt -60.62 -34.9 74.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 28.1 t -93.96 -11.99 29.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.597 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.84 -13.72 23.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.088 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.501 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 13.3 m-85 -116.11 -11.56 11.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.588 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.5 -45.14 99.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.065 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -47.96 -17.14 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.313 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.617 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 59.5 m-85 -88.69 -41.34 12.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.855 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 173.59 148.98 6.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -40.96 128.92 2.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.0 110.866 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 58.4 mt -101.22 147.6 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 4.4 p -115.2 -36.59 4.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -140.92 133.81 29.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.406 ' HB3' ' HE3' ' A' ' 114' ' ' LYS . . . -164.2 128.76 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.088 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.496 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.3 OUTLIER -151.92 161.64 42.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.847 -179.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.668 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.1 p -118.48 99.85 8.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.144 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 51.5 t -51.24 117.06 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.468 ' HG2' ' N ' ' A' ' 137' ' ' SER . 12.7 mttp -110.03 160.34 16.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.915 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -66.6 156.34 35.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.903 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 8.5 tpt -96.56 -10.41 27.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.66 -50.72 3.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.3 p -94.05 -29.26 15.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.65 17.89 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.438 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.1 mtpp -101.19 145.73 28.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.879 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.468 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 68.3 m -47.07 105.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 12.6 mttp -44.03 -36.3 2.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 126.94 14.19 2.82 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.535 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -155.7 152.81 29.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.945 0.403 . . . . 0.0 110.901 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.493 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -148.43 -171.19 17.05 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -134.68 137.6 43.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.874 0.369 . . . . 0.0 110.868 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 92.5 t -137.47 118.05 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.134 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 88.8 p -98.08 152.85 18.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.586 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 26.7 m-85 -129.53 141.44 50.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.897 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -57.59 -40.86 79.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.862 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -117.7 178.81 4.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 45.7 tttt -87.18 -48.38 8.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 18.3 tp -48.02 -65.1 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -41.98 -51.32 4.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.586 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -55.52 -47.15 76.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -57.81 -42.1 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.914 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -51.3 -47.69 62.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.617 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.43 -53.97 20.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.062 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.429 ' CD1' ' CZ2' ' A' ' 172' ' ' TRP . 96.6 mt -41.37 -35.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 95.4 t -91.4 -47.43 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.148 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -63.82 -63.77 1.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.581 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 93.0 mmm -60.52 -37.99 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.929 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 94.06 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.58 -28.31 9.36 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.508 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . 73.3 tp60 -37.69 156.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.778 0.323 . . . . 0.0 110.92 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.568 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.6 m95 -98.95 90.99 4.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.597 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.1 tt -86.15 -70.14 0.62 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.881 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.33 117.74 3.54 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.92 -92.7 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.3 mtt85 -80.89 179.66 7.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.314 . . . . 0.0 110.865 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.568 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 80.9 mt-30 -80.9 178.01 8.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.412 HD11 ' HE3' ' A' ' 158' ' ' MET . 29.4 pt -133.52 168.63 23.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.71 ' O ' HG13 ' A' ' 101' ' ' VAL . 55.9 ttt180 -129.54 154.23 47.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.885 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.606 HG22 HG22 ' A' ' 101' ' ' VAL . 44.5 p -141.95 148.22 38.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.083 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -174.24 147.07 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.429 ' CZ2' ' CD1' ' A' ' 155' ' ' ILE . 96.5 m95 -61.7 122.72 16.02 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.959 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.931 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . 0.517 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 7.1 m170 . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.843 0.354 . . . . 0.0 110.838 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.558 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 3.9 m-85 -91.14 139.61 30.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -93.16 131.86 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.926 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 48.2 t -124.05 129.34 74.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' ND2' ' A' ' 171' ' ' ASN . 1.8 t80 -99.42 149.86 22.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.604 HG13 ' O ' ' A' ' 169' ' ' ARG . 43.5 t -137.41 130.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.25 173.29 16.27 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 139' ' ' GLY . 5.4 m-20 61.74 36.38 16.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.819 0.342 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.422 HD13 HD11 ' A' ' 113' ' ' ILE . 39.1 mt -80.18 110.87 16.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -38.66 153.06 0.16 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 121.634 0.731 . . . . 0.0 110.874 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -15.21 36.79 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.678 2.252 . . . . 0.0 112.307 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.416 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 7.6 tt0 -90.63 -6.19 54.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.909 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 109' ' ' THR . 25.5 mm -67.48 156.06 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.448 ' N ' HG22 ' A' ' 108' ' ' ILE . 76.1 p -145.72 157.29 43.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.631 ' OG1' HG12 ' A' ' 128' ' ' VAL . 32.4 m -55.03 -39.06 68.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.074 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -71.58 -17.0 62.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -84.49 -46.32 11.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.51 HG23 ' CE1' ' A' ' 117' ' ' PHE . 7.7 mt -63.23 -38.76 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.462 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 19.4 mtpt -60.09 -36.12 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -92.84 -20.01 21.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.509 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -83.88 -16.92 42.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.8 m-85 -115.24 -7.55 12.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.581 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.72 -45.72 99.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.612 0.72 . . . . 0.0 111.114 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.0 Cg_exo -47.99 -18.1 1.04 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.654 2.236 . . . . 0.0 112.353 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.644 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 44.0 m-85 -89.77 -37.11 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.439 ' HA3' ' CG ' ' A' ' 150' ' ' ASP . . . 172.97 -171.24 44.3 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.456 ' HD2' ' N ' ' A' ' 123' ' ' ILE . 0.0 OUTLIER -77.77 120.05 22.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.781 0.324 . . . . 0.0 110.929 179.97 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.598 HG21 ' HB2' ' A' ' 126' ' ' ALA . 95.8 mt -91.91 101.12 12.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 93.1 p -67.84 -27.42 66.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.819 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -156.23 140.0 16.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.598 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -163.29 126.71 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.098 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.519 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.8 OUTLIER -143.69 162.78 35.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.854 -179.895 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.631 HG12 ' OG1' ' A' ' 110' ' ' THR . 6.5 p -121.15 100.19 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.0 t -53.73 120.38 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.481 ' HG2' ' N ' ' A' ' 137' ' ' SER . 32.1 mttm -115.29 164.88 13.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -65.44 148.61 51.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -90.91 -3.44 57.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.856 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -111.5 -54.91 2.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.11 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 24.5 p -89.76 -27.19 20.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.59 28.13 59.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 pttt -108.58 138.83 44.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.78 0.324 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.481 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 14.6 t -41.85 109.17 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -51.19 -33.77 28.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.5 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 121.38 20.44 3.27 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.429 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -161.05 140.96 10.84 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.957 0.408 . . . . 0.0 110.924 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -136.61 -168.74 11.52 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -138.54 143.87 39.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.4 t -144.02 124.73 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.17 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.2 m -100.82 141.13 34.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.839 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -125.01 133.92 52.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.879 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.517 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.1 m-85 -53.35 -48.92 68.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -113.31 167.24 10.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.558 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 30.4 tttp -74.68 -42.29 58.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -46.86 -52.09 15.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.439 ' CG ' ' HA3' ' A' ' 121' ' ' GLY . 88.9 m-20 -54.42 -43.79 71.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -66.54 -61.12 2.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.072 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -41.16 -44.31 2.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 -55.29 -59.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.644 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -58.09 -54.25 49.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.615 HD13 ' CE2' ' A' ' 172' ' ' TRP . 85.4 mt -44.42 -35.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.75 -60.98 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.118 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.7 m-70 -56.68 -66.96 0.35 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.811 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 24.3 mmt -43.51 -47.12 7.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.93 95.22 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.458 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.77 -30.72 6.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.488 ' N ' ' O ' ' A' ' 158' ' ' MET . 7.5 tp60 -37.5 155.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.905 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.546 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 89.2 m95 -101.15 91.7 4.65 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.92 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.542 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.0 tt -86.18 -70.7 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.416 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.73 118.1 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.492 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -92.14 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.503 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -80.25 175.12 10.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.758 0.313 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.546 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 38.8 mt-30 -74.01 177.43 5.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 20.0 pt -135.31 164.62 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.134 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.604 ' O ' HG13 ' A' ' 101' ' ' VAL . 29.7 ttp180 -128.01 154.13 45.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.566 HG22 HG22 ' A' ' 101' ' ' VAL . 22.4 p -142.68 154.05 43.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . 0.534 ' ND2' ' CD1' ' A' ' 100' ' ' PHE . 4.6 p30 -173.44 163.33 4.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.615 ' CE2' HD13 ' A' ' 155' ' ' ILE . 88.4 m95 -80.73 123.44 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.922 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.085 179.886 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . 0.497 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 28.2 m170 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.838 0.352 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.557 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 26.9 m-85 -102.2 129.67 48.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -96.34 133.39 40.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.465 HG22 HD11 ' A' ' 155' ' ' ILE . 62.3 t -114.01 127.19 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.115 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 24.4 t80 -87.63 136.4 32.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.426 HG13 ' O ' ' A' ' 169' ' ' ARG . 43.8 t -125.72 135.74 62.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.105 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.67 178.05 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 55.34 32.25 18.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 33.1 mt -78.85 118.84 21.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.6 t -50.36 152.47 3.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.82 23.45 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.678 2.252 . . . . 0.0 112.327 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -69.32 -13.2 62.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.532 HD12 HD22 ' A' ' 163' ' ' LEU . 14.6 mm -66.1 159.1 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.16 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.494 ' N ' HG22 ' A' ' 108' ' ' ILE . 68.9 p -134.9 -175.82 4.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.178 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 97.3 m -78.97 -36.98 40.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.126 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -78.95 -16.35 57.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -72.29 -48.42 42.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.0 mt -62.25 -42.48 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.13 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 65.2 mttt -57.28 -35.26 69.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 6.9 t -93.83 -19.33 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.685 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -83.62 -20.09 34.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.089 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.556 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 12.9 m-85 -110.96 -7.16 14.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.53 -45.98 99.82 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.535 0.683 . . . . 0.0 111.076 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.01 -17.09 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.136 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.637 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.9 m-85 -90.69 -32.85 16.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.874 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.85 -165.6 37.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.51 ' HG2' ' CE1' ' A' ' 146' ' ' TYR . 72.4 tttt -78.84 131.71 36.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -104.44 113.64 41.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.105 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 3.2 t -79.46 -32.39 42.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -152.5 143.5 23.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -173.25 132.36 0.49 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.155 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -152.06 164.65 36.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.607 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.6 p -114.58 100.7 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -52.88 122.76 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.467 ' HG2' ' N ' ' A' ' 137' ' ' SER . 78.0 mttt -120.92 161.26 21.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -71.38 158.51 36.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.838 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -95.85 -15.83 22.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -94.63 -60.44 1.71 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 15.3 p -83.42 -31.19 26.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.16 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.2 25.6 63.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.3 mmtm -108.24 144.63 35.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.842 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.467 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 11.2 t -46.76 105.89 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -44.14 -37.82 3.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.22 10.08 3.52 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.8 p90 -153.56 153.13 31.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.946 0.403 . . . . 0.0 110.907 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -148.18 -171.73 17.42 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -130.97 142.12 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.897 0.38 . . . . 0.0 110.874 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 25.3 t -140.9 105.61 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.158 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 17.8 m -85.77 147.91 26.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.872 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.9 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 11.1 m-85 -129.23 129.21 44.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.51 ' CE1' ' HG2' ' A' ' 122' ' ' LYS . 21.1 m-85 -43.8 -46.96 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.95 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 23.7 m-20 -114.32 -178.87 3.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.853 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.557 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 25.9 tttm -87.1 -48.74 7.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.901 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.1 tp -50.11 -64.97 0.65 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 20.2 p-10 -39.73 -51.88 2.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.9 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -60.41 -58.37 8.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.082 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -43.58 -47.39 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -45.36 -50.64 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.637 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.67 -52.34 64.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.098 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.465 HD11 HG22 ' A' ' 99' ' ' VAL . 92.1 mt -44.15 -39.54 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.8 t -77.29 -48.48 24.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 64.8 m-70 -72.05 -65.56 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.556 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.3 mmt -43.3 -49.61 6.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.2 96.6 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.455 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.59 -30.29 7.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.482 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.473 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.8 tp60 -40.16 154.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.915 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.577 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -98.92 91.17 4.92 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.685 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.6 tt -85.54 -73.14 0.46 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.462 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.94 117.17 3.57 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.477 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.69 -92.7 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.458 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -80.95 -177.29 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.861 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 33.3 mt-30 -82.5 177.15 8.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.492 ' CD1' ' SD ' ' A' ' 158' ' ' MET . 41.9 pt -134.4 173.95 13.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.138 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.426 ' O ' HG13 ' A' ' 101' ' ' VAL . 21.2 ttm180 -136.76 158.46 44.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.04 156.1 47.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -163.88 168.25 19.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.879 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -94.83 105.68 17.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.951 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 38.5 m170 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.803 0.335 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.526 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 85.3 m-85 -86.89 124.92 33.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -93.02 134.82 34.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.498 HG22 HD11 ' A' ' 155' ' ' ILE . 28.9 t -115.82 128.47 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.17 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -89.82 131.08 35.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.783 HG11 HD21 ' A' ' 104' ' ' LEU . 82.2 t -119.99 133.38 66.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.133 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -125.35 -178.43 15.31 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.526 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 47.4 43.58 15.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.883 0.373 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.783 HD21 HG11 ' A' ' 101' ' ' VAL . 45.1 mt -79.57 97.02 6.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -35.74 153.64 0.07 OUTLIER Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.684 0.754 . . . . 0.0 110.839 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.83 -14.6 36.09 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.622 2.215 . . . . 0.0 112.341 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -89.82 -3.62 58.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 109' ' ' THR . 15.1 mm -76.79 156.86 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.426 ' N ' HG22 ' A' ' 108' ' ' ILE . 26.7 p -142.19 160.93 39.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.184 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.785 ' OG1' HG12 ' A' ' 128' ' ' VAL . 21.0 m -56.14 -33.43 65.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.173 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -74.6 -39.08 62.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.5 ' O ' ' N ' ' A' ' 116' ' ' ALA . 19.2 m-20 -55.06 -57.44 11.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.545 HG23 ' CE1' ' A' ' 117' ' ' PHE . 28.1 mt -52.77 -39.79 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.128 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.64 ' HA ' HD13 ' A' ' 123' ' ' ILE . 6.9 mtpm? -62.89 -41.86 99.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.6 t -90.53 -10.17 44.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.877 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.567 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -93.27 -23.44 18.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.128 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' PHE . . . . . 0.565 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.7 m-85 -105.05 -6.98 19.5 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.574 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -55.15 -46.43 99.68 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.553 0.692 . . . . 0.0 111.083 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.574 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.4 Cg_exo -47.96 -19.0 1.32 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.354 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.688 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 44.2 m-85 -89.41 -50.24 6.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.81 165.7 33.69 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.455 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -50.83 131.54 26.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.64 HD13 ' HA ' ' A' ' 114' ' ' LYS . 57.3 mt -99.44 117.48 44.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 57.8 p -86.93 -31.21 20.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -152.1 122.87 7.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.839 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.567 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -149.13 114.21 5.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.129 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.1 155.15 47.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.905 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.785 HG12 ' OG1' ' A' ' 110' ' ' THR . 5.0 p -112.51 99.94 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.178 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 25.9 t -52.65 122.81 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.106 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.512 ' HE3' HG13 ' A' ' 128' ' ' VAL . 4.3 mtmp? -117.16 156.76 27.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.886 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -58.16 151.36 19.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.894 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' MET . . . . . 0.403 ' O ' ' SD ' ' A' ' 132' ' ' MET . 0.0 OUTLIER -96.47 16.34 18.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -131.14 -56.38 1.03 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.1 p -84.53 -28.46 26.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.12 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.77 23.17 62.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.494 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.407 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 13.8 mmtp -108.48 167.35 10.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.777 0.322 . . . . 0.0 110.911 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 80.1 p -57.07 117.65 4.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.867 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.429 ' HG3' ' C ' ' A' ' 130' ' ' LYS . 41.5 mttt -60.54 -39.53 88.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.62 16.72 2.22 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.511 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -166.08 151.42 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.902 0.382 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.56 -171.9 14.09 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -138.69 139.33 38.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.517 HG21 ' CG2' ' A' ' 113' ' ' ILE . 54.4 t -145.09 108.22 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 6.0 m -86.05 154.75 21.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -130.7 141.46 50.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.874 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -60.42 -32.86 71.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -125.54 162.35 25.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.934 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.526 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 70.8 tttt -73.94 -47.87 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -52.04 -43.05 63.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -60.29 -34.26 73.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.836 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -74.51 -45.22 47.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.117 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.524 ' O ' HG23 ' A' ' 156' ' ' VAL . 17.0 mt-10 -58.22 -42.14 85.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.894 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -53.14 -54.87 29.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . 0.688 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -62.42 -55.88 23.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.498 HD11 HG22 ' A' ' 99' ' ' VAL . 79.2 mt -42.0 -37.78 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 152' ' ' GLU . 82.5 t -80.15 -58.84 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.173 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -59.64 -65.42 0.68 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' MET . . . . . 0.565 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.7 mmt -42.54 -48.12 5.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.54 104.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.484 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.81 -31.46 3.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.496 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' GLN . . . . . 0.499 ' N ' ' O ' ' A' ' 158' ' ' MET . 34.1 tp60 -37.28 149.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 81.5 m95 -96.24 93.55 6.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.567 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.5 tt -86.36 -70.43 0.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.97 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.406 ' HA3' HD13 ' A' ' 108' ' ' ILE . . . -125.6 118.81 3.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 58.4 -95.28 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -84.86 170.26 13.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.581 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 39.0 mt-30 -68.7 172.28 6.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 14.9 pt -129.59 164.7 31.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.159 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.421 ' HG3' ' N ' ' A' ' 170' ' ' THR . 21.0 tpp180 -125.05 156.44 38.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.922 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' THR . . . . . 0.467 HG21 ' HB2' ' A' ' 158' ' ' MET . 72.2 p -144.52 156.87 44.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -174.37 173.58 2.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' TRP . . . . . 0.474 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.2 m95 -90.91 108.55 19.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.042 179.9 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.5 t -79.28 153.4 29.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.922 0.391 . . . . 0.0 110.809 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.1 m -98.4 173.67 6.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.9 -161.27 10.3 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.1 m -81.9 151.94 27.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.876 0.369 . . . . 0.0 110.845 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 45.9 t -68.8 96.99 0.78 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.841 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -103.81 44.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -70.03 169.23 13.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 110.876 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 15.2 tptm -92.79 -55.1 3.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -128.3 133.47 48.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.89 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -61.13 108.87 0.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 37.4 p -56.58 131.14 47.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -82.61 72.91 9.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.882 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 58.93 42.79 18.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 61.1 m170 -82.84 170.47 14.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.858 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -107.86 121.53 44.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -84.09 123.97 30.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.0 t -112.3 122.86 67.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.105 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.522 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 2.1 t80 -83.02 141.21 32.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.854 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.493 HG22 HG22 ' A' ' 170' ' ' THR . 96.1 t -135.55 110.67 11.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.155 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.12 -174.25 30.26 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 45.73 52.6 9.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.429 ' O ' ' C ' ' A' ' 105' ' ' SER . 21.3 mt -91.41 100.28 13.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -36.19 153.56 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.692 0.758 . . . . 0.0 110.869 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -27.23 26.67 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.726 2.284 . . . . 0.0 112.317 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -75.97 -12.41 60.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.893 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.496 HG22 ' N ' ' A' ' 109' ' ' THR . 24.1 mm -63.45 157.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.157 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 108' ' ' ILE . 77.7 p -145.66 144.04 30.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.168 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.637 ' OG1' HG12 ' A' ' 128' ' ' VAL . 76.5 m -44.64 -38.08 4.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -70.89 -35.96 72.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 116' ' ' ALA . 27.1 m-20 -63.58 -52.14 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.431 HG23 ' CE1' ' A' ' 117' ' ' PHE . 51.9 mt -56.67 -46.04 82.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.599 ' O ' HD12 ' A' ' 123' ' ' ILE . 68.0 mttt -56.7 -33.87 66.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.963 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -94.01 -18.44 21.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.652 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -85.3 -13.05 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.12 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.47 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.7 m-85 -115.87 -6.55 12.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.852 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -57.68 -46.11 99.78 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.571 0.7 . . . . 0.0 111.118 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.93 -17.19 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.649 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 48.0 m-85 -90.47 -48.18 7.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -176.45 175.56 47.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.467 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 11.8 tptp -62.86 134.83 56.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.771 0.32 . . . . 0.0 110.882 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.599 HD12 ' O ' ' A' ' 114' ' ' LYS . 77.3 mt -101.31 133.04 45.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 39.8 t -106.76 -40.43 5.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -143.48 122.52 12.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -149.94 133.15 16.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.597 ' HA ' HG23 ' A' ' 110' ' ' THR . 22.2 ptt180 -155.41 153.15 29.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.637 HG12 ' OG1' ' A' ' 110' ' ' THR . 7.3 p -115.49 100.0 9.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.565 HG11 ' OH ' ' A' ' 140' ' ' TYR . 78.8 t -49.85 114.3 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.133 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.483 ' HG2' ' N ' ' A' ' 137' ' ' SER . 41.7 mttt -118.07 155.67 29.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.21 149.58 49.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 mmt -91.92 -8.73 45.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.71 -58.52 2.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.092 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 11.8 p -87.69 -38.54 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 85.11 34.38 14.9 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -118.3 138.96 52.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.77 0.319 . . . . 0.0 110.905 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.483 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 21.4 t -40.9 104.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.89 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 21.3 mttp -45.25 -36.76 4.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.926 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.31 23.37 2.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.501 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.565 ' OH ' HG11 ' A' ' 129' ' ' VAL . 52.4 p90 -165.52 143.06 5.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.929 0.395 . . . . 0.0 110.914 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.15 -173.37 19.73 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.442 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -133.24 141.16 47.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.907 0.384 . . . . 0.0 110.906 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.19 106.34 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 50.9 m -86.36 154.29 21.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -130.89 147.22 52.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -60.96 -40.72 94.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.94 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -122.76 176.23 6.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 32.3 tttt -83.54 -55.68 4.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 19.1 tp -42.75 -53.97 4.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -51.6 -45.78 63.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -61.0 -51.54 68.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.104 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -50.02 -42.62 49.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.891 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -52.2 -48.98 64.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.91 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.649 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.0 -52.34 36.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.09 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.625 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 88.5 mt -44.03 -38.78 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.146 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.92 -54.53 8.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.114 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 -58.84 -64.16 1.04 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 89.5 mmm -57.54 -39.72 77.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.69 93.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 94.31 -29.5 8.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.493 ' N ' ' O ' ' A' ' 158' ' ' MET . 71.8 tp60 -38.86 148.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.361 . . . . 0.0 110.917 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.575 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 91.1 m95 -90.7 92.54 8.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.652 HD11 ' CB ' ' A' ' 116' ' ' ALA . 3.4 tt -88.7 -69.81 0.68 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.934 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.14 117.03 3.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.445 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.57 -91.3 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.494 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.3 mpt_? -83.14 175.73 9.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.859 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.575 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 51.0 mt-30 -77.08 177.43 7.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.502 HD11 ' HE3' ' A' ' 158' ' ' MET . 19.8 pt -137.35 162.69 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.07 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.3 mmt180 -118.98 165.07 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.493 HG22 HG22 ' A' ' 101' ' ' VAL . 3.8 p -149.81 141.4 23.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.108 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . 0.451 ' ND2' ' O ' ' A' ' 170' ' ' THR . 35.0 m120 -159.88 165.17 32.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.625 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 91.9 m95 -83.95 84.17 7.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.522 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -41.06 -38.79 1.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 26.4 m -63.87 137.31 57.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.157 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 16.4 ttt85 -121.74 135.67 54.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 67.9 mttt -118.09 141.68 29.77 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.531 0.681 . . . . 0.0 110.927 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 143.11 50.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.687 2.258 . . . . 0.0 112.366 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 141.94 46.59 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.711 2.274 . . . . 0.0 112.352 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -74.61 144.07 79.94 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.576 0.703 . . . . 0.0 111.108 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 179.47 3.68 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 25.0 p -129.01 175.78 8.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -139.44 71.42 0.44 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 173.4 11.01 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.674 2.249 . . . . 0.0 112.361 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 78.3 p -170.78 130.4 0.82 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 86.1 p -155.01 169.88 23.06 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.86 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.487 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 68.9 m -125.62 177.41 6.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.955 0.407 . . . . 0.0 110.834 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 26.1 m -114.97 177.38 4.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.846 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 85.99 72.18 1.29 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.498 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 78.0 p -113.41 129.99 56.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.846 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.7 t -72.37 -60.37 2.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -104.66 158.77 16.25 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.526 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -92.04 158.5 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.884 0.373 . . . . 0.0 110.903 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -110.76 167.0 10.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.882 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.2 mtmm -94.28 40.61 1.09 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.918 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -165.18 141.39 5.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.936 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 41.8 p -60.18 124.07 19.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.149 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 40.7 t -117.52 -60.78 1.78 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.841 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -110.85 41.97 1.7 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.93 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.432 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 44.5 m170 -110.76 155.93 21.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -103.03 128.14 50.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 29.6 m-70 -83.4 131.85 35.02 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.831 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.415 HG21 ' HB1' ' A' ' 151' ' ' ALA . 58.6 t -118.51 124.37 73.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.099 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.436 ' CZ ' ' HB2' ' A' ' 140' ' ' TYR . 10.4 t80 -86.41 138.85 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.661 ' CG1' HD21 ' A' ' 104' ' ' LEU . 92.7 t -132.34 111.8 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.097 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.31 -175.32 26.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 49.35 41.66 20.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.661 HD21 ' CG1' ' A' ' 101' ' ' VAL . 67.9 mt -85.78 108.02 17.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.8 t -35.94 152.16 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.658 0.742 . . . . 0.0 110.855 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -19.43 35.88 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.684 2.256 . . . . 0.0 112.316 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -87.81 1.4 54.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 15.8 mm -75.38 146.34 9.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.123 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.6 p -139.59 145.79 39.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.175 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.409 ' OG1' HG12 ' A' ' 128' ' ' VAL . 88.6 m -39.01 -35.97 0.25 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.192 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -67.34 -48.89 66.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 116' ' ' ALA . 8.8 t0 -54.39 -52.72 60.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.457 HG23 ' CE1' ' A' ' 117' ' ' PHE . 64.6 mt -56.69 -42.68 77.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.159 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.439 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 36.0 mttt -63.51 -37.56 87.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.932 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -92.55 -8.93 42.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.841 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . -97.4 -23.59 16.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.061 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 22.7 m-85 -105.29 -11.59 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.885 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.583 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -52.51 -45.9 95.52 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.603 0.716 . . . . 0.0 111.122 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.3 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 0.0 112.336 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.625 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 58.7 m-85 -90.31 -51.19 5.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -178.46 158.64 23.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.498 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.4 tptt -48.64 128.7 15.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.712 0.291 . . . . 0.0 110.856 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.557 HG21 ' HB2' ' A' ' 126' ' ' ALA . 60.0 mt -96.39 137.76 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 10.6 t -112.88 -39.52 4.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.865 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -134.92 103.0 5.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.557 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -136.18 131.5 34.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 22.5 ptt180 -155.55 156.38 35.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.597 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.6 p -118.62 100.44 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.107 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.59 HG12 ' HG3' ' A' ' 138' ' ' LYS . 75.8 t -52.34 122.81 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.104 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? -119.03 155.53 31.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.883 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.95 148.66 51.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 35.1 mtm -95.46 -9.41 32.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.876 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -91.13 -52.5 4.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.086 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.7 p -100.89 -40.38 7.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.152 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.59 26.25 8.21 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.48 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -109.3 149.27 29.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 110.915 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 11.9 m -43.09 114.65 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.824 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.59 ' HG3' HG12 ' A' ' 129' ' ' VAL . 13.2 mtpt -53.6 -39.82 65.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.927 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.77 19.34 1.83 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.555 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 44.2 p90 -167.53 150.28 6.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.899 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.65 -171.5 16.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.453 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 71.2 m-85 -136.48 136.91 39.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.907 0.384 . . . . 0.0 110.878 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 70.2 t -140.53 108.31 2.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.182 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.3 t -93.52 141.82 28.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -117.27 147.21 42.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.432 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 10.1 m-85 -57.79 -38.22 75.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -124.95 155.64 39.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.87 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 41.4 tttt -61.43 -60.55 3.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 21.1 tp -40.01 -49.95 2.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -49.49 -40.68 38.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.845 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.415 ' HB1' HG21 ' A' ' 99' ' ' VAL . . . -69.3 -48.87 60.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.07 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -52.57 -38.89 60.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.924 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -56.53 -54.5 45.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.625 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.31 -61.62 2.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.087 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.533 HD13 ' CE2' ' A' ' 172' ' ' TRP . 68.3 mt -38.64 -39.73 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.159 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 20.3 t -70.55 -64.37 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.132 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 77.6 m-70 -63.63 -61.17 2.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 29.0 mmt -43.9 -48.44 8.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.44 92.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 97.68 -30.1 9.88 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.525 ' CD ' ' N ' ' A' ' 162' ' ' TRP . 1.0 OUTLIER -36.74 154.94 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.811 0.338 . . . . 0.0 110.863 -179.851 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.586 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 77.1 m95 -101.43 91.24 4.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.978 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.549 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.2 tt -84.29 -70.89 0.54 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.921 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -125.58 120.33 3.82 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.458 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 57.37 -95.3 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -81.15 179.26 7.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.744 0.306 . . . . 0.0 110.921 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.586 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 53.9 mt-30 -79.57 -178.43 6.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.434 ' O ' ' N ' ' A' ' 160' ' ' GLY . 20.8 pt -136.66 162.19 35.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.7 ttm180 -126.4 144.07 50.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.519 HG21 ' HA ' ' A' ' 155' ' ' ILE . 1.3 p -121.6 153.18 38.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . 0.416 ' CG ' ' O ' ' A' ' 170' ' ' THR . 12.0 m120 -169.15 159.97 9.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.533 ' CE2' HD13 ' A' ' 155' ' ' ILE . 94.9 m95 -89.41 129.42 35.92 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -94.21 -44.19 8.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.07 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 39.8 m -52.89 103.58 0.07 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.094 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 34.0 mtt-85 -134.94 147.07 49.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 17.4 ttmt 65.55 52.4 0.93 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.522 0.677 . . . . 0.0 110.925 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.7 Cg_endo -69.72 149.23 66.87 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.362 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 130.71 19.79 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.655 2.237 . . . . 0.0 112.33 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -169.11 145.13 2.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.594 0.711 . . . . 0.0 111.079 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 139.17 39.33 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.696 2.264 . . . . 0.0 112.323 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 55.7 m -85.36 90.61 7.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 67.92 81.38 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 136.63 33.46 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.712 2.275 . . . . 0.0 112.34 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 17.9 t -105.9 99.08 8.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.842 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 54.5 p -58.98 141.69 53.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.864 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.498 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 32.0 m -122.37 -53.46 1.91 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.894 0.378 . . . . 0.0 110.9 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 13.8 t -63.71 169.3 4.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.836 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -86.24 110.12 3.45 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 15.4 m -122.02 123.89 42.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 0.0 110.844 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 47.5 t -68.9 117.66 10.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 61.95 101.62 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 54.1 mt-30 -81.6 102.55 10.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.857 0.36 . . . . 0.0 110.894 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 16.3 ttmt -110.49 125.19 53.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.915 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.5 mttt -94.14 28.61 2.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.914 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.436 ' O ' ' C ' ' A' ' 93' ' ' THR . 1.1 m-20 53.0 50.75 17.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.453 ' O ' ' N ' ' A' ' 95' ' ' ASN . 41.1 p 34.17 53.03 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.154 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 95' ' ' ASN . 1.3 t -44.96 92.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.843 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.453 ' N ' ' O ' ' A' ' 93' ' ' THR . 24.5 p30 34.43 36.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.441 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 38.1 m170 -50.66 174.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -104.72 121.4 43.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 5.2 m-70 -89.3 134.42 34.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -118.21 122.1 68.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 45.4 t80 -84.91 141.43 30.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.844 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.6 t -125.73 143.05 40.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.44 159.22 23.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.459 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 t0 68.06 33.77 4.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.88 0.372 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.49 HD12 ' C ' ' A' ' 140' ' ' TYR . 31.3 mt -70.91 99.06 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.933 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.4 t -35.85 153.22 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.739 . . . . 0.0 110.866 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -18.93 36.6 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.335 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.452 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 9.6 tt0 -87.71 -3.43 58.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.438 HG21 HD22 ' A' ' 104' ' ' LEU . 18.1 mm -69.36 144.59 13.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.6 p -134.49 148.8 50.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.118 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 88.4 m -50.87 -30.71 15.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.183 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -78.23 -23.16 47.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -78.91 -48.92 13.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.507 HG23 ' CD1' ' A' ' 117' ' ' PHE . 17.5 mt -57.85 -42.42 82.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.144 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.3 mttt -58.45 -43.98 89.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.7 t -81.94 -16.87 49.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.487 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -89.5 -20.11 24.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.066 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.3 m-85 -108.63 -10.59 15.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.855 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.585 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.12 -45.43 99.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.57 0.7 . . . . 0.0 111.042 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -47.98 -17.03 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.706 2.27 . . . . 0.0 112.33 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.65 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 34.6 m-85 -93.58 -32.13 14.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.16 178.79 36.34 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.579 ' HG3' ' CE1' ' A' ' 146' ' ' TYR . 32.0 tptt -62.82 143.68 57.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.802 0.334 . . . . 0.0 110.877 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.533 HG21 ' HB2' ' A' ' 126' ' ' ALA . 62.6 mt -113.57 126.24 70.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 1.7 t -93.77 -37.44 11.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -145.89 117.43 8.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.533 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -146.43 119.2 8.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -148.45 163.27 37.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.509 HG13 ' O ' ' A' ' 128' ' ' VAL . 3.9 p -115.76 104.26 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.128 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.0 t -57.49 124.65 11.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -122.36 157.98 30.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.912 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -64.83 158.23 25.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.932 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 42.7 mmm -101.92 -13.13 17.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.883 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.36 -47.69 7.59 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.119 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.8 p -102.55 -38.86 7.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.104 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.28 32.79 9.25 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 92.9 mttt -111.84 155.5 23.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.741 0.305 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.1 t -55.23 102.61 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 65.0 mttt -45.03 -39.0 5.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.892 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.92 16.96 2.87 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.455 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.49 ' C ' HD12 ' A' ' 104' ' ' LEU . 32.8 p90 -160.5 145.81 14.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.976 0.417 . . . . 0.0 110.927 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -141.55 -176.17 15.64 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -129.82 142.15 50.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.869 0.366 . . . . 0.0 110.924 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 19.8 t -149.35 106.03 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.155 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 48.9 m -92.0 142.1 27.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.652 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 23.7 m-85 -112.42 144.67 41.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.913 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.579 ' CE1' ' HG3' ' A' ' 122' ' ' LYS . 8.5 m-85 -56.98 -35.75 69.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.557 ' ND2' ' N ' ' A' ' 147' ' ' ASN . 0.0 OUTLIER -127.15 179.7 5.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.901 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 35.7 tttt -86.98 -40.96 14.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 55.9 tp -52.44 -65.07 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.456 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 14.6 p-10 -43.8 -53.63 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.844 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.652 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -55.0 -57.16 12.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.066 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.441 ' O ' HG23 ' A' ' 156' ' ' VAL . 26.8 mt-10 -46.38 -47.21 18.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 64.6 m-20 -49.8 -55.09 15.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.65 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -57.05 -60.73 3.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.081 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.623 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 83.3 mt -39.31 -37.72 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.152 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 152' ' ' GLU . 90.4 t -77.76 -48.6 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.139 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -75.56 -62.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.568 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 23.2 mmt -45.31 -47.27 13.12 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.45 94.96 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.446 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 96.59 -30.69 8.43 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.46 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.474 ' N ' ' O ' ' A' ' 158' ' ' MET . 6.2 tm0? -38.25 157.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.801 0.334 . . . . 0.0 110.923 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 167' ' ' GLN . 87.1 m95 -102.56 95.0 5.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.958 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.522 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.3 tt -90.88 -70.5 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.414 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.09 116.77 3.53 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.505 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.42 -91.53 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.504 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -82.07 178.81 8.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.78 0.324 . . . . 0.0 110.839 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 162' ' ' TRP . 43.9 mt-30 -80.63 177.83 8.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 7.7 pt -137.3 170.19 18.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.111 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 13.4 ttm-85 -131.29 149.57 52.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.9 p -126.67 150.85 48.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -168.77 154.56 6.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.623 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.2 m95 -81.05 113.24 19.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -52.45 -52.24 55.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.111 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 13.1 t -100.59 152.76 20.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.101 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.427 ' HB2' ' NH1' ' A' ' 175' ' ' ARG . 22.4 mtm105 -117.01 146.14 43.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.404 ' HD3' ' C ' ' A' ' 176' ' ' LYS . 0.0 OUTLIER -107.62 146.59 33.67 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.567 0.699 . . . . 0.0 110.92 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 158.89 55.41 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.712 2.275 . . . . 0.0 112.314 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 100.76 0.85 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.688 2.259 . . . . 0.0 112.35 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -53.82 151.71 11.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.555 0.693 . . . . 0.0 111.144 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -44.53 2.05 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.701 2.267 . . . . 0.0 112.349 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 84.4 p -59.3 175.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.825 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 155.86 76.53 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.48 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 148.53 65.5 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.726 2.284 . . . . 0.0 112.364 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 t -146.67 120.21 9.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.828 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 10.7 t -168.04 152.77 6.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.836 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.453 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.3 m -154.67 158.28 39.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.869 0.366 . . . . 0.0 110.897 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.6 m -119.58 128.67 54.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 70.0 173.03 10.98 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.502 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -108.31 -57.32 2.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.891 0.377 . . . . 0.0 110.859 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 29.0 m -55.93 -49.62 72.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 115.9 159.4 11.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.515 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -99.16 -55.74 2.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 5.0 ptpp? -95.29 46.78 1.12 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -53.23 106.3 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 93' ' ' THR . 0.4 OUTLIER -67.85 119.04 11.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.852 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 92' ' ' ASP . 22.5 p -35.29 125.79 0.61 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.1 t -128.33 -50.35 1.29 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.897 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -117.27 43.15 2.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.899 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.405 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 30.6 m170 -122.88 153.03 40.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.817 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -94.12 130.24 40.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . 0.507 ' CB ' ' HB3' ' A' ' 173' ' ' ALA . 54.6 m-70 -88.28 128.12 35.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 95.6 t -116.44 124.65 72.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -89.57 141.86 28.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 169' ' ' ARG . 61.2 t -131.59 134.89 60.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.46 17.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.479 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.96 36.09 23.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.879 0.371 . . . . 0.0 110.836 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.492 HD21 HG11 ' A' ' 101' ' ' VAL . 31.2 mt -81.1 110.03 16.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -41.61 153.31 0.27 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 110.88 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -23.64 30.52 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.336 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -75.84 -18.53 59.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.646 HD12 HD22 ' A' ' 163' ' ' LEU . 20.2 mm -66.33 133.09 31.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 60.8 p -121.21 151.42 39.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 52.9 m -43.98 -34.54 1.74 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.136 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -70.93 -43.81 67.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.4 m-20 -58.76 -53.83 53.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.608 HG23 ' CE1' ' A' ' 117' ' ' PHE . 43.3 mt -56.34 -38.68 56.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.542 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 7.0 mtpt -63.58 -39.13 93.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.3 t -93.3 -11.92 31.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.836 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.748 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.72 -20.94 21.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.09 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.608 ' CE1' HG23 ' A' ' 113' ' ' ILE . 19.6 m-85 -107.4 -8.65 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.73 -45.66 99.8 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.589 0.709 . . . . 0.0 111.064 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -48.0 -17.07 0.7 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.283 . . . . 0.0 112.361 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.631 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.7 m-85 -90.73 -38.84 12.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.896 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.97 167.29 31.1 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.466 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -54.54 126.63 24.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.445 HD12 ' O ' ' A' ' 114' ' ' LYS . 85.7 mt -95.76 132.85 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.147 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 92.1 p -99.99 -44.92 5.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -141.1 120.65 13.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.542 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -143.21 128.32 18.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.099 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.8 ptm180 -156.44 151.75 26.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.718 HG13 ' HE2' ' A' ' 130' ' ' LYS . 7.2 p -108.59 100.08 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 68.7 t -49.49 130.37 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.077 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.718 ' HE2' HG13 ' A' ' 128' ' ' VAL . 29.9 mtmt -125.55 167.75 14.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 30.3 t0 -68.53 157.33 36.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -94.57 -12.53 27.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.874 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.58 -62.55 1.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.6 p -81.08 -28.38 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.131 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.26 33.45 53.71 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.411 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 7.1 mmpt? -106.03 158.33 16.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.307 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.412 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 16.5 m -65.47 100.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 37.4 mttt -44.21 -36.77 2.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 121.17 18.58 3.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.485 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -156.71 142.45 17.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.908 0.385 . . . . 0.0 110.952 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.1 -169.76 12.26 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -134.23 142.38 47.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 73.1 t -144.83 110.55 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.136 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 15.8 m -89.67 145.01 25.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -121.88 149.18 43.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.405 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 10.1 m-85 -58.63 -46.64 86.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -128.66 165.23 21.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' A' ' 151' ' ' ALA . 14.3 ttmt -62.13 -62.22 1.92 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.925 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 65.0 tp -38.19 -50.88 1.44 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.913 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -55.68 -39.62 71.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.907 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.602 ' HB3' ' HH2' ' A' ' 172' ' ' TRP . . . -67.02 -51.19 57.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.149 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.423 ' O ' HG23 ' A' ' 156' ' ' VAL . 5.5 mm-40 -50.14 -48.04 53.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -42.03 -36.59 1.16 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.631 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -86.0 -54.53 4.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.095 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.629 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 76.1 mt -47.67 -34.31 3.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.16 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 152' ' ' GLU . 46.7 t -81.37 -46.33 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.129 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -74.92 -65.26 0.89 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.892 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.72 ' HB2' HG21 ' A' ' 170' ' ' THR . 8.1 mmt -42.33 -48.66 5.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -35.51 103.04 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.467 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 82.08 -32.53 2.74 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.3 tp-100 -34.32 149.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.756 0.312 . . . . 0.0 110.966 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.564 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 90.8 m95 -99.89 92.51 5.32 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.926 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.748 HD11 ' CB ' ' A' ' 116' ' ' ALA . 7.0 tt -87.24 -71.04 0.58 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.583 ' HA3' HD11 ' A' ' 108' ' ' ILE . . . -120.63 117.67 3.59 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.483 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.94 -92.78 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.504 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.1 mtt180 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.735 0.302 . . . . 0.0 110.864 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.564 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 71.5 mt-30 -77.15 -178.96 5.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 25.0 pt -137.96 163.68 29.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.724 ' O ' HG13 ' A' ' 101' ' ' VAL . 0.1 OUTLIER -126.45 152.14 46.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.944 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.72 HG21 ' HB2' ' A' ' 158' ' ' MET . 16.4 p -134.16 158.46 43.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.156 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . 0.413 ' HB2' ' NH1' ' A' ' 169' ' ' ARG . 24.4 t-20 -172.07 173.18 4.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.843 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.629 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 83.8 m95 -95.04 106.97 19.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.507 ' HB3' ' CB ' ' A' ' 98' ' ' HIS . . . -53.84 -57.43 10.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 10.0 t -85.19 143.97 28.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.099 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.412 ' HD3' ' C ' ' A' ' 175' ' ' ARG . 0.0 OUTLIER -137.68 117.22 12.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 32.1 mttp -86.74 144.36 37.07 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.559 0.695 . . . . 0.0 110.895 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 147.07 62.34 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.721 2.281 . . . . 0.0 112.346 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 151.03 68.9 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -134.22 142.6 43.7 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.577 0.704 . . . . 0.0 111.068 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 143.92 52.43 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.662 2.242 . . . . 0.0 112.373 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 8.4 t -79.19 172.9 13.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.826 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -132.85 152.88 20.45 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.484 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 163.59 37.72 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.715 2.277 . . . . 0.0 112.379 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 19.6 m -72.31 -56.26 5.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 46.8 p -89.65 134.74 34.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.966 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 20.2 m -143.44 144.54 32.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.9 0.381 . . . . 0.0 110.858 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 20.2 t -154.66 139.32 17.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.838 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 79.15 50.55 5.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.9 m -91.88 132.53 36.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.838 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 85.4 p -161.35 129.72 4.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.815 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -92.92 -114.17 2.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.419 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -105.45 91.12 3.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.882 0.373 . . . . 0.0 110.912 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -129.95 100.5 5.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.2 44.77 1.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.945 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -105.46 106.71 17.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.824 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.42 ' CG2' ' HB2' ' A' ' 124' ' ' SER . 69.1 p -96.49 105.9 18.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.5 m -124.32 -59.13 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -98.94 43.4 1.06 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.92 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -106.12 164.02 12.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.866 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.532 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 58.2 m-85 -113.48 134.24 54.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -91.29 128.35 37.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 98.3 t -111.59 135.48 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.508 ' C ' ' CD1' ' A' ' 100' ' ' PHE . 2.7 t80 -100.24 139.38 36.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 54.7 t -131.39 114.78 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.42 172.83 19.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 139' ' ' GLY . 1.6 m-20 58.71 37.73 25.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.359 . . . . 0.0 110.853 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.508 HD12 ' C ' ' A' ' 140' ' ' TYR . 31.7 mt -71.88 101.08 2.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 104' ' ' LEU . 0.7 OUTLIER -36.64 155.23 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.663 0.744 . . . . 0.0 110.88 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -13.11 34.14 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -89.9 -16.72 29.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.894 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.483 HG21 HD22 ' A' ' 104' ' ' LEU . 10.7 mm -66.93 144.24 14.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 80.4 p -142.55 145.93 34.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.183 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 49.2 m -39.75 -37.49 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.101 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -68.27 -45.35 73.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.487 ' O ' ' N ' ' A' ' 116' ' ' ALA . 75.4 m-20 -64.32 -50.72 66.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CD1' ' A' ' 117' ' ' PHE . 13.1 mt -53.52 -45.4 58.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.475 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 13.3 mtpt -61.35 -35.64 77.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 31.2 t -91.54 -13.59 31.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.76 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.71 -17.59 21.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.058 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.578 ' CE1' ' SD ' ' A' ' 158' ' ' MET . 25.5 m-85 -108.34 -11.03 15.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.845 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.591 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.16 -44.79 99.06 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 0.0 111.106 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.591 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -48.06 -16.75 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.261 . . . . 0.0 112.341 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -94.31 -41.47 9.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 174.5 147.94 6.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -43.89 126.89 5.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.889 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 62.5 mt -91.63 134.33 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . 0.42 ' HB2' ' CG2' ' A' ' 93' ' ' THR . 87.9 p -100.29 -42.92 6.46 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.859 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -145.39 107.31 4.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.858 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HB1' HG22 ' A' ' 143' ' ' VAL . . . -137.34 135.46 37.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.077 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -157.6 165.99 34.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.514 HG13 ' O ' ' A' ' 128' ' ' VAL . 3.8 p -123.07 100.04 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.142 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 41.9 t -53.4 128.04 12.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.403 ' HG2' ' C ' ' A' ' 136' ' ' LYS . 49.6 mttt -121.26 171.31 8.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -75.82 159.29 31.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.85 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.424 ' N ' ' SD ' ' A' ' 132' ' ' MET . 0.3 OUTLIER -101.95 9.55 40.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -122.72 -44.01 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.5 p -98.92 -31.23 11.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.98 30.09 56.2 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.403 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 51.5 mmtt -114.06 155.14 26.49 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.1 t -50.67 110.9 0.46 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.852 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -53.32 -34.74 58.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.935 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 123.99 11.17 4.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.508 ' C ' HD12 ' A' ' 104' ' ' LEU . 48.8 p90 -154.97 159.24 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.892 0.377 . . . . 0.0 110.966 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -160.06 -167.95 21.35 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.476 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -141.37 152.39 44.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.38 . . . . 0.0 110.902 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.599 HG22 ' HB1' ' A' ' 126' ' ' ALA . 43.0 t -153.91 109.52 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.182 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 70.8 m -85.07 150.89 24.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -129.89 149.15 51.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.859 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -63.3 -43.55 97.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.927 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -120.06 157.96 27.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.532 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 57.3 tttt -65.51 -49.99 66.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.948 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.5 tp -47.65 -56.08 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.889 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -45.83 -39.46 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.407 ' HB1' ' CG2' ' A' ' 99' ' ' VAL . . . -67.8 -49.58 61.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.125 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.446 ' O ' HG23 ' A' ' 156' ' ' VAL . 23.6 mt-10 -51.47 -46.31 63.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.918 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 18.2 m-80 -52.68 -47.9 66.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.875 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.27 -55.93 18.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.588 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 96.4 mt -50.0 -35.01 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 152' ' ' GLU . 74.3 t -78.98 -49.33 20.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.135 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.7 m-70 -72.67 -67.07 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.864 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.578 ' SD ' ' CE1' ' A' ' 117' ' ' PHE . 14.9 mmt -44.86 -47.28 11.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.53 101.22 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.528 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 84.5 -31.57 3.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.527 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.9 tp-100 -34.78 151.51 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.819 0.342 . . . . 0.0 110.91 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.58 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.9 m95 -97.02 90.63 5.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.92 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.76 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.5 tt -85.31 -70.08 0.61 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.1 117.94 3.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.506 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.78 -93.68 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.465 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 27.7 mtt85 -80.47 -179.73 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.733 0.302 . . . . 0.0 110.897 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.58 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 40.1 mt-30 -83.77 176.16 9.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.935 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.424 ' O ' ' N ' ' A' ' 160' ' ' GLY . 18.9 pt -131.81 167.79 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -130.91 149.23 52.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 20.1 p -126.54 162.09 26.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -173.0 156.9 3.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.913 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.588 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.0 m95 -87.07 119.19 27.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -87.53 42.97 1.07 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.139 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -115.47 142.45 46.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.137 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 50.3 mtt-85 -124.84 144.03 50.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.858 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.439 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 0.8 OUTLIER 43.97 54.74 11.89 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.585 0.707 . . . . 0.0 110.89 179.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.5 Cg_endo -69.76 159.74 52.28 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 157.58 59.94 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 0.0 112.354 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -158.38 152.53 20.02 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.638 0.732 . . . . 0.0 111.095 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 170.99 15.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.728 2.285 . . . . 0.0 112.308 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 5.6 t -117.73 105.39 11.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.877 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 86.85 178.71 49.09 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.474 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 128.43 16.03 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.707 2.271 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 1.8 m -132.05 121.87 24.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.852 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 24.8 t -140.25 131.0 25.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.833 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.383 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.9 t -71.24 135.32 47.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.881 0.372 . . . . 0.0 110.889 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 73.4 p -137.72 148.49 45.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.845 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 137.22 -142.58 13.63 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.522 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 t -133.49 146.3 50.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 110.904 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 22.0 m -76.84 97.97 4.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 50.82 93.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.502 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -79.31 115.83 19.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.901 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.8 pttt -98.26 -39.46 8.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -47.55 111.07 0.37 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.902 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -53.3 -60.68 2.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 37.3 p -46.96 132.39 11.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.133 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.1 t -129.93 -56.1 1.12 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 -61.21 -60.03 4.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.0 m170 -42.28 152.92 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.544 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 88.7 m-85 -89.43 154.35 20.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -111.77 135.77 51.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.81 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.421 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 60.7 t -126.65 121.07 57.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.156 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.405 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 87.6 t80 -86.14 139.34 31.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.903 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 169' ' ' ARG . 47.0 t -130.11 120.17 48.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.178 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -111.43 -175.36 20.09 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 46.34 43.64 11.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.871 0.367 . . . . 0.0 110.838 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.517 HD21 HG11 ' A' ' 101' ' ' VAL . 39.5 mt -85.0 110.1 18.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -39.67 153.44 0.19 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.686 0.755 . . . . 0.0 110.884 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.408 ' HA ' ' HB2' ' A' ' 137' ' ' SER . 54.0 Cg_endo -69.75 -20.01 35.44 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 0.0 112.345 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -82.98 -20.62 34.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.876 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 46.8 mm -50.0 151.02 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.127 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 37.3 p -139.14 148.29 43.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.157 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.587 ' OG1' HG12 ' A' ' 128' ' ' VAL . 27.7 m -48.91 -38.11 21.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.153 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -71.89 -32.7 67.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.9 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.496 ' O ' ' N ' ' A' ' 116' ' ' ALA . 10.9 m-20 -65.21 -53.59 42.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.842 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 31.6 mt -56.25 -48.01 80.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.091 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.9 mttm -56.41 -39.32 72.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.913 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.4 t -92.37 -8.98 43.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.635 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -94.21 -13.9 26.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.121 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.581 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 26.6 m-85 -115.49 -11.6 11.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.862 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.595 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -49.82 -46.63 80.63 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.603 0.716 . . . . 0.0 111.157 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.595 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 63.8 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.695 2.263 . . . . 0.0 112.31 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.582 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 50.0 m-85 -92.42 -33.05 14.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.921 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.06 157.84 9.18 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.527 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 18.5 tptp -49.09 145.29 4.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.88 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 53.6 mt -115.21 143.42 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 51.4 p -108.26 -33.98 6.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.76 136.35 22.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -164.68 129.12 2.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.478 ' HA ' HG23 ' A' ' 110' ' ' THR . 9.0 ptp85 -150.42 154.23 37.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.723 HG13 ' HE2' ' A' ' 130' ' ' LYS . 7.4 p -113.12 100.08 9.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.423 HG11 ' OH ' ' A' ' 140' ' ' TYR . 47.1 t -51.74 114.26 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.723 ' HE2' HG13 ' A' ' 128' ' ' VAL . 32.3 mtmt -109.09 163.14 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 158.3 7.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.865 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 ttt -98.93 -8.52 25.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -108.06 -48.79 3.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.11 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.9 p -96.96 -24.45 15.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.089 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.92 19.97 78.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.468 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -95.99 143.29 27.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.47 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 37.3 m -47.61 106.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -50.15 -45.1 52.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.922 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 133.26 29.99 0.48 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.427 ' C ' HD12 ' A' ' 104' ' ' LEU . 41.3 p90 -171.98 144.68 1.74 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.956 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.446 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -145.96 -172.01 15.95 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.498 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -131.57 140.78 49.54 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.897 0.38 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.8 t -140.78 122.15 14.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.089 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 63.6 p -101.68 147.67 26.17 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.873 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.65 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 11.1 m-85 -125.36 148.68 48.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.833 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 13.8 m-85 -64.5 -35.99 82.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.934 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -130.62 154.39 47.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.916 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.544 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 11.3 ttmt -60.1 -66.74 0.47 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.906 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 148' ' ' LYS . 14.9 tp -35.3 -59.49 0.52 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -47.47 -41.86 21.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.65 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -71.52 -54.07 11.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.5 ' HA ' HD12 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -47.82 -39.39 18.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.911 -179.948 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -52.3 -46.39 65.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.489 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.64 -53.21 44.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.5 HD12 ' HA ' ' A' ' 152' ' ' GLU . 81.9 mt -41.01 -35.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.123 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.4 t -89.23 -53.74 8.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -59.27 -62.45 1.88 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.838 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.582 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 83.7 mmm -64.04 -36.36 83.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.37 92.03 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.91 -28.58 12.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.487 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.7 tp-100 -38.61 155.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.882 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.575 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.1 m95 -95.64 90.91 5.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.959 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.635 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.9 tt -87.09 -69.83 0.66 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.888 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -119.72 116.97 3.44 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.94 -91.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 26.8 mtt180 -82.63 178.14 8.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.838 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.575 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 34.0 mt-30 -78.14 175.47 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.929 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.463 HD11 ' HB3' ' A' ' 158' ' ' MET . 32.9 pt -132.64 168.64 23.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.127 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.559 ' O ' HG13 ' A' ' 101' ' ' VAL . 65.2 ttt180 -126.39 160.87 29.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.899 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 31.7 p -146.8 147.58 31.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.134 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -160.77 164.05 31.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 11.7 m95 -79.14 83.37 5.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.951 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -39.52 -37.83 0.52 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.123 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 m -127.38 108.75 11.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.142 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 78.6 mtt85 -82.03 -43.01 18.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.448 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 24.9 ttmt 40.94 53.64 6.65 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.534 0.683 . . . . 0.0 110.939 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . 0.448 ' CD ' ' N ' ' A' ' 176' ' ' LYS . 53.9 Cg_endo -69.75 164.04 36.0 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.688 2.259 . . . . 0.0 112.352 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 144.12 53.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.32 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -121.58 145.21 42.28 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.553 0.692 . . . . 0.0 111.081 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 181' ' ' SER . 53.5 Cg_endo -69.77 -14.2 35.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.677 2.252 . . . . 0.0 112.37 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 180' ' ' PRO . 7.7 t -36.42 120.6 0.68 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 93.33 73.31 1.22 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.43 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -19.03 36.58 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.694 2.262 . . . . 0.0 112.311 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 34.8 m -69.94 138.48 52.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.6 m -72.86 -45.23 59.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.855 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.483 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.9 p -116.21 161.84 18.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.885 0.374 . . . . 0.0 110.833 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 97.6 p -87.39 12.36 12.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.855 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -176.42 -84.19 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.492 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 63.5 p -156.56 157.9 36.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.89 0.376 . . . . 0.0 110.853 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 32.8 t -94.87 119.9 34.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.878 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -150.23 116.84 0.8 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.476 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -105.85 79.11 1.39 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 0.0 110.896 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 20.7 pttt -169.0 145.47 3.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.3 mttt -153.86 110.49 3.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -57.15 -69.58 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 60.6 p -69.44 112.16 5.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.137 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.5 m -111.76 -65.98 1.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -50.67 -41.81 56.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.88 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.1 m170 -57.48 151.76 16.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -96.96 128.97 44.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -87.71 119.6 28.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.88 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.412 HG13 HG12 ' A' ' 155' ' ' ILE . 65.6 t -109.79 119.75 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.13 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.425 ' CD1' ' C ' ' A' ' 100' ' ' PHE . 3.2 t80 -84.14 145.4 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.469 HG13 ' O ' ' A' ' 169' ' ' ARG . 61.9 t -132.76 140.79 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -130.23 -169.37 12.48 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.501 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 44.9 36.71 2.0 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.831 0.348 . . . . 0.0 110.883 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 40.9 mt -78.74 106.15 10.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.961 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -40.44 153.6 0.21 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.685 0.755 . . . . 0.0 110.844 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -28.31 25.51 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.733 2.289 . . . . 0.0 112.325 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -77.41 -7.4 56.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.862 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.568 HG22 ' N ' ' A' ' 109' ' ' THR . 9.5 mm -68.56 161.96 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.568 ' N ' HG22 ' A' ' 108' ' ' ILE . 56.4 p -142.96 172.1 13.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.474 ' OG1' HG12 ' A' ' 128' ' ' VAL . 15.5 m -69.0 -39.15 79.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.165 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -74.0 -17.95 60.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.93 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 17.9 m-20 -75.32 -54.54 6.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CE1' ' A' ' 117' ' ' PHE . 14.5 mt -53.62 -48.18 59.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.62 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 16.8 mtpp -54.57 -41.78 70.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -87.32 -15.88 36.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.881 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.604 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.28 -14.8 32.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.067 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.598 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 16.4 m-85 -114.65 -8.82 12.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.581 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.0 -46.28 98.69 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.594 0.712 . . . . 0.0 111.105 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.581 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.4 Cg_exo -47.93 -17.12 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.658 2.238 . . . . 0.0 112.388 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.572 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 56.6 m-85 -89.98 -32.87 16.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.882 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.81 171.14 26.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.492 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.576 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 0.0 OUTLIER -55.86 132.62 50.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.762 0.315 . . . . 0.0 110.872 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.409 HD13 ' HA ' ' A' ' 114' ' ' LYS . 96.5 mt -102.52 123.84 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.14 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 83.9 p -86.02 -49.69 7.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.841 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -143.84 117.6 9.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.852 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.62 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -141.75 134.31 28.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.473 ' HB3' ' CZ ' ' A' ' 127' ' ' ARG . 1.7 ptp180 -158.81 164.93 35.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.474 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.3 p -112.94 100.06 9.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.093 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -49.68 126.5 4.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.192 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -121.46 171.99 8.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -76.76 156.96 31.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.89 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 17.2 ttp -94.89 -11.79 28.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.92 -62.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 71.1 p -82.9 -30.69 28.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.98 28.45 60.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.5 mmtp -106.32 152.3 23.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.829 0.347 . . . . 0.0 110.874 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 50.6 p -45.99 109.59 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.846 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -53.95 -36.3 62.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 123.97 12.81 4.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.503 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 30.8 p90 -162.64 146.73 11.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.907 0.384 . . . . 0.0 110.922 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -133.97 -169.59 12.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.479 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -136.99 141.87 42.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 41.4 t -145.04 108.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 13.3 t -88.48 150.98 22.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.49 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 57.6 m-85 -127.54 151.62 48.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.576 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 14.3 m-85 -69.38 -42.42 75.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 -115.23 178.96 4.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.908 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.8 tttm -87.15 -41.59 13.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 14.4 tp -53.49 -65.06 0.63 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.459 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 12.4 p-10 -41.81 -53.97 3.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -53.95 -51.11 64.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.123 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -53.39 -44.81 68.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -50.25 -48.58 54.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.857 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.572 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -67.07 -60.56 2.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.101 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.586 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 97.4 mt -38.32 -41.26 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.146 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.3 t -79.66 -58.48 3.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 30.2 m-70 -57.81 -65.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.897 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.598 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 15.8 mmt -46.59 -45.84 19.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -40.16 91.77 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.486 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 99.77 -32.08 7.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.506 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.444 ' N ' ' O ' ' A' ' 158' ' ' MET . 3.2 tp-100 -39.06 149.02 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.835 0.35 . . . . 0.0 110.92 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.563 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 78.9 m95 -95.31 91.65 6.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.632 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.1 tt -87.34 -71.71 0.55 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.497 ' HA3' HD11 ' A' ' 108' ' ' ILE . . . -119.89 119.26 4.18 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.476 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.39 -92.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.497 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -85.42 169.3 13.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.756 0.312 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.563 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 85.7 mt-30 -68.65 177.18 2.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 29.1 pt -135.8 169.87 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.469 ' O ' HG13 ' A' ' 101' ' ' VAL . 2.6 ptp180 -137.23 163.43 30.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.832 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 101' ' ' VAL . 42.8 p -140.18 163.51 32.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -162.86 157.77 21.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.586 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 82.6 m95 -88.69 96.96 10.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.925 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.88 37.81 0.72 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.7 t -128.56 142.74 50.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.17 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -117.4 126.9 53.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.53 144.34 45.89 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 110.879 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 147.42 62.67 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.673 2.248 . . . . 0.0 112.299 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 145.95 58.49 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.641 2.227 . . . . 0.0 112.343 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -139.27 144.67 41.32 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.619 0.723 . . . . 0.0 111.109 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 176.98 6.08 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.719 2.279 . . . . 0.0 112.365 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 22.8 m -94.94 -45.27 7.34 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 116.72 166.39 14.28 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 166.31 27.98 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.712 2.275 . . . . 0.0 112.357 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.3 m -130.86 95.33 3.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 6.2 t -66.53 148.32 52.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.824 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.501 -179.986 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 54.5 p -62.35 155.21 25.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.861 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 59.6 p -115.72 -44.09 2.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 103.17 66.43 0.74 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.515 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.2 t -97.77 148.49 23.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.86 0.362 . . . . 0.0 110.851 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 23.4 m -156.0 155.35 32.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.87 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.17 43.04 2.66 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.477 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -126.38 152.72 45.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.872 0.368 . . . . 0.0 110.923 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 33.8 mmtm -106.43 143.2 34.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.9 mmtp -150.82 143.47 24.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -49.85 174.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.867 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 70.6 p -82.73 125.56 31.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.159 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 23.6 t -102.53 87.43 3.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.858 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 46.46 43.52 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.516 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 48.6 m170 -77.39 162.11 27.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.855 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.566 ' CE1' ' HE3' ' A' ' 148' ' ' LYS . 85.2 m-85 -89.6 131.86 35.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.877 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -93.25 124.82 37.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.819 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 65.5 t -111.26 130.96 63.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.491 ' C ' ' CD1' ' A' ' 100' ' ' PHE . 1.9 t80 -98.9 140.74 32.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.534 HG13 ' O ' ' A' ' 169' ' ' ARG . 21.5 t -130.55 134.99 61.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.114 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.75 172.79 16.45 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.534 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.0 t0 58.63 40.3 23.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 110.877 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.477 HD13 HG23 ' A' ' 128' ' ' VAL . 35.6 mt -77.28 97.58 4.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.912 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.6 t -35.0 152.45 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.655 0.74 . . . . 0.0 110.882 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 -14.13 35.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.728 2.286 . . . . 0.0 112.37 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -93.42 1.68 56.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 9.4 mm -76.77 146.82 8.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.109 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 57.6 p -134.43 158.99 42.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 90.0 m -57.22 -33.69 67.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.142 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -75.93 -17.67 59.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' CB ' ' A' ' 116' ' ' ALA . 11.9 m-20 -81.78 -48.08 12.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.475 HG23 ' CE1' ' A' ' 117' ' ' PHE . 30.9 mt -64.39 -39.58 86.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.142 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.42 ' O ' HD12 ' A' ' 123' ' ' ILE . 57.8 mttt -63.83 -42.83 97.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 1.3 t -86.08 -16.47 37.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 112' ' ' ASP . . . -85.51 -29.63 24.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.508 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 9.0 m-85 -100.39 -8.3 23.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.58 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.71 -46.45 99.36 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.569 0.7 . . . . 0.0 111.108 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.58 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.2 Cg_exo -47.98 -17.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.642 2.228 . . . . 0.0 112.358 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.514 ' CE2' ' HG2' ' A' ' 158' ' ' MET . 46.4 m-85 -91.56 -36.4 13.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.873 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.09 176.9 40.02 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.3 tttt -68.5 121.2 15.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.758 0.313 . . . . 0.0 110.92 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.42 HD12 ' O ' ' A' ' 114' ' ' LYS . 56.8 mt -91.89 127.77 43.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.128 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.6 t -92.45 -42.34 9.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.882 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -142.66 124.56 15.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.892 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -154.73 126.81 7.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.7 ptm180 -150.55 156.32 41.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.6 p -108.59 99.95 9.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.115 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 45.6 t -51.84 122.55 2.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.459 ' HG2' ' N ' ' A' ' 137' ' ' SER . 69.4 mttt -115.92 172.45 7.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.901 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -75.25 143.51 43.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.893 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 25.3 tpp -89.28 3.41 52.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -106.64 -62.94 1.33 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.119 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 43.7 p -91.94 -27.53 17.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.144 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.38 30.34 22.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 137' ' ' SER . 49.1 mtmt -112.03 135.71 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.76 0.314 . . . . 0.0 110.918 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.459 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 67.4 m -37.24 119.31 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.803 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -60.75 -42.35 97.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.46 26.91 0.64 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.434 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.443 ' C ' HD12 ' A' ' 104' ' ' LEU . 16.4 p90 -169.82 144.77 2.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.944 0.402 . . . . 0.0 110.904 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -138.4 -177.99 15.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.486 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -134.2 139.7 45.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.845 0.355 . . . . 0.0 110.898 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 53.5 t -141.85 127.9 18.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.103 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 1.5 m -104.92 144.45 31.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 150' ' ' ASP . 19.6 m-85 -124.1 145.1 49.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.855 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.516 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.7 m-85 -62.0 -46.95 86.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.966 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -118.45 165.8 13.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.566 ' HE3' ' CE1' ' A' ' 97' ' ' PHE . 10.9 ttmt -67.52 -56.19 10.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.945 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.7 tp -39.26 -53.9 1.87 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.897 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.403 ' HB3' ' CD1' ' A' ' 145' ' ' PHE . 65.0 m-20 -51.28 -39.44 56.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -70.24 -58.03 4.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.11 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -46.88 -47.48 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 28.1 m-20 -51.01 -47.38 61.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.482 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -69.08 -49.71 54.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.61 ' CD1' ' CE2' ' A' ' 172' ' ' TRP . 91.8 mt -48.54 -34.53 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.136 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 88.1 t -89.41 -55.8 5.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.0 m-70 -57.01 -63.01 1.35 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.622 ' CE ' HD11 ' A' ' 168' ' ' ILE . 92.0 mmm -57.53 -40.03 77.91 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 92.25 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.529 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 95.48 -29.35 9.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.482 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.2 tp-100 -37.3 153.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.796 0.332 . . . . 0.0 110.888 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.566 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 90.7 m95 -96.82 91.02 5.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.965 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.481 HD12 ' HE1' ' A' ' 158' ' ' MET . 4.8 tt -85.47 -70.22 0.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.11 118.02 3.43 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.04 -93.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.52 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -82.25 174.31 11.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.842 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.566 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 84.5 mt-30 -76.16 178.23 6.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.859 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.622 HD11 ' CE ' ' A' ' 158' ' ' MET . 9.2 pt -139.91 166.99 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.158 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.534 ' O ' HG13 ' A' ' 101' ' ' VAL . 51.8 mtt180 -126.71 167.74 15.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 4.2 p -147.76 143.76 27.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.165 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 42.2 t30 -153.67 166.95 31.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.88 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.61 ' CE2' ' CD1' ' A' ' 155' ' ' ILE . 97.0 m95 -88.11 109.87 20.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -81.55 62.71 5.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.12 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 79.4 m -132.98 122.6 24.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.152 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -100.71 85.72 2.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.2 ttpm? -167.32 137.49 2.36 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.581 0.705 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 151.92 68.8 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.707 2.271 . . . . 0.0 112.298 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 107.06 1.77 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.694 2.263 . . . . 0.0 112.349 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -61.86 144.86 93.16 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.63 0.729 . . . . 0.0 111.083 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 139.4 40.1 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.339 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 94.8 p -116.92 173.68 6.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -121.22 169.69 14.45 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 113.86 3.51 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.666 2.244 . . . . 0.0 112.381 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 50.8 m -91.37 166.4 12.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 15.7 m -115.22 167.93 10.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.861 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.484 179.997 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 88.8 p -166.31 124.65 1.47 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.359 . . . . 0.0 110.861 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 85.9 p -115.44 155.75 26.88 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.74 -79.05 0.63 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.49 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 9.8 t -71.02 144.99 50.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.83 0.348 . . . . 0.0 110.89 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 78.8 p -172.99 168.84 4.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.809 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -126.05 70.13 0.49 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.457 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -58.24 -35.78 72.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.811 0.339 . . . . 0.0 110.854 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -81.26 -32.42 33.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.92 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.3 tmtm? -163.5 108.72 1.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -79.38 146.85 32.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 41.4 p -108.27 123.1 48.27 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.117 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.5 p -130.04 -36.78 1.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.837 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -111.42 27.1 9.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.7 m170 -119.91 155.9 31.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.906 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.569 ' CE1' ' HD3' ' A' ' 148' ' ' LYS . 90.5 m-85 -93.45 157.64 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.904 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -112.66 129.12 56.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.455 HG22 HD11 ' A' ' 155' ' ' ILE . 49.5 t -119.88 117.63 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.46 132.52 34.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.893 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.73 HG22 HG22 ' A' ' 170' ' ' THR . 91.1 t -124.11 120.49 59.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -110.46 177.78 19.66 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 53.83 46.35 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 110.913 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.496 HD12 ' N ' ' A' ' 141' ' ' GLY . 28.1 mt -90.85 113.81 26.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -45.53 152.73 0.65 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.715 0.769 . . . . 0.0 110.847 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -33.96 15.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.658 2.239 . . . . 0.0 112.317 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -66.41 -22.95 66.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.902 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.401 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 22.6 mm -55.41 150.31 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.157 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 44.3 p -130.74 164.01 26.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.185 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.703 HG23 ' HA ' ' A' ' 127' ' ' ARG . 90.6 m -64.63 -32.64 74.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.11 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -79.95 -11.84 59.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -83.53 -50.53 8.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.881 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.603 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.6 mt -57.84 -39.57 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.157 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 58.7 mttt -60.43 -35.77 76.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.4 t -92.48 -16.18 26.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.845 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.718 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -89.34 -16.27 31.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.085 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.603 ' CE1' HG23 ' A' ' 113' ' ' ILE . 21.1 m-85 -112.19 -9.5 13.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.64 -46.09 99.38 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.548 0.689 . . . . 0.0 111.102 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.1 Cg_exo -48.01 -17.08 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.71 2.273 . . . . 0.0 112.335 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.633 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 49.3 m-85 -91.27 -31.95 15.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 159.67 172.49 26.92 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 59.9 tttt -58.37 140.07 54.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 110.912 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.46 HG21 ' HB2' ' A' ' 126' ' ' ALA . 89.6 mt -109.92 131.02 62.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 79.3 p -96.57 -26.0 15.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -159.81 125.04 4.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.46 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -150.16 124.4 9.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.703 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.0 OUTLIER -151.32 155.56 38.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.591 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.0 p -108.22 100.06 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.123 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.4 t -49.03 122.67 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.168 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 38.4 mttt -119.1 168.9 10.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -73.34 145.69 45.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.884 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 tpt -87.41 15.72 6.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -130.19 -55.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.134 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 7.5 p -85.93 -28.47 24.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.122 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.03 22.69 70.81 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 6.3 mmpt? -106.59 150.11 26.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 44.6 m -54.2 109.27 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.865 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -49.35 -35.29 18.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.45 15.25 2.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -160.91 144.34 13.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.934 0.397 . . . . 0.0 110.92 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.496 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -136.13 -176.0 14.12 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -129.29 136.44 50.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 54.7 t -137.16 119.07 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.133 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 11.4 m -99.18 145.3 27.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -124.51 148.99 47.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.866 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -65.1 -46.33 81.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -119.77 150.56 40.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.569 ' HD3' ' CE1' ' A' ' 97' ' ' PHE . 20.8 tptt -55.88 -56.66 17.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.886 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 148' ' ' LYS . 28.8 tp -37.36 -49.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.944 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 1.0 OUTLIER -57.26 -42.09 80.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.809 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.458 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -64.85 -47.02 79.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -58.15 -46.43 85.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -48.78 -46.85 42.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.916 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.633 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -70.72 -60.44 2.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.586 HD13 ' CE2' ' A' ' 172' ' ' TRP . 66.6 mt -39.03 -36.78 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.116 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 69.2 t -78.7 -60.76 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -62.88 -66.13 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.851 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.581 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 29.4 mmt -37.8 -50.63 1.25 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.926 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.14 102.43 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.525 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 88.58 -30.66 5.21 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 51.0 tp60 -35.27 152.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.759 0.314 . . . . 0.0 110.923 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.567 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 84.8 m95 -100.76 91.42 4.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.937 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.718 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.4 tt -87.42 -70.36 0.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.401 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.22 118.72 3.97 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.532 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.29 -92.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.442 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.6 mtt180 -80.4 178.07 8.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.567 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 22.4 mt-30 -79.24 -178.79 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 23.2 pt -138.33 171.17 15.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.492 ' O ' HG13 ' A' ' 101' ' ' VAL . 12.5 ttm180 -136.45 141.95 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.73 HG22 HG22 ' A' ' 101' ' ' VAL . 24.0 p -127.11 148.69 50.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.129 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -159.94 166.41 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.916 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.586 ' CE2' HD13 ' A' ' 155' ' ' ILE . 85.8 m95 -82.7 107.01 15.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -53.86 89.98 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.4 ' N ' ' O ' ' A' ' 172' ' ' TRP . 39.2 m -124.19 140.56 52.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.124 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -122.65 142.42 50.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -134.09 136.4 26.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.522 0.677 . . . . 0.0 110.913 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 157.89 58.88 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.688 2.258 . . . . 0.0 112.352 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 81.45 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.7 2.267 . . . . 0.0 112.345 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -141.73 144.16 31.88 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.578 0.704 . . . . 0.0 111.077 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 131.13 20.61 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.711 2.274 . . . . 0.0 112.373 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 73.9 m -103.87 -46.32 4.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.802 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 139.92 173.92 13.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.514 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 -46.52 1.19 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.669 2.246 . . . . 0.0 112.372 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 t -75.36 162.23 28.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.831 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 8.4 t -64.7 -48.95 72.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.831 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.471 -179.994 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 23.4 m -57.68 132.76 54.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.857 0.36 . . . . 0.0 110.872 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.0 p -153.13 156.37 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.842 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 81.38 130.99 1.18 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.515 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.5 m -149.73 174.36 12.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.879 0.371 . . . . 0.0 110.826 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 9.4 t -114.89 123.41 49.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.834 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 90' ' ' LYS . . . 167.51 114.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.506 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -48.02 93.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.842 0.353 . . . . 0.0 110.901 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' GLY . 35.8 mmtm -141.91 135.19 29.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.9 mtmt 43.61 26.57 0.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.918 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -106.03 108.33 19.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 5.0 p -91.99 140.58 29.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -130.77 -47.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.873 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -74.15 -28.41 61.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.843 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.508 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 60.0 m170 -65.52 172.92 2.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.85 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.533 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 25.4 m-85 -107.19 133.33 51.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -87.88 129.02 35.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.877 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.0 t -120.39 122.83 69.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.551 ' C ' ' CD1' ' A' ' 100' ' ' PHE . 0.6 OUTLIER -86.46 145.47 26.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.577 ' CG1' HD21 ' A' ' 104' ' ' LEU . 98.7 t -137.53 110.74 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -102.05 -172.77 27.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.503 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 45.78 46.34 11.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.577 HD21 ' CG1' ' A' ' 101' ' ' VAL . 65.7 mt -87.69 109.49 19.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.4 t -43.12 153.23 0.35 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.627 0.727 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -18.23 36.92 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.662 2.241 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -87.4 -4.41 59.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.434 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 24.5 mm -69.19 147.82 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 70.3 p -136.49 144.6 44.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.157 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.428 ' OG1' HG12 ' A' ' 128' ' ' VAL . 89.6 m -46.77 -35.71 6.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -72.29 -31.57 65.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -69.49 -49.18 57.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.45 HG23 ' CE1' ' A' ' 117' ' ' PHE . 17.6 mt -58.44 -47.25 88.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.134 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.492 ' CG ' ' HB3' ' A' ' 126' ' ' ALA . 27.8 mtpt -60.09 -35.2 74.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.942 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 30.0 t -90.74 -8.67 49.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.64 -24.91 14.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.068 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.9 m-85 -100.59 -8.68 22.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.578 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -54.07 -46.19 98.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.729 . . . . 0.0 111.107 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.578 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 66.0 Cg_exo -48.0 -17.16 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.658 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 52.2 m-85 -90.99 -38.31 12.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.39 179.28 41.74 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.455 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.469 ' HG2' ' CZ ' ' A' ' 146' ' ' TYR . 20.9 tptt -66.1 133.26 50.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.727 0.299 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.4 HD13 ' HA ' ' A' ' 114' ' ' LYS . 67.9 mt -106.4 128.42 60.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.6 t -100.57 -27.82 13.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -148.43 138.76 22.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.824 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.492 ' HB3' ' CG ' ' A' ' 114' ' ' LYS . . . -168.08 123.4 0.99 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 14.6 ptp180 -148.07 156.6 42.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.873 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.5 p -116.39 100.61 10.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.101 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.713 HG11 ' OH ' ' A' ' 140' ' ' TYR . 23.0 t -53.25 119.44 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.069 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.471 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.6 mttm -119.62 157.8 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -64.07 153.95 35.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.884 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 48.2 tpp -95.52 -13.32 24.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -96.85 -56.39 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -87.83 -34.91 18.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.165 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 83.56 29.98 31.22 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 14.5 mmtp -112.18 147.68 35.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.839 0.352 . . . . 0.0 110.882 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.471 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 39.1 t -49.09 104.8 0.07 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 58.0 mttt -44.75 -36.13 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.904 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 124.21 27.67 1.32 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.713 ' OH ' HG11 ' A' ' 129' ' ' VAL . 49.2 p90 -167.37 151.64 6.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.935 0.398 . . . . 0.0 110.904 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -150.13 -177.81 24.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.511 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -133.9 141.22 47.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.882 0.372 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 90.4 t -143.64 116.57 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.159 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 67.6 m -94.04 139.11 31.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.47 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 12.2 m-85 -117.65 138.44 51.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.885 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.508 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 6.5 m-85 -51.79 -45.52 63.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.7 168.9 11.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.91 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.533 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 53.0 tttt -74.58 -59.26 2.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.1 tp -39.69 -49.02 2.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.906 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -58.97 -40.24 84.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.47 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -67.99 -43.93 77.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -56.66 -44.73 81.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -52.26 -46.47 65.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.658 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.97 -51.89 34.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.685 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 96.9 mt -46.0 -37.27 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.4 t -86.58 -54.94 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -57.31 -60.74 3.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.588 ' HE1' HD12 ' A' ' 163' ' ' LEU . 94.2 mmm -60.5 -38.93 85.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.13 94.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.0 -31.59 5.86 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.518 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.4 tp-100 -35.21 152.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.807 0.337 . . . . 0.0 110.888 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.569 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -93.99 91.01 6.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.588 HD12 ' HE1' ' A' ' 158' ' ' MET . 4.9 tt -87.57 -70.26 0.64 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -118.5 116.62 3.45 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.55 -91.11 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.473 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -83.84 174.19 10.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.793 0.33 . . . . 0.0 110.819 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.569 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 58.9 mt-30 -75.51 170.69 15.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.963 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.587 HD11 ' HE3' ' A' ' 158' ' ' MET . 15.7 pt -129.03 167.27 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.118 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 8.6 mmt85 -121.59 165.4 15.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.868 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 2.6 p -149.77 128.28 12.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.166 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -144.47 157.78 44.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.685 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 79.0 m95 -81.01 107.24 13.66 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.914 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.416 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -89.12 80.12 7.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.114 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.4 t -159.3 144.03 15.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.173 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 1.3 tpm_? -86.11 148.97 25.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -93.71 129.73 37.28 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.556 0.693 . . . . 0.0 110.893 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 148.86 65.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.662 2.241 . . . . 0.0 112.328 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 163.98 36.23 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.64 2.226 . . . . 0.0 112.349 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -157.91 144.18 12.81 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.613 0.721 . . . . 0.0 111.064 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 108.01 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.645 2.23 . . . . 0.0 112.352 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 83.7 p -110.79 102.66 11.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -170.95 70.31 0.12 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 159.6 52.83 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.392 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 1.4 t -71.24 124.54 24.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.838 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 26.4 m 49.08 41.83 20.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.818 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.502 179.976 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.2 t -125.89 -51.43 1.57 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.831 0.348 . . . . 0.0 110.832 -179.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 78.0 p -93.42 147.67 22.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.915 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -135.14 -72.87 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.501 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.7 m -148.56 114.0 5.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.918 0.389 . . . . 0.0 110.871 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 29.4 t -41.75 156.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.856 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.12 -75.75 0.12 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.47 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -126.8 37.91 4.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.892 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -99.03 163.94 12.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -140.04 157.59 45.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.88 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.429 ' O ' ' CE1' ' A' ' 96' ' ' HIS . 25.6 t70 -89.09 108.14 19.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 26.8 p -121.13 72.67 0.99 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.9 m -95.34 -38.24 10.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.819 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -116.58 19.73 14.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.86 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.429 ' CE1' ' O ' ' A' ' 92' ' ' ASP . 21.9 m170 -99.35 157.46 16.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.886 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.451 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 94.8 m-85 -103.34 136.88 42.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.846 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 60.0 m-70 -96.07 127.0 41.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.416 HG21 ' HB1' ' A' ' 151' ' ' ALA . 25.2 t -117.19 131.95 68.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' OD1' ' A' ' 171' ' ' ASN . 2.2 t80 -97.64 138.78 34.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.516 HG22 HG22 ' A' ' 170' ' ' THR . 88.4 t -125.05 115.42 44.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.152 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.03 -178.72 30.43 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 45.78 47.02 12.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.831 0.348 . . . . 0.0 110.903 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.562 HD12 ' C ' ' A' ' 140' ' ' TYR . 32.7 mt -78.88 100.49 7.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -40.81 155.2 0.2 Allowed Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.634 0.73 . . . . 0.0 110.882 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -19.01 36.51 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.698 2.265 . . . . 0.0 112.292 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -82.02 -22.44 36.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.848 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.633 HD12 HD22 ' A' ' 163' ' ' LEU . 6.8 mm -60.91 137.97 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.111 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.437 ' O ' ' N ' ' A' ' 111' ' ' GLU . 52.8 p -133.0 140.5 47.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.151 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.44 ' OG1' HG12 ' A' ' 128' ' ' VAL . 91.2 m -36.74 -32.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.159 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 109' ' ' THR . 15.0 tt0 -73.74 -48.96 27.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.466 ' O ' ' N ' ' A' ' 116' ' ' ALA . 77.1 m-20 -58.6 -51.33 70.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.896 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 22.2 mt -50.76 -38.8 17.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.112 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.493 ' O ' HD12 ' A' ' 123' ' ' ILE . 22.3 mttp -67.18 -35.34 79.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 22.9 t -92.95 -11.1 34.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.835 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.922 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -90.85 -32.89 15.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.083 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.56 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.7 m-85 -95.85 -5.02 42.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.582 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -57.67 -46.64 99.74 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.603 0.715 . . . . 0.0 111.087 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.582 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.98 -17.02 0.68 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.696 2.264 . . . . 0.0 112.32 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.689 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 36.0 m-85 -93.2 -30.67 15.09 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.848 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.18 179.93 36.23 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.515 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.548 ' HG2' ' CE2' ' A' ' 146' ' ' TYR . 41.1 tptt -63.82 140.24 58.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.761 0.315 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.493 HD12 ' O ' ' A' ' 114' ' ' LYS . 97.7 mt -108.34 130.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.107 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.9 p -98.31 -50.76 4.21 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.863 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -136.44 118.83 15.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -142.11 124.82 15.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.091 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -148.09 156.15 42.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.44 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.1 p -113.13 100.11 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.126 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.794 HG11 ' CE1' ' A' ' 140' ' ' TYR . 46.1 t -49.12 127.52 4.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -130.53 151.87 50.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.909 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.82 155.88 5.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 5.2 ptp -97.62 -17.79 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.857 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.75 -57.54 2.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.147 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.7 p -81.51 -32.78 32.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.123 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.43 28.38 61.77 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.474 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -101.88 162.62 12.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.804 0.335 . . . . 0.0 110.877 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 77.7 p -58.86 98.45 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.849 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.516 ' HB3' ' CE2' ' A' ' 140' ' ' TYR . 20.5 mmtt -42.95 -42.98 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.87 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.41 19.18 4.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.794 ' CE1' HG11 ' A' ' 129' ' ' VAL . 47.7 p90 -163.37 153.45 15.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.892 0.377 . . . . 0.0 110.951 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -151.22 -172.01 19.78 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.466 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -135.54 140.16 44.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.875 0.369 . . . . 0.0 110.875 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 28.6 t -145.52 107.64 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 3.5 t -89.19 154.06 20.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.531 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 13.6 m-85 -129.46 150.34 50.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.865 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.548 ' CE2' ' HG2' ' A' ' 122' ' ' LYS . 16.0 m-85 -66.37 -33.52 75.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.895 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -129.52 165.44 21.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.889 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.451 ' HB2' ' CE2' ' A' ' 97' ' ' PHE . 22.9 tttm -69.35 -61.97 1.57 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.7 tp -39.4 -63.19 0.58 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -40.77 -45.31 2.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -69.76 -60.75 2.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -40.41 -47.06 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 17.7 m-80 -47.66 -56.97 6.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.881 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.689 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -56.72 -53.72 54.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.474 HD13 ' CE2' ' A' ' 172' ' ' TRP . 47.7 mt -41.86 -35.39 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.8 t -84.5 -56.64 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 66.3 m-70 -62.09 -64.67 0.86 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.579 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 11.9 mmt -44.86 -47.01 11.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.56 102.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.489 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.74 -28.67 3.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.484 ' N ' ' O ' ' A' ' 158' ' ' MET . 62.7 tp60 -35.8 152.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.79 0.328 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.589 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 85.2 m95 -99.16 91.02 4.79 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.922 HD11 ' CB ' ' A' ' 116' ' ' ALA . 6.6 tt -86.77 -70.45 0.61 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.902 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.18 118.43 3.78 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.461 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.65 -92.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.488 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 14.7 mtt-85 -79.41 -178.38 6.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.759 0.314 . . . . 0.0 110.87 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.589 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 30.1 mt-30 -84.14 179.82 7.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.419 ' O ' ' N ' ' A' ' 160' ' ' GLY . 19.7 pt -136.87 171.95 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.486 ' O ' HG13 ' A' ' 101' ' ' VAL . 41.3 ttt180 -134.64 160.5 37.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.858 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.516 HG22 HG22 ' A' ' 101' ' ' VAL . 17.1 p -145.12 152.54 40.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.152 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . 0.576 ' OD1' ' CD1' ' A' ' 100' ' ' PHE . 3.0 p30 -172.96 149.9 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.474 ' CE2' HD13 ' A' ' 155' ' ' ILE . 99.2 m95 -68.98 133.14 47.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.89 61.13 6.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.089 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 2.2 m -149.46 151.47 34.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.163 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 10.2 ptm180 -125.1 56.23 1.34 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -165.15 136.09 3.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.589 0.709 . . . . 0.0 110.944 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 140.37 42.42 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.648 2.232 . . . . 0.0 112.329 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 145.32 56.77 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.741 2.294 . . . . 0.0 112.342 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -65.58 144.04 98.8 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 0.0 111.097 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 119.38 6.34 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.73 2.287 . . . . 0.0 112.359 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 3.7 m -44.38 168.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.85 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -156.19 83.22 0.15 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.441 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 150.7 68.32 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.346 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 29.2 t -118.64 128.03 54.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 16.1 t -139.69 168.45 19.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.845 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.482 179.975 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.5 t -48.88 -46.39 42.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.844 0.354 . . . . 0.0 110.845 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -49.72 -47.31 50.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.838 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.29 145.04 44.91 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 3.1 t -88.38 153.41 21.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.849 0.357 . . . . 0.0 110.857 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 16.2 m -83.8 128.13 34.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.68 120.24 0.89 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 29.4 mt-30 -111.32 148.87 32.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.85 0.357 . . . . 0.0 110.926 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -113.3 41.65 2.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.0 ttpt 45.5 39.63 4.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.883 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -148.99 125.28 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 34.6 p -84.51 96.97 9.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 27.8 t -117.21 -49.25 2.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 t30 -64.22 -50.8 66.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -44.47 165.56 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.835 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.431 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 66.9 m-85 -96.68 140.95 30.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.888 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -100.57 131.89 46.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.401 ' CG2' ' HB1' ' A' ' 151' ' ' ALA . 58.5 t -122.27 124.48 71.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -91.2 140.02 30.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.482 HG11 HD21 ' A' ' 104' ' ' LEU . 77.7 t -127.6 126.78 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -121.93 -178.45 15.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.475 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 50.87 39.63 22.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.83 0.348 . . . . 0.0 110.852 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.482 HD21 HG11 ' A' ' 101' ' ' VAL . 44.0 mt -84.21 126.03 32.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.7 t -50.51 152.15 3.48 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.678 0.751 . . . . 0.0 110.857 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 -14.18 35.83 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -91.8 -6.73 51.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.886 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.29 153.1 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 40.5 p -139.09 -179.96 6.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.13 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.8 m -69.92 -40.42 75.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.094 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -70.65 -36.74 73.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 116' ' ' ALA . 5.0 m-20 -58.09 -52.31 66.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.837 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.509 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.5 mt -60.69 -42.41 91.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.412 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 14.2 mtpt -59.69 -36.6 76.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.883 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.5 t -94.03 -17.4 22.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.549 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -84.62 -18.31 35.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.564 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 14.3 m-85 -111.63 -5.49 14.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.569 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.1 -46.2 99.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.559 0.695 . . . . 0.0 111.09 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.569 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.02 -19.57 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.696 2.264 . . . . 0.0 112.325 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.578 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 45.0 m-85 -87.96 -36.93 16.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 170.96 -161.95 34.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.496 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.9 tmtt? -87.17 124.64 33.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 110.883 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.401 HD12 ' O ' ' A' ' 114' ' ' LYS . 46.6 mt -96.54 134.28 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.107 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 87.6 p -100.13 -45.88 5.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.902 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -134.41 122.02 21.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.837 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -151.16 122.61 7.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.414 ' NE ' ' HB2' ' A' ' 142' ' ' PHE . 0.0 OUTLIER -146.62 159.49 43.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -114.15 99.95 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.143 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 23.5 t -51.73 134.14 13.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.11 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.46 ' HG2' ' N ' ' A' ' 137' ' ' SER . 35.5 mttt -124.98 168.15 13.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -75.73 152.11 37.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.849 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.1 mpp? -97.49 16.71 19.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -123.67 -38.26 2.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 13.7 p -111.25 -24.15 10.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 78.33 20.61 71.84 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 20.0 mmtp -106.63 154.19 21.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.761 0.315 . . . . 0.0 110.938 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.46 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 28.3 m -51.18 120.11 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.852 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.2 mttm -60.18 -36.77 78.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.52 13.9 2.47 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.497 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -158.74 145.59 17.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 0.0 110.905 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -137.7 -175.85 14.11 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.414 ' HB2' ' NE ' ' A' ' 127' ' ' ARG . 41.6 m-85 -133.4 143.24 48.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.949 0.404 . . . . 0.0 110.888 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 45.0 t -145.51 127.38 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 32.2 t -105.13 151.15 24.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.498 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 73.6 m-85 -129.32 138.99 51.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -50.43 -42.47 53.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.941 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -127.27 164.55 21.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.914 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.475 ' O ' ' N ' ' A' ' 151' ' ' ALA . 13.7 ttmt -62.41 -62.37 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 148' ' ' LYS . 58.5 tp -34.58 -58.29 0.5 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.963 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -48.5 -42.47 33.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.498 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -70.69 -50.44 36.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.088 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 3.8 tm-20 -53.75 -46.12 70.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -45.99 -47.84 16.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.496 ' HB1' ' HG3' ' A' ' 158' ' ' MET . . . -66.08 -63.18 1.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.102 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 154' ' ' ALA . 45.6 mt -34.76 -46.53 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.0 t -67.77 -61.19 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.164 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -65.8 -64.66 0.81 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.835 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.578 ' HG2' ' CZ ' ' A' ' 120' ' ' PHE . 18.5 mmt -42.11 -48.6 4.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.41 100.71 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.508 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.417 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.21 -28.12 5.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.486 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 158' ' ' MET . 4.0 tp-100 -37.14 154.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.758 0.313 . . . . 0.0 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.577 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.4 m95 -98.7 90.99 4.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.587 HD23 ' C ' ' A' ' 163' ' ' LEU . 2.6 tt -85.06 -71.32 0.53 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -122.24 118.25 3.6 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.456 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.93 -93.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.503 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 44.2 mtt85 -79.5 178.45 8.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.745 0.307 . . . . 0.0 110.862 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 86.2 mt-30 -79.96 178.85 7.93 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.431 HG22 HD23 ' A' ' 104' ' ' LEU . 32.1 pt -137.64 170.33 17.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.143 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 27.6 ttm-85 -133.68 154.98 50.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.441 HG22 HG22 ' A' ' 101' ' ' VAL . 5.7 p -138.87 147.27 42.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -157.63 151.86 24.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 76.9 m95 -72.44 130.1 39.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -114.61 117.69 31.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.077 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.6 t -145.94 147.28 31.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.156 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 19.2 ttp180 -72.13 115.92 11.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.867 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 8.3 pttt -64.55 123.96 84.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.617 0.723 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 148.55 65.52 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.654 2.236 . . . . 0.0 112.388 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.08 2.17 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.67 2.247 . . . . 0.0 112.367 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -43.97 150.0 0.63 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.562 0.696 . . . . 0.0 111.13 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 119.81 6.69 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.655 2.237 . . . . 0.0 112.332 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 7.1 t -51.98 168.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -111.19 73.0 0.21 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.455 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 151.57 69.47 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.65 2.234 . . . . 0.0 112.406 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 3.2 m -85.88 -58.06 2.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.861 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 60.5 p -60.24 -47.14 87.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.843 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.99 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.461 -0.255 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 27.4 t -52.55 143.82 14.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.847 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 43.7 t -44.27 -66.01 0.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 153.11 -85.75 0.14 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.485 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 p -89.82 40.21 0.99 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.871 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 38.6 m -147.8 129.7 15.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.856 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 133.98 -150.68 20.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 27.1 mm-40 -103.59 169.72 8.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.896 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.56 68.9 0.68 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.9 mmpt? -103.52 100.33 10.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 38.6 t0 -78.41 118.75 20.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.819 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 44.4 p -95.82 126.3 40.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.9 m -100.34 82.36 2.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.808 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.6 m120 62.45 41.39 9.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.861 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.449 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 27.3 m170 -83.65 165.19 19.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.522 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 5.3 m-85 -99.81 133.91 43.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.846 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -95.35 135.67 36.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.448 HG22 HD11 ' A' ' 155' ' ' ILE . 78.8 t -121.43 121.22 64.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.091 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -85.02 145.9 27.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.905 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.59 HG13 ' O ' ' A' ' 169' ' ' ARG . 17.7 t -135.45 128.1 47.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.15 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -118.08 -179.05 17.25 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.512 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 48.38 46.86 20.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.878 0.37 . . . . 0.0 110.845 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.617 HD23 HG22 ' A' ' 168' ' ' ILE . 34.0 mt -88.13 105.35 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.936 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -36.09 153.39 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.654 0.74 . . . . 0.0 110.893 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -23.66 30.73 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.737 2.291 . . . . 0.0 112.327 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -79.3 -10.96 59.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.438 ' CD1' ' HA3' ' A' ' 164' ' ' GLY . 17.3 mm -65.69 143.8 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.472 ' HG1' ' CG ' ' A' ' 112' ' ' ASP . 65.2 p -126.14 164.32 21.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.468 ' OG1' HG12 ' A' ' 128' ' ' VAL . 66.8 m -63.72 -29.69 70.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.097 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -79.97 -34.2 38.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.882 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.472 ' CG ' ' HG1' ' A' ' 109' ' ' THR . 98.1 m-20 -60.34 -55.53 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.468 HG23 ' CE1' ' A' ' 117' ' ' PHE . 11.7 mt -52.69 -40.12 33.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.474 ' HA ' ' CD1' ' A' ' 123' ' ' ILE . 62.7 mttt -64.34 -35.18 80.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.5 t -94.07 -9.71 35.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.79 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.14 -23.06 17.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.595 ' CZ ' ' SD ' ' A' ' 158' ' ' MET . 28.6 m-85 -105.92 -6.8 18.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.575 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -58.26 -45.98 99.68 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.559 0.695 . . . . 0.0 111.133 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.575 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 64.2 Cg_exo -47.96 -17.1 0.7 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.653 2.235 . . . . 0.0 112.352 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.584 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 46.2 m-85 -90.66 -41.44 11.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.87 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 175.68 -174.16 46.69 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.7 tptm -71.46 138.43 49.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.751 0.31 . . . . 0.0 110.923 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 114' ' ' LYS . 97.1 mt -104.01 139.34 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 5.8 t -116.49 -37.64 3.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.861 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -142.57 105.4 4.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -138.75 121.56 16.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.476 ' HB3' ' CZ ' ' A' ' 127' ' ' ARG . 2.4 ptp180 -153.11 154.71 35.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.88 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.614 HG13 ' HE2' ' A' ' 130' ' ' LYS . 2.4 p -107.72 100.05 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.148 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 47.4 t -50.04 133.87 9.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.097 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.614 ' HE2' HG13 ' A' ' 128' ' ' VAL . 20.5 mtmt -129.52 162.53 27.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.924 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -64.4 159.45 21.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 9.7 ttp -107.55 3.48 24.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -103.74 -45.67 4.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.121 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.3 p -110.52 -38.8 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.156 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 94.8 40.9 4.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.3 mttm -116.11 143.67 45.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.455 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 17.1 p -45.92 109.25 0.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 59.7 mttt -54.41 -35.67 63.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 119.99 19.35 4.02 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -161.2 146.69 14.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.909 0.385 . . . . 0.0 110.929 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -142.97 177.83 21.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -123.85 140.12 53.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.91 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.9 t -139.31 117.03 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.139 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 49.8 m -102.15 147.6 26.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -123.49 145.13 49.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.449 ' HA ' ' CE1' ' A' ' 96' ' ' HIS . 19.2 m-85 -58.24 -36.65 73.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.952 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -121.34 174.26 6.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.869 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.522 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 44.6 tttt -85.01 -52.35 6.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.859 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 26.7 tp -47.68 -53.6 14.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.955 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -49.19 -44.36 43.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -62.53 -52.3 64.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.1 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -49.49 -43.11 45.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.903 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -48.24 -51.79 24.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.562 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -65.49 -65.89 0.62 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.057 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.448 HD11 HG22 ' A' ' 99' ' ' VAL . 80.9 mt -34.59 -34.79 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.124 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 154' ' ' ALA . 20.1 t -74.02 -63.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.163 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -69.44 -59.2 3.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.595 ' SD ' ' CZ ' ' A' ' 117' ' ' PHE . 20.1 mmt -40.39 -51.11 2.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -38.15 102.33 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.491 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 87.94 -31.3 4.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.465 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.483 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.9 tp60 -34.27 150.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.573 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 92.3 m95 -96.96 91.03 5.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.937 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.79 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.9 tt -87.47 -70.56 0.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.907 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.52 117.35 3.67 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.475 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -91.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.457 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 15.0 mtp180 -79.55 -174.81 4.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.766 0.317 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.573 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 63.9 mt-30 -86.09 179.43 6.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.617 HG22 HD23 ' A' ' 104' ' ' LEU . 9.3 pt -136.84 169.31 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.59 ' O ' HG13 ' A' ' 101' ' ' VAL . 30.2 ttp180 -129.25 162.87 26.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.9 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 32.6 p -141.38 150.5 42.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.091 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -163.02 164.32 25.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 94.2 m95 -93.65 107.95 19.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -84.11 37.64 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.064 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 30.0 m -132.04 132.33 43.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.126 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 26.1 ttt180 -109.45 148.11 31.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.14 145.95 49.76 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.602 0.715 . . . . 0.0 110.879 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 143.92 52.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.659 2.239 . . . . 0.0 112.376 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 143.81 52.04 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.683 2.256 . . . . 0.0 112.342 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . 0.41 ' HB1' ' HD2' ' A' ' 180' ' ' PRO . . . -161.92 155.13 17.52 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.558 0.694 . . . . 0.0 111.078 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . 0.437 ' O ' ' C ' ' A' ' 181' ' ' SER . 54.2 Cg_endo -69.72 2.79 3.2 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.672 2.248 . . . . 0.0 112.376 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 180' ' ' PRO . 22.9 m -34.59 124.69 0.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.831 -179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.419 ' HA2' ' HD2' ' A' ' 183' ' ' PRO . . . -99.43 101.14 2.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.491 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.419 ' HD2' ' HA2' ' A' ' 182' ' ' GLY . 54.4 Cg_endo -69.72 162.76 40.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.691 2.261 . . . . 0.0 112.338 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 44.5 p -152.56 146.35 25.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 29.6 m -152.44 144.59 23.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.838 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.464 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 13.7 t -97.57 114.3 26.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.888 0.375 . . . . 0.0 110.835 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.6 t -100.23 159.11 15.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.863 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.27 112.76 2.82 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.463 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.7 m -42.24 107.96 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.859 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.8 m -81.36 147.83 29.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.853 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 66.18 73.36 0.63 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.512 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 4.6 pm0 -78.12 161.46 27.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 0.0 110.913 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -133.34 90.28 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? 39.51 31.69 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.876 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -136.99 116.46 12.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 54.9 p -73.64 141.62 46.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.116 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.5 m -133.23 -53.46 0.9 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -102.17 31.76 3.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 36.1 m170 -119.4 156.54 29.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.538 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 74.5 m-85 -100.0 161.38 13.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.6 m-70 -114.22 134.35 54.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.9 t -124.58 118.25 52.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.137 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.612 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 16.5 t80 -88.47 129.73 35.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.6 t -118.18 111.99 36.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.113 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -100.83 -179.09 29.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 48.0 54.84 9.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.451 HD12 ' C ' ' A' ' 140' ' ' TYR . 33.8 mt -92.31 106.58 18.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.931 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.487 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.5 t -35.51 152.33 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.707 0.765 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -18.77 36.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.5 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 9.3 tt0 -90.08 1.13 56.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.938 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 17.4 mm -74.72 147.38 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.128 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 51.3 p -132.04 163.58 28.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.086 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 25.5 m -58.71 -41.06 85.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.91 -35.4 76.8 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 116' ' ' ALA . 64.0 m-20 -60.17 -54.59 44.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.851 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.9 mt -57.99 -45.82 87.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.118 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.825 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 13.2 mtpp -57.44 -39.01 75.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.865 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 32.7 t -92.35 -9.15 42.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.839 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.533 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.64 -9.6 31.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.104 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.54 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 21.0 m-85 -120.26 -8.75 9.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.915 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.582 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -54.1 -45.97 98.9 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.639 0.733 . . . . 0.0 111.093 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.8 Cg_exo -47.98 -22.76 3.71 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.708 2.272 . . . . 0.0 112.321 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.685 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 39.7 m-85 -85.66 -35.62 20.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.863 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.59 174.7 34.63 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.453 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.646 ' CG ' ' CE1' ' A' ' 146' ' ' TYR . 0.8 OUTLIER -59.46 140.36 56.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.768 0.318 . . . . 0.0 110.877 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.763 HG21 ' HB2' ' A' ' 126' ' ' ALA . 82.7 mt -111.91 105.37 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.132 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 52.2 p -67.69 -32.15 72.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -159.67 123.93 3.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.825 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -146.51 125.45 12.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.097 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 6.2 ptm180 -149.12 166.76 27.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.568 HG13 ' O ' ' A' ' 128' ' ' VAL . 6.3 p -120.36 99.85 8.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.173 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 43.3 t -51.18 119.77 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.431 ' CA ' ' HG3' ' A' ' 138' ' ' LYS . 29.0 mtmt -114.81 152.38 32.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -56.72 155.45 7.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.882 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -98.07 -6.79 31.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -102.82 -61.64 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.14 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.9 p -81.67 -34.57 30.65 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 82.12 33.46 26.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.477 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -117.68 152.12 35.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.8 m -43.34 108.95 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.431 ' HG3' ' CA ' ' A' ' 130' ' ' LYS . 6.4 mtpm? -51.41 -38.19 52.24 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 125.35 12.94 3.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.462 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.451 ' C ' HD12 ' A' ' 104' ' ' LEU . 32.5 p90 -161.8 154.18 19.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.921 0.391 . . . . 0.0 110.919 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -147.06 -175.42 19.95 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.492 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -131.27 140.28 49.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.891 0.377 . . . . 0.0 110.858 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 40.8 t -144.86 109.58 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.12 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 73.7 m -86.71 141.92 28.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.594 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 17.8 m-85 -120.61 140.43 51.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.646 ' CE1' ' CG ' ' A' ' 122' ' ' LYS . 4.4 m-85 -54.48 -50.38 67.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.933 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -115.59 171.02 8.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.538 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 59.0 tttt -80.28 -38.44 30.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.893 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 24.6 tp -57.35 -51.93 67.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.94 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -56.78 -41.47 77.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.896 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.594 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -66.3 -49.11 68.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.092 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -51.0 -43.91 60.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 62.9 m-20 -49.56 -48.93 48.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.685 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -66.09 -54.88 20.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.5 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 97.5 mt -47.55 -35.29 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 77.5 t -82.24 -49.03 17.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.159 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 25.0 m-70 -71.51 -65.46 0.75 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.54 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 8.2 mmt -45.21 -46.52 12.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.48 103.6 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.458 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.41 -29.61 3.94 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.491 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.9 tp60 -40.98 149.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.926 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.439 ' CE2' ' HG2' ' A' ' 167' ' ' GLN . 84.0 m95 -93.87 92.33 7.36 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.928 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.622 HD23 ' C ' ' A' ' 163' ' ' LEU . 5.5 tt -87.03 -72.34 0.52 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.487 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -120.33 117.11 3.43 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.501 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 56.09 -93.05 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.5 mpt_? -83.52 175.99 9.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.749 0.309 . . . . 0.0 110.86 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.439 ' HG2' ' CE2' ' A' ' 162' ' ' TRP . 32.7 mt-30 -74.61 177.33 6.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.917 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 22.0 pt -136.23 165.09 30.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -129.56 152.33 49.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.848 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 29.8 p -130.07 160.46 33.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.166 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -169.81 163.35 9.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.872 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.5 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 85.5 m95 -90.87 100.23 13.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.612 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -71.72 81.92 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.084 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.5 t -168.36 140.82 2.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.119 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.418 ' N ' ' HD2' ' A' ' 175' ' ' ARG . 10.8 mpt_? -103.63 133.54 48.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.874 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.47 143.24 31.75 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.523 0.677 . . . . 0.0 110.928 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . 0.473 ' HA ' ' HD2' ' A' ' 178' ' ' PRO . 53.6 Cg_endo -69.77 110.37 2.54 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.659 2.239 . . . . 0.0 112.366 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . 0.473 ' HD2' ' HA ' ' A' ' 177' ' ' PRO . 53.6 Cg_endo -69.76 103.32 1.14 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.713 2.275 . . . . 0.0 112.348 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -117.84 150.48 47.18 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.555 0.693 . . . . 0.0 111.112 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -164.46 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.718 2.279 . . . . 0.0 112.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 3.7 m -114.48 156.91 23.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.867 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -51.16 146.53 10.4 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 106.1 1.6 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.707 2.271 . . . . 0.0 112.304 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 8.7 m -161.14 146.14 13.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.877 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 8.2 m -71.65 -49.74 37.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.884 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.514 -179.971 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.3 p -77.68 143.55 38.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.9 0.381 . . . . 0.0 110.835 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.1 t -132.99 144.86 50.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.821 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.7 86.28 0.19 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.478 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 t -79.99 146.9 31.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 40.9 m -114.82 -59.02 2.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.851 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . 159.32 -125.86 1.56 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.477 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 88' ' ' GLY . 33.1 mt-30 -34.7 137.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 91' ' ' LYS . 42.6 mmtt -49.31 -30.14 7.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 90' ' ' LYS . 51.1 mmtt 36.32 53.17 0.97 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.846 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -99.26 92.76 5.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.896 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 18.8 p 43.96 29.46 0.32 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 88.5 p -68.45 -47.67 66.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 54.3 m-20 -77.52 -42.23 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 28.1 m170 -51.56 147.14 6.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.85 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.533 ' CD1' ' HD3' ' A' ' 148' ' ' LYS . 90.6 m-85 -102.44 145.09 30.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.894 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 15.5 m-70 -100.27 138.68 37.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.846 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 25.2 t -124.23 130.23 73.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.184 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -91.77 138.09 31.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.7 118.31 46.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.098 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -106.62 172.05 17.95 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.513 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 54.53 53.37 10.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.41 HD23 ' HA ' ' A' ' 104' ' ' LEU . 26.1 mt -87.93 104.48 16.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.941 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 164' ' ' GLY . 1.3 t -38.03 153.57 0.13 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.702 0.763 . . . . 0.0 110.877 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -20.48 34.86 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.736 2.29 . . . . 0.0 112.31 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -83.21 -17.9 41.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.475 HG22 ' N ' ' A' ' 109' ' ' THR . 37.1 mm -57.61 156.95 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.123 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.475 ' N ' HG22 ' A' ' 108' ' ' ILE . 40.5 p -143.87 170.61 15.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.437 ' OG1' HG12 ' A' ' 128' ' ' VAL . 56.9 m -66.13 -33.87 76.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.149 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -78.24 -35.21 48.59 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 116' ' ' ALA . 67.1 m-20 -59.1 -55.89 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.841 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.457 HG23 ' CE1' ' A' ' 117' ' ' PHE . 7.8 mt -55.6 -42.68 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.11 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 17.7 mttp -61.64 -36.34 80.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.922 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 5.1 t -93.4 -10.41 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.848 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.512 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -94.02 -18.77 21.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.575 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 7.1 m-85 -111.57 -5.78 14.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.586 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.41 -45.71 99.89 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.593 0.711 . . . . 0.0 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 64.7 Cg_exo -48.04 -25.23 6.24 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.659 2.239 . . . . 0.0 112.382 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.557 ' CZ ' ' HG2' ' A' ' 158' ' ' MET . 54.0 m-85 -78.83 -38.84 37.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 168.02 179.13 40.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 35.2 tptt -59.41 142.21 52.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.77 0.319 . . . . 0.0 110.942 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.7 mt -114.33 137.1 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.11 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 6.3 p -112.35 -23.6 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -154.02 143.31 21.41 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -174.77 123.62 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.06 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -148.2 159.35 44.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.441 HG13 ' O ' ' A' ' 128' ' ' VAL . 2.6 p -112.55 99.9 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.165 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.514 HG11 ' CZ ' ' A' ' 140' ' ' TYR . 80.5 t -51.32 126.59 6.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.152 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.485 ' HG2' ' N ' ' A' ' 137' ' ' SER . 34.2 mttm -125.84 159.94 31.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -62.52 159.51 15.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.873 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 3.0 ptp -102.38 -14.78 16.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -99.39 -38.02 8.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.076 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 70.6 p -105.78 -29.42 10.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 75.05 36.85 45.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.478 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 36.8 mmtm -119.86 151.3 39.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.816 0.341 . . . . 0.0 110.893 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.485 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 56.2 p -45.97 113.26 0.59 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.873 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 16.5 mttp -59.57 -36.73 76.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.37 14.25 2.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.43 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.514 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 34.1 p90 -160.83 149.89 16.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.867 0.365 . . . . 0.0 110.937 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.28 -177.54 18.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -127.33 140.72 52.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 25.3 t -140.7 118.94 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.4 p -98.58 149.76 22.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -129.0 150.66 50.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -65.59 -40.73 93.03 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.88 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -125.24 162.81 23.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.541 ' HE3' ' CZ3' ' A' ' 172' ' ' TRP . 15.0 tptm -67.42 -58.5 4.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 15.9 tp -39.11 -51.03 1.9 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.924 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -51.92 -41.92 62.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -65.18 -53.31 46.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.062 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -49.46 -41.09 39.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.87 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -57.3 -52.68 64.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.53 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.76 -51.11 69.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.657 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 95.0 mt -43.96 -51.69 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 63.9 t -72.62 -59.76 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.151 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 13.1 m-70 -50.92 -64.7 0.73 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.903 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.575 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 92.7 mmm -57.77 -39.24 77.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.97 94.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.46 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 91.87 -29.46 7.42 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.504 ' N ' ' O ' ' A' ' 158' ' ' MET . 9.1 tp60 -36.3 152.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.761 0.315 . . . . 0.0 110.952 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.573 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.0 m95 -96.71 91.68 5.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.937 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.512 HD11 ' CB ' ' A' ' 116' ' ' ALA . 2.0 tt -88.64 -69.84 0.68 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.936 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 105' ' ' SER . . . -117.68 116.98 3.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 50.95 -90.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 164' ' ' GLY . 40.9 mtt180 -80.3 179.98 7.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.827 0.346 . . . . 0.0 110.836 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.573 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 45.7 mt-30 -81.77 179.84 7.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.918 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.565 HD11 ' CE ' ' A' ' 158' ' ' MET . 15.3 pt -139.14 163.52 26.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.117 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 46.9 ttt-85 -129.71 156.53 44.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.6 p -129.83 162.46 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -168.55 163.69 12.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.864 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.657 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 97.5 m95 -94.16 114.25 26.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -82.91 38.73 0.6 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.8 t -139.07 137.24 36.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.142 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 36.2 mtt180 -48.41 143.69 4.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.867 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.66 156.94 16.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.537 0.684 . . . . 0.0 110.904 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . 0.432 ' HA ' ' HD2' ' A' ' 178' ' ' PRO . 53.8 Cg_endo -69.78 116.43 4.56 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.65 2.233 . . . . 0.0 112.34 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 177' ' ' PRO . 53.8 Cg_endo -69.87 153.64 68.2 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.658 2.239 . . . . 0.0 112.328 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -154.81 145.19 15.92 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.575 0.702 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -45.91 1.41 Allowed 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.675 2.25 . . . . 0.0 112.348 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 18.8 m 59.19 45.76 13.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -98.79 146.33 18.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.457 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 141.32 45.13 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.658 2.238 . . . . 0.0 112.348 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 6.4 t -124.93 103.84 8.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.844 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.5 m -149.24 141.97 24.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.478 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 94.2 p -117.77 42.08 2.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.867 0.365 . . . . 0.0 110.86 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 15.3 m -66.94 118.89 11.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.814 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -105.18 -50.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 62.5 m 50.7 42.94 27.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.889 0.376 . . . . 0.0 110.891 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 3.0 m -68.56 96.25 0.69 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.47 -151.0 10.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 65.6 mt-30 -83.55 126.24 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.904 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 23.3 ttmt -69.99 -47.68 61.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.99 120.77 28.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -81.08 -56.61 3.98 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.896 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 29.7 p -83.37 97.0 8.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.133 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.3 t -93.07 -47.97 6.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.853 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -58.94 -46.36 88.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 48.3 m170 -56.44 152.95 10.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.882 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 148' ' ' LYS . 93.8 m-85 -90.65 135.37 33.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 82.4 m-70 -94.13 124.37 38.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 63.7 t -112.67 116.17 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.127 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.54 ' C ' ' CD1' ' A' ' 100' ' ' PHE . 1.4 t80 -84.28 136.74 33.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.9 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 169' ' ' ARG . 38.6 t -127.16 115.54 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.113 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -103.73 -174.48 25.8 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 46.29 50.74 11.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.903 0.382 . . . . 0.0 110.912 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.5 mt -91.28 110.61 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -42.41 153.68 0.3 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.696 0.76 . . . . 0.0 110.863 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -20.0 35.4 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.719 2.279 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -84.08 -14.02 51.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 20.4 mm -60.58 150.36 6.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.147 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.6 p -142.91 154.86 44.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.16 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 18.2 m -48.05 -42.18 27.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -65.47 -43.18 91.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.49 ' O ' ' N ' ' A' ' 116' ' ' ALA . 6.9 m-20 -59.22 -52.96 63.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.462 HG23 ' CE1' ' A' ' 117' ' ' PHE . 30.6 mt -60.96 -43.0 95.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.463 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 30.0 mttm -62.35 -36.17 81.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 38.6 t -94.01 -13.27 27.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.531 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -91.93 -13.21 31.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.104 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.503 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.1 m-85 -113.0 -9.8 13.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -59.03 -45.5 99.53 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.586 0.707 . . . . 0.0 111.06 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.9 Cg_exo -47.97 -17.08 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.656 2.237 . . . . 0.0 112.341 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.484 ' CE2' ' HA ' ' A' ' 117' ' ' PHE . 38.9 m-85 -91.9 -40.36 11.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.14 174.56 44.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -67.54 120.9 14.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.812 0.339 . . . . 0.0 110.883 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 93.3 mt -85.77 140.08 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.118 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 65.5 p -110.58 -30.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -156.31 123.93 5.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.463 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -150.07 132.38 15.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.105 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 19.9 ptt180 -152.06 147.43 26.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 2.1 p -108.46 99.94 9.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.653 HG12 ' CG ' ' A' ' 138' ' ' LYS . 73.0 t -52.43 114.67 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 43.8 mttm -113.08 160.98 17.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -68.59 157.86 35.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.845 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 7.8 tpt -94.35 -27.86 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -90.65 -55.71 3.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 65.3 p -80.73 -38.78 28.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.136 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 84.43 18.62 61.91 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.479 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.9 mttp -105.75 146.9 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 110.906 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.1 t -39.03 114.26 0.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.653 ' CG ' HG12 ' A' ' 129' ' ' VAL . 12.3 mtpt -52.94 -38.79 62.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.97 20.65 1.44 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.525 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.47 ' CZ ' HG11 ' A' ' 129' ' ' VAL . 9.1 p90 -171.39 154.04 3.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.96 0.41 . . . . 0.0 110.9 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -149.47 -169.99 16.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.78 142.48 38.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.902 0.382 . . . . 0.0 110.831 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 43.3 t -147.3 108.97 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 44.3 m -92.25 149.27 21.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -126.46 152.89 45.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 12.7 m-85 -60.66 -45.66 93.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.908 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -127.72 160.14 32.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.896 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 151' ' ' ALA . 12.2 tptm -58.66 -60.3 4.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 49.0 tp -38.47 -47.4 1.27 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -57.94 -38.89 76.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.88 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.479 ' N ' ' O ' ' A' ' 148' ' ' LYS . . . -68.92 -57.07 6.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.415 ' O ' HG23 ' A' ' 156' ' ' VAL . 4.6 mm-40 -43.32 -46.64 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -40.09 -47.48 2.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.555 ' HB1' ' HG3' ' A' ' 158' ' ' MET . . . -76.93 -55.99 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.676 HD12 ' CZ2' ' A' ' 172' ' ' TRP . 87.8 mt -42.93 -38.58 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 152' ' ' GLU . 42.2 t -81.33 -48.7 18.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.118 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 -75.3 -67.11 0.69 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.555 ' HG3' ' HB1' ' A' ' 154' ' ' ALA . 23.2 mmt -42.17 -47.97 4.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.42 102.18 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.467 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 86.92 -34.51 3.55 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.479 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.445 ' N ' ' O ' ' A' ' 158' ' ' MET . 5.4 tp60 -35.14 151.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.798 0.333 . . . . 0.0 110.927 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.562 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 86.1 m95 -98.15 91.36 5.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.58 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.9 tt -85.41 -71.2 0.54 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.925 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.88 118.05 3.58 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 54.4 -93.05 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.514 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -82.13 170.35 15.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.759 0.314 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.562 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 80.8 mt-30 -71.3 -179.4 2.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 15.5 pt -136.98 168.77 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.603 ' O ' HG13 ' A' ' 101' ' ' VAL . 36.5 ttp180 -131.88 158.71 40.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.896 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.429 ' CB ' ' HA ' ' A' ' 155' ' ' ILE . 0.9 OUTLIER -139.64 150.9 45.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.148 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 22.1 m-20 -166.96 158.46 12.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.676 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.0 m95 -85.48 100.54 11.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -56.06 -30.31 61.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 87.1 m -49.54 119.95 3.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.09 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 21.0 ttm180 -44.2 -62.46 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -147.03 134.4 10.27 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.546 0.689 . . . . 0.0 110.937 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 147.41 63.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.676 2.251 . . . . 0.0 112.372 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 140.08 41.8 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.692 2.261 . . . . 0.0 112.314 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -121.8 146.25 45.4 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 111.094 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 134.87 29.0 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.698 2.265 . . . . 0.0 112.329 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.9 p -86.61 131.58 34.12 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.885 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.58 -179.16 26.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 174.12 9.96 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.667 2.244 . . . . 0.0 112.308 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.5 t -115.14 -53.16 2.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.6 p -72.25 98.33 2.15 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.833 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.494 -179.991 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 64.4 m -106.59 115.25 29.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.897 0.38 . . . . 0.0 110.848 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 20.1 m -137.81 151.72 48.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.894 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -98.52 -145.9 19.56 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.499 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.7 t 69.09 42.4 1.26 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.885 0.374 . . . . 0.0 110.861 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 13.0 t -100.3 -46.3 5.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . 121.57 -82.7 0.35 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.507 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.402 ' C ' ' O ' ' A' ' 88' ' ' GLY . 9.8 tt0 -37.95 143.6 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.872 0.368 . . . . 0.0 110.962 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 47.6 mttt -101.65 42.61 1.12 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.06 83.26 1.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.881 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -49.78 6.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.0 p -93.94 96.57 9.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.15 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 t -101.41 -54.19 2.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.816 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -89.21 -41.77 12.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -40.43 153.28 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.849 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -91.03 133.0 35.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.928 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -96.58 122.3 39.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.861 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.5 t -109.81 126.04 66.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.126 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.2 t80 -90.48 138.49 31.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 169' ' ' ARG . 92.7 t -128.7 124.55 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -115.65 -179.25 18.38 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 54.23 34.15 19.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.893 0.378 . . . . 0.0 110.917 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.493 HD12 ' N ' ' A' ' 141' ' ' GLY . 40.5 mt -80.12 113.4 18.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.3 t -45.3 153.54 0.55 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.665 0.745 . . . . 0.0 110.832 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -25.88 28.44 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.671 2.248 . . . . 0.0 112.396 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -77.89 -7.72 57.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 6.4 mm -72.81 148.09 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.13 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.2 p -134.93 159.97 39.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.099 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.668 ' OG1' HG12 ' A' ' 128' ' ' VAL . 36.3 m -54.66 -44.65 73.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -63.05 -31.14 72.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.431 ' O ' ' N ' ' A' ' 116' ' ' ALA . 92.9 m-20 -69.7 -51.37 35.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.843 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.448 HG23 ' CE1' ' A' ' 117' ' ' PHE . 17.0 mt -58.49 -43.93 87.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 118' ' ' ALA . 58.3 mttt -60.62 -34.9 74.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 28.1 t -93.96 -11.99 29.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.597 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -95.84 -13.72 23.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.088 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.501 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 13.3 m-85 -116.11 -11.56 11.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.588 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -56.5 -45.14 99.96 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.065 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.3 Cg_exo -47.96 -17.14 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.313 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.617 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 59.5 m-85 -88.69 -41.34 12.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.855 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 173.59 148.98 6.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -40.96 128.92 2.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.0 110.866 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 58.4 mt -101.22 147.6 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 4.4 p -115.2 -36.59 4.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -140.92 133.81 29.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.826 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.406 ' HB3' ' HE3' ' A' ' 114' ' ' LYS . . . -164.2 128.76 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.088 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.496 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.3 OUTLIER -151.92 161.64 42.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.847 -179.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.668 HG12 ' OG1' ' A' ' 110' ' ' THR . 2.1 p -118.48 99.85 8.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.144 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 51.5 t -51.24 117.06 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.468 ' HG2' ' N ' ' A' ' 137' ' ' SER . 12.7 mttp -110.03 160.34 16.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.915 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -66.6 156.34 35.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.903 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 8.5 tpt -96.56 -10.41 27.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -101.66 -50.72 3.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.3 p -94.05 -29.26 15.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.65 17.89 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.438 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 13.1 mtpp -101.19 145.73 28.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.879 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.468 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 68.3 m -47.07 105.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 12.6 mttp -44.03 -36.3 2.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 126.94 14.19 2.82 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.535 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -155.7 152.81 29.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.945 0.403 . . . . 0.0 110.901 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.493 ' N ' HD12 ' A' ' 104' ' ' LEU . . . -148.43 -171.19 17.05 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.499 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -134.68 137.6 43.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.874 0.369 . . . . 0.0 110.868 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 92.5 t -137.47 118.05 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.134 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 88.8 p -98.08 152.85 18.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.858 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.586 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 26.7 m-85 -129.53 141.44 50.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.897 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -57.59 -40.86 79.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.862 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -117.7 178.81 4.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 45.7 tttt -87.18 -48.38 8.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 18.3 tp -48.02 -65.1 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -41.98 -51.32 4.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.921 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.586 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -55.52 -47.15 76.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -57.81 -42.1 83.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.914 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -51.3 -47.69 62.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.617 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -68.43 -53.97 20.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.062 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.429 ' CD1' ' CZ2' ' A' ' 172' ' ' TRP . 96.6 mt -41.37 -35.6 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 95.4 t -91.4 -47.43 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.148 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -63.82 -63.77 1.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.581 ' HG2' ' CE2' ' A' ' 120' ' ' PHE . 93.0 mmm -60.52 -37.99 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.929 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -38.63 94.06 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.58 -28.31 9.36 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.508 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 158' ' ' MET . 73.3 tp60 -37.69 156.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.778 0.323 . . . . 0.0 110.92 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.568 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.6 m95 -98.95 90.99 4.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.597 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.1 tt -86.15 -70.14 0.62 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.881 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -121.33 117.74 3.54 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 53.92 -92.7 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 36.3 mtt85 -80.89 179.66 7.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.314 . . . . 0.0 110.865 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.568 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 80.9 mt-30 -80.9 178.01 8.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.412 HD11 ' HE3' ' A' ' 158' ' ' MET . 29.4 pt -133.52 168.63 23.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.71 ' O ' HG13 ' A' ' 101' ' ' VAL . 55.9 ttt180 -129.54 154.23 47.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.885 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.606 HG22 HG22 ' A' ' 101' ' ' VAL . 44.5 p -141.95 148.22 38.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.083 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -174.24 147.07 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.429 ' CZ2' ' CD1' ' A' ' 155' ' ' ILE . 96.5 m95 -61.7 122.72 16.02 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.959 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -66.63 -61.97 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.089 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 85.0 m -44.47 115.11 0.79 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.098 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 6.0 ptm180 -94.88 140.99 29.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.862 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.7 pptp? -171.77 145.87 1.75 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.583 0.706 . . . . 0.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 148.7 66.2 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.712 2.275 . . . . 0.0 112.337 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 145.76 58.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.323 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -44.74 144.08 1.97 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.61 0.719 . . . . 0.0 111.09 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 100.66 0.83 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.673 2.249 . . . . 0.0 112.354 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 13.9 t -88.72 108.67 19.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.865 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -39.04 146.19 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 131.92 22.2 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 0.0 112.326 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 20.7 t -160.84 157.72 27.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 41.4 m -42.28 -47.89 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.99 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.9 m 47.93 42.26 16.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.871 0.367 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 t -168.48 176.69 5.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.859 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -99.88 -177.92 30.71 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.3 p -165.44 177.87 7.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.918 0.39 . . . . 0.0 110.835 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 9.5 t -85.0 130.16 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.845 -179.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 164.01 -76.76 0.16 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.511 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -38.31 157.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.42 37.1 4.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.878 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 64.7 mttt -107.01 159.33 16.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -118.74 80.78 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 73.8 p -104.23 88.0 2.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.143 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.1 m -107.66 -59.62 1.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.85 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.401 ' O ' ' C ' ' A' ' 96' ' ' HIS . 9.3 m120 -67.18 -51.85 48.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.919 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.517 ' CD2' ' HA ' ' A' ' 146' ' ' TYR . 7.1 m170 -37.87 143.96 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.838 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.558 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 3.9 m-85 -91.14 139.61 30.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -93.16 131.86 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.926 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 48.2 t -124.05 129.34 74.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' ND2' ' A' ' 171' ' ' ASN . 1.8 t80 -99.42 149.86 22.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.604 HG13 ' O ' ' A' ' 169' ' ' ARG . 43.5 t -137.41 130.43 43.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.139 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -123.25 173.29 16.27 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 139' ' ' GLY . 5.4 m-20 61.74 36.38 16.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.819 0.342 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.422 HD13 HD11 ' A' ' 113' ' ' ILE . 39.1 mt -80.18 110.87 16.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -38.66 153.06 0.16 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 121.634 0.731 . . . . 0.0 110.874 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -15.21 36.79 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.678 2.252 . . . . 0.0 112.307 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.416 ' O ' ' CG ' ' A' ' 107' ' ' GLU . 7.6 tt0 -90.63 -6.19 54.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.909 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 109' ' ' THR . 25.5 mm -67.48 156.06 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.448 ' N ' HG22 ' A' ' 108' ' ' ILE . 76.1 p -145.72 157.29 43.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.631 ' OG1' HG12 ' A' ' 128' ' ' VAL . 32.4 m -55.03 -39.06 68.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.074 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -71.58 -17.0 62.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -84.49 -46.32 11.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.51 HG23 ' CE1' ' A' ' 117' ' ' PHE . 7.7 mt -63.23 -38.76 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.117 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.462 ' HG2' ' HB3' ' A' ' 126' ' ' ALA . 19.4 mtpt -60.09 -36.12 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 7.6 t -92.84 -20.01 21.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.509 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -83.88 -16.92 42.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 25.8 m-85 -115.24 -7.55 12.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.581 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -58.72 -45.72 99.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.612 0.72 . . . . 0.0 111.114 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.581 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 65.0 Cg_exo -47.99 -18.1 1.04 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.654 2.236 . . . . 0.0 112.353 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.644 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 44.0 m-85 -89.77 -37.11 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.439 ' HA3' ' CG ' ' A' ' 150' ' ' ASP . . . 172.97 -171.24 44.3 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.456 ' HD2' ' N ' ' A' ' 123' ' ' ILE . 0.0 OUTLIER -77.77 120.05 22.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.781 0.324 . . . . 0.0 110.929 179.97 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.598 HG21 ' HB2' ' A' ' 126' ' ' ALA . 95.8 mt -91.91 101.12 12.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 93.1 p -67.84 -27.42 66.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.819 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -156.23 140.0 16.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.885 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.598 ' HB2' HG21 ' A' ' 123' ' ' ILE . . . -163.29 126.71 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.098 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.519 ' HA ' HG23 ' A' ' 110' ' ' THR . 0.8 OUTLIER -143.69 162.78 35.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.854 -179.895 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.631 HG12 ' OG1' ' A' ' 110' ' ' THR . 6.5 p -121.15 100.19 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 22.0 t -53.73 120.38 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.481 ' HG2' ' N ' ' A' ' 137' ' ' SER . 32.1 mttm -115.29 164.88 13.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -65.44 148.61 51.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -90.91 -3.44 57.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.856 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -111.5 -54.91 2.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.11 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 24.5 p -89.76 -27.19 20.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 76.59 28.13 59.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.468 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 28.0 pttt -108.58 138.83 44.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.78 0.324 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.481 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 14.6 t -41.85 109.17 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -51.19 -33.77 28.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.5 ' O ' ' N ' ' A' ' 103' ' ' ASP . . . 121.38 20.44 3.27 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.429 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -161.05 140.96 10.84 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.957 0.408 . . . . 0.0 110.924 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -136.61 -168.74 11.52 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.512 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -138.54 143.87 39.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 55.4 t -144.02 124.73 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.17 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 25.2 m -100.82 141.13 34.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.839 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -125.01 133.92 52.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.879 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.517 ' HA ' ' CD2' ' A' ' 96' ' ' HIS . 11.1 m-85 -53.35 -48.92 68.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -113.31 167.24 10.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.558 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 30.4 tttp -74.68 -42.29 58.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -46.86 -52.09 15.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.439 ' CG ' ' HA3' ' A' ' 121' ' ' GLY . 88.9 m-20 -54.42 -43.79 71.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -66.54 -61.12 2.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.072 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -41.16 -44.31 2.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 52.8 m-20 -55.29 -59.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.864 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.644 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -58.09 -54.25 49.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.15 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.615 HD13 ' CE2' ' A' ' 172' ' ' TRP . 85.4 mt -44.42 -35.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.156 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.75 -60.98 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.118 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 26.7 m-70 -56.68 -66.96 0.35 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.811 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.561 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 24.3 mmt -43.51 -47.12 7.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -37.93 95.22 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.458 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.77 -30.72 6.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.508 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.488 ' N ' ' O ' ' A' ' 158' ' ' MET . 7.5 tp60 -37.5 155.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.905 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.546 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 89.2 m95 -101.15 91.7 4.65 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.92 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.542 HD23 ' C ' ' A' ' 163' ' ' LEU . 4.0 tt -86.18 -70.7 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.416 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -120.73 118.1 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.492 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 52.73 -92.14 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.503 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -80.25 175.12 10.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.758 0.313 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.546 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 38.8 mt-30 -74.01 177.43 5.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 20.0 pt -135.31 164.62 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.134 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.604 ' O ' HG13 ' A' ' 101' ' ' VAL . 29.7 ttp180 -128.01 154.13 45.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.566 HG22 HG22 ' A' ' 101' ' ' VAL . 22.4 p -142.68 154.05 43.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . 0.534 ' ND2' ' CD1' ' A' ' 100' ' ' PHE . 4.6 p30 -173.44 163.33 4.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.615 ' CE2' HD13 ' A' ' 155' ' ' ILE . 88.4 m95 -80.73 123.44 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.922 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -90.43 91.86 8.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.085 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 19.3 m -131.62 145.58 51.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -117.38 50.93 1.06 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.74 143.96 27.63 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.583 0.706 . . . . 0.0 110.913 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.86 153.93 67.92 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.669 2.246 . . . . 0.0 112.328 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 110.94 2.68 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.693 2.262 . . . . 0.0 112.333 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -114.4 146.07 35.09 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.533 0.682 . . . . 0.0 111.111 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 126.18 13.01 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.687 2.258 . . . . 0.0 112.317 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 11.5 m -96.75 127.53 42.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -72.87 144.62 35.38 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 132.99 24.55 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.685 2.257 . . . . 0.0 112.313 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 60.5 p -101.97 149.58 24.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.885 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.2 m -154.43 161.6 41.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 179.988 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 75.0 m -69.48 -52.77 23.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 5.3 t -172.56 154.98 3.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.812 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -88.29 -171.62 46.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.521 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.1 p -105.69 145.14 31.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.857 0.361 . . . . 0.0 110.848 -179.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 7.8 t -100.14 -64.26 1.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.852 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.24 -76.08 0.12 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.501 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -79.65 122.4 26.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.929 0.395 . . . . 0.0 110.908 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -149.41 -175.92 5.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.918 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? 50.75 49.4 21.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.906 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -87.37 58.37 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.9 p -96.04 73.81 3.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.136 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 35.7 t -110.35 -26.57 9.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.849 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 32.3 m120 -132.79 36.38 3.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.497 ' CE1' ' HA ' ' A' ' 146' ' ' TYR . 28.2 m170 -96.0 160.35 14.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.557 ' CZ ' ' HB2' ' A' ' 148' ' ' LYS . 26.9 m-85 -102.2 129.67 48.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -96.34 133.39 40.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.465 HG22 HD11 ' A' ' 155' ' ' ILE . 62.3 t -114.01 127.19 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.115 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 24.4 t80 -87.63 136.4 32.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.426 HG13 ' O ' ' A' ' 169' ' ' ARG . 43.8 t -125.72 135.74 62.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.105 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -131.67 178.05 18.16 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.468 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 55.34 32.25 18.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 33.1 mt -78.85 118.84 21.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.6 t -50.36 152.47 3.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.82 23.45 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.678 2.252 . . . . 0.0 112.327 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -69.32 -13.2 62.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.532 HD12 HD22 ' A' ' 163' ' ' LEU . 14.6 mm -66.1 159.1 4.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.16 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.494 ' N ' HG22 ' A' ' 108' ' ' ILE . 68.9 p -134.9 -175.82 4.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.178 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 97.3 m -78.97 -36.98 40.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.126 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -78.95 -16.35 57.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -72.29 -48.42 42.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.511 HG23 ' CE1' ' A' ' 117' ' ' PHE . 5.0 mt -62.25 -42.48 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.13 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 65.2 mttt -57.28 -35.26 69.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 6.9 t -93.83 -19.33 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.858 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.685 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -83.62 -20.09 34.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.089 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.556 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 12.9 m-85 -110.96 -7.16 14.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.573 ' N ' ' CD ' ' A' ' 119' ' ' PRO . . . -57.53 -45.98 99.82 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.535 0.683 . . . . 0.0 111.076 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 118' ' ' ALA . 66.1 Cg_exo -48.01 -17.09 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.136 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.637 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 47.9 m-85 -90.69 -32.85 16.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.874 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.85 -165.6 37.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.51 ' HG2' ' CE1' ' A' ' 146' ' ' TYR . 72.4 tttt -78.84 131.71 36.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -104.44 113.64 41.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.105 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 3.2 t -79.46 -32.39 42.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.843 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -152.5 143.5 23.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -173.25 132.36 0.49 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.155 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -152.06 164.65 36.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.607 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.6 p -114.58 100.7 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.7 t -52.88 122.76 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.467 ' HG2' ' N ' ' A' ' 137' ' ' SER . 78.0 mttt -120.92 161.26 21.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -71.38 158.51 36.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.838 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -95.85 -15.83 22.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -94.63 -60.44 1.71 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 15.3 p -83.42 -31.19 26.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.16 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 77.2 25.6 63.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.3 mmtm -108.24 144.63 35.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.842 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.467 ' N ' ' HG2' ' A' ' 130' ' ' LYS . 11.2 t -46.76 105.89 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -44.14 -37.82 3.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 128.22 10.08 3.52 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.8 p90 -153.56 153.13 31.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.946 0.403 . . . . 0.0 110.907 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -148.18 -171.73 17.42 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -130.97 142.12 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.897 0.38 . . . . 0.0 110.874 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 25.3 t -140.9 105.61 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.158 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 17.8 m -85.77 147.91 26.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.872 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.9 ' HB2' ' HB2' ' A' ' 151' ' ' ALA . 11.1 m-85 -129.23 129.21 44.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.84 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.51 ' CE1' ' HG2' ' A' ' 122' ' ' LYS . 21.1 m-85 -43.8 -46.96 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.95 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 23.7 m-20 -114.32 -178.87 3.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.853 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.557 ' HB2' ' CZ ' ' A' ' 97' ' ' PHE . 25.9 tttm -87.1 -48.74 7.82 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.901 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 30.1 tp -50.11 -64.97 0.65 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 20.2 p-10 -39.73 -51.88 2.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.9 ' HB2' ' HB2' ' A' ' 145' ' ' PHE . . . -60.41 -58.37 8.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.082 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -43.58 -47.39 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -45.36 -50.64 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.637 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -61.67 -52.34 64.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.098 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.465 HD11 HG22 ' A' ' 99' ' ' VAL . 92.1 mt -44.15 -39.54 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.8 t -77.29 -48.48 24.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 64.8 m-70 -72.05 -65.56 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.556 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.3 mmt -43.3 -49.61 6.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -39.2 96.6 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.455 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 158' ' ' MET . . . 92.59 -30.29 7.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.482 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.473 ' N ' ' O ' ' A' ' 158' ' ' MET . 38.8 tp60 -40.16 154.41 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.915 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.577 ' CH2' ' HG3' ' A' ' 167' ' ' GLN . 92.2 m95 -98.92 91.17 4.92 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.685 HD11 ' CB ' ' A' ' 116' ' ' ALA . 5.6 tt -85.54 -73.14 0.46 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.462 ' HA3' ' CD1' ' A' ' 108' ' ' ILE . . . -118.94 117.17 3.57 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.477 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 55.69 -92.7 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.458 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 12.5 mtt-85 -80.95 -177.29 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.861 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HG3' ' CH2' ' A' ' 162' ' ' TRP . 33.3 mt-30 -82.5 177.15 8.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.492 ' CD1' ' SD ' ' A' ' 158' ' ' MET . 41.9 pt -134.4 173.95 13.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.138 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.426 ' O ' HG13 ' A' ' 101' ' ' VAL . 21.2 ttm180 -136.76 158.46 44.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -139.04 156.1 47.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -163.88 168.25 19.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.879 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -94.83 105.68 17.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.951 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 100' ' ' PHE . . . -72.27 103.88 3.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.414 ' O ' HG23 ' A' ' 174' ' ' THR . 15.1 t -145.85 128.84 16.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.149 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 66.6 mtm180 -84.38 133.85 34.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.884 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 15.8 ttpt -170.18 132.7 1.03 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.525 0.679 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 139.5 40.42 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.707 2.271 . . . . 0.0 112.368 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -178.93 2.55 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.653 2.235 . . . . 0.0 112.327 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . . . . . . . . . . . -132.79 146.96 63.6 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.559 0.695 . . . . 0.0 111.084 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 131.23 20.79 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.633 2.222 . . . . 0.0 112.363 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 8.0 t -144.75 159.06 43.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.854 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 120.11 145.37 7.42 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -16.8 37.96 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.671 2.247 . . . . 0.0 112.352 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 23.0 t 51.3 36.15 15.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 5.0 t -111.54 -58.01 2.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.86 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.515 179.996 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 25.1 t -149.42 135.96 19.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 0.0 110.849 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 5.3 t -108.46 97.93 7.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.859 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.4 -118.96 0.23 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.519 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.0 m 46.85 51.52 12.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 110.887 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.0 p -118.51 142.72 47.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.11 -168.33 29.65 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.517 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -103.45 -2.11 27.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.893 0.378 . . . . 0.0 110.928 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 11.7 ttmt -84.23 110.69 18.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.845 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.3 mtmt -83.05 45.98 1.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.88 129.07 38.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 73.3 p -64.95 129.37 39.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.149 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.3 m -128.32 -49.8 1.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.83 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -127.21 36.98 4.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.887 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 38.5 m170 -105.3 155.41 19.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.526 ' CE1' ' HB2' ' A' ' 148' ' ' LYS . 85.3 m-85 -86.89 124.92 33.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.868 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 3.8 m-70 -93.02 134.82 34.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.869 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.498 HG22 HD11 ' A' ' 155' ' ' ILE . 28.9 t -115.82 128.47 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.17 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -89.82 131.08 35.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.783 HG11 HD21 ' A' ' 104' ' ' LEU . 82.2 t -119.99 133.38 66.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.133 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -125.35 -178.43 15.31 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.526 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 47.4 43.58 15.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.883 0.373 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.783 HD21 HG11 ' A' ' 101' ' ' VAL . 45.1 mt -79.57 97.02 6.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 104' ' ' LEU . 1.3 t -35.74 153.64 0.07 OUTLIER Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.684 0.754 . . . . 0.0 110.839 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.83 -14.6 36.09 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.622 2.215 . . . . 0.0 112.341 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -89.82 -3.62 58.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 109' ' ' THR . 15.1 mm -76.79 156.86 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.426 ' N ' HG22 ' A' ' 108' ' ' ILE . 26.7 p -142.19 160.93 39.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.184 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.785 ' OG1' HG12 ' A' ' 128' ' ' VAL . 21.0 m -56.14 -33.43 65.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.173 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 13.8 tm-20 -74.6 -39.08 62.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.5 ' O ' ' N ' ' A' ' 116' ' ' ALA . 19.2 m-20 -55.06 -57.44 11.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.545 HG23 ' CE1' ' A' ' 117' ' ' PHE . 28.1 mt -52.77 -39.79 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.128 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.64 ' HA ' HD13 ' A' ' 123' ' ' ILE . 6.9 mtpm? -62.89 -41.86 99.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.6 t -90.53 -10.17 44.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.877 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.567 ' CB ' HD11 ' A' ' 163' ' ' LEU . . . -93.27 -23.44 18.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.128 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' PHE . . . . . 0.565 ' CE2' ' HG3' ' A' ' 158' ' ' MET . 15.7 m-85 -105.05 -6.98 19.5 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.574 ' HB3' ' HD3' ' A' ' 119' ' ' PRO . . . -55.15 -46.43 99.68 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.553 0.692 . . . . 0.0 111.083 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.574 ' HD3' ' HB3' ' A' ' 118' ' ' ALA . 65.4 Cg_exo -47.96 -19.0 1.32 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.354 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.688 ' CD2' ' HB2' ' A' ' 154' ' ' ALA . 44.2 m-85 -89.41 -50.24 6.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 178.81 165.7 33.69 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.455 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -50.83 131.54 26.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.64 HD13 ' HA ' ' A' ' 114' ' ' LYS . 57.3 mt -99.44 117.48 44.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 57.8 p -86.93 -31.21 20.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -152.1 122.87 7.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.839 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.567 ' HB3' ' HG2' ' A' ' 114' ' ' LYS . . . -149.13 114.21 5.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.129 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.1 155.15 47.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.905 -179.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.785 HG12 ' OG1' ' A' ' 110' ' ' THR . 5.0 p -112.51 99.94 9.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.178 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 25.9 t -52.65 122.81 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.106 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.512 ' HE3' HG13 ' A' ' 128' ' ' VAL . 4.3 mtmp? -117.16 156.76 27.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.886 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -58.16 151.36 19.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.894 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' MET . . . . . 0.403 ' O ' ' SD ' ' A' ' 132' ' ' MET . 0.0 OUTLIER -96.47 16.34 18.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -131.14 -56.38 1.03 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.101 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.1 p -84.53 -28.46 26.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.12 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.77 23.17 62.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.494 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.407 ' C ' ' HG2' ' A' ' 130' ' ' LYS . 13.8 mmtp -108.48 167.35 10.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.777 0.322 . . . . 0.0 110.911 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 80.1 p -57.07 117.65 4.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.867 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.429 ' HG3' ' C ' ' A' ' 130' ' ' LYS . 41.5 mttt -60.54 -39.53 88.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 127.62 16.72 2.22 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.511 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -166.08 151.42 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.902 0.382 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -143.56 -171.9 14.09 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -138.69 139.33 38.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.517 HG21 ' CG2' ' A' ' 113' ' ' ILE . 54.4 t -145.09 108.22 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' SER . . . . . . . . . . . . . 6.0 m -86.05 154.75 21.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -130.7 141.46 50.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.874 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -60.42 -32.86 71.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -125.54 162.35 25.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.934 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.526 ' HB2' ' CE1' ' A' ' 97' ' ' PHE . 70.8 tttt -73.94 -47.87 34.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.858 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' LEU . . . . . . . . . . . . . 16.4 tp -52.04 -43.05 63.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -60.29 -34.26 73.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.836 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -74.51 -45.22 47.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.117 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.524 ' O ' HG23 ' A' ' 156' ' ' VAL . 17.0 mt-10 -58.22 -42.14 85.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.894 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -53.14 -54.87 29.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.688 ' HB2' ' CD2' ' A' ' 120' ' ' PHE . . . -62.42 -55.88 23.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.498 HD11 HG22 ' A' ' 99' ' ' VAL . 79.2 mt -42.0 -37.78 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 152' ' ' GLU . 82.5 t -80.15 -58.84 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.173 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -59.64 -65.42 0.68 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' MET . . . . . 0.565 ' HG3' ' CE2' ' A' ' 117' ' ' PHE . 22.7 mmt -42.54 -48.12 5.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 158' ' ' MET . . . -36.54 104.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.484 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 161' ' ' GLN . . . 83.81 -31.46 3.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.496 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . 0.499 ' N ' ' O ' ' A' ' 158' ' ' MET . 34.1 tp60 -37.28 149.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 167' ' ' GLN . 81.5 m95 -96.24 93.55 6.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.567 HD11 ' CB ' ' A' ' 116' ' ' ALA . 4.5 tt -86.36 -70.43 0.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.97 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.406 ' HA3' HD13 ' A' ' 108' ' ' ILE . . . -125.6 118.81 3.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . 58.4 -95.28 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -84.86 170.26 13.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.581 ' HG3' ' CZ2' ' A' ' 162' ' ' TRP . 39.0 mt-30 -68.7 172.28 6.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 14.9 pt -129.59 164.7 31.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.159 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.421 ' HG3' ' N ' ' A' ' 170' ' ' THR . 21.0 tpp180 -125.05 156.44 38.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.922 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . 0.467 HG21 ' HB2' ' A' ' 158' ' ' MET . 72.2 p -144.52 156.87 44.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -174.37 173.58 2.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' TRP . . . . . 0.474 ' CZ2' HD12 ' A' ' 155' ' ' ILE . 98.2 m95 -90.91 108.55 19.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -44.99 -56.94 4.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.042 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.0 t -108.33 136.21 48.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -128.34 123.94 35.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.833 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 16.5 tptt -106.38 87.09 2.42 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.635 0.731 . . . . 0.0 110.928 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 125.79 12.56 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.67 2.247 . . . . 0.0 112.355 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 163.49 38.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.683 2.255 . . . . 0.0 112.38 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' ALA . . . . . 0.474 ' HB1' ' HD2' ' A' ' 180' ' ' PRO . . . -91.59 157.02 42.61 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.6 0.714 . . . . 0.0 111.067 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' PRO . . . . . 0.474 ' HD2' ' HB1' ' A' ' 179' ' ' ALA . 54.4 Cg_endo -69.78 2.83 3.19 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.674 2.25 . . . . 0.0 112.379 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 35.4 t -82.05 143.36 31.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.76 146.53 4.35 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 168.67 20.92 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 0.0 112.368 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' SER . . . . . . . . . . . . . 2.1 m -139.5 161.24 37.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.83 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 4.1 m -129.75 137.68 50.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.829 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.455 -179.998 . . . . . . . . 0 0 . 1 stop_ save_